Looking for the Missing Link: Application of Copper Isotope Metallomics to Amyotrophic Lateral Sclerosis by Enge, T. Gabriel
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
2017+ University of Wollongong Thesis Collections 
2018 
Looking for the Missing Link: Application of Copper Isotope Metallomics to 
Amyotrophic Lateral Sclerosis 
T. Gabriel Enge 
University of Wollongong 
Follow this and additional works at: https://ro.uow.edu.au/theses1 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Recommended Citation 
Enge, T. Gabriel, Looking for the Missing Link: Application of Copper Isotope Metallomics to Amyotrophic 
Lateral Sclerosis, Doctor of Philosophy thesis, School of Earth and Environmental Sciences, University of 
Wollongong, 2018. https://ro.uow.edu.au/theses1/334 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Looking for the Missing Link:
Application of Copper Isotope Metallomics




Associate Professor Anthony Dosseto
Associate Professor Heath Ecroyd
Professor Dianne F. Jolley
This thesis is presented as required
for the conferral of the degree:
Doctor of Philosophy
1stApril 2018
School of Earth and Environmental Sciences
e University of Wollongong
No part of this work may be reproduced, stored in a retrieval system,
transmitted, in any form or by any means, electronic, mechanical,
photocopying, recording, or otherwise, without the prior permission of the
author or the University of Wollongong.
This work © copyright by T. Gabriel Enge, 2018. All Rights Reserved.
is thesis is dedicated to the pure and honourable pursuit of science.
It is further dedicated in memory of the work of my personal scientic heroes,
Johan Hultin and Jeery K. Taubenberger, with the hope that my humble
work presented here may one day add to the global eort in nding
new ways of looking at medical challenges.

is thesis was typeset using Texpad editor 1.8 (Valletta
Ventures Ltd.) and the LATEX typesetting system (MacTex 2017)
originally developed by Leslie Lamport, based on TEX created by
Donald Knuth.
e text body is typeset in 12/14.7pt on a 31pc measure using
the Renaissance-era inspired neohumanistic serif typefaceMinion
Pro designed by Robert Slimbach (Adobe Systems Inc, 1989). e
geometric sans-serif typeface Montserrat, designed by Julieta
Ulanovsky, inspired by posters and signage from the historical
Buenos Aires neighbourhood of Montserrat, was used for the
document hierarchy. Within gures, the humanist sans-serif
typeface Myriad Pro, designed by Robert Slimbach, Carol
Twombly, Christopher Slye and Fred Brady (Adobe Systems
Inc, 2000), was used for a beautifully clean typeset.
Typographical decisions were based on the recommendations
given in The Elements of Typographic Style by Bringhurst (2002).
e guidelines found in e Visual Display of Quantitative
Information by Tue (2001) were followed when creating diagrams
and tables. Stave symbols were adopted from the Museum of
Icelandic Sorcery and Witchcra (http://tinyurl.com/25979m).
e use of colours, layout and appearance was inspired by the
thesis Social Navigation on the social Web - Unobtrusive
Prototyping of Activity Streams in Established Spaces by Uggedal
(2008), with the colour scheme motivated by the marketing




Amyotrophic lateral sclerosis (ALS) is one of the most common motor
neuron diseases (MND), and arguably the most devastating. During the disease
course of MNDs, motor neurons undergo progressive degeneration leading to
cascading symptoms of muscle paralysis. In ALS, this paralysis aects voluntary
muscle groups, with a few exceptions, and impacts general mobility, speech and
respiration. Death oen occurs as a result of asphyxiation within 2 – 5 years of
diagnosis. While a variety of gene mutations and molecular mechanisms have
been proposed to play a role in the aetiology of ALS, a specic disease trigger
remains to be identied. Mutations in Cu,Zn superoxide dismutase 1 (SOD1), an
abundant and ubiquitously expressed antioxidant enzyme, account for ∼20% of
all familial cases of ALS and are the most studied. One of the proposed
mechanisms that triggers disease is the propensity of mutant forms of SOD1
(mSOD1), to aggregate, misfold and develop a toxic-gain-of-function, as a result
of inadequate metal coordination. An improved acumen of ALS-induced
perturbations to Cu metabolism may help improve the understanding of disease
mechanisms and triggers.
is thesis investigates metal concentrations and Cu isotope ratios in the
context of ALS to gain new insights into perturbations in metal metabolism
associated with this disease. e work has a particular focus on Cu metabolism.
e onset and progression of ALS was studied using samples from the well
characterised SOD1G93A mouse model of ALS and human blood samples of MND
cases and healthy controls. Finally, the potential of metal concentrations or Cu
isotope ratios to act as a biomarker for ALS is evaluated.
To perform the proposed analyses, an automated Cu chromatography
method was developed for the separation of Cu from biological samples prior to
stable, naturally occurring, isotope analysis. is approach is characterised by its
ability to process >30 samples in 24 h, low carry-over between samples and high
quantitative yields. It provides a solution to process large sample numbers in
relatively short time, enabling application to medical problems, where typically
large datasets have to be generated.
Work as part of this thesis found no discernible dierences in Cu isotope
ratios associated with ALS in the mouse tissues, or human MND samples
compared to controls. Rather than an ALS signal, a Cu isotope ratio signal,
associated with ageing, was observed in brain and muscle tissue of the G93A
mice; the Cu isotope ratios move towards that of food as the mice age.
Concerning metal concentrations, accumulation of Cu and Zn associated with
ALS was found in tissues controlled by the autonomous nervous system (muscle,
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liver, intestine and heart tissue), while no accumulation was observed in tissues of
the CNS (brain and spinal cord).
ese results suggest that it is unlikely that Cu isotope ratios can serve as a
biomarker for ALS or MNDs in general. A mass balance model was developed to
understand and explain the lack of change in blood Cu isotope ratios in response
to the development of MND in humans. Based on this modelling approach it is
concluded that not enough Cu euxes from the cerebro-spinal-uid (CSF) into
the blood, to signicantly impact the Cu isotope ratio of blood. It is proposed that
the use of Cu isotope ratios should be investigated in CSF, as this bio-uid is
closer to the source of the pathology and therefore more likely to carry a disease
signal.
Concerning metal concentrations, the ndings presented here represent an
important step towards a greater understanding of the role of Cu metabolism in
ALS. e global accumulation of Cu and Zn in heart, liver and intestinal tissue in
the G93A mouse could not be clearly linked to a pathological processes. However,
the accumulation of Cu, Zn and Fe in muscle tissue was identied as a result of
pathological processes. An updated mode-of-action is proposed for the
involvement of Cu in ALS: it may trigger mSOD1 toxic-gain-of-function, as
partially metalated forms of mSOD1 aggregate and are toxic leading to axonal
retraction and motor neuron loss. Additionally, the accumulation of Cu in muscle
tissue contributes to toxicity at the neuromuscular junction, resulting in axonal
retraction and mitochondrial dysfunction. It is therefore proposed that the
dying-forward and dying-back hypotheses to explain motor neuron loss in MND
are not mutually exclusive; rather they occur in unison. is provides a new way
of thinking about the role of Cu in ALS. Moreover, it explains why both synthetic
Cu binding compounds and Cu chelators act to prolong survival of SOD1 mouse
models, emphasising the potential role of Cu in the aetiology of ALS and likely
other MNDs.
It is recommended that future research assesses the biochemical pathways
through which Cu and other metals act within the context of ALS. Future
investigations using mouse models of ALS should be accompanied by protein
assays (e.g., SOD1) to scrutinise and dierentiate metal accumulation driven by
true pathological processes and those induced by the mutations used to induce
ALS in these mouse models. In muscle tissue, the application of laser ablation
methods could identify the locus of metal accumulation. is will aid in
understanding the role that this accumulation plays in the development of the
disease. Additionally, future work should focus on the application of Cu isotope
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Amyotrophic lateral sclerosis (ALS), rst described in 1869 by Charcot and Joroy, is
a fatal neurodegenerative disorder, resulting in progressive muscle paralysis, aecting
mobility, speech and respiration (Hardiman et al., 2011), as a result of selective motor
neuron (MN) death (Redler and Dokholyan, 2012; Rowland and Shneider, 2001). Of all
ALS cases, 5 – 10% are familial (Rowland and Shneider, 2001), which are associated with
mutations in the genes encoding for proteins including Cu,Zn superoxide dismutase
(SOD1) (Robberecht and Philips, 2013); SOD1 mutations account for about 20% of the
familial cases of ALS (Rosen et al., 1993).
e mechanisms behind the selective degeneration of motor neurons in ALS remain
unclear (see Chapter 1): oxidative stress, glutamate-mediated excitotoxicity, protein
aggregation and transition metal-induced toxicity (Cozzolino et al., 2008) appear to
contribute to its development. e toxicity induced by mutant SOD1 protein (mSOD1),
which leads to motor neuron death, is a toxic gain-of-function (Bruijn, 1998; Gurney
et al., 1994), due to an increased propensity to destabilise, aggregate and misfold without
adequate Zn and Cu coordination.
Essential trace elements (e.g., Cu and Zn) function as catalytic cofactors in
metalloenzymes (e.g., SOD1), and are toxic at high concentrations (Gaetke and Chow,
2003; Jomova and Valko, 2011; Valko et al., 2005). Within an organism, metal
concentrations are maintained within a tight concentration range by proteins which
mediate their uptake, distribution, storage and/or excretion (Hare et al., 2013; Tapiero
et al., 2003). Evidence suggests the involvement of transition metals, in particular Cu
(see Chapter 2), in the pathogenesis of neurodegenerative disorders, such as Cu and Fe in
Parkinson’s (Davies et al., 2014; Dusek et al., 2015; Hare et al., 2013; Larner et al., 2013),
and Cu, Fe and Al in Alzheimer’s disease (Greenough et al., 2013; House et al., 2012;
Kaden et al., 2011; Shore et al., 1984). However, the specic role of Cu and Zn homeostasis
in the toxic gain-of-function of mSOD1 associated with the development of ALS remains
unresolved (Roberts et al., 2014).
Copper isotopic ratios in blood and various organs were proposed to reect the overall
body Cu metabolism (Harvey et al., 2005; Lyon and Fell, 1990; Lyon et al., 1996; Turnlund
et al., 1989, 1982). Only recently have tools to test this become available. e naturally
occurring stable isotopes of Cu (65Cu/63Cu) are expected to distribute as a function of
their coordination and bond energy: the heavy isotopes are anticipated to be enriched
in the strongest bonds, since the vibrational energy decreases at higher isotope mass
(Albarède, 2015; Bigeleisen and Mayer, 1947). At a cellular level, it is therefore likely that
the Cu isotopic ratio is inuenced by Cu-specic cell ligands (Balter et al., 2013, 2015).
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Recent research has seen the application of medical isotope metallomics to a variety
of medical conditions (Albarède, 2015; Albarede et al., 2016; Costas-Rodŕıguez et al.,
2016). Important pilot studies were able to demonstrate the potential of medical isotope
metallomics as a medical diagnostic tool (see Chapter 3): Ca isotope ratios in blood
and urine were used as proxies for bone loss (Morgan et al., 2011, 2012), cancer disease
progression was traced via Cu and S isotopes in blood plasma (Balter et al., 2015; Télouk
et al., 2015), a correlation between liver cirrhosis severity and blood serum Cu isotope
ratios was discovered (Costas-Rodŕıguez et al., 2015) and breast cancer cells identied
via Zn isotopes (Larner et al., 2015). ese ndings support the hypothesis that other
disorders may produce Cu isotope signals that can serve as potential biomarkers.
AIMS AND OBJECTIVES OF THESIS
e overall aim of this thesis is to use medical Cu isotope metallomics to gain new insights
into ALS, and evaluate the potential of this approach to be used for the detection of an
(early) disease biomarker. To achieve this aim, the thesis uses a combination of analyses
of Cu isotope ratios and transition element concentrations in a mouse model of ALS
and samples from ALS patients. e work described in this thesis involved the following
objectives:
1) To develop a simplied, high-throughput automated Cu chromatography method,
capable of satisfying demand for large sample numbers for biomedical studies
(Chapter 4);
2) To investigate detectable ALS signals in key-organs of the well-characterised
SOD1G93A mouse model, using transition metal concentrations and Cu isotope
ratios as disease proxies (Chapters 5 and 6); and,
3) To evaluate transition metal concentrations in conjunction with Cu isotope ratios
in human blood and their potential to serve as a biomarker for ALS, due to their
perturbation by the disease (Chapter 7).
4
ORGANISATION OF THESIS
e thesis begins with a literature review of ALS (Chapter 1), Cu and its metabolism
(Chapter 2) and isotope metallomics (Chapter 3), contained within Part I. Following, in
Part II, is a description of themethods developed and used in this thesis (Chapter 4), which
also outlines the rationale behind developing an automated Cu chromatography method.
Within Part III, Chapters 5 through 7 present the ndings from the mouse and human
sample studies. Part IV concludes the thesis with Chapter 8 containing the thesis’ major
conclusions, along with limitations and areas of future research. Additional information,
referred to throughout the thesis is placed in Part V, which contains the appendices.
Appendix A, presents data, while details on the used certied reference materials and
relevant ethics approvals can be found in Appendices B and C, respectively.
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Begin at the beginning, the King said gravely,
and go on till you come to the end: then stop.





e Great Acceleration started about 1750 with the early beginnings of the industrial
revolution (Steen et al., 2007), and has led to a dramatic population increase on Earth to
the current ∼7 billion people. With a growing, as well as continuously ageing population,
diseases like Parkinson’s disease, frontotemporal dementia and amyotrophic lateral
sclerosis (ALS) present an increasingly signicant health and economic concern.
Amyotrophic lateral sclerosis is in most cases a fatal neurodegenerative disorder, and
classied as one of the motor neuron diseases (MND) due to its progressive paralysis of
the voluntary muscle groups. Pathological and clinical investigations of ALS have been
proceeding hand-in-hand since its rst description by Charcot and Joroy (1869).
Amyotrophic lateral sclerosis is currently the most common adult-onset MND
(Redler and Dokholyan, 2012), with a median incidence rate1 of 2.08/100,000 and a
median prevalence2 of 5.40/100,000 individuals (Chiò et al., 2013). e continued disease
progression of ALS leads to the denervation of skeletal and respiratory muscles.
Consequentially, this results in death, most commonly within ve years from diagnosis
(Pasinelli and Brown, 2006). At this point it has to be noted that the terms ALS and
MND are oen used synonymously, particularly in Europe (Rosenfeld, 2012). However,
in this thesis the term ALS is used to describe a multi-system disorder in which the
motor system is aected early and the patient’s symptoms are progressive (Strong, 2001);
MND is used to describe a general spectrum of disorders, involving the degeneration of
upper and/or lower motor neurons (UMN/LMN), which includes ALS (Rosenfeld, 2012).
A two-category system is used to classify ALS: familial ALS (fALS) and sporadic ALS
(sALS). e two are identical in their clinical expression, with the dierence being that
fALS is hereditary and in most cases autosomal dominant3, caused by mutations in one of
a heterogeneous set of identied genes (Chen et al. 2013; White and Sreedharan
2016; Table 1.1). It is rare for these mutations to be X-linked recessive4 (Andersen and
Al-Chalabi, 2011). Familial ALS patients, i.e., those who carry a mutation in an
1Incidence rate is dened as the measure of the frequency (probability) with which ALS occurs in
a population over a period of time. e denominator is the population at risk; the numerator is
the number of new cases occurring during a given time period.
2Prevalence describes the number or proportion of ALS cases in a given population.
3In an autosomal dominant disease, ospring may inherit the abnormal gene from one parent.
e child is therefore likely to express the disease.
4In an X-linked recessive disease, a mutation on the X chromosome may result in the expression
of the disease in male children (they are hemizygous, carrying both X and Y chromosomes) and
may result in the female children being carriers of the disease (carrying two X chromosomes).
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ALS-associated gene, who do not have any family history (or other family members
aected) are conventionally classied as sALS patients (Robberecht and Philips, 2013);
this also includes patients with no identiable genetic case of the disease. e major
pathophysiological hallmarks dening ALS are protein aggregation, neuroinammation,
as well as oxidative stress (Cozzolino et al., 2008; Ferrante et al., 2002). Whether oxidative
stress and neuroinammation are a possible primary cause of ALS, or the toxic result of a
chain of events, is still unclear. A proposed gain of pro-oxidant function for mutant
Cu,Zn superoxide dismutase 1 (mSOD1), rather than loss of anti-oxidant function
(Barnham et al., 2004), supports this hypothesis (see Section 1.5.1.1).
e classication of ALS as a solely degenerative disease of the motor system has
been challenged by the discovery of varying degrees of involvement of the prefrontal and
temporal cortex neurons (Ringholz et al., 2005), which may result in dysfunction of the
frontal lobe in up to 50% of patients (Strong, 2008; Strong et al., 2009). About 5 – 15% of
these patients are reported to develop ALS with frontotemporal dementia (ALS-FTD)
(Lomen-Hoerth et al., 2002; Redler and Dokholyan, 2012; Robberecht and Philips, 2013).
e symptoms of ALS, such as respiratory decline, result from the disruption and
ultimately failure of axonal connections, in which the axon retracts and denervation of the
LMNs occurs. is retraction occurs at a focal point of onset and then progresses outward
from this point (Ravits and La Spada, 2009). Initially compensation for the progressive
degeneration occurs by sprouting and collateral re-innervation by other surrounding
axons, which appear to be more resistant to neuronal degeneration (Saxena and Caroni,
2011). With disease progression this compensatory mechanism fails, and further disease
progression leads to the degeneration of previously unaected motor neurons. Aer this
initial stage of axonal dysfunction and retraction, neuronal cells become visibly abnormal
and die, as demonstrated in animal models (Fischer et al., 2004; Saxena and Caroni, 2011).
e age of onset of ALS is variable, but the majority of cases occur aer the fourth
decade of life. Very few cases occur at a juvenile stage; a set biological time of disease onset
is unknown (Robberecht and Philips, 2013). Transgenic rodent models (e.g., involving the
over-expression of mutations of mSOD1) have been used extensively to study ALS and
show that disease specic pathological abnormalities are present as early as the embryonic
stage of development (Amendola et al., 2004; van Zundert et al., 2008). Like human
patients, animal models do not display clinical symptoms until later stages of pathological
disease progression. erefore, it is assumed that in humans, the pathological onset of the
disease is much earlier in life than the apparent clinical expression.
Since the clinical expression occurs later than pathological onset, the diagnosis of ALS
in new patientsmust be sucient to rule out any other possible disease process with similar
clinical and electrophysiological symptoms (e.g., spinal muscular atrophy). Even though
the overall symptomatic prole and distribution of symptoms along the neuraxis can vary
considerably between individual patients (Rosenfeld, 2012) (Table 1.2), symptoms of upper
and lower motor neuron involvement are distinct (Strong and Rosenfeld, 2003). Accurate
diagnosis therefore depends upon the combination of specic ndings in a neurological
assessment (Table 1.3). For further information on diagnosis and management of ALS,















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1.2:e diversity of MND with regards to their pathological and symptomatic expression
(modied from Rosenfeld, 2012)
Disorder Pathology Symptoms Genetics Disease Course
Amyotrophic
lateral sclerosis

































































Sporadic Similar to bulbar













































Table 1.3: A diagnostic algorithm for ALS (modied from Ross et al., 1998)
e diagnosis requires the presence of each of the
following
e diagnosis requires the absence of the
following
• LMN signs in at least two regions • Sensory signs (except for age-appropriate)
• UMN signs in at least one region (bulbar,
cervical or lumbosacral)
• Neurogenic sphincter abnormalities
• Disease progression dened as a progressive
symptomatic impairment with time. May involve
the same or additional regions.
• Additional peripheral nervous system disease
with a natural history of progression (i.e.,
hereditary polyneuropathy)
• Additional CNS disease dierent to ALS with
a natural history of progression (i.e., dementia,
Parkinson’s)
• ALS-like syndromes (i.e., structural spinal
lesions, hyperthyroidism, lead poisoning and
history of radiation to brain and spinal cord
In addition to these neurological ndings, the literature presents cases of
geographical regions which display disproportionally high incident rates of MND
subtypes (i.e., Northern Sweden), indicating a potential for distinct aetiology in those
patients (Andrew et al., 2017; Bharucha et al., 1983; Cox et al., 2009; Horner et al., 2008;
Tesauro et al., 2017). Motor neuron diseases are unfortunately characterised by a variety
of clinical variabilities, for which distinct aetiologies have been proposed, such as genetic,
biomechanical, metabolic, cytoskeletal and inammatory mechanisms (Strong and
Rosenfeld, 2003). However, with the exception of toxic protein aggregation, the
biochemical mechanisms that underlie these aetiologies remain largely unclear at this
stage (Lovejoy and Guillemin, 2014). Other possible mechanisms include glutamate
excitotoxicity5(Rothstein, 2009), overproduction of reactive oxygen species (ROS) and
reactive nitrogen species (Barber and Shaw, 2010), mitochondrial dysfunction (Rothstein,
2009), endoplasmic reticulum stress (Atkin et al., 2008), axonal deterioration and
formation of toxic ubiquitinated neuronal inclusions (Arai et al., 2006; Rothstein, 2009).
It remains a great challenge to nd a common underlying reason accommodating the
heterogeneity for patients diagnosed with ALS and their clinical presentation. In addition,
it is unclear if the clinical spectrum reects dierent aetiologies with distinct pathogeneses
or multiple presentations of a single pathogenic mechanism (Rosenfeld, 2012). Many of
the proposed mechanisms appear to trigger a snowball eect and exacerbate each other
(Lovejoy and Guillemin, 2014) (Figures 1.1).
In ALS the spread of motor neuron death is progressive and is usually fatal within
three to ve years of diagnosis; however, there is large variability reported in the rate of
disease progression. Some patients are reported to have died a couple of months aer
diagnosis, while others (perhaps most famously the late Prof. Stephen Hawking), survive
for several decades (Pupillo et al., 2014). Dierences in disease onset, progression and
survival within family members displaying the identical genetic type of fALS, has led to
5Pathological process that damages and kills neurons through the over-activation of receptors for
































































































































































































































































































































































































































































































































































































the conclusion that other factors play a role (e.g., environmental factors), impacting on
the progression of the disease in an individual (Régal et al., 2006). In fALS, gender
appears to be of minor relevance in general and with regard to mean age of disease onset
or lifespan aer diagnosis. Contrastingly, in sALS, men show an earlier disease onset,
characterised by higher incidence and prevalence rates, as well as apparent dierences in
the clinical expression (men display a predominant onset in the spinal regions; women
display a predominant onset in the bulbar region) (McCombe and Henderson, 2010).
ese dierences might be explained by varying exposure to environmental toxins,
dierent responses to exogenous toxins and dierences in the nervous system and its
capability to repair itself (Andrew et al., 2017; Johnson and Atchison, 2009; Tesauro et al.,
2017; Vinceti et al., 2012, 2017). Such variable ndings have lead to extensive
epidemiological studies of the disease.
1.2 EPIDEMIOLOGY
ere are two particularly interesting epidemiological aspects concerning ALS. First,
ALS appears to be overall age dependent; its incidence and mortality rate increases with
increasing age (Hudson et al., 1986; Riggs, 1990). Earlier diagnosis of the disease expanded
the time span from disease onset/diagnosis to death, even though a universal biomarker
and treatment are yet to be developed. Secondly, ALS incident rates are predicted to
increase by 69% by 2040, mainly as a result of an ageing population (Arthur et al., 2016).
However, it was also hypothesised that an ageing population may not be sucient to
explain this increase (Durrleman and Alperovitch, 1989; Lilienfeld et al., 1954). Ageing in
developing nations is going to account for a large amount of this increase (Arthur et al.,
2016), but environmental and non-genetic factors (see review by Ingre et al. (2015)), such
as exposure to heavy metals and pesticides (Vinceti et al., 2012) have also been considered
triggers for the pathological cascade (Table 1.4), ultimately resulting in the development
of ALS symptoms. One notable example can be found in a cohort from Mount Etna, Italy,
where a higher incidence rate of ALS was reported, potentially due to the involvement
of volcanogenic trace elements Nicoletti et al. (2016). To-date no single environmental
or non-genetic factor has been identied as causative of fALS or triggers for sALS. On
the contrary, reports of apparent geographical clusters of sALS in Umeå, Sweden have
been attributed to a common underlying genetic origin, rather than an environmental
one (Mitchell, 2000). is raises the question as to whether fALS actually accounts for
more than the proposed 5 – 10% of all ALS cases, and if there may actually be a single
pathogenic mechanism for ALS.
1.3 CLINICAL EXPRESSION
Since its rst description by Charcot and Joroy (1869), ALS has been considered a
neurodegenerative disease with an overall homogenous clinical presentation of its most
common symptoms: muscle weakness and atrophy. ese symptoms were understood to
appear at a focal site and continue to spread along contiguous anatomical pathways
(Ravits and La Spada, 2009), and serve as diagnostic criteria for the description of the
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Table 1.4: A non-exhaustive list of potential environmental exposure factors hypothesised to be
associated with ALS
Exposure factor Reference
Athletic activity Bracco et al. 2009; Felmus et al. 1976
Exposure to toxins, i.e. metals and
fertilisers/pesticides
Abarbanel et al. 1989; Felmus et al. 1976; Hawkes
et al. 1989; Kamel et al. 2005, 2002; Norris and
Padia 1989; Provinciali and Giovagnoli 1990;
Strickland 1996; Su et al. 2016; Yu et al. 2014
Exposure to electro magnetic elds/electric
shocks
Davanipour et al. 1997; Noonan et al. 2002; Savitz
et al. 1998; Zhou et al. 2012
Manual labour Bracco et al. 2009; Gallagher and Sanders 1983;
Giagheddu et al. 2009; Granieri et al. 1988;
Gunnarsson and Palm 1984; Provinciali and
Giovagnoli 1990
Metabolic perturbance Garruto and Yanagihara 2009; Patten andMallette
1976; Plato et al. 1986
Military-service Gallagher and Sanders 1987; Haley 2003; Horner
et al. 2008
Nutrition/Diet Felmus et al. 1976; Garruto 1991; Garruto and
Yanagihara 2009; Garruto et al. 1985; Patten and
Mallette 1976
Pet exposure Norris and Padia 1989; Tarras et al. 1985
Physical and emotional stress Gallagher and Sanders 1987
Smoking and body weight Nelson et al. 2000; Yu et al. 2014
Surgery Angelini et al. 1983
Trauma Gallagher and Sanders 1987
clinical motor manifestation of ALS. However, the phenotypic expression of ALS and the
distribution of symptoms can vary greatly from patient to patient (Swinnen and
Robberecht, 2014). As a result, the diagnostic criteria is not able to address this
heterogeneity of symptoms found in ALS patients, with respect to progression,
localisation and impact on the quality of life (Rosenfeld, 2012). For example, in most
cases symptoms are motor in nature, however evidence from patients with mutations in
the C9orf72 gene show clinical characteristics well beyond the classical manifestation of
ALS and ALS-FTD; the presence of chorea (abnormal involuntary movement disorder)
and neuropsychiatric abnormalities may lead to a misdiagnosis of ALS as Huntington’s
disease (Hensman Moss et al., 2014). While some variability may be explained by the
mode and timing of diagnosis, as well as the diagnostician’s expertise with ALS, the
majority appears to be indicative of a variability in vulnerability of certain motor neurons
over others (Swinnen and Robberecht, 2014). Highly variable disease presentation has
been observed even in families with a monogenetic cause of ALS, indicating the presence
of disease-modifying factors (Régal et al., 2006), possibly of environmental nature.
is variable disease presentation has wide-reaching implications:
a) ere may be a potential for variable responses to therapy, possibly meaning that
a variety of treatments will have to be developed and tested based on genotypes,
phenotypes and environmental triggers;
b) Uniform biomarkers independent of specic disease genotypes and phenotypes
have to be identied through the study of carefully and uniformly genotyped and
phenotyped patient populations; and
c) ere is an urgent need for early disease biomarkers, as the same symptoms could
indicate varying stages of development for dierent phenotypes. While the
challenges of nding a potential cure ahead are signicant, it may be possible to
treat the disease one day, slow its progression and ultimately halt its development
altogether.
1.4 NEUROPATHOLOGY
Amyotrophic lateral sclerosis is staggeringly complex on a sub-cellular level
(Figures 1.1 and 1.4). It includes abnormalities in almost every cellular compartment,
many of which are undoubtedly secondary eects or compensatory mechanisms.
Unfortunately, these eects do not aect all motor neurons equally. For example, lower
motor neurons in the ventral horns in the spinal cord, facial nerve, motor trigeminal,
ambiguous and hypoglossal nuclei in the brainstem (Highley and Ince, 2012) are aected,
while the oculomotor cranial nerve nuclei (Okamoto et al., 1993) and the nucleus of
Onufrowicz are spared (Kihira et al., 1997), which leaves terminal stage patients with
intact vision, as well as urinary and bowel movement.
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Evenwith the current level of knowledge and 20 years of extensivemolecular searching,
the trigger of ALS is yet to be found. Whilst this complexity could be seen as a hindrance
to research, it may also be regarded as an opportunity to commit and solve the puzzle
of ALS. Key biochemical processes as proposed to-date, contributing to the complex
neuropathology underlying ALS, are briey discussed below.
1.4.1 Impaired protein degradation
Protein aggregates are hallmarks of many neurodegenerative diseases, including
Alzheimer’s, Parkinson’s and Huntington’s disease (Ciechanover and Kwon, 2015; Soto,
2003). In ALS it is assumed that oligomeric precursors of these aggregates disturb normal
protein homeostasis (proteostasis), including protein degradation in the cell (Bendotti
et al., 2012; Saxena and Caroni, 2011). is can interfere with cellular functions and lead
to cell death via apoptosis (Figure 1.1).
Aggregated forms of mSOD1 and other ALS-associated proteins, such as mutant
transactive response DNA-binding protein 43 (mTDP-43) and mutant Fused in Sarcoma
(mFUS), have the ability to interfere with proteostasis and particularly with the protein
degradation pathways in the cell (i.e., the ubiquitin-proteasome-system and autophagy)
(Yerbury et al., 2016) (Figure 1.1). Progressive cellular failure is characterised by protein
clumping, aggregate and inclusion formation, endoplasmic reticulum stress and disruption
to Golgi and mitochondrial function. is results in loss of axonal function, leading
to the retraction of the axon and denervation of neurons or muscles (Robberecht and
Philips, 2013). is retraction and denervation is one of the factors that plays a key role
in determining the phenotype of ALS, and it occurs long before the loss of cell bodies
(Fischer et al., 2004; Schmidt et al., 2009).
1.4.2 Inclusions
e literature on ALS neuropathology presents a vast variety of protein aggregates and
(inclusion) bodies found in ALS patients, such as Bunina Bodies (Mori et al., 2010; Piao
et al., 2006), Hyaline conglomerate inclusions (Highley and Ince, 2012; Ince et al., 1998)
and Axonal speroids (Carpenter, 1968; Sobue et al., 1990).ese inclusions, predominantly
consisting of ubiquitinated aggregates, classied as Lewy body-like hyaline inclusions
or skein-like inclusions (Blokhuis et al., 2013), are found in degenerating motor neurons
and other parts of the brain, and remain poorly understood hallmarks of fALS and sALS
patients. In the past 20 years, an ever-growing number of mutations have been linked
to ALS (Table 1.1), which oen only implicate a small subgroup of patients. Interestingly,
many of these proteins are found in non-mutation associated inclusions (Blokhuis et al.,
2013), giving rise to speculation of the wider involvement of protein aggregation in ALS
pathogenesis. Recent ndings suggest thatmetastable proteinsmay be prone to aggregation
and could tigger the breakdown of cellular proteostasis (Ciryam et al., 2017).
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1.4.3 Direction of degeneration
Classication of motor neuron death remains controversial within ALS (Baker, 2014). It
had been assumed that the process is a ‘dying forward’ process (Braak et al., 2013; Eisen
and Weber, 2001) whereby the dysfunction of the motor neuron leads to apoptosis and
associated denervation of the motor endplates, independent of input from surrounding
cells. However, studies aimed at trying to gather evidence for this hypothesis have failed
to do so. Rather, it has been demonstrated that neuron-specic expression of high
concentrations of human mSOD1 is not sucient to cause ALS in mice (Lino et al., 2002;
Pramatarova et al., 2001). Further work has demonstrated that surrounding cells, i.e.,
astrocytes (Yamanaka et al., 2008), microglia (Boilee et al., 2006) and Schwann-cells
(Turner et al., 2010), targeted by knock-out experiments, do aect (either speeding up or
slowing down) the disease progression. us, non-neuronal cells do inuence ALS
pathology and disease progression, suggesting that the originating site of dysfunction
might not be the motor neuron itself (Redler and Dokholyan, 2012) and that phenotypes
may be aected by non-neuronal cell interactions.
When mSOD1 is only expressed in mouse muscle tissue, animals developed early
motor decits, followed by neuromuscular junction dismantlement with motor neuron
loss occurring late in disease progression (Wong and Martin, 2010). Being able to provoke
motor neuron degeneration through muscle-restricted mSOD1 expression, accompanied
by neuromuscular denervation, strongly suggests ALS involves a ‘dying back’ process
(Kiernan et al., 2011): as motor neurons were not the initiating locus of the degeneration,
distal axonal degeneration may precede neuronal degeneration (Fischer et al., 2004).
Studies have provided growing evidence for the ‘dying back’ hypothesis (Redler and
Dokholyan, 2012). Further work indicates that microRNA found in skeletal muscle may
be able to slow down disease progression through the detection of motor neuron injury
and promotion of compensatory regeneration of neuromuscular synapses in mSODG93A
mice (Williams et al., 2009). is highlights that skeletal muscle might play a bigger role
in the development of ALS than previously thought.
1.5 CU,ZN-SUPEROXIDE DISMUTASE 1
Cu,Zn-Superoxide dismutase 1 (SOD1) is a ubiquitous cytosolic enzyme, that can bind
one copper atom and one zinc atom (Fridovich, 2006). It exists as a homodimer via an
intermolecular disulphide bond (Ahuja et al., 2015).e formation of this disulphide bond
is promoted by the Cu chaperone for SOD1 (CCS), which incorporates Cu into apo-SOD1
(Ahuja et al., 2015), leading to oxidation of an intra-subunit disulphide bond (Seetharaman
et al., 2009).e exceptional structural stability of SOD1 is the result of coordination of the
Zn and Cu atoms by three histidine residues and one aspartic acid residue (Doucette et al.,
2004). ese processes are mutually interdependent: metal binding promotes disulphide
bond formation, disulphide bond formation and metal binding promote dimerisation,
and dimeric SOD1 is very resistant to disulphide reduction and metal loss (Ding and
Dokholyan, 2008; Doucette et al., 2004) (Figure 1.2).
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In SOD1, the Cu atom is responsible for its catalytic activity. When reduced, the
atom is coordinated by three histidine residues, whereas when in the oxidised state it is
coordinated by a fourth bridging histidine (shared with the Zn ion) (Ahuja et al., 2015;
Valentine et al., 2005) (Figure 1.2). It is assumed that the main function of SOD1 is free
radical scavenging via superoxide dismutation, whereby superoxide (O2−), a reactive
oxygen species (ROS), generated as a product of mitochondrial respiration, is converted
to hydrogen peroxide (H2O2) and oxygen (O2) (Equations 1.1 and 1.2):
SOD1 − Cu2+ + O−2 → SOD1 − Cu
+
+ O2 (1.1)
SOD1 − Cu+ + O−2 + 2H
+
→ SOD1 − Cu2+ +H2O2 (1.2)
e H2O2 produced by this reaction is further converted into O2 and H2O, by the
enzymatic action of catalase or glutathione peroxidase (Xu, 2000).
1.5.1 Mutations in SOD1 associated with ALS
Gene mutations in SOD1 account for 15 – 20% of all hereditary ALS cases. Over 160
dierent mutations in SOD1 have been identied (Sreedharan and Brown 2013, and also
see http://alsod.iop.kcl.ac.uk, Wroe et al. (2008)). Many of these mutations are associated
with specic disease phenotypes (Table 1.5), correlating with specic rates of disease
progression (Rosenfeld, 2012), and pathology (such as the presence of inclusions) (Ince
et al., 1998; Tan et al., 2004).
It is generally accepted that SOD1 mutations are toxic, which was demonstrated to
not be the result of a general loss of function, but rather a toxic gain-of-function (Bruijn,
1998; Gurney et al., 1994). is neurotoxic property is believed to result from an increased
propensity of mSOD1 to misfold and aggregate, a function of the decreased stability of
the homodimer, and/or a tendency to lose the stabilising post translational-modication
(Redler and Dokholyan, 2012) (Figure 1.3). It remains unknown, which post-translational
modications malfunction to make SOD1 aggregate (Furukawa et al., 2008). While this is
assumed to be the primary pathogenic mechanism, there is no conclusive understanding
of the denitive process by which this toxicity occurs; there is a potential that it occurs via
perturbations in DNA and/or RNAmetabolism, mitochondrial function, axonal transport
and maybe even immunologically-mediated pathways (Beleza-Meireles and Al-Chalabi,
2009; Kabashi et al., 2007; Pasinelli and Brown, 2006; Rosen et al., 1993; Siddique et al.,
1991; Valentine et al., 2005).
In familial cases of SOD1-related ALS, the activity of SOD1 was measured to be
lower in lymphoblasts (Deng et al., 1993; Pramatarova et al., 1995), suggesting a loss of
SOD1 function as the underlying mechanism. Later studies demonstrated a toxic gain-of-
function for mSOD1 by:
1) the development of ALS in mSOD1 transgenic mice with greater-than-normal
SOD1 expression (level of superoxide dismutase activity unchanged) (Gurney et al.,











Figure 1.2: Crystal structure of the G37R mutant human Cu,Zn Superoxide dismutase 1 dimer
(Eisenberg et al., 1998). Copper and zinc atoms are represented by orange and blue spheres,
respectively (A). Panels B and C show the coordination of the Cu and Zn. Copper is coordinated
by three histidine residues, while Zn is coordinated by three histidine and one aspartate residues.
Molecular graphics rendered with the UCSF Chimera package (Pettersen et al., 2004).
Abbreviations: Asp: aspartate; His: histidine.
Table 1.5: Phenotypic variability of SODmutations in familial ALS
(modied from Rosenfeld, 2012)
Phenotype SOD1 mutation
LMN predominant A4V, L84V, D101N
UMN predominant D90A
Slow progression G37R (18 years), G41D (11 years), G93C, L144S, L144F
Fast progression A4T (1.5 years), N86S (5 months), L106V (1.2 years),
V148G (2 years), G93A (3 years)
Late onset G85R, H46R
Early onset G37R, L38V
Female predominant G41D
Bulbar onset V148I
Low penetrance⋆ D90A, I113T
Posterior column involvement† E100G
⋆ the frequency with which a heritable trait is manifested by individuals carrying the
principal gene or genes conditioning it




































Figure 1.3: Schematic diagram of the molecular processes triggering aberrant oligomerisation of
SOD1. (I)Unfolded, freshly nascent, apo-SOD1 (nometals). (II) Foldedmonomeric apo-SOD1. (III)
Native dimeric SOD1, binding Cu and Zn. (IV) Intermediate folded state, destabilised monomeric
apo-SOD1. is partially folded state acts as the gateway to oligomerisation a pathologic hallmark
in ALS. (V) Non-native dimer or oligomer. e arrows indicate equilibria, with their boldness
indicating the balance across each equilibrium. is balance is unique to specic mutations.
Molecular graphics rendered with the UCSF Chimera package (Pettersen et al., 2004).
2) the fact that the presence ofmSOD1, which had retained its normal levels of enzyme
activity, does not aect the availability and stability of the wild type SOD1 enzyme
(Borchelt et al., 1995, 1994);
3) the over-expression or knock-out of wild type SOD1 in transgenic mice, does not
cause ALS disease pathology. is leads to the conclusion that neither an increase
nor decrease in SOD1 activity is the reason for the development of the disease
(Gurney et al., 1994; Wong et al., 1995);
4) the over-expression or knock-out of wild type SOD1 in mSOD1 mice does not
change disease progression, indicating that neither an increase nor decrease of wild
type SOD1 inuences the progression of the disease (Bruijn, 1998).
is accumulation of evidence conclusively demonstrates that it is not a change in the
level of SOD1 activity that leads to the development of the disease, but rather a gain of
toxic property of mSOD1.
1.5.1.1 SOD1 toxicity
ere are three major hypotheses postulated to explain the toxic properties of mSOD1,
which induce motor neuron degradation (Durham et al., 1997).
First, mSOD1 may damage cells by producing peroxynitrite (ONOO−), an oxidant
and nitrating agent (Estévez et al., 1999).is production is possibly a result of a decreased
anity of mSOD1 for Zn , causing a structural change, enabling the reduction of Cu2+
to Cu1+ by cellular antioxidants (Beckman et al., 1993). is mechanism has so far only
been demonstrated in vitro, where Zn-decient SOD1 is a signicantly toxic form of
SOD1: Zn-decient mSOD1 and Zn-decient WT SOD1 are both toxic to motor neurons
due to their capacity to promote peroxynitrite mediated damage (Estévez et al., 1999).
While it was proposed that the protein neurolament subunit-L (NF-L), which is part
of the axoskeleton and plays a role in the intracellular transport to axons and dendrites,
could enhance this process by removing Zn from mSOD1 (Estévez et al., 1999), it was
subsequently shown in mice with increased concentrations of NF-L, that this does not
play a signicant role in vivo (Kong and Xu, 2000).
Second, mSOD1 may damage cells as a result of the mutations enhancing its
peroxidase activity (Wiedau-Pazos et al., 1996; Yim et al., 1996). is is thought to be
through catalysing the oxidation of a spin trap compound DMPO
(5,5’-dimethyl-1-pyrroline N-oxide), a by-product from oxygen metabolism, in the
presence of H2O2 (Pham et al., 2013). While there are some data to support this, including
an elevated amount of derivatives from oxidative damage of nucleic acids, proteins and
lipids in human ALS and mouse models (Ferrante et al., 2002; Liu et al., 1998), the exact
mechanism is still unclear and it has not been demonstrated that such a mechanism
would be capable of damaging biologically relevant molecules in vivo (Xu, 2000).
With regards to the two hypotheses discussed above, no one has yet been able to
provide a denitive explanation for the toxicity of mSOD1 (Figure 1.4). Reactive oxygen
species (for a comprehensive review of ROS see Halliwell and Gutteridge, 2015), which are
involved in both the above proposed mechanisms, can originate as by-products from a
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wide range of aerobicmetabolic processes (Coyle and Puttfarcken, 1993; Halliwell, 2006a,b;
Lenaz et al., 2002). Many studies have found evidence of increased oxidative stress in
ALS pathogenesis (Barber et al., 2006; Barber and Shaw, 2010). e majority of ROS
present in a cell are a direct result of leakage from mitochondrial respiration, which
increases as a function of age (Genova et al., 2004; Lenaz et al., 2002). e late onset of
ALS could be related to the age-dependent increase of ROS. Additionally, mSOD1 could
also negatively aect the endoplasmic reticulum, increasing ROS production (Saxena
et al., 2009). Whether these increases of ROS trigger a down-stream cascade of neuronal
degeneration or reect upstream events related to the mutated enzyme, is not yet known
(Xu, 2000). e common element in both these hypotheses is a role for Cu (Xu, 2000).
us, a crucial aspect of these hypotheses is to understand whether Cu is required for the
development of mSOD1 toxicity.
ird, a growing body of evidence has demonstrated a common propensity of
mSOD1 to misfold and aggregate, and proposed that this is the primary toxic
gain-of-function pathway (Redler and Dokholyan, 2012). Analyses of in vitro mSOD1
behaviour and fALS patient survival demonstrated that protein instability and increased
aggregation rates correlate with decreased survival time (Byström et al., 2010; McAlary
et al., 2016; Wang et al., 2008). e presence of proteinaceous aggregates in motor
neurons of ALS patients (Gruzman et al., 2007) led to the conclusion that ALS is a protein
conformational disorder, similar to other neurodegenerative diseases (Bruijn et al., 2004).
In general, SOD1 aggregation in ALS can be understood as a process in which dimer
dissociation and associated subsequent metal loss (and/or disulphide reduction) result in
structural distortions, favouring the assembly of non-native oligomers (Teilum et al.,
2009) (Figure 1.3). e direct relationship between SOD1 aggregation, aggregate structure,
mechanism of formation and toxicity with ALS is currently unknown.
1.5.2 Increased vulnerability of motor neurons to mSOD1
compared to other cells
Even though SOD1 is a ubiquitously expressed protein, and its mutant forms are similarly
as wide spread as the non-mutated protein, motor neurons appear to be most susceptible
to perturbations incurred by mSOD1. Several studies have tried to answer the question
of this selective vulnerability. One proposed reason is that there are naturally higher
concentrations of SOD1 found in neuronal cells (Liu et al., 1998). Opposing this hypothesis
is that other neuronal cells exist that similarly express high concentrations of SOD1, such
as pyramidal neurons in the hippocampus (Rothstein et al., 1999), however, these are not
aected by ALS.
A second possibility could be the large size of motor neurons: they are the largest
neurons with the longest axons in mammals (up to 1 m length in some instances). is
also means that they require a high metabolic rate (e.g., to produce enough energy for
active transport along the axons), resulting in an increased presence of ROS. Transfection
of sciatic nerve cells (largest nerve) in G93A mice, led to motor neuron atrophy and
an increase in the number of small axons (<4.5 µm) (Kong and Xu, 1999). When the
ALS end-stage was reached in these mice, it was observed that the newly formed small
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A) Ca release by RyR, IPTR
B) RyR channel opening
Glutamate
excitotoxicity
Figure 1.4: Complex pathological processes in SOD1-related fALS are highly interrelated and
many appear to be the direct consequence to SOD1 misfolding/aggregation and cytosolic calcium
overload (modied from Redler and Dokholyan, 2012).
Abbreviations: AMPA: Ca2+-permeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid;
ASK1: apoptotic protein kinase; ETC: electron transport chain; NOS: nitric oxide synthase; Rac1:
Ras-related C3 botulinum toxin substrate 1; RNS: reactive nitrogen species; ROS: reactive oxygen
species; RyR: Ryanodine receptors; UTR: untranslated region; VDAC: voltage-dependent anion
channel; VEGF: vascular endothelial growth factor.
axons had been spared by the disease, while the remaining large axons had degenerated at
the expected rate, suggesting that size is a contributing factor to susceptibility in motor
neurons (Kong and Xu, 1999).
A third possibility for why mSOD1 is selectively toxic to motor neurons is due to
the complex structure of motor neurons once again, due to their large size. As motor
neurons rely heavily on intracellular transport of cellular organelles, mSOD1 might have
an indirect eect on them by compromising mitochondrial function (see Section 1.5.1.1).
is could lead to general reduction of transport- and metabolic rates, leading to disease
(Crow et al., 2002; Warita et al., 1999; Williamson and Cleveland, 1999).
1.5.3 The G93A mouse model
Disease models in mice have been developed in the last century as the primary
mammalian model system for genetic research (Hardouin and Nagy, 2001). Even though
yeast, worms and ies are excellent models for studying cell cycles and many
developmental processes in diseases, mice are much more suitable to test the immune,
endocrine, nervous, cardiovascular, skeletal and other complex physiological systems,
common to mammals. Mice also oer the ability to manipulate and analyse the genome
with ease, whilst being of close genetic and physiological similarity to humans, are
relatively cheap to maintain and reproduction is fast (Vandamme, 2014). While mice
develop diseases similarly to humans (e.g., cancer), diseases that aict humans but
normally do not develop in mice, such as Alzheimer’s or ALS, can be modelled by
manipulating the mouse genome and environment.
For ALS, a plethora of inbred and genetically engineered mouse models exist
(e.g., G93A, G85R) (Julien and Kriz, 2006; McGoldrick et al., 2013; Turner and Talbot,
2008), which generally reproduce many features of ALS in humans. Shortly aer the
discovery of the involvement of mSOD1 in fALS (Rosen et al., 1993), a transgenic mouse
model was developed. is model over-expresses 20 – 24 copies of the human SOD1
coding sequence with the G93A mutation (a glycine-to-alanine change at residue 93)
under control of the human SOD1 promoter, compared to the expression of regular SOD1
(Gurney et al., 1994; Turner and Talbot, 2008). is provides a primary disease model,
which is a good human analogue, replicating many key aspects of human ALS
(McGoldrick et al., 2013). It further provides a very well dened timeline of symptomatic
progression (i.e., onset of paralysis at 90 d) which compares well with human ALS
pathology (Synofzik et al., 2010), making it an ecient model for the study of ALS
(Acevedo-Arozena et al., 2011; Durham et al., 1997).
In this model the phenotypical disease onset is generally observed aer ∼3 months,
with a disease duration of 1 – 2 months (Gurney et al., 1994) (Figure 1.5); pre-symptomatic
features, such as changes to neuromuscular transmission and increased expression of
metallothionein isoforms in spinal cord tissue, have been observed (Rocha et al. 2013;
Saxena et al. 2009; Tokuda et al. 2007; Zhou et al. 2015). Since the development of this
model, over twenty other SOD1 models have been created and SOD1 transgenic rodents
have been used as the primary rodent models of ALS. e most rapid progression of ALS



















Figure 1.5:Clinical and neuropathological hallmark events in the transgenic G93Amousemodel of
ALS over time: the onset of molecular changes precedes the onset of symptoms by several months.
By about 90 d, the phenotypical expression of the disease becomes apparent, predominantly
marked by initial tremors leading to advanced paralysis (modied from Turner and Talbot 2008).
Abbreviations: ER: endoplasmatic reticulum; IPC: insoluble protein complexes; NMJ:
neuromuscular junction; UPS: ubiquitin-proteasome system.
Chaperone-for-SOD (CCS) in SODG93A mice. ese animals die of ALS at about 30 – 50
days, which is about eight times faster than those without expression of human CCS (Son
et al., 2007).
Findings in the SOD1G93A mSOD1 mouse model, as well as others (e.g., SOD1G85R,
see Table 1.5) have been used extensively to demonstrate the development of
pre-symptomatic pathological changes, such as vacuolation, astrogliosis, SOD1
aggregation, fragmentation of the Golgi apparatus and neurolament accumulation in
proximal axons (e.g., Bruijn et al., 1997; Bruijn, 1998; Wong et al., 1995). Further work
demonstrated that cell death is non-autonomous, as astrocytes and microglial cells,
whose activation could result in neuroinammation (Philips and Robberecht, 2011),
contribute to disease onset and progression (Ilieva et al., 2009).
In order to obtain an overall picture of the consequence of pathological events and
their correlation with symptomatic progression, detailed studies were completed with
transgenic G93A mice at various stages of disease progression (Kong and Xu, 1998; Levine
et al., 1999). Two important ndings resulted from these studies. First, it was discovered
that massive motor neuron loss does not occur during the early stages of the disease,
but rather towards the end-stage, suggesting that there may be an important therapeutic
time window whereby motor neurons could be rescued from degeneration aer disease
diagnosis. Second, widespread mitochondrial abnormalities occur at pre-symptomatic
stages, accompanied by massive mitochondrial vacuolation (Kong and Xu, 1998). e
number of vacuolation peaks at disease onset and declines gradually with its progression,
suggesting that mSOD1 toxicity targets mitochondria. e question remains as to how
mSOD1 toxicity damages mitochondria.
1.6 BIOMARKERS FOR ALS
A biomarker is dened as a characteristic or parameter which can be objectively
measured, acting as an indicator of biological and pathogenic processes, or
pharmacological responses to therapeutic intervention (Bowser et al., 2012; Strimbu and
Tavel, 2010). Since the rst proposal (Poser, 1965), a variety of ALS biomarkers have been
proposed (Bowser et al., 2011; Ryberg and Bowser, 2008; Turner et al., 2009), oen
resulting from advances in molecular biology, its techniques and other technological and
medical advances. It is attractive to pursue the concept of the ‘ALS signature’, potentially
leading to preventative intervention. However, challenges are posed by the clinical and
genetic heterogeneity of ALS, identication of at-risk populations and where the clinical
horizon lies in relationship to early pathologies. is understanding is crucial for any
meaningful interpretation of such biomarkers (Bowser et al., 2012).
e ideal biomarker characteristics for ALS are summarised in Table 1.6. Due to ALS’s
complex pathologic nature, it is important to assess whether a bio uid and/or tissue can be
used for the assessment of the sine qua non feature of ALS (degeneration ofmotor neurons).
All easily accessible bio uids and tissues are remote from the proposed source of the
disease. In the absence of a non-destructive biopsy of the central nervous system, readily
available muscle tissue or blood may have to serve as a biomarker (Bowser et al., 2012).
Available bio uids include urine, blood, salvia and cerebrospinal uid. Urine and saliva
are non invasive to collect and have the least molecular complexity (Bowser et al., 2012).
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Table 1.6:e optimal ALS biomarker (adapted from Bowser et al., 2012)
1. Sensitive and specic for the heterogeneous syndrome of ALS
2. Detectable before the onset of signicant atrophy/weakness
3. Discriminate between clinical phenotypes based on:
a) ULM and LMN involvement
b) Patterns of regional involvement
c) Cognitive involvement
d) Extremes of survival
4. Able to predict regional involvement and the pattern of spread in advance:
a) Bulbar dysfunction for early percutaneous endoscopic gastronomy
b) Respiratory dysfunction for early non-invasive ventilation
c) Cognitive impairment
5. Change in a predictable way with disease progression
6. Sensitivity to condentially judge therapeutic response within weeks of challenge
7. Easily accessible and aordable technology
8. Practical to measure in the physically disabled patient
Unfortunately they are distant from theCNS pathology and undergo signicant proteolysis
before ‘being ready to be sampled’. Blood is closer, while cerebro-spinal-uid (CSF) is
closest to CNS pathology. ese latter uids though are of high molecular complexity
and have a higher invasiveness in terms of their sampling requirements compared to
saliva and urine.
When assessing metal homeostasis in these bio uids, blood is the most understood,
with research demonstrating its prognostic and monitoring capabilities in relationship to
general and neurodegenerative diseases (e.g., Hendriks et al. 2017; Huynh and Mohan
2017; Jones and Jarvis 2017; Misra et al. 2017; Nisenblat et al. 2016). In ALS, it is unlikely
that CNS-based pathological processes are captured in a systemic compartment like
blood (Turner et al., 2009) (see Chapter 7). Even when CSF is analysed, issues remain:
CSF is a complex uid containing thousands of proteins with signicant variations in
concentration range (Hühmer et al., 2006), which uctuate depending on the time of the
day. Clean sampling is dicult with the introduction of blood or other artefacts being a
concern during the spinal tap procedure (Bowser et al., 2012). However, it is likely that a
CSF-based marker cannot fully envelope a heterogeneous disease such as ALS, and others
are needed in a multimodal approach (Ryberg and Bowser, 2008). Here lies the chance for
a CSF-based metal homeostasis marker to establish itself, as disrupted metal homeostasis
could be an underlying cause of ALS; the ALS signature, so to speak. In contrast with
organic biomarkers which degrade with time, isotope compositions of metals can be
analysed on biological samples years aer the samples have been taken.
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is chapter has reviewed and discussed the key principles of ALS, identifying a
general mechanism leading to mSOD1 aggregation, development of a toxic-gain-
of-function and establishment of symptoms. e reason behind the toxic-gain-
of-function still remains to be established. Proposed mechanisms include a potential
malfunction of metal binding within the mutant form of SOD1, based on ndings that
the mSOD1 aggregates are largely partly-metallated. is identies Cu as a potential
treatment target with either the holo- or apo-SOD1 forms as the subjects of interest. To
understand a potential Cu metabolic disruption as a disease trigger, the longitudinal





Copper is a reddish brown, tough, malleable, ductile metal, which is a good conductor
of heat and electricity. Elemental Cu oxidises with a green coating of hydroxy carbonate
and/or hydroxyl sulphate by the absorption of CO2 or SO2 from air in moist conditions.
It has been used by humans as long ago as ∼9000 BC in the Middle East (Hesse, 2007),
for its ability to be worked with stone tools available at the time.
Copper is commonly found in the environment at an average concentration of
50 µg g−1 in the Earth’s crust (Emsley, 2003). Anthropogenic sources of Cu, such as
mining, metal and electrical manufacturing, agricultural and domestic discharge through
pesticides and fungicides (Nicholas Hewitt and Rashed, 1990; Rice et al., 2002; Shaheen,
1975), can enrich the natural occurrence of Cu by up to 100-fold.
2.1 CHEMICAL CHARACTERISTICS
Copper is the 29th element on the periodic table. Its most common and stable isotopes are
63Cu and 65Cu with abundances of 69.17% and 30.83% respectively (Emsley, 1988). ere
are 27 further radioactive isotopes, which generally undergo β-decay with short half-lives
of mostly under one minute: 67Cu is the most stable with a half-life of 61.83 h. Copper is a
transition metal characterised by a low redox potential between Cu2+ and Cu+, and can
be found in four oxidisation states (I – IV): Cu+ (cuprous ion) and Cu2+ (cupric ion) are
of high signicance to biological processes, while Cu3+ and Cu4+ are rare and have little
to no relevance in biochemical processes (Daniel et al., 2004). Further comprehensive
information on the general biochemistry of Cu beyond the scope of this thesis, is provided
by Cotton et al. (1999), Linder (1991) and Emsley (1988).
2.2 ABUNDANCE OF COPPER
Copper is one of themost abundant elements on the planet. It has been estimated that there
is ∼15×1017 kg of Cu on Earth, most commonly found in the mineral form of chalcopyrite
(CuFeS2), which accounts for about 80% of its worldly abundance (Emsley, 1988). Only a
small fraction is present in living organisms: ∼2.9×1010 kg in plants and ∼2.4×105 kg in
animals (Nriagu, 1980).
e overall concentration of Cu in living organisms is ∼2 µg g−1 (Table 2.1). Within
multicellular organisms and organisms with distinct organs and departments, the Cu
concentration varies substantially between compartments. In humans, little Cu is stored
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Table 2.1: Copper concentrations in select living organisms
Organism Cu concentration (µg/g) wet weight References
Human, adult 1.7 Underwood, 1977
Animals⋆, adult 1.5−2.5 † Underwood, 1977
Animals⋆, newborn 2.9−4.3 † Underwood, 1977
Fish (sea) 2−3 Souci et al., 1981
Fish (freshwater) 0.4−3 ‡ Linder, 1991
Insects 3−31 ‡ Linder, 1991
Plant roots 0.5−1.5 Souci et al., 1981
Plant stems 0.5−1.5 Souci et al., 1981
Plant leaves 0.3−0.7 Souci et al., 1981
⋆ pig, cat, rabbit and rat
† concentration in fat free tissue
‡ dry-weight × 0.25
in the body compared to other trace metals. e total content of Cu in the body is
∼100 mg, which is predominantly stored in the musculoskeletal system, due to its large
size (53% of total body mass, contains 56% of total Cu) (see Table 2.2). However, the
liver, followed by the brain, kidneys and the heart have the highest concentrations of
Cu (Table 2.2) (Turnlund, 1998). e trends found in humans are somewhat similar in
mice (Table 2.3), where it has been shown that the liver, brain and kidneys have the
highest concentration of Cu, and these are similar concentrations to those in humans
(Balter et al., 2013; Linder, 1991).
Overall, themajority of Cu in the human body is functional, due to its aptitude to cycle
between its oxidised and reduced forms. It acts as a cofactor to various redox enzymes
and is involved in >300 oxidative reactions (Crisponi et al., 2010). One of the best known
cupro-proteins is ceruloplasmin (CP), which at the same time is proposed to bind most
Cu transported in blood (Musci et al., 1999). A selection of the major and most important
enzymes and proteins which incorporate Cu as a crucial part of their biological activity is
listed in Table 2.4 (Linder and Hazegh-Azam, 1996).
In blood, 40 – 70% of the Cu is bound to CP which has six Cu2+ binding sites
(Kosman, 2002; Linder, 2016). e remaining plasma Cu is bound to albumin (10 – 15%)
and transcuprein/macroglobulin (5 – 15%) (Linder, 1991, 2016). Additionally, Cu plays
important non-enzymatic roles, e.g., in angiogenesis (development of blood vessels from
existing blood vessels) (Lane et al., 1994), during pregnancy and early human brain
development, as well as in cancer pathology (Linder, 1991, 2016).
Copper stores are replenished through a tight control of Cu metabolism, whereby
the majority of Cu is taken up through the small intestine (Linder, 1991). Uptake of Cu
in the stomach has been observed in rats: a substantial portion (∼30%) of a dose of 0.01 –
0.06 µmol 64Cu2+ placed in the stomach and other parts of the digestive tract was absorbed

























































































































































































































































































































































































































































































































































































































































































































































































































Table 2.3: Comparison of Cu concentrations: humans and mice
Tissue/Organ Copper concentration (µg/g)⋆ wet weight
Human Mouse
Linder, 1991† Linder, 1991† Balter et al., 2013‡ Kuo et al., 2006a
Kidney 12 ± 7 (19) 4.4 ± 1.1 (3) 12.7 ± 2.7 (5) 2.8 ± 0.4
Liver 6.2 ± 0.8 (9) 4.1, 4.7 (2) 15.8 ± 4.8 (10) 9.0 ± 2.3
Brain 5.2 ± 1.1 (10) 4.0 ± 2.1 (4) 18.5 ± 3.0 (4) 1.7 ± 0.7
Heart 4.8 ± 1.9 (14)
Bone 4.1 ± 1.3 (8) 0.8 ± 0.2 (4)
Stomach 2.2 ± 0.7 (7)
Intestine 1.0, 0.3 (2) 1.7 (1) 5.3 ± 1.4 (4)
Spleen 1.5 ± 0.4 (14) 1.2, 4.2 (2) 3.7 ± 0.6 (4)
Lung 1.3 ± 0.4 (11) 3.9 (1)
Blood 1.11 ± 0.13 (5) 2.4 ± 0.2 (9)
Muscle 0.9 ± 0.3 (7) 0.38 (1) 3.1 ± 0.4 (4)
Skin 0.8 ± 0.4 (9) 2.7 ± 0.6 (4)
Adipose 0.2,0.3 (2) 2.4 (1)
⋆ Mean ± SD for n of reported values in parentheses; if N ≤ 2, the values are stated
† based on Owen (1982) and Hurley et al. (2008)
‡ personal communication; appear elevated compared to other values
a 16 d old mouse pups
Table 2.4:Major copper-binding enzymes and proteins in mammals
Linder and Hazegh-Azam, 1996
Intracellular proteins Extracellular proteins
Cytochrome c oxidase Ceruloplasmin
Superoxide dismutase Extracellular superoxide dismutase
Metallothionein Extracellular metallothionein
Dopamine-β-monooxygenase Lysyl oxidase
Tyrosinase (catechol oxidase) Albumin
α-Amidating enzyme Amine oxidase
Phenylalanine hydroxylase Blood clotting factors V and VIII
Diamine oxidase Ferroxidase II
Cartilage matrix glycoprotein Transcuprein/macroglobulin
conrm these ndings: when a dose of 64Cu(NO3)2 was given to rats via gastric intubation
or orally, only 0.1% of the dose was detected in the blood between 0.5 and 4 h (Fields et al.,
1986). is leads to the conclusion that it is unlikely (though it is yet to be denitively
established) that gastric absorption plays a signicant role in Cu metabolism (Linder,
1991). Even though during a meal the stomach is exposed to dietary Cu rst, the small
intestine is the primary organ for dietary Cu uptake, due to its much larger surface area
and length (Linder, 1991).
Interestingly, Cu uptake has been demonstrated to be tightly (inversely) correlated
with the total amount of Cu ingested: young men that consumed 1.7 mg of Cu per day
retained 36% of it, whereas, when given 0.8 mg and 7.5 mg, they retained 56% and 12%,
respectively (Turnlund et al., 1989). Later work demonstrated that the absorption and
endogenous excretion of Cu is a direct response to dietary Cu intake, helping to protect
against Cu deciency and potential toxicity (Turnlund, 1998; Turnlund et al., 1998).
2.2.1 The essential need for copper
In the early 1800s, Cu was discovered to be present in plant material (Meissner, 1816) and
bovine blood ash. By the late 1920s Cu was understood as an essential element to animal
and plant life (McHargue, 1925;McHargue et al., 1928;McHargue and Shedd, 1930). Copper
deciency was documented in humans in the 1960s (Cordano et al., 1964). Since then,
Cu’s crucial signicance at the cellular level across the whole body has been recognised,
where it is required for a wide range of functions, including respiration, neurotransmitter
biosynthesis and connective tissue strength (e.g., Gybina et al., 2009; Lech and Sadlik,
2007; Lutsenko, 2016; Lutsenko et al., 2007).
2.3 COPPER AS A PRO-OXIDANT -
OXIDATIVE STRESS
e redox state of Cu critically aects ion transport pathways. Its uptake and intracellular
oxidative eects are predominantly based on Cu2+, whereas the eect on membrane
transport are largely based on Cu+. Copper is reduced at the cell membrane surface,
where six-transmembrane epithelial antigen of prostate (STEAP) (2, 3 and 4) proteins act
as cupro-reductases, stimulating Cu uptake into the cell (Knutson, 2008; Ohgami, 2006).
It is well known that Cu can be a toxin and induce cell death (see Gaetke et al. (2014)
and Gaetke and Chow (2003), for comprehensive reviews). While the specic mechanisms
through which Cu induces necrosis are still unclear, two potential mechanisms have been
proposed to be likely responsible for Cu-induced toxicity: 1) a fenton-like reaction that
can directly catalyse the production of ROS (Prousek, 2007), and 2) exposure to high Cu
concentrations signicantly decreases levels of the anti-oxidant glutathione (GSH) in the
cell (Mattie and Freedman, 2004; Speisky et al., 2009).
With regard to 1) above, in a biological context, both oxidation states (1+ and 2+)
of free Cu can participate in oxidation and reduction reactions (Britton, 1996; Luza and
Speisky, 1996) involving superoxides, or reducing agents such as ascorbic acid. In their
presence, Cu2+ can be reduced to Cu+ (Equation 2.1a), which is capable of catalysing
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the formation of hydroxyl radicals (OH⋅) from H2O2 via the Haber-Weiss/Fenton-like
reactions (Equation 2.1b) (Bremner, 1998; Letelier et al., 2005; Aruoma et al., 1991; Kadiiska
et al., 1993).
Cu2+ + O−2 → Cu
+
+ O2 (2.1a)
Cu+ +H2O2 → Cu2+ + OH− + OH⋅ (2.1b)
Possibly the most powerful oxidising radical in biological systems is the hydroxyl
radical, which is formed from the above reaction (Equations 2.1a and 2.1b) (Buettner,
1993). It has the ability to react with most, if not all biological molecules and induces
cell damage through the removal of hydrogen from an amino-bearing carbon to form
a carbon-centred protein radical and/or from an unsaturated fatty acid to form a lipid
radical (Powell, 2000; Stadtman, 1990).
With regard to the relationship between Cu and GSH in the cell (2), GSH being a
powerful antioxidant, participates in intracellular Cu metabolism and detoxication by
directly chelating the metal (Mattie and Freedman, 2004). is maintains the metal in a
reduced state, making it unavailable for redox cycling (Jomova and Valko, 2011). Redox
active metals undergo cycling reactions, by which electrons are transferred from the metal
to the substrate and vice versa. is may play an important role in the maintenance of
redox homeostasis, which is closely linked to metal homeostasis (Lindeque et al., 2010).
Elevated levels of cellular Cu as a result of dysfunctional Cu homeostasis, reduce GSH
concentrations andmay therefore contribute to a shi in the cellular redox balance towards
more oxidising conditions (Jomova and Valko, 2011; Linder, 1991). is may also enhance
the cytotoxicity of ROS and allow the metal to be more catalytically active, resulting in
the production of even more ROS (Ahuja et al., 2015).
Work exploring the specic processes in cells associated with Cu toxicity have shown
that in hepatocytes incubated in the presence of high concentrations of Cu2+, lysosomes
(a cytosolic organelle containing degradation enzymes) were observed to be the primary
site of endogenous cytotoxic ROS formation (Farinati et al., 2003). It was also shown that
ROS were generated by mitochondria, independent of cytosolic ROS formation due to
redox cycling (Pourahmad and O’Brien, 2000) and the activation of the extracellular
single-regulated kinase cascade (Nawaz et al., 2006). In Wilson’s disease, where Cu
overload in the liver is a pathological feature, Cu deposition in the mitochondria induces
severe structural and respiratory impairments, provoking ROS production and
consequently causes the mitochondrial membranes to disintegrate, leading to cellular
apoptosis (Zischka and Lichtmannegger, 2014). Overall it appears that Cu toxicity in cells
may not be attributable to a single mechanism or pathway, but rather is the result of a
system/cell-wide perturbation to normal function.
Mechanisms to protect against Cu toxicity include the intrinsic stress response of
the heat shock proteins (e.g., heat shock protein 70), (Urani et al., 2001), which can
be triggered by a sub-lethal shock of Cu. is mechanism is not yet well understood.
Additionally, the metal-responsive transcription factor 1 (MTF-1) (Balamurugan and
Schaner, 2006) acts under both high and lowCu concentrations to control the expression
of metallothioneins and other components that control Cu homeostasis; under high
36
Cu concentrations, MTF-1 activates metallothioneins to protect the cell from oxidative
damage; under low Cu concentrations MTF-1 activates the Cu importer CTR2, to acquire
more Cu from the surround.
2.4 COPPER METABOLISM
2.4.1 Absorption and transport to liver
e general uptake of Cu through the intestinal tract is well studied and it is known that
the doses of absorbed Cu are variable, depending on the amount of dietary Cu intake.
Overall, the body is able to control the amount of absorption, enhancing it when Cu is less
available and vice versa (Linder, 1991; Turnlund et al., 1989).is relationship appears to be
stable for doses up to 12 mg of Cu (Marceau et al., 1970). Beyond 12 mg, the total amount
absorbed increases, but at a lower rate relative to the amount administered (Linder, 1991),
suggesting the existence of two separate mechanisms for Cu uptake through the intestinal
lumen, prior to transport via the portal vein to the liver (Bremner, 1980).
e mechanisms by which Cu is taken up specically via the brush border in the
small intestine into enterocytes6 is not yet well known (Crisponi et al., 2010; Lutsenko,
2016) beyond the speculation that the uptake pathways in the intestine are most likely
dierent to ones used in other tissues and cell types. is becomes obvious when the
environments are considered more closely, in particular the dierence in pH between
the gut lumen and for example blood. In general, chemical speciation of Cu contained
in food as it is digested plays the major role in Cu absorption; while Cu-salts (carbonate,
acetate, sulphate and chloride) are more easily absorbed, Cu-oxides seem to be absorbed
signicantly less eciently (Ledoux et al., 1995). In general it is assumed that dietary Cu
is predominantly present in its oxidised form of Cu2+ and it has to either be reduced to be
absorbed, or there is a specialised, currently unknown, pathway that enables the uptake
of Cu2+ complexed with smaller molecules or peptides (Lutsenko, 2016). is could be
achieved through the various metabolites secreted by species of commensal bacteria living
in the intestine, which may inuence and/or modulate Cu uptake through binding it, or
through signalling mechanisms, as observed for other nutrients (Li et al., 2013).
Further factors aecting the uptake of Cu in the intestine include7:
1) food conservation methods (e.g., the use of salt as preservative) may modify the
solubility of protein-bound Cu and therefore its bioavailability (Clydesdale, 1988);
2) pH, as an acid environment is necessary to free Cu ions (Gollan, 1975);
3) the presence of chelating agents, such as citric acid or EDTA8, which favour Cu
absorption (Shah, 1981);
6Intestinal absorptive cells, which are columnar epithelial cells.
7See Linder 1991, chapter 2 for a more comprehensive overview.
8Ethylenediaminetetraacetic acid
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It also has to be noted that the presence of other divalent metal cations (i.e., with a
charge of 2+, such as Zn2+), can act competitively with Cu for uptake (Fosmire, 1990;
Mills, 1985). In particular Zn has been described to be mutually antagonistic (Walsh et al.,
1994): in humans, chronic ingestion of 100 mg of Zn per day can lead to Cu deciency
(Porter et al., 1977; Prasad, 1978), which in return can result in severe anaemia. In this
case, Zn displaces Cu from its specic carrier in the enterocyte, leading to an increase in
metallothionein (MT), whose synthesis is directly related to the Zn status (Richards and
Cousins, 1975). Metallothionein has the ability to bind to physiological and xenobiotic
heavy metals within cells, blocking Cu tracking and favouring its loss through apoptosis
of the enterocytes back into the intestine (Richards and Cousins, 1976).
e physiological uptake of Cu by enterocytes is completed by copper transporter 1
(CTR1) and the divalent metal transporter 1 (DMT1), which is also capable of transporting
Cu (Arredondo et al., 2003); however, under normal conditions, CTR1 is the primary
uptake mechanism (Figure 2.1), and responsible for at least 50% of Cu entering the cell
(Espinoza et al., 2012; Lutsenko, 2016). CTR1 is an essential protein, involved in early
embryonic development and intestinal Cu and Ag uptake (Bertinato et al., 2010; Eisses
et al., 2005). It is located at the apical plasma membrane and responsible for transport
of Cu from the endosome into the cytosol; however, it can be internalised if the Cu
concentration is elevated in the enterocyte (Lee et al., 2002). Additionally, a small amount
of the low anity Cu transporter (CTR2) is localised at the apical plasma membrane
which may stimulate Cu uptake (Bertinato et al., 2008), while the majority of it is found
in vesicular structures inside the cell (van den Berghe et al., 2007). e role of CTR1 as the
major driving factor for the intestinal absorption of Cu in mammals has been shown in
CTR1 knockout mice, which exhibit severe growth and viability deciency, iron-overload,
cardiac hypertrophy and growth decits (Kuo et al., 2006).
In addition to CTR1, DMT1 contributes to Cu uptake into enterocytes, but divalent
cations such as Zn2+ or Fe2+ can compete for transport via this pathway (Figure 2.1).
Rats with induced iron deciency demonstrated a strong increase in Cu-transporting
P-type ATPase A (ATP7A9) in the duodenal epithelium, followed by a signicant Cu
overload in the liver and intestine, suggesting a ‘supercharging’ of Cu transport during iron
deprivation, and demonstrating that Cu and Fe share the same transporters, balancing
one another to avoid toxicity (Ravia et al., 2005). e same study also noted that Cu-
transporting P-type ATPase B (ATP7B10) expression did not change, suggesting that liver
Cu excretion was not altered.
2.4.2 Copper transport through the cytoplasm of enterocytes
Copper transport through the cytoplasm of enterocytes is predominantly mediated by
metallothionein (MT) and the metallo-chaperone antioxidant 1 copper chaperone
(ATOX) (Figure 2.1), protecting the cell from metal-induced toxicity and oxidative
damage (Sturniolo et al., 1999). Zinc, Hg, Ag and Cd can be in competition over the MT
sites (Hg > Cu > Cd > Ag > Zn); in vivo only Zn, Cu and Cd binding is thought to be
signicant (Linder and Hazegh-Azam, 1996). It was further demonstrated that Zn can
9Also known as the Menkes’ protein.



























































































































































































































































































































































































































































































































































































increase the amount of MT signicantly through the enhancement of the MT synthesis
(Coyle et al., 2002). Apart from MT, there is a range of general Cu-binding proteins
involved in the overall transport (compare Table 2.5).
When Cu ions arrive at the basolateral pole of the enterocytes as a result of being
chaperoned byMT (Figure 2.1) or ATOX, they are transferred to the main Cu transporters
in the body by passing through the basal cell membrane and into the portal vein (Mercer,
1998). is process is regulated by ATP7A, which is released from the transgolgi network
following an increase in the intracellular Cu concentration (Monty et al., 2005). For Cu to
exit the cell, ATP7A ‘pumps’ the Cu ions into vesicles, which fuse with the cell membrane,
releasing the Cu (Monty et al., 2005). Even though the specic processes of intracellular
transport have been largely identied, an understanding as to how these proteins are
regulated in detail to achieve Cu balance is still unknown. It is suggested that even though
ATP7A has six potential copper-binding sites, only two appear to be necessary for ecient
Cu transport (Mercer, 1998); the additional four could be used for Cu concentration
detection. It may also be the case that Cu-induced-redistribution of ATP7A towards the
basolateral pole and production of vesicles may be a form of regulation of Cu uptake by
sequestration in these vesicles (Monty et al., 2005).
2.4.3 Copper transport from the intestine to the liver
Directly aer the Cu ions have le enterocytes (Figure 2.1), they are bound to the main
Cu carriers in blood: serum albumin, the most abundant protein in blood and CSF; the
amino acid histidine; and the proteins transcuprein and transferrin (Crisponi et al., 2010;
Linder, 1991; Linder and Hazegh-Azam, 1996; Linder et al., 1998). rough binding to
those carriers, Cu is transported via the portal vein, a blood vessel 8 – 10 cm long, from
the gastrointestinal tract to the liver. e potential for Cu to be bound to various other
carriers, such as amino acids (besides histidine), peptides or fatty acids, appears to have
little to no physiological relevance (Carter and Ho, 1994). Once Cu reaches the liver, it is
taken up into hepatocytes across the sinusoidal plasma membrane, following its general
reduction to Cu+ (Roberts and Sarkar, 2008).
2.4.4 Copper in the liver
Copper is delivered to the hepatocytes’ sinusoidal pole as Cu2+ ions, from where it is
heterogeneously distributed (Luza and Speisky, 1996). Independent of the transporter
and oxidation state, Cu is removed from the high anity complexes and reduced to Cu+.
is reduction is most likely performed by outward facing sulphhydryl groups on the
cell membrane surface (STEAP 2 – 4) (Bogdanova et al., 1999) or by NADH oxidase
on the plasma membrane (van den Berg and McArdle, 1994), in which case the uptake
is stimulated and sped up by the reducing agent ascorbic acid (Bingham and McArdle,
1994). is reduction step through the sinusoidal lumen is essential to the hepatocyte
(independent of whichever metalloreductase it is performed on) to reduce the stability
of the complexes and enable Cu to be taken up by the cell (Crisponi et al., 2010). Post-
reduction, high anity Cu permeases CTR1 and CTR2 mediate the physiological uptake
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Table 2.5: Copper-binding proteins involved in cellular Cu transport
(from Prohaska, 2008)
Protein Gene Putative Cu function
Membrane
Cation (Copper) transporter 1 CTR1 Plasma membrane uptake
Cation (Copper) transporter 2 CTR2 Endosomal pump
Divalent metal transporter 1 DMT1 Cu import
Intracellular
Menkes disease protein ATP7A⋆ Enzyme biosynthesis and eux
Wilson’s disease protein ATP7B⋆ Enzyme biosynthesis and eux
Human homologue of ATX1p† HAH1 Binding of Cu, chaperone
Metallothionein MT General storage and chaperone
Copper metabolism MURR domain COMMD1 Hepatic eux
X-linked inhibitor of apoptosis XIAP Hepatic eux
Chaperones
Antioxidant 1 copper chaperone ATOX1 ATP7A/B⋆ target
Copper chaperone SOD CCS SOD target
Assembly factor 17 for CCO‡ COX17 CCO‡ target
Assembly factor 11 for CCO‡ COX11 COX2 site B
Suppressor of COX17 mutation 1 SCO1 COX1 site A
Suppressor of COX17 mutation 2 SCO2 COX1 site A
⋆ ATPase: adenosine-tri-phosphate
† Hung et al. 1998
‡ CCO: cytochrome c oxidase
of Cu from the extracellular environment (Figure 2.2) (Rees et al., 2004); CTR2 appears to
additionally play a role in low-anity Cu import (Bertinato et al., 2008) and in intracellular
Cu mobilisation (Rees et al., 2004).
Copper imported through the cell membrane via CTR1 rapidly binds to intracellular
Cu chaperones, which deliver Cu ions to specic sites within the cell (see Section 2.4.6 for
a brief overview). e overall knowledge with regard to molecules participating in Cu
distribution from the liver to peripheral tissues is limited (Crisponi et al., 2010).
Ceruloplasmin (CP), produced in hepatocytes, is understood to be the principal Cu
transporter in blood (Healy and Tipton, 2007; Martin et al., 2005). Its primary
production occurs aer Cu is chaperoned to the trans-golgi-network, where it is oxidised
from Cu+ to Cu2+ (Bingham et al., 1997). e details of this oxidation mechanism remain
elusive. e Cu2+ is then incorporated into locally synthesised CP inside vesicles, which
then cross the plasma membrane and release CP-bound Cu into the blood plasma
(Mehta et al., 2006) (Figure 2.2).
Besides the crucial role of CP production, hepatocytes are also responsible for the
biliary excretion of excess Cu. ATP7A and ATP7B are both located in the trans-golgi-
network and provide Cu ions to essential cuproenzymes. While ATP7A has been shown
to play a major role in general Cu eux from cells (Ke et al., 2006), ATP7B has been
predominantly detected in hepatocytes (La Fontaine andMercer, 2007).When under high
Cu stress, ATP7A and ATP7B act as sensors for the increase in cellular Cu concentration
and translocate to the cell membrane to excrete the excess Cu (La Fontaine and Mercer,
2007). is is achieved by accumulating Cu in vesicles, which subsequently undergo
exocytosis, releasing the excess Cu through the plasma membrane (Cater et al., 2006).
When cellular Cu concentrations increase, Cu is additionally aggregated into vesicles
and redistributed by ATP7B into the biliary canaliculi, which end up in the gallbladder,
discharging the Cu into the small intestine (Schaefer et al., 1999).
2.4.5 Copper in blood
Human blood carries a variety of copper-binding components (Table 2.6). Ceruloplasmin
(CP), an abundant Cu-containing enzyme in the serum, is produced in the liver and
accounts for 40 – 90% of the total post-liver serum Cu (Kosman, 2002; Linder, 1991,
2016; Lutsenko, 2016). However, inactivation of ceruloplasmin in mice does not result in
notable changes in the gastrointestinal absorption, hepatic uptake, or biliary excretion
of Cu (Meyer et al., 2001). is suggests that CP may not be as crucial to whole body
Cu metabolism as previously presumed with its particular role in the distribution of Cu
not well understood (Bento et al., 2007; Crisponi et al., 2010; Hellman and Gitlin, 2002;
Linder, 2016; Meyer et al., 2001).
Albumin is considered the major Cu carrier of exchangeable Cu in human plasma,
binding ∼17% of total Cu due to the presence of high anity sites for Cu2+ at the amino
terminus (Bal et al., 1998). In one mL of human plasma, ∼40 µg Cu could theoretically
bind to these high anity sites, however only ∼180 ng has been observed to be bound in
vivo (Linder et al., 1998). is might indicate the presence of a buering capacity for the
sudden release of Cu when required. In the case of analbuminemia (absence of albumin),














































































































































































































































































































































































































































































































In the absence of albumin it is suggested that transferrin, which binds Cu2+ more strongly
than albumin (Løvstad, 2004), may play a role in Cu plasma transport (Crisponi et al.,
2010); however due to the much higher concentration of plasma albumin it seems unlikely
that such a hypothetical competition has any physiological relevance (Løvstad, 2004). It
was reported that albumin has the ability to inhibit the uptake of ionic Cu by hepatocytes
(Ettinger et al., 1986), which regardless do not have specic receptors for Cu transported
by albumin (Linder et al., 1998).erefore it is assumed that albumin plays a passive role in
Cu transport, carrying large quantities of exchangeable Cu in circulation and releasing this
to other carriers for cell-specic uptake, of which one might be transcuprein (Linder et al.,
1998). Surprisingly, in vitro and in vivo results demonstrate that hepatocytes and other
cells take Cu from every available source, e.g., transcuprein, albumin, and ceruloplasmin
(Linder et al., 1998), without discrimination.
In light of these ndings, there may be transient compensatory changes in Cu-binding
protein pools that help explain the lack of impact onCu homeostasis following inactivation
of individual Cu-binding components. Recent ndings of a small Cu carrier(s), suggest
that they may play a signicant role in the regulation of Cu distribution between tissues
(Linder, 2016; Lutsenko, 2016). Although the protein(s) have been repeatedly observed
(Cabrera et al., 2008; Linder, 2016;Wirth and Linder, 1985) identication of theirmolecular
nature and specic role in Cu homeostasis has been challenging.
2.4.6 Copper in other mammalian cells
In most mammalian cells, CTR1 is most likely the predominant factor that mediates Cu
uptake. Once inside the cell, Cu has four major, possible fates (Choi and Zheng, 2009;
Linder, 2016; Lutsenko, 2016; Zheng and Monnot, 2012) (Figure 2.3):
1) it can be scavenged by metallothionein into a transient storage pool;
2) it can be incorporated into cytochrome c oxidase in the mitochondria;
3) it can be taken up by the Cu chaperone for SOD (CCS) and be incorporated into
superoxide dismutase 1; and
4) it can be transported to ATP7A or ATP7B within the trans-golgi network for
vesiculation and transport out of the cell.
2.4.7 Copper in the kidneys
In the kidneys, ATP7A and ATP7B are the predominant regulators of Cu metabolism.
Overloading of Cu is prevented by ATP7A, which contributes to the export of excess Cu
via the basolateral membranes (Linz et al., 2008). Both proteins are also in glomeruli11,
and may play a role in the regulation of Cu concentrations of the ltrate. ATP7B may
also play a role in Cu reabsorption, as it was detected in the loops of Henle in the renal
medulla (Moore and Cox, 2002). Moreover, kidney cells contain CTR1 (Eisses et al., 2005)
and CTR2 (Bertinato et al., 2008), localised in the plasma membrane that promote Cu
uptake and regulate intracellular Cu concentrations.
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.3:Major copper pathways in a generalised mammalian cell. Cu can be bound to MT (1).
COX17 may transport Cu to be incorporated into CCOwithin mitochondria (2). CCS incorporates
Cu into SOD1 (3) and ATOX delivers Cu to both, ATP7A and ATP7B for transport out of the cell
via other vesicles (4) (see Figures 2.1 and 2.2).
Abbreviations: ATOX: Cu chaperone antioxidant-1; ATP7A/ATP7B: Cu-transporting P-type
ATPase; CCO: cytochrome-c-oxidase; CCS: Cu chaperone for superoxide dismutase; COX17:
cytochrome-c-oxidase Cu chaperone; CTR1: Cu transporter 1; DMT1: divalent metal transporter 1;
MT: metallothionein; SOD1: Cu,Zn Superoxide dismutase 1.
2.4.8 Copper in blood-brain-barrier, central nervous system and
brain
2.4.8.1 Brain and central nervous system
Copper is present throughout the brain at relatively uniform concentrations of
∼4.5 µg g−1 wet tissue (Davies et al., 2013). e substantia nigra, basal ganglia,
hippocampus and cerebral granular neurons (Madsen and Gitlin, 2007), are exceptions
with higher concentrations of ∼11 µg g−1, most likely associated with elevated levels of
oxidative stress in these regions and therefore a higher need for Cu as an antioxidant
(Davies et al., 2013). Besides the involvement of Cu in the production of myelin, it is
crucial for the synthesis of neurotransmitters (Beal, 2000; Desai and Kaler, 2008) and
general control of communication between neurons (Opazo et al., 2014). Neuronal Cu
homeostasis is handled by the amyloid precursor protein and the prion protein (Crisponi
et al., 2010), while a still uncharacterised human Cu transporter could be relevant to
intracellular Cu tracking (Li et al., 2005). e discovery of very high MT levels, and
presence of a brain-specic isoform (MT-III) in the central nervous system, indicate that
MTs could be essential to the sequestration and dispersal of metal ions and cellular
cytoprotection from ROS in the brain (Aschner et al., 2006).
As in all major tissues, ATP7A and ATP7B play the central role in the
compartmentalisation and distribution of Cu in the brain (Barnes et al., 2005; Crisponi
et al., 2010), even though their functional relationship is poorly understood. It is assumed
that ATP7B is overall responsible for Cu distribution to the brain through its localisation
in the choroid plexus12 (Iwase et al., 1996), while the specic functions of the ATPases in
other brain regions remain unknown. e expression of CTR1 on endothelial cells13 of
the blood-brain-barrier suggests that Cu could also be transported from the plasma into
the central nervous system via CTR1 (Kuo et al., 2006). Generally, ATP7A, which is more
concentrated in the cerebellum (Davies et al., 2013), delivers Cu to ceruloplasmin
(Barnes et al., 2005), while ATP7B is likely to regulate the amount of Cu in Bergmann
glia14 and to export Cu for delivery to Purkinje neurons15 (Barnes et al., 2005). Overall no
relationship between ATP7A or ATP7B and brain Cu concentrations was observed
(Davies et al., 2013).
2.4.8.2 The brain barrier systems
e brain barrier systems are made up of the blood-brain-barrier (BBB), which separates
circulating blood from the brain interstitial uid, and the blood-cerebrospinal uid-barrier
(BCB), which separates circulating blood from the cerebrospinal uid. Even though the
majority of Cu in circulation in blood is bound to ceruloplasmin, only free, unbound Cu
passes through the brain barriers to be transported into the brain and the central nervous
system (CNS) (Choi and Zheng, 2009; Fu et al., 2014; Zheng and Monnot, 2012).
12Cells that produce cerebrospinal uid in the ventricle of the brain.
13Layer of simple squamous cells lining the interior surface of blood vessels and lymphatic vessels.
14Cells that grow new neurons, astrocytes and oligodendrocytes.
15Longest neurons in brain, crucial to brain function.
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Figure 2.4: Copper transport by the blood-brain-barrier (BBB) and blood-cerebrospinal uid-
barrier (BCB). Free Cu ions are transported predominantly via the BBB into the CNS, where they
distribute following a concentration gradient. e removal of Cu from the CNS is currently not
well understood but appears to occur via the BCB (modied from Zheng and Monnot, 2012).
Knowledge on uxes of Cu across the BBB or BCB are limited (Figure 2.4). e Cu
concentration in the CSF has been estimated to be 22.3 ± 2.2 µg L−1, while concentration
of Cu in serum is considerably higher 1129 ± 124 µg L−1 (Forte et al., 2004; Nischwitz et al.,
2008). is suggests that the brain barriers eectively regulate Cu in the CNS, presumably
via transport by CTR1 and possibly DMT1 (Kuo et al., 2006; Zheng and Monnot, 2012);
ndings indicate CTR1 to be the major transporter (Zheng et al., 2012).
Similar to other cells, the samemajor Cu proteins are active in cells that make up those
brain barriers (e.g., ATOX, COX17, MT and CCS) (Monnot et al., 2012). It is unknown
how the proteins and the barriers as a whole respond to changes in Cu concentration in
the blood or the CSF/interstitial uid, or whether they aect the directional tracking
of Cu within the BBB and BCB (Zheng and Monnot, 2012). e binding of MT by Cu
at the brain barriers likely plays a role in regulating intracellular Cu storage; the precise
mechanism for the interplay between MT, CTR1 and DMT1 are, at this stage, unknown
(Zheng and Monnot, 2012).
Export of Cu from the barrier cells is mediated by ATP7A and ATP7B, both of which
are expressed by epithelial cells of the barrier (Choi and Zheng, 2009; Fu et al., 2014).
e relative expression levels of these proteins at the BBB and BCB is dierent: ATP7A
is expressed 13-fold higher than ATP7B in the BBB, whereas ATP7B is expressed 6-fold
higher than ATP7A in the BCB (Fu et al., 2014). When intracellular Cu concentrations
rise, both ATP7A and ATP7B are known to facilitate Cu eux from the cells, which is not
only necessary for Cu trans-barrier transport, but also important for preventing excess
Cu accumulation inside the barrier cells. e exact functional dierences between ATP7A
and ATP7B in the CNS remain unknown, including regulation and directional tracking
of Cu at the brain barriers, and their respective roles in CNS Cu homeostasis (Zheng and
Monnot, 2012). At present, the question as to whether or not the BBB transports Cu from
the brain interstitial uid back to the blood is unanswered.
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e relative contribution of the BBB and BCB to CNS Cu metabolism depends on a
variety of factors, including the direction of Cu ow, the rate of Cu delivery, and surface
area through which the barrier transmits the volume (Zheng and Monnot, 2012). e
choroid plexus, which produces the CSF, has the highest capacity to acquire Cu,
irrespective of speciation, and tightly regulates the movement of Cu from blood into the
CSF (Choi and Zheng, 2009; Monnot et al., 2011; Zheng and Monnot, 2012). Interestingly,
the uptake rate of Cu into the brain parenchyma is far greater than to the CSF, meaning
that while Cu uptake by the BBB is slower than that of the BCB, the acquired Cu appears
to be more eciently transported to the brain parenchyma than Cu in the choroid plexus
is delivered to the CSF. e apparent lack of a barrier between the interstitial uid and the
CSF may mean that the Cu in the choroid plexus is derived from ‘leaked’ Cu by neurons
and glial cells (Zheng and Monnot, 2012). erefore, overall the BBB appears to be the
more important inux pathway for Cu into the CNS, while the BCB is the predominant
eux route (Fu et al., 2014).
2.5 COPPER AND NEURODEGENERATIVE DISEASES
e involvement of metals in neurodegenerative disease is varied and complex (Adlard
and Chung, 2015). Findings have long supported the hypothesis that perturbation to
Cu metabolic processes, and associated changes in Cu concentrations, may result in the
development of several neurological diseases (Basun et al., 1991; Hartmann and Evenson,
1992; Hershey et al., 1983; Levenson, 2005; Lutsenko, 2010; Lutsenko et al., 2010; Nischwitz
et al., 2008; Strausak et al., 2001). is short review focuses on the association of Cu with
a selection of neurodegenerative diseases.
2.5.1 Copper in amyotrophic lateral sclerosis
As described previously (see Section 1.5.1.1), the most well-understood trigger of ALS
involves mSOD1 forming toxic aggregates that ultimately result in for example
mitochondrial dysfunction and apoptosis. It has yet to be established whether Cu plays a
crucial role in the development of this toxicity. Available data in the context of mSOD1
related disease suggests that the binding of Cu and Zn by mSOD1 may be defective (Carr̀ı
et al., 1994; Eum and Kang, 1999; Hayward et al., 2002). For example, analysis of mSOD1
from mouse models of ALS has shown that insoluble fractions (representing aggregated
mSOD1) were not enriched in Cu and Zn, whereas the soluble fractions (representing
non-aggregated mSOD1) were enriched. As high metallation stabilises the protein, it was
hypothesised that immature nascent apo-SOD1 (without metals) is the primary substrate
for aggregation (Lelie et al., 2011). is was accompanied by ndings in the brain of G93A
and G37R mice, where a redistribution of Cu was observed from grey matter to white
matter correlating to areas of high SOD1 (Lelie et al., 2011). Additionally, even though
SOD1 metallation, or lack thereof, appears to be of major importance in the promotion of
aggregation, failure to fold because of disrupted formation of the stabilising disulphide
bond is also a critical factor (Seetharaman et al., 2009).
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It was shown that other cupro-enzymes, such as CP and MT, may also be implicated:
a study of CP in ALS patients revealed that the function of CP might be severely impaired
(Conti et al., 2008); work using the G93A SOD1 mouse model of ALS with either MT-1/2
or MT-3 knocked down showed that ALS progression was accelerated (Nagano et al.,
2001), suggesting that Cu may play an important role in ALS pathology.
Apart from the above-presented evidence, metals and their neurotoxic properties,
as a result of exposure, have been proposed to contribute to ALS development (Roos,
2017). Metals enter the body through a plethora of exposure routes, including respiratory,
olfactory, enteric, dermal, and intravenous pathways (Roos, 2013). e metal uptake is
typically tissue specic. While the general ndings of metals in blood in association with
ALS over the past 40 years have been inconsistent (Table 2.7), there is evidence to suggest
that Pb appears to be an associated factor in ALS (Roos, 2017). Concerning Cu, there are
some indications for general Cu accumulation in ALS patients, e.g., in blood (Peters et al.,
2016), and in CSF compared to healthy controls (Roos, 2013; Roos et al., 2013). Elevated
concentrations of Cu and Zn were also found in erythrocytes (Vinceti et al., 2002), and
spinal cord tissue (Kurlander and Patten, 1979) of SOD1 fALS patients, as well as in the
G93A SOD1 and A315T TDP-43 mouse models of ALS (Dang et al., 2014; Hilton et al.,
2016; Li et al., 2006; Tokuda et al., 2013).
e above ndings suggest the existence of a treatment target involving Cu. As a
consequence, Cu chelators have been trialled for their promise as treatment options. is
follows the assumption that labile intermediate forms of SOD1 can be transformed through
the chelation into apo-SOD1 (Roberts et al., 2014). Ammonium tetrathiomolybdate was
shown to signicantly improve ALS symptoms by 20% and survival in G93A SOD1 mice
by 25% (Tokuda et al., 2008), and resulted in a three-fold reduction of the accumulation
of Cu in the spinal cord (Tokuda et al., 2013). Diethyldithiocarbamate and penicillamine
were able to reverse the mSOD1 reactivity in A4V and G93A SOD1 mice (Wiedau-Pazos
et al., 1996); D-penicillamine delayed onset and prolonged survival in G93A SOD1 mice
(Hottinger et al., 1997). Trietine and ascorbate showed a slight extension of survival
when given in water to G93A SOD1 mice, when compared to untreated diseased controls
(Nagano et al., 2003). is eect was signicant in a dose dependent manner where the
increase from 0.2% w v−1 (no eect compared to controls) to 0.5% showed a signiant
improvement, while an additional increase to 1.2% resulted in a decrease in survival similar
to that of the control (Nagano et al., 2003). While these results may be promising in some
aspects, they present with inherent issues. For one they are based on the assumption that
there is an ‘overloaded’ tissue from which Cu can be removed; while bulk analyses do
indicate elevated concentrations of Cu in specic tissues, chelators will removemetals from
(CNS) tissue in a non-discriminatory fashion, which can be problematic (Barnham and
Bush, 2014). Additional side and adverse eects of specic chelators have to be considered
in its application (see Aaseth et al. (2016) for more details on the risks and drawbacks
of chelation therapy).Second, for a chelator to simultaneously bind Cu eciently and
selectively, and to cross the BBB whilst providing good bioavailability, present a big
challenge (Crisponi et al., 2010).ird, the specic activity of these metal-chelating agents
on a cellular level still poorly understood (Crouch and Barnham, 2012). e G37R mouse
model of ALS was crossed with carriers of the X-linked mottles/brindles (Mobr) mutation,
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































resulted in Cu concentrations in the spinal cord being reduced by 60% and an increase in
life expectancy by 9%, providing strong support for the notion that Cu plays an important
role in SOD1 related fALS (Lovejoy and Guillemin, 2014).
e synthetic Cu binding compound, Cu-diacetyl-bis(N4-methyl-thiosemi
carbazone) (Cu-ATSM) was originally developed as a PET-imaging agent to deliver Cu
rapidly to the CNS (Dearling et al., 2002). e application of this compound, which
delivers Cu rather than chelates it, has shown promise as a therapeutic agent in the
SOD1G93A and SOD1G37R mouse models of ALS (Table 2.7) (Hilton et al., 2017 Williams et
al., 2016; McAllum et al., 2013; Roberts et al., 2014; Soon et al., 2011). Cu-ATSM has the
advantage over most chelators in that it has low toxicity and readily crosses the BBB of
ALS patients (Ikawa et al., 2015). e oral administration of the drug aer the onset of
symptoms resulted in reduced protein nitration and increased antioxidant activity in
spinal cord. It is remarkable that the treatment preserved motor neurons, attenuated
astrocyte and microglial activity, and prevented the accumulation of TDP-43 inclusions
(Soon et al., 2011). ese ndings were reproducible when the drug was administered
orally or transdermally and resulted in an average lifespan extension of 8 – 26%; while
dosing did have a signicant eect on determining the increase in survival, the onset of
treatment appears of greater importance (Table 2.7). erapeutic outcomes involved
broad protection against the toxic eects of mSOD1 as treatment with Cu2+-ATSM
preserved the number of α-motor neurons in the spinal cord, decreased levels of
oxidatively damaged proteins and the abundance of activated glia cells (Roberts et al.,
2014). Prior to treatment spinal cord SOD1 was characterised to be Cu depleted, whereas
treatment with Cu-ATSM signicantly increased Cu binding such that it reached almost
normal levels (Roberts et al., 2014). Binding of Cu transforms mSOD1 into a stable,
non-toxic holo isoform (Hilton et al., 2017; Roberts et al., 2014).
Williams et al. (2016) also tested treatment with Cu-ATSM on high copy SOD1G93A
mice, co-expressing CCS.Mice co-expressing human CCSwere shown to die much sooner
(30 – 50 d) compared to SOD1G93A mice not co-expressing CCS (Son et al., 2007). is
is of importance, as ALS patients have been shown to express human CCS in a much
higher ratio to SOD compared to the ratio of mouse CCS to human SOD1G93A expressed
in transgenic mice (Rothstein et al., 1999). In the SOD1G93Amice the co-expression of CCS
leads to a Cu depletion in the spinal cord, which results in an impaired Cu import into
mitochondria (Son et al., 2007), the distribution of Cu to this tissue was enhanced through
Cu-ATSM treatment and lead to an increase of survival of 2800% compared to the controls
given a placebo (Table 2.7) (Hilton et al. 2017; Williams et al., 2016). From a therapeutic
point of view these ndings support the conclusion that at least part of the toxic-gain-
of-function of SOD1 resides in it being metal decient. Additionally, it has to be noted
that the extreme extension of survival observed by Williams et al., (2016) was the result of
extreme starting circumstances due to the co-expression of high levels of SOD1G93A, as
well as CCS. How these results can be translated into experiments or treatments closer to

















































































































































































































































































































































2.5.2 Copper in Alzheimer’s disease
Alzheimer’s disease (AD) is a prevalent neurodegenerative disease and the most common
form of dementia in the elderly. It is characterised by the presence of neurobrillary
tangles, the deposition of the amyloid-β(Aβ) peptide into insoluble plaques, neuropil
threads, Aβ-deposits and selective loss of neurons (Ahuja et al., 2015). Aβ-deposition is
an age-dependent mechanism, which has been observed to co-localise with increased
Cu concentrations (Miller et al., 2006). is involvement of metals in the production of
Aβhas been coined theMetal Hypothesis (Bush and Tanzi, 2008). Mechanistically, the
transmembrane protein APP, which has multiple selective Cu-binding sites, has a high
anity to bindCu, reduces it to Cu+ and generatesH2O2 (Opazo et al., 2002), which causes
Aβprecipitation. Interestingly, accumulations of Cu have also been observed in other
brain areas aected by AD (Bartzokis and Tishler, 2000), while bulk brain concentrations
decrease (Schrag et al., 2011). e apparent Cu accumulation associated with Aβ, and lack
of an increase of production with age, suggests that Cu plays a key role in the formation
of Aβ-deposits (Squitti et al., 2017): Cu dyshomeostasis results in a decrease of overall
available Cu, triggering a chain reaction leading to the accumulation of Aβ (Strausak et al.,
2001). e resulting protein aggregates bind even more Cu, while disabling the protective
action of MT. A consequential release of Cu stores to combat low Cu availability, results in
it being sequestered by the aggregates.e increasing number of toxic aggregates results in
physical damage to the cell membrane and excessive oxidative stress, resulting in neuronal
death and synapse loss. Amyloid plaques spread through the brain, eventually leading
to memory and brain function loss accompanied by other severe Alzheimer’s disease
pathology and symptoms (see Ahuja et al., 2015).
2.5.3 Copper in Menkes disease
Menkes disease is a Cu-metabolic, X-linked multi systemic disorder, resulting in lethal
neurodegeneration. e disease occurs due to mutations in the ATP7A gene, which are
mostly intragenic mutations or partial gene deletions (Tümer and Møller, 2010). ATP7A
is a crucial component of Cu metabolism (see Section 2.4); as a result, patients suer
from systemic Cu deciency due to the overall poor absorption of Cu (Hartmann and
Evenson, 1992; Strausak et al., 2001). Observed Cu concentrations in brain, liver and blood
serum are reduced, while increased in kidneys and intestine. is misdistribution results
in the reduced activity of cupro-enzymes, such as cytochrome c oxidase, dopamine β-
hydroxylase, lysl oxidase and tyrosinase. e disease is ultimately fatal, due to progressive
cerebral atrophy, seizures, hypotonia and connective tissue anomalies (see e.g., Ahuja
et al., 2015 and Tümer and Møller, 2010).
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is chapter has reviewed and discussed general mammalian Cu metabolism and
its involvement in several diseases. Evidence is building to show that Cu metabolism is
perturbed in a signicant way within ALS (see Chapter 1), though no consistent evidence
for a Cu-based disease proxy has been found in human blood studies as of yet. To better
understand and establish a specic role of Cu within an ALS context, a multi-method
approach is required to produce new insights into the expected Cumetabolic perturbation.
An approach involvingCu, and othermetals’ concentration analysis pairedwithCu isotope
ratiomeasurements in various tissues and at various time points reective of distinct stages
of disease development, may yield valuable insight into the perturbed Cu metabolism,




Isotope fractionation is the general terminology referring to variability in isotopic
composition of a particular element, resulting in variation in the relative abundance of
the isotopes. Isotopic fractionation is controlled thermodynamically among coexisting
species (e.g., Cu bound to histidine or cysteine) or reservoirs (e.g., Cu in blood serum or
red blood cells), but can also be controlled kinetically (e.g., intestinal absorption may be
somewhat controlled kinetically (Albarède et al., 2017). Variations in Cu isotope
abundances of natural materials have been identied since the late 1950s, using thermal
ionisation mass spectrometry (Walker et al., 1958). However, back then mass bias
variability of the analytical technique was too large, rendering it unsuitable for the
assessment of biochemical tracers.
Even though a range of isotope eects for the ubiquitous light elements, such as
hydrogen, oxygen and carbon have been known for decades, it was not until the early 21st
century that advances in multi collector-inductively coupled plasma-mass spectrometry
(MC-ICP-MS) and ion exchange chromatography (Albarede and Beard, 2004; Maréchal
and Albarède, 2002; Maréchal et al., 1999; Zhu et al., 2000) enabled the detection of a
measurable variation in stable isotopes of biologically relevant elements, such as Fe, Cu
and Zn, in a variety of samples, including those of biological origin.
Isotope fractionation in biological systems is based on the ‘isotope eect’. is eect
refers to a small energy change induced by the substitution of one isotope with another in
a compound (Bigeleisen andMayer, 1947; Galimov, 1987, 1985; Schauble, 2004; Urey, 1947).
is small dierence is the consequential result of the Heisenberg uncertainty principle,
which states that in a quantum mechanical space, the position and velocity of an object
cannot simultaneously be known with innite precision. Even at the zero-point energy
level (level of lowest potential energy at 0K = -273.15 ○C), named the zero-point vibrational
energy (Einstein and Stern, 1913), the bonds remain vibrating. As the kinetic energy of
the bond partially depends on the massM of the bonding atoms (i.e., 65Cu and 63Cu), the
zero-point energy and successive energy levels dier between the isotopes of an element,
resulting in mass-dependent stable isotope fractionation. Overall a system is always trying
to reduce the total energy within it. e observed preferential concentration of heavier
isotopes into stronger bonds (O- and N-bonds) over weaker bonds (S-bonds) results
in a minimisation of the overall energy in the system (Albarède et al., 2011) at ambient
temperatures.
e two major potential factors of isotopic fractionation are oxidation state and
the nature of ligands. In reference to Cu, heavy isotopes appear to concentrate in the
stiest bonds16, in particular those involving the oxidised form (Cu2+ over Cu+) and





















Figure 3.1:e electronegativity of the elements vs ionisation energy. Bond strength can be
estimated through the rst ionisation potential and the element’s electronegativity: higher
energy/potential = stronger bonds.
bind preferentially with ligands with stronger electronegativity (O>N>S) (Figure 3.1)
(Moynier et al., 2013). Available ab initio calculated fractionation factors for Cu (Fujii
et al., 2013; Seo et al., 2007) show that these general trends are closely obeyed in nature,
with compounds containing Cu in the oxidised forms being isotopically heavier than the
ones using Cu in the reduced form (Balter et al., 2013). It is anticipated that Cu binding
to oxygen-bonds, such as found in lactate and carbonic anhydrase, and nitrogen-bonds,
like in histidine, favour heavy isotopes, while sulphide-bonds, such as in cysteine and
methionine preferably bind the light isotope (Albarede et al., 2016; Albarède et al., 2011;
Balter et al., 2013).
In addition to the above principle of the isotope eect and preferential binding of
isotopes to certain ligands, the principles of mass balance dictate that physical or chemical
conversions must be incomplete for isotope fractionation to occur within a context of
metalloproteins. If all atoms of an element are transported from the source (A) to the
target compartment (B), no isotopic fractionation can occur: there is no change to the
isotopic composition (A = B). is can be observed in the inter cellular transport of
Cu by ATOX (see Figure 2.3, page 46 of Cu pathways in a generalised mammalian cell)
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(Albarède et al., 2011). In return that means that for isotope fractionation to occur, there
needs to be a dissociation of the metal-compound from its source (A) to one or more
compartments (at equilibrium or kinetically) (C and D), into at least two distinct products
(B, C and D). e observable isotopic fractionation therefore depends upon the eciency
by which the element’s transport is completed (Figure 3.2 B). e isotopic shi in the
target compartment becomes smaller the more of the element is transferred and larger if it
is less (Schauble, 2004; Young et al., 2002). Further, if such a shi in isotopic composition
occurs, it also slightly alters the mean atomic weight of the element (and its density)
which is determined both by the abundances and the nuclide masses of its stable isotopes
(Hotz et al., 2012).
e isotopic composition of a compound is expressed by the delta (δ) notation
(Equation 3.1), where the delta notation provides the relative dierence between an
isotope ratio in the sample and that in a standard. e result is reported in parts per
thousand (per mil, 1‰ = 0.1%). A negative δ value indicates an enrichment in light
isotopes compared to the reference material. e specic reference material used in this
thesis for the expression of all δ65Cu ratios is the European Reference Material
ERM-AE633. is certied reference material was produced by the Institute for Reference
Materials and Measurements (Geel, Belgium) from NIST SRM 976, a Cu reference
material that is no longer commercially available (Moeller et al., 2012), and has a known
ratio of 65Cu/63Cu of 0.44563 ± 0.00042 (see Appendix B.1 for the certicate of analysis).
is originally reported uncertainty has since been rened by one order of a magnitude




− 1] × 1000 (3.1)
In the body, each compartment (organ, body uid or group of tissues) can be
considered a ‘reservoir’, which is regulated and controlled by the uptake and excretion of
Cu based on metabolic processes (Balter et al., 2013). erefore each compartment that
does not irreversibly accumulate Cu can be assumed to be either in a steady state, where
uptake equals excretion, or transient, where it is either accumulating or loosing Cu. An
estimation of the Cu isotope ratio in an organ can therefore be calculated (Equation 3.2),
where α is the measure of the isotope fractionation of 65Cu with respect to the reference
isotope 63Cu upon transfer from one environment to the next (Balter et al., 2013).
δ65Cuorgan ≈ δ65Cublood + 1000 × (α65uptake − α
65
excretion) (3.2)
is parameter α is determined by ab initio calculations from the ratio of the reduced
partition functions β of isotopologues (e.g., 65Cu-X vs 63Cu-X) (for further information,
please consult Fujii et al., 2013, 2014, 2011; Seo et al., 2007 and Galimov, 2006).
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Isotope fractionation from A to B, A to C and A to D




Figure 3.2: Simplied isotope fractionationmodel for fractionation specic tometalloproteins. (A)
at steady-state, each isotope of the element is transferred from a single input A via a compartment
to a single output B, resulting in no isotope fractionation. (B) in a scenario where there are
selective pathways associated with a compartment, such as the uptake of Cu into the cell (A to B)
or competitive, coexisting pathways (e.g., storage, biosynthesis or excretion) (A-B to C, and
A-(B+C) to D), can result in isotope fractionation.
Table 3.1: Summary of yeast cell lines used by Cadiou et al. (2017)
Cell line
Cu reduction ability Cu isotope ratio imparted⋆ Reference in
(µmol L−1 min−1) (∆65Cu‰) Figure 3.3
SKY34 1.25 ± 0.003 −0.02 ± 0.07 A
SKY FRE 2.07 ± 0.32 −0.26 ± 0.02† B
SKY34 + AA‡ NA∫ −0.90 ± 0.02 C
DTY165 3.62 ± 0.12 −0.85 ± 0.06 D
⋆ δ65Cu value within cell vs the extra cellular medium Cu ratio (∆65Cu); errors
indicate the SD between replicate experiments
† Error indicates SD between the replicate measurements made for one
experiment (n = 1)
‡ Ascorbic acid
∫ All Cu is reduced
On a cellular level, three main mechanisms have been proposed to induce Cu isotope
fractionation: reduction of divalent to monovalent ions (see above), adsorption onto the
cell surface, and transport through the cell membrane (Cadiou et al., 2017). Adsorption
of Cu onto organic surfaces has been found to induce isotopic fractionation in bacteria,
where metabolical processes lead to the preferential uptake of 63Cu (Navarrete et al., 2011).
Recent ndings in yeast have suggested that adsorption of 63Cu onto yeast cells is very
limited and most likely not a signicant driver of Cu isotopic fractionation (Cadiou et al.,
2017). Cadiou et al. (2017) determined that the observed Cu isotope fraction into cells
occurs during uptake into the cell, where the fractionation is generated as a function of
extracellular reductases and Cu transporters.e experimental setup (Figure 3.3) elegantly
used four dierent yeast cell lines to test this hypothesis (Table 3.1): SKY34 has a reduced
capacity (∼50%) to reduce Cu compared to SKY FRE and ∼33% that of the control (DTY165).
Surprisingly the ∆65Cu dierence, representing the isotope fractionation relative to the
Cu isotope ratio of the extracellular medium, increases proportionally with the cell lines’
Cu reducing ability (Figure 3.3). In a control experiment it was conrmed that it was
indeed the ability to reduce Cu, rather than a function of variability of the Cu importer:
when all Cu is reduced via admixed ascorbic acid (SKY34 + ascorbic acid), creating a
de facto innite pool of Cu+, the ∆65Cu matches that of the DTY165 strain that has a
high capacity to reduce Cu (Figure 3.3 and Table 3.1). is means that the intracellular
Cu isotope ratio is a function of the eciency of the extracellular Cu reductase and the
therefore resulting size of the available Cu+ pool. Additionally, the preferential uptake
of 63Cu by the Cu transporters plays a role: Cu+ binds preferential with the S-bonds
present in the N-terminal of CTR1, where cysteine (Cys) and particularly methionein
(Met) rich sites (Mets motifs) are postulated to bind Cu prior to transport into the cytosol
(Cadiou et al., 2017), resulting in an enrichment of the light isotope. It remains to be shown
if this transport and associated fractionation is sucient to impart signicant isotope


























































all Cu is reduced
Figure 3.3: Schematic demonstrating potential drivers of Cu isotope fractionation in yeast cells in
experiments performed by Cadiou et al. (2017). (A) in the SKY34 yeast cell line, characterised by a
low functioning Cu reductase, all reduced Cu is transported into the cell, resulting in no isotope
fractionation between the cell and the extracellular medium. (B) the intermediate capacity of the
SKY FRE cell line to reduce Cu results in a Cu pool large enough to be available so that the low
anity Cu importer imparts a moderate isotope fractionation signal. (C) in a scenario where all
Cu is reduced through admixed ascorbic acid, the low anity Cu importer of SKY34 imparts the
greatest observed isotope fractionation, driven solely by the importer. e observed dierence in
(C) is equivalent to a control cell line (DTY165) in (D), characterised not only by a high capacity
reductase but also both high and low anity Cu importers. is demonstrates that the reduction
and associated size of the available Cu pool, as well as the Cu importers govern the fractionation
of Cu isotopes during cellular uptake, and enrichment in the light isotope.
ere are three main ways through which Cu interacts with cancer cells: cellular
metabolism, angiogenesis, and hypoxia (Albarède et al., 2017). Copper has been proposed
to act as a tumour promoter, regulating oxidative phosphorylation in rapidly proliferating
cancer cells within solid tumours (Ishida et al., 2013). Surprisingly it was shown that
in cancerous cells, the prior described mechanisms leading to Cu isotope fractionation
appears to be overwritten by (a) cancer specicmechanism(s). Rather than being extremely
elevated in 63Cu following the above outlined processes identied in yeast, the tumour’s
increasing hypoxia towards the centre has been proposed to lead to an enrichment in
heavy isotope (65Cu) in the cancer cells (Bondanese et al., 2016). A specic mechanism
leading to this pathological enrichment in 65Cu remains unknown. It was proposed that
CTR1 as well as the Cu reductase STEAP3 may play a role: within human-derived cancer
cell lines it was observed that the expression of STEAP3 is repressed in tumours, as it
is under hypoxia in-vitro; additionally, CTR1 availability at the membrane is increased
by hypoxia and when CTR1 is knocked out, there is counteraction to the hypoxic 65Cu
enrichment, conrming a role for CTR1 in this enrichment (Bondanese, 2016).
Another explanation for this wondrous 65Cu enrichment can be attributed to cancer-
specic metabolism. Within ‘healthy’ cells, glucose degradation, or glycolysis (rst step
of ATP production) is slow. e end product of this process, pyruvate, is oxidised in
mitochondria, where it fuels the more ecient steps of the citric acid cycle and oxidative
phosphorylation. Cancer cells show enhanced glycolysis followed by lactate production,
known as the Warburg eect (Vander Heiden et al., 2009). Interestingly, both pyruvate
and lactate, whose production is enhanced in cancer cells, are predicted to be isotopically
heavy (Télouk et al., 2015). At lactate concentrations typically found in tumour cells,
50 – 80% of the total cellular Cu is chelated in stable lactate complexes (Equation 3.3),
resulting in a pool of heavy Cu that is measurable.
Cu2+ + L − lact− ⇐⇒ Cu+(L − lact−)
Cu2+ + 2L − lact− ⇐⇒ Cu+(L − lact−)2
(3.3)
In a non-disease context, in general, any higher organism could potentially be
isotopically described in terms of transfer processes, such as the transfer eciency of the
metal between organs, tissues and chemical species within the organism/compartment,
as well as overall dietary uptake eciency and system losses (Bullen and Walczyk, 2009).
Pioneering results arise from work on mice and sheep, where it was found that Cu
isotope ratios in mice blood was similar to that of humans (Balter et al., 2013). Kidneys in
both mice and sheep were found to be isotopically heavy (Balter et al., 2013), likely due to
the breakdown of ascorbic acid into oxalic acid, via the production of Cu-oxalate, which
is predicted to be isotopically heavier than Cu ascorbate (Fujii et al., 2013). Sheep livers
were found to be isotopically light, similar to human tissue (Balter et al., 2013). e large
discrepancies observed between the tissues of sheep and mice highlights the question of
the role of metallo-proteins within metal homeostasis. It is unlikely that the discrepancies
reect digestive variabilities, due to the general similarities in breeding conditions and
diet (Balter et al., 2013), but rather likely presents dierences in cellular import or export,
or even larger scale variations due to the presence of dierent isoforms of ubiquitous
metallo-proteins between species.
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Besides these ndings, studies targeting whole organism Cu isotopic distribution and its
dynamics are scarce due to signicant limitations:
1) while large advances have been made, our current understanding of metal
metabolism remains limited; for example some Cu carriers in blood remain
elusive, but have been postulated to potentially play a large role (Linder, 2016).
2) even within a framework where the general contributors and uxes are known, a
secondary limitation arises which is the identication and quantication of uxes.
Direction and size of mass ows are crucial for the interpretation of isotopic data
within a whole organism.
3) assuming that points 1) and 2) are known and well understood, a nal challenge
arises, which is the prediction of Cu isotope ratios based on chemical bondswithin a
metal-protein bond. While ab initio calculations, energetics and isotopic properties
have been applied very successfully to inform about metal-protein interactions in
the past (Fujii et al., 2014), the calculations have been limited to simple molecules.
With the advent of more aordable computing power, computational fractionation
models of larger and more complex proteins will become available. Additionally,
experimental work is needed to inform about real-life expression and interaction
of protein isoforms as well as to conrm the modelled fractionation predictions.
For the above presented reasons much of the currently available Cu isotope
metallomics data is based on specic disease pathologies, where a reasonably well
characterised disease process is postulated to impart isotope fractionation. Landmark
studies of a variety of isotopic systems and their application to pathologies is discussed in
the following section.
3.1 MEDICAL APPLICATION OF CHANGES IN
METALLIC ISOTOPE FRACTIONATION
e application of isotope ratio analysis in a medical context was pioneered in iron
isotopes in adult humans’ blood (Walczyk and von Blanckenburg, 2002).is studywith its
revolutionary nding of an isotopic dierence betweenwomen andmen (see Section 3.1.2)
led to the dawn of the age of medical isotope metallomics (Albarède, 2015).
Several dierent elements and their isotopic fractionation have been analysed using
multi collector-inductively coupled plasma-mass spectrometry (MC-ICP-MS) for their
medical application. Following is a general overview of keystone ndings.
3.1.1 Calcium
Osteoporosis and some forms of cancer (e.g., myeloma) can result in bone loss. Bone loss
is typically monitored via bone density scans, which oen have a high detection limit,
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Figure 3.4: Variation in urine Ca isotopes before, during, and aer bed rest. Values are expressed
as dierence between the measured and pre-bed rest average. Grey bar represents pre-best rest
average ± 1SD (modied fromMorgan et al., 2012).
overall correlate with Ca concentrations: e.g., bone is Ca rich and 44Ca-depleted, and red
blood cells are Ca poor and 44Ca-enriched (Tacail et al., 2014). Calcium isotope studies
in bio uids have revealed that changes in bone density can be identied much sooner
than with conventional methods (days vsmonths or years) (Morgan et al., 2011, 2012). In
a NASA-sponsored long-term resting study, inspired by the bone loss observed during
spaceight, subjects underwent 17 weeks of bed rest. Results from the calcium isotope
ratio analysis of 44Ca/40Ca in urine, showed good correlation to changes in bone mineral
balance in femoral neck and lumbar spine (Skulan et al., 2007): the δ44Ca value decreases
during bed rest due to skeletal deterioration and increases as a consequence of physical
exercise. A follow-up study was even able to show that bone loss could be detected one
week aer commencing bed rest, long before mineral density changes were able to be
detected (Figure 3.4) (Morgan et al., 2012).
e monitoring of patients with multiple myeloma demonstrated that patients with
the active disease had lower δ44Ca values in blood, compared to patients in remission,
indicating that the general bone metabolism had shied to bone resorption (Gordon et al.,
2014). In rats with chronic kidney disease, no specic Ca isotope signature was found in
bones and blood serum; surprisingly though δ44Ca values for the serum samples were
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closely related to the bone mineral density parameters in these rats (Tanaka et al., 2017) .
e here-presented results strongly indicate the potential of Ca isotope measurements in
urine as well as blood serum for diagnosis, study, and assessment of bone formation and
resorption in metabolic bone disease, and associated cancers in humans.
3.1.2 Iron
In general, Fe is a tightly regulated bio-metal, which has no specic excretion pathway
in humans. When testing for dierences between women and men it was found that
their respective Fe isotopic composition varied, displaying sexual isotopic dimorphism
(Walczyk and von Blanckenburg, 2002). is observation is likely the result of a variety of
factors, including a greater anity for intestinal iron absorption as well as menstrual blood
loss in females (Jaouen and Balter, 2014; Tanaka et al., 2017; VanHeghe et al., 2014;Walczyk
and von Blanckenburg, 2002). Menstrual blood loss, similar to the phlebotomies17 used to
treat the Fe overload disorder hemochromatosis are the only known pathway removing
(excess) Fe from the body (Barton et al., 1998). Due to the inherent blood loss in females
and associated higher Fe needs, general uptake is more ecient in women compared to
men and may therefore be the origin of the heavier Fe isotopic composition observed in
women (Van Heghe et al., 2014); a second possible hypothesis proposes thatlost blood-Fe
is replaced with liver-Fe, which carries a heavier Fe isotope ratio compared to blood
(Figure 3.5) (Hotz et al., 2012; Krayenbuehl, 2005). Upon completion of menopause, or if
menstruation is absent due to contraception, women’s blood Fe isotope ratio resembles
that of men (Jaouen and Balter, 2014; Van Heghe et al., 2013).
Within the human body, Fe isotope ratios are highly compartmentalised and vary
between organs, e.g., muscle vs liver (Figure 3.5), as a function of isotope fractionation
during intestinal uptake as well as during distribution to various tissues (Hotz et al.,
2011). Patients suering from hemochromatosis show a 0.2 – 0.4‰ 56Fe/54Fe ratio (more
heavier isotopes) in blood than healthy controls (Krayenbuehl, 2005). Even though no
preferential loss of lighter isotopes or preferential uptake of heavier isotopes through
physiological pathways was identied (Walczyk and von Blanckenburg, 2005), it is likely
that perturbed intestinal Fe absorption in these patients is counter balanced through
the utilisation of bodily Fe stores (Albarède, 2015). Dierences in δ56Fe whole blood
values between individuals partly reect dierences in the eciency in Fe absorption
and a person’s Fe status (Hotz et al., 2011, 2012; Hotz and Walczyk, 2013; Van Heghe
et al., 2013). Interestingly, blood Fe isotopic composition is impacted by dietary sources:
when analysing food sources (vegetarian: -0.45‰; omnivore: 0.82‰ δ56Fe), associated
blood isotope ratios of -2.0‰ and -2.3‰ for vegetarians (female and male, respectively),
and -1.3‰ and -1.5‰ for omnivores (female and male, respectively) were observed (von
Blanckenburg et al., 2013). is represents an important consideration for future work
applying δ56Fe to medical contexts. As diet can have a signicant impact on an individual’s
blood isotope ratios, it has to be controlled for, as to not introduce a bias into the dataset.
e application of blood Fe isotope composition as a medical tool was pioneered
in hereditary hemochromatosis (Krayenbuehl, 2005), demonstrating that Fe isotope






Figure 3.5: Iron isotope variation in human body. It was proposed that heavier Fe from the liver is
released to replenish Fe lost during menstrual blood loss (pink box and arrow), resulting in the
observed dierence between women and men (modied fromWalczyk and von Blanckenburg,
2002). More recently, Van Heghe et al. (2014) proposed that the increased need for Fe due to
menstrual blood loss could result in an up-regulation of Fe uptake and therefore an increase in
isotope fractionation which is then reected in the blood.
samples, aected patients were found to have a heavier (0.7‰ vs 0.3‰) blood isotopic
composition (Krayenbuehl, 2005; Van Heghe et al., 2013). Contrastingly, patients suering
from chronic inammation with anaemia (lack of red blood cells) were observed to have
a lighter (∼0.3‰) Fe isotopic composition in whole blood compared to controls (Van
Heghe et al., 2013). Iron isotopes were also found to be sensitive to chronic kidney disease,
which is associated with the development of anaemia, where patients were found to have a
heavier isotopic composition in blood serum compared to controls (Anoshkina et al., 2017).
is heavier isotopic composition was correlated with Fe-deciency anaemia, compared
to erythropietin-related anaemia, demonstrating the ability to distinguish between the
two anaemias in the disease context (Anoshkina et al., 2017). e here summarised
ndings show that Fe isotope analysis can present a powerful tool for the assessment of
inammation driven pathologies.
3.1.3 Zinc
In comparison to Cu, Zn isotopic fractionation is less pronounced, and appears to be a
preferential binding of heavy isotopes between four- and six-fold coordination (Albarède
et al., 2017). Zinc isotopes are generally heterogeneously distributed in organisms: in mice
Zn is isotopically light in liver and brain (Balter et al., 2013), likely as a result of preferential
binding of binding with cysteine-rich residues in MT and SOD1; isotopically heavy ratios
were observed in blood and bone, likely due to specic cycling of carbonic anhydrase
withinmouse blood, however, specicmechanisms remain elusive (Balter et al., 2013, 2010;
Moynier et al., 2013).eZn isotopicmeasurements (δ66Zn) of humanwhole blood, serum





Figure 3.6: Zinc isotope variation in tissue of breast cancer patients and controls
(modied from Larner et al., 2015).
cells are isotopically heavier by ∼0.2‰ compared to blood serum, as a result of preferential
binding of Zn to histidine in carbonic anhydrase within erythrocytes and cysteine bonds
in albumin in serum (Albarède et al., 2011). Surprisingly, it was observed that there may
be an enrichment of heavy Zn isotopes in human whole blood over time (Jaouen et al.,
2013). However, this may represent a specic signature of the studied Yakut population,
characterised by a mostly uniform diet, due to their remote living circumstances. is
becomes apparent when comparing the δ66Zn ratios of several European and Japanese
data sets: the Yakut isotopic signature is vastly dierent, and therefore the enrichment
may rather be a representation of metabolic specicity or dietary source of this particular
population, than a general mechanism (Jaouen et al., 2013). is is further supported by
Van Heghe et al. (2014), who found no association between age and Zn isotopic ratios
in whole blood. Further, δ66Zn in whole blood was found to be higher for vegetarians
compared to omnivores (Costas-Rodŕıguez et al., 2014; Van Heghe et al., 2012). e role
of diet in blood Zn isotope ratios has to be further explored.
Larner et al. (2015) found that δ66Zn varied in breast cancer cells compared to
adjacent healthy tissue. Breast cancer tissue has a lighter Zn isotopic composition
(∼0.4‰) compared to the adjacent healthy breast tissue. Healthy breast tissue was
generally found to be isotopically much lighter compared to patients’ blood samples as
well as controls (Figure 3.6). e lighter isotopic composition of cancerous and healthy
breast tissue were related back to the Zn binding ability of cysteine-rich MT, which
appears enhanced in cancerous tissue (Larner et al., 2015). In contrast, no dierence was
found in serum between cancer patients and healthy controls of any age (Albarède et al.,
2017). e attribution of the tumour signature to scavenging of Zn by MT, raises the
question if this accumulation of Zn represents a trigger for the cancer development and
presence of MT a response. If the tumour Zn accumulation is indeed identied as a
trigger, this isotopic signature could serve as a biomarker, for it represents a pathologic













Figure 3.7: Sulphur isotope composition of serum and red blood cells of hepatocellular carcinoma
patients and controls (modied from Balter et al., 2015). ** p = 0.001 – 0.01; *** p < 0.001.
development of the breast cancer through a) its direct association with the development
of the cancer and b) it could potentially serve as a biomarker and carry information to
develop a disease timeline as a function of an isotopic shi from the composition of
healthy tissue. However, if the Zn isotope signature is a result of the development of the
cancer, it still carries biomarker potential, though in this case a timeline of cancer
development would have to be established to make its interpretation meaningful. e low
sample number of the study by Larner et al. (2015), paired with the general invasiveness
of a breast cancer biopsy, requires follow-up studies to further determine the viability and
feasibility of this Zn signature as a breast cancer biomarker.
3.1.4 Sulphur
Sulphur is a non-metal, associated with metal metabolism. In human adults, the mean
δ34S ratio is around 6‰ in serum and 5‰ in red blood cells (Albalat et al., 2016; Balter
et al., 2015). Between sexes, womens’ blood was shown to be 0.2‰ lower compared to men
(Albalat et al., 2016). In comparison to adults, children have a slightly heavier and more
scattered serum S isotope composition; Australians were found to have an extraordinarily
heavy serum S isotopic composition of 12.0 ± 1.7‰ (n = 5) (Albalat et al., 2016).
Concerning the application of S isotopes to medical problems, there have been eorts
in applying the method to liver (hepatocellular carcinoma) and other cancers. In patients
suering from hepatocellular carcinoma, S isotope ratios in serum and red blood cells
were lower compared to controls (Figure 3.7) (Balter et al., 2015).e approximately similar
magnitude of oset of S isotope ratios in both serum and red blood cells compared to
healthy controls strongly suggests that fractionation occurs systemically. is process was
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postulated to be a result of enrichment with S, partly originating from tumour-derived
sulphides, which carries an isotope ratio 20‰ lower than the co-existing sulphate in blood
(Balter et al., 2015). Inammation was not found to have an impact on the serum S isotope
ratios, and while dierent cancer pathologies had little aect on the serum δ34S ratio, the
observed standard deviation in breast and liver cancer cohorts was doubled compared to
controls (Albalat et al., 2016). To validate whether S isotopes can serve as biomarkers for
specic cancer pathologies, it has to be determined if the S isotope signal is of hepatic
origin or a true cancer tissue/tumour signal.
3.1.5 Copper
Copper isotope measurements have been applied in a wide range of disease contexts, to
test its potential as a biomarker for several medical conditions; these include a selection
of dierent cancer pathologies, neurodegenerative and metabolic disorders.
3.1.5.1 Cancers
Copper isotope ratios in blood serum of patients suering from breast (n = 20) and
colorectal (n = 8) cancers were assessed by Télouk et al. (2015). Samples were collected
longitudinally and compared to a healthy reference population (n = 50). e results
revealed that there may be a serum δ65Cu threshold value (∼ 0.35‰), beyond which if
the ratio drops, could serve as a biomarker/mortality predictor in these cancer patients:
colorectal cancer (p = 0.018) and breast cancer (p = 0.0006) (Figure 3.8A). Indeed, those
patients of that study whose serum isotope ratios reached below the ‘threshold’ level did
not survive beyond a few months. is drop in Cu isotope ratio preceded biomarkers
typically used to detect those cancers (e.g., carcinoembryonic antigen) by several months
(Télouk et al., 2015). is shi towards a lighter isotopic composition may be the result of
extensive oxidative chelation of Cu by cytosolic lactate, as a result of the ‘Warburg eect’
(Télouk et al., 2015) (see page 63). e lactate produced by anaerobic respiration has the
ability to chelate isotopically heavy, cytosolic Cu, enriching the cancer cells with it, while
depleting the blood serum, meaning it becomes isotopically lighter (Bondanese et al.,
2016).While these results appear very favourable towards the notion that Cu isotope ratios
could serve as a diagnostic tool for breast and colorectal cancer, it has to be cautioned that
this ‘absolute’ indicator for increased mortality has not been calibrated for specic pheno-
and genotypes of the cancers studied. It should further be noted that a relative threshold
value, taking into account, sex, age, menopausal state, diet and other personal/ethnic/local
variations, which are known or predicted to change the Cu isotopic composition in blood,
should be the desired outcome. Such a relative measure could indeed serve as a powerful
cancer biomarker in the future.
Assessment of serum and red blood cells of hepatocellular carcinoma (liver cancer)
patients showed that red blood cells of patients are isotopically lighter (Figure 3.8C);
both serum and red blood cells in the cancer patients were found to have elevated Cu
concentrations, compared to those of controls (Figure 3.8B) (Balter et al., 2015). e
observed isotopic signature is likely not the result of enhanced dietary Cu uptake, as
the blood isotope signature would be expected to have shied towards the typical δ65Cu
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Figure 3.8: Copper isotope application as a cancer biomarker. Panel (A) compares δ65Cu ratio
(black line) with typically used cancer biomarkers: CA15.3 (carbohydrate antigen, purple) and CEA
(carcinoembryonic antigen, yellow). Copper isotope ratios appear to precede the increase of the
cancer biomarkers, which indicates a worsening of the disease (modied from Télouk et al. (2015).
(B) Copper concentrations (µg g−1) in tissues of hepatocellular carcinoma patients compared to
controls; Cu is elevated in blood compartments in cancer patients, while the comparison of adjacent
tumour and healthy liver tissue show no dierence. (C) δ65Cu ratio in blood compartments and
liver tissue of hepatocellular carcinoma patients compared to healthy controls; serum shows no
dierence, while red blood cells and tumour tissue compared to healthy liver tissue do (B and C
modied from Balter et al., 2015). ** p = 0.001 – 0.01; *** p < 0.001.
ratio of diet (+0.4‰), which Balter et al. (2015) proposed to not be compatible with the
observed Cu isotope signature in the blood compartments. e Cu isotope signature was
proposed to represent (Balter et al., 2015):
1) a reduced discharge of Cu via the bile, a common complication in liver cancer,
leading to a systemic accumulation of reduced Cu;
2) a release of Cu from endogenous, cysteine-rich stores, of which MT was
hypothesised to be the most likely. is was estimated based on the three most
common cellular metallo-proteins (SOD1, CCO and MT), of which MT would be
the one with the lightest Cu isotope composition, therefore its release could result
in the observed light isotopic signature; and
3) assuming non-mutual exclusivity to the previous two hypotheses, a third was
proposed, based on the observation of systematical enrichment of tumour tissue
with 65Cu (Figure 3.8C); involving mass conservation following the initial release of
a pool of isotopically light Cu from MT, resulting in the enrichment of the tumour
with isotopically heavy Cu. is accumulation of 65Cu could then further enhance
the observed depletion observed in the blood compartments (Balter et al., 2015).
Such a relationship could indicate that further enrichment within the tumour leads
to enhancement of the original light isotopic Cu signature in blood, as a function
of the cancer’s ‘severity’18 (Balter et al., 2015).
In particular the third hypothesis could present a more universal indicator for a
parameter such as tumour size or impact on the organism as enrichment in 65Cu does not
appear to be a process exclusive to liver cancer. Interestingly, Lobo et al. (2017) made a
similar observation to Balter et al. (2015) in patients with oral squamous cell carcinoma19
where tumour tissue was signicantly (p = 0.0017) enriched in 65Cu compared to adjacent
non-tumour tissue. One major drawback of this signal would be the relative size and
proportion of the cancer in relation to the size of the liver and blood Cu pool. For the
modest enrichment (∼0.5‰) of the cancer with isotopically heavy Cu, the cancer would
have to dominate a signicant amount of the liver to shi the Cu isotopic composition in
serum relative to healthy controls and above background variation. For the tumour to
dominate a large amount of the liver is dicult: while in a healthy liver as little as 20% of
its volume is required to sustain life, in an already diseased liver more than 40% is required
(Guglielmi et al., 2012). Furthermore to aid the establishment of a Cu isotope liver cancer
biomarker, applied terminologies, such as ‘cancer’ and ‘tumour’ have to be clearly dened
concerning the number of tumours present within the aected tissue, size of the largest
tumour within the pool of tumours, as well as total tumour volume if multiple are present
(Germani et al., 2011).
As a nal point of consideration it has to be questioned how red blood cells and the
observed Cu isotopic signature (Figure 3.8C) relate to the liver tumour, if this signature
is to become useful as a biomarker. Albarède et al. (2011) postulated that the Cu isotope
ratio carried by red blood cells is a reection of the redox conditions present during
18Severity could refer to factors such as size, presence/spread, localisation, staging and aggression
of the cancer/tumour.
19Cancer of the oral cavity with possible location from the mucosal surface of the lips to the back
of the tongue, excluding the nasal cavity and throat.
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erythropoiesis in the bone marrow, which become enriched in heavy Cu (+0.5‰) relative
to serum (-0.3‰). Given that only 1/1000th of the serum Cu is involved in the synthesis of
red blood cells (Albarède et al., 2011), it seems unlikely that there is a direct link between
the tumour, serum (which shows no cancer specic isotope signature) and red blood cells.
Focus should be placed on identifying a mechanism that can explain why red blood cells
potentially carry a signature related to the tumour.
3.1.5.2 Other disorders
In Wilson’s disease, a genetic disorder aecting Cu metabolism, it was found that patients’
blood serum had a δ65Cu ratio of ∼-1.7‰, while controls had a δ65Cu ratio of ∼-0.7‰
(Aramendı́a et al., 2013). is was proposed to be a consequence of low eciency of
incorporation of Cu into ceruloplasmin, leading to an enrichment in 63Cu in patients’
serum. Further work showed dierences in the δ65Cu values of urine of untreatedWilson’s
disease patients (-20 – -35‰), compared to urine of patients treated with a Cu chelating
drug (-0.06 – -1.8‰) (Resano et al., 2013). More work is needed to explore specic
mechanisms.
Several neurodegenerative diseases, such as Parkinson’s and ALS have been proposed
to be associated with perturbed Cu metabolism, and could therefore result in a
disease-isotopic signature in blood which should be measurable. In a longitudinal study,
Parkinson’s patients ingested a single dose of 65Cu tracer. Blood samples were collected at
predened intervals over 72 h, analysed and revealed a potentially perturbed Cu
metabolism and less ecient Cu absorption in Parkinson’s patients, compared to controls
(Larner et al., 2013). ese results seem promising, though no single mechanism was
identied responsible for this observation. Future work needs to better characterise the
origin for the apparent perturbation in Cu metabolism.
e Cu isotopic composition of serum was investigated in liver cirrhosis patients,
which showed that patients’ had a Cu isotopic composition signicantly lighter
(δ65Cu = -0.04 – -1.15‰) compared to that of a control group (∼-0.29‰)
(Costas-Rodŕıguez et al., 2015). Copper isotope ratios were positively correlated with a
variety of liver cirrhosis-related parameters, such as aspartate aminotransferase, and
bilirubin. Inverse correlations were observed for δ65Cu with albumin and Na
concentrations. Negative correlations were found between δ65Cu and the Child-Pugh
score, and Mayo Clinic Model for End-stage Liver Disease score. is dierence was
proposed to be the result of hepatocellular and biosynthetic dysfunction of the liver, as
well as inammation and water retention. is is supported by ndings that demonstrate
patients with end stage liver disease and associated complications (e.g., ascites20) had the
lowest δ65Cu values (Figure 3.9A) (Costas-Rodŕıguez et al., 2015); lower values and a
wider spread in the measurements appear to indicate an elevated mortality risk.
In patients with end-stage liver disease, transplantation is currently the only viable
treatment option. Copper isotope ratios in serum of patients with end-stage liver disease
and hepatocellular carcinoma and those without the cancer did not dier signicantly
from one another (average: -0.80 ± 0.57‰, 2SD, N = 32) (Lauwens et al., 2016), while the
dierence to healthy controls (∼-0.26‰) was signicant. Interestingly, aer
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Figure 3.9: Copper isotope application as a liver cirrhosis biomarker. Figure (A) compares δ65Cu
values in the serum of liver cirrhosis patients with and without ascites compared to healthy
controls. Solid and dotted line indicate the reference population (mean ± 2SD) (modied from
Costas-Rodŕıguez et al., 2015). (B) Data compilation of follow-up study of serum δ65Cu values
in patients without recurrence of liver failure. e grey area represents the healthy reference
population (mean ± 1SD). A steady increase of the δ65Cu values post liver-transplantation
(LTx) is indicated by red arrows. Dierent colours in the dataset indicate distinct patients
(modied from Lauwens et al., 2016).
transplantation of a donor liver, the serum isotope composition for the liver disease
patients normalised following the restoration of normal liver function following
transplantation (Figure 3.9B). is trend is associated with restoration of normal liver
function, as well as restoration of hepatic metabolism and/or the restoration of the biliary
secretion pathways. About 40% of patients were reported to have reached the reference
range of a healthy liver three months post-transplantation, increasing to about 60% aer
nine months (Lauwens et al., 2016). A later decrease in the isotope ratios appears to
indicate a reoccurrence of the disease, potentially making this a powerful tool for the
detection of liver failure reoccurrence.
is chapter has reviewed and discussed medical isotope metallomics, its applications
and general principles. Previous work has shown the great potential of natural isotope
ratios to serve as biomarkers for a variety of conditions, ranging from bone loss to cancers.
As Cu isotope ratios are sensitive to changes in binding anities, it is a suitable approach to
reevaluate the perturbations in Cu metabolism associated with ALS. is can be achieved
through analysis of tissues from mouse models of ALS, as well as from ALS patients.
Further, using such tissues, it can be evaluated if Cu isotopes have the potential to serve
as an (early) biomarker, similar to the above proposed cancer scenarios. For such an
approach to be feasible, high sample throughput is required. Herefore an automated Cu










PROCEDURE OPTIMIZED FOR ANALYSIS OF
STABLE CU ISOTOPES FROM BIOLOGICAL
MATERIALS
Data used to generate gures for this chapter can be found in Appendix A.2.
Portions of this chapter were previously published in:
Enge, T.G., Field, M.P., Jolley, D.F., Ecroyd, H., Kim, M.H., Dosseto, A., 2016. An
automated chromatography procedure optimized for analysis of stable Cu isotopes from
biological materials. Journal of Analytical Atomic Spectrometry, 31(10), 2023 – 2030.
doi:10.1039/C6JA00120C
Author contributions: TGE performed and analysed all experiments. TGE and MPF
conceived the method; MHK assisted in the original method setup. TGE, DFJ, HE and AD
developed the method into its nal form, and assisted with data interpretation. TGE wrote
the manuscript and generated gures; all authors edited the manuscript for submission.
79
4.1 STUDY RATIONALE
e development of multi collector-inductively coupled plasma-mass spectrometry
(MC-ICP-MS) has facilitated high precision Cu isotope ratio measurements with a
precision of oen better than ±0.1 – 0.2‰ (2s) (Maréchal et al., 1999), enabling the
resolution of small natural Cu isotope eects. An increasing interest in stable 65Cu/63Cu
isotope measurements originating from biological source material has led to the
application of isotope ratio measurements in medical research, with varying degrees of
success (see Chapter 3 for review). For biomarkers, medical and diagnostic tools to be
developed based on Cu isotope analysis, automation and the ability to process large
sample numbers is required (Costas-Rodŕıguez et al., 2015; Télouk et al., 2015).
Methods conventionally used to separate Cu from complex sample matrices for
isotopic analysis typically utilise a variation of ion exchange chromatography (Costas-
Rodŕıguez et al., 2015; Larner et al., 2011; Maréchal et al., 1999). Maréchal et al. (1999)
used the 100-200 mesh, macroporous anion-exchange resin AG MP-1 (Bio-Rad, USA) in
chloride form, where Cu was loaded on the resin in HCl + H2O2. Hydrogen peroxide was
used as an oxidising agent to ensure all Cu was present as Cu2+. Copper is moderately
retained at high HCl concentrations, during which the matrix was removed and eluted in
the same 7 M HCl + 0.001% H2O2 solution, used for sample loading and matrix removal
(Maréchal et al., 1999). Several problems may arise in this procedure:
1) the potential for incomplete Cu elution,
2) unwanted Cu fractionation, and
3) the overlapping of the Cu elution with matrix elements, induced by varying
sample types.
ese issues mean that a second column pass and adjustment of the method for each
individual application is oen required (Archer and Vance, 2004; Borrok et al., 2007;
Chapman et al., 2006; Larner et al., 2011; Zhu et al., 2002).
Amethod by Larner et al. (2011) improved the extraction of Cu frombiological samples
by making use of the varying distribution coecients of Cu+ and Cu2+ on the strongly
basic, 200 – 400 mesh, anion exchange resin AG-1 X8 (Bio-Rad) (Larner et al., 2011).
is approach achieved a reproducibility of ±0.15‰ of 65Cu/63Cu ratio measurements,
and was therefore deemed suitable for the isotopic analysis of biological material (Larner
et al., 2011). While this method does provide signicant improvements over previous
methodological approaches, it is still complex and time intensive, relies on the complete
reduction of Cu through the introduction of an oxidising agent (ascorbic acid), and does
not provide an automated approach for increased sample throughput.
e aim of the work presented here is the development and adaption of an automated
approach to Cu ion exchange chromatography, optimised for biological materials. It is
optimised to enable high sample throughput and circumvent the manual labour cost
associated with traditional methods. e commercially available automated
chromatography system prepFAST-MCTM (Elemental Scientic, USA) has been
successfully used for the analysis of Ca and Sr in a wide range of matrices (Romaniello
et al., 2015), and was therefore chosen as the development platform. e prepFAST-MCTM
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is a low-pressure automated chromatography system that uses one reusable column to
process samples sequentially, including a cleaning step between each new sample. A
highly reusable column, used for the extraction of Cu, enables the simple, reliable, robust
and ecient separation of Cu from biological source material on a large scale.
4.2 SAMPLES
4.2.1 Synthetic samples
ree types of sample were prepared to develop, test and calibrate the automated method:
pure isotopic standard solutions, pseudosamples, and chicken liver. Pure isotopic
standard solutions were diluted from the certied reference material solution
ERM-AE633 (European Reference Materials, European Commission, Geel, Belgium) and
used to initially assess the chromatography’s suitability to process isotopic material
without inducing isotope fractionation. e concentrations were adjusted to 200 ng g−1
and 500 ng g−1 in 0.3 M HNO3.
Since at the time of analysis no biological reference materials certied for total Cu
content and Cu isotope composition were available, four pseudosamples were prepared
from high purity single element standard solutions, with a purity of 99.99 – 99.9995%,
(Inorganic Ventures, USA and Elemental Scientic Inc., USA) to simulate the matrix
composition of fully digested biological material, with the exception of carbon.
Pseudosamples 1, 2 and 4 imitate the matrix composition of a typical chicken liver
(Table 4.1) as characterised by the United States Department of Agriculture (Basic Report
05027, National Nutrient Database for Standard Reference Release 28) with the exception
of C, while pseudosample 3 followed the same proportions as the other pseudosamples,
but replaced K with Na, Mn with Hg, Na with Li, P with Se, Se with In and Zn with Ni,
due to limited availability of single element standards. In pseudosamples 1 and 2, Cu was
added from a high purity single element standard (Inorganic Ventures, USA) whilst in
pseudosamples 3 and 4, the Cu was added from the ERM-AE633 isotopically certied
solution (Moeller et al., 2012), both resulting in a nal Cu concentration of 492 ng g−1.
Pseudosamples 1 and 2 were exclusively used for the determination of the elution prole,
column yield and to assess carry over, while pseudosamples 3 and 4 were used to assess
isotopic precision and accuracy of the chromatographic extraction.
4.2.2 Chicken liver samples
To test the applicability of the method to real biological matrices, two aliquots of chicken
liver were prepared. Several livers were purchased from the local butcher, split into
subsamples, and freeze dried at -55 ○C under vacuum for 48 h. Two subsamples were
chosen and crushed with a chromium alloy rotary disk mill for 30 seconds and
additionally homogenised manually using an agate mortar and pestle.
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4.3 ANALYTICAL PROTOCOLS
4.3.1 Reagents and materials
All reagents for work in this thesis were made up from Suprapur® and Ultrapur®HCl,
HNO3, H2O2 (Merck, Germany), and iQ® and Baseline®HCl, HNO3, H2O2 (Seastar
Chemicals, Canada) while deionised 18.2 MΩ-cm H2O (Merck Millipore, USA) was used
to prepare dilutions and stock solutions. Stock solutions were volumetrically diluted. e
pH of the 0.001 M HCl solution was tested for every new batch to be pH 3.
Peruoroalkoxy alkane (PFA) vials were used for sample digestion and to dry down
solutions. Vials used for MC-ICP-MS analysis were made of high-density polyethylene
(HDPE) and for Q-ICP-MS analysis of polypropylene (PP). e PFA vials were washed
overnight at 100 ○C in 7.5 M HNO3 and rinsed with H2O.e HDPE and PP vials were
rinsed using 0.3 M HNO3 and H2O at room temperature.
4.3.2 Freeze drying
All freeze drying of samples was performed using an Alpha 1-2 LDPlus (Fisher Bioblock
Scientic, France). e freeze drying procedure was optimised using chicken breast and
mincedmeat samples purchased from a local butcher. Varying sample sizes of each sample
type were separated into centrifuge tubes, weighed and frozen overnight at -20 ○C.e
frozen samples were placed in the freeze dryer chamber and frozen to -55 ○C for two hours,
before the main drying stage was initiated by setting the chamber under vacuum. To
assess when the freeze-drying process was complete, the samples were initially removed in
one-hour intervals and weighed to assess how much water had been removed (Figure 4.1).
In both sample types, a mass-dependent water removal eciency was detected by about
eight hours, aer which the maximum level of water removal was achieved. Following
the continuation of the process overnight, no signicant dierence was detected aer 20
hours. erefore, it was decided to freeze-dry all samples in excess of 24 hours to allow
for any potential irregularities in the various sample matrices.
4.3.3 Microwave assisted acid digestion
e digestion of samples for processing via the automated chromatography was
performed using a MARS 5 or MARS 6 microwave digestion systems (CEM Corporation,
North Carolina, USA) at the University of Wollongong (UOW) and the University of
Technology, Sydney (UTS) respectively. e method details for each machine are given
below. While the details vary slightly, repeat processing of the identical certied reference
material demonstrated that their performance is equivalent to one another (see Section
4.3.5.1).
MARS 5 – UOW
Samples of chicken liver (0.06 – 0.21 g) and DORM-2 (∼0.1 g; Dogsh muscle certied
reference material, National Research Council, Canada) were weighed, and then
pre-digested in MARSXpress 75 mL PFA vessels in 2 mL of 15 M Ultrapur®HNO3
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Table 4.1: Typical chicken liver (Basic Report 05027, National Nutrient Database for Standard
Reference Release 28, United States Department for Agriculture)
Element Unit Value per 100 g Std. Error n
Ca mg 8 1.040 4
Mg mg 19 0.403 4
P mg 297 8.109 4
K mg 230 13.720 4
Na mg 71 5.542 4
Zn mg 2.67 0.054 4
Mn mg 0.255 0.014 4
Se µg 54.6 8.247 4
Cu mg 0.492 0.102 4








































Figure 4.1: Results of the freeze dryer assessment with regards to % water removed from total
mass against time, following a two hour freezing period at -55 ○C. For the chicken breast samples,
sample masses are shown, demonstrating a mass dependent eciency of water removal. Aer
about eight hours, the freeze drying process is complete.
overnight at room temperature. e following day samples were digested using a MARS 5
microwave digestion system. e temperature was ramped to 210 ○C over 30 min and
then held constant for 90 min to ensure that all organic carbon was oxidised to CO2.
Before opening, the vials were le to cool to room temperature.
MARS 6 – UTS
When digesting with the MARS 6, samples and DORM-2 (∼0.25 g) were weighed, and
pre-digested at room temperature in MARSXpress 20 mL PFA vessels in 2.5:1 mixture of
15 M Ultrapur®HNO3 and Ultrapur® 30% H2O2 for 30 minutes. ese samples were
further digested using a MARS 6 (CEM Corporation, USA) microwave system. In
agreement with the manufacturer recommendations, the temperature was ramped to
210 ○C over 15 min and then held constant for 150 min to ensure that all organic carbon
was oxidised to CO2(g). Vials were le to cool before the clear solutions were decanted.
Upon removal from the microwave, all digestion solutions were clear. At this point,
0.32 mL aliquots were taken from the samples and diluted with 9.68 mL of H2O for
trace metal concentration analysis via quadrupole-inductively coupled plasma-mass
spectrometer (Q-ICP-MS) (Figure 4.2). e remaining solutions were then evaporated
to dryness under Class 10 cleanroom conditions and reuxed in 2 mL of 0.001 M HCl
overnight and ultrasonicated for 15 min. To avoid any potential residual particulate matter
from being loaded onto the column, the samples were centrifuged for 5 min at 1287 × g.
e supernatant was decanted into pre-cleaned 15 mL centrifuge tubes before loading
onto the prepFAST-MCTM Cu column.
4.3.4 Copper separation and matrix removal
To eciently separate the Cu from the matrix of biological samples in an ecient way, a
new chromatography method was developed and performed on prepFAST-MCTM
systems at Elemental Scientic (ESI) and the Wollongong isotope geochemistry
laboratory at the University of Wollongong (WIGL) using a 500 µL Cu column (Part
Number: MC-CF-Cu-500). Samples were loaded in 2 mL 0.001 M HCl onto the column.
e separation protocol used two reagents, 0.001 M HCl (pH 3) to load and wash the
matrix, and 8 M HCl to elute Cu and clean the resin (Figure 4.3 and Table 4.2).
Flow rates and volumes were syringe-driven and programmed independently for each
step of the method. is enabled faster ow rates (3000 µL min−1) for the cleaning of the
column, conditioning and washing of the matrix, while it permitted slower ow rates
for the loading and elution steps (Table 4.2), where fractionation of Cu on the column
could have potentially occurred.is tight control of the ow rates and volumes is a major
advantage of the prepFAST-MCTM system over conventional gravity-driven and vacuum
box chromatography methods.emethod allows for possible adjustments of the method
for longer washes to remove complex sample matrices from a wide range of sample, as Cu
will not liberate from the stationary phase until the pH of the solution passing through
the column drops below pH 1. is setup enables a sample throughput of ∼36 samples per
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Table 4.2: Chromatographic steps for the automated
separation of Cu (500 µL Cu column)
Step Purpose Volume (mL) Flow rate (µL min−1) Reagent
1 Clean column 2×1.5 3000 8 M HCl
2 Condition column 2×3 3000 0.001 M HCl (pH 3)
3 Load sample 2 400 0.001 M HCl (pH 3)
4 Elute sample matrix 2×2 3000 0.001 M HCl (pH 3)
5 Elute Cu fraction 2×1.25 1000 8 M HCl
Table 4.3: Selection of major isobaric and matrix interferences for Cu and Ni isotope
measurements for biological samples (Larner et al., 2011; May et al., 1998)
Element Mass Interferences
Cu 63 23Na40Ar+, 23Mg38Ar+, 26Mg37Cl+, 31P16O2+, 47Ti16O+
65 25Mg40Ar+, 32S33S+, 33S16O2+, 49Ti16O+, 130Ba2+
Ni 60 23Na37Cl+, 24Mg36Ar+, 44Ca16O+
62 23Na216O+, 24Mg38Ar+, 26Mg36Ar+, 31P2+, 46Ti16O+
Table 4.4: Copper recovery from pseudosamples, as well as isotope analysis of select samples
(‰, 2SE) compared to certied and accepted value
Pseudo





1 8 Ca, Fe, Mg, Zn, Cu, Se, P, K, Na, Mn 96 ± 2% NA⋆
2 10 Ca, Fe, Mg, Zn, Cu, Se, P, K, Na, Mn 99 ± 2% NA⋆
3 5 Ca, Fe, Mg, Cu, Se, Na, Li, Hg, Ni, In 95 ± 3% -0.01 ± 0.02 0.00 ± 0.94†
4 5 Ca, Fe, Mg, Zn, Cu, Se, P, K, Na, Mn 96 ± 4% -0.03 ± 0.02 0.00 ± 0.05‡
NA⋆: Pseudosample 1 & 2 did not contain Cu-isotopic reference material and were therefore not analysed for
their isotopic composition
† see ERM-AE633 certicate, appendix B.1











































































































































































































































































roughout the processing of samples with the new chromatography method, all
collected method aliquots (load, wash matrix and elution) were dried down and
reconstituted in 2 mL of 0.3 M HNO3 for analysis.
High precision Cu isotopic analysis of biological samples can be aected by elements
present at high concentrations in the matrix (e.g., P, Mg, Na). ese elements can impede
on the ve monitored isotopes of Cu and Ni through mass bias and result in inaccurate
results.emass bias is a result of the variation in transport eciency between the dierent
isotopes from the plasma ion source to the multi-collector. Presence of matrix elements
can further lead to the formation of polyatomic ions and/or isobaric nuclides, which
lead to spectral overlap and interference (May et al., 1998) (Table 4.3). It is consequently
essential that these elements be eciently removed. All monitored elements were only
present at background levels in the tested samples aer the chromatography (Table 4.4),
with the exception of Fe, which is not an interference-forming element for the observed
isotopes.
To compile an elution prole, 1 mL fractions across the entire chromatographymethod
(Figure 4.3) and 0.25 mL fractions for the Cu elution (inset Figure 4.3) were collected and
analysed. e elution prole served to calibrate the column and optimise the volumes
used in the chromatography, in order to achieve the reproducible collection of matrix free
Cu elutions with high yields (Tables 4.4 and 4.5).
e nal chromatography volumes were optimised to 2 x 2 mL of 0.001 M HCl for
complete matrix removal in the tested samples and 2 x 1.25 mL of 8 M HCl for the Cu
elution, resulting in the ecient removal of Na (99.9%), Mg (99.8%), K (100%),
Ca (99.9%), Mn (98.6%), Fe (96.6%), Zn (98.5%), P (99.2%) and Se (99.1%) (Figure 4.3;
Tables 4.2 and 4.5). In the Cu elution fraction, only negligible residual Fe was observed.
e high capacity of the resin (3 mg Cu g−1) and ability to operate under ow rates of up
to 6 mL min−1 makes it ideal for an automated system.
4.3.5 Measurements
4.3.5.1 Q-ICP-MS
Elemental concentration analysis was performed on an iCAPTM quadrupole-ICP-MS
(ermo Scientic) at WIGL and an ElementTM 2 sector eld-ICP-MS (ermo
Scientic) at Elemental Scientic. Recoveries of metals from the certied reference
material (DORM-2, NRCC) were between 84 and 105% of the expected values (Table 4.6)
for all aliquots measured in work described in this thesis. A 1 ng g−1 multi-element
solution, measured in regular intervals was used to assess the measurement
reproducibility, which was typically less than ±1%. e concentrations were quantied
using a multi-element standard external calibration curve, and long-term instrument
dri was corrected by using a 50 ng g−1 Ga solution as an internal standard.
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Table 4.6: Recoveries of selected metals from DORM-2 (µg g−1 ); for the certicate of the CRM,
see Appendix B.2
MARS5 MARS6
Element Certied 2SD Measured 2SD Recovery (%) n Measured 2SD Recovery (%) n
Co 0.182 0.031 0.164 0.081 90 4 0.171 0.032 94 14
Cu 2.34 0.16 2.38 0.11 102 4 2.33 0.08 100 14
Fe 142 10 133 19 94 4 136 22 96 14
Ni 19.4 3.1 16.5 1.6 85 4 16.2 4.8 84 14
Zn 25.6 2.3 26.9 1.8 105 4 25 5 98 14
4.3.5.2 MC-ICP-MS
Aer the collected eluates were dried down, they were reuxed in variable volumes of 0.3
M HNO3 solution, to dilute them to a target concentration of approximately 100 ng g−1
Cu for analysis.
Variations of stable isotope ratios are usually small and expressed relative to a standard
reference material. Transition metal isotope ratios, like Cu, can be described using the
unit-less δ-notation, expressed as a per mil (‰) deviation from the standard value. e




− 1] × 1000 (4.1)
For the specic work described here, δ65Cu is expressed relative to the 65Cu/63Cu
ratio of the ERM-AE633 Cu isotopic reference material (0.44563, Moeller et al., 2012;
see appendix B.1), unless specied otherwise.
Isotopic analyses of any sort must comply with fundamental requirements for results
to be meaningful. It is important to conrm that the analysis represents the true isotopic
composition of the sample. To answer this question, factors that may aect the isotopic
composition of the samples have to be controlled. e composition of the sample may
potentially have a signicant inuence on the ionisation of the element of interest, as
described by the matrix eect. e magnitude of the matrix eect’s inuence on the
true isotopic ratio has to be evaluated and matrix elements removed if signicant or
disregarded if negligible (Albarede and Beard, 2004). Matrix elements signicant to Cu
isotopic analysis can be removed via ion exchange chromatography, as described above
(Larner et al., 2011; Maréchal and Albarède, 2002).
Further sources of error on the isotopic ratio that have to be considered, and arise
as part of the mass spectrometer apparatus, such as the sample introduction system, ion
extraction from the plasma and isotope mass bias as a function of increasing eciency of
ion transfer through the instrument (Albarède et al., 2015) (Figure 4.4). Additionally, dri
with time has to be corrected.
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Table 4.7: Standard operating conditions for the Neptune PlusTM MC-ICP-MS
RF power 1200 W
Cool gas 17 L min−1
Auxiliary gas 0.7 L min−1
Sample gas ∼1 L min−1
Sensitivity for Cu ∼35 V ppm−1
Sample uptake rate 100 µL min−1
Measurement resolution low
To correct and account for the above mentioned sources of error, samples were
doped with a Ni solution, to obtain a nal concentration of 250 ng g−1 Ni. is admixed
Ni is used as an internal standard to correct mass bias (Maréchal et al., 1999; Mason
et al., 2004). Copper isotope measurements were performed with a Neptune PlusTM
MC-ICP-MS (ermo Scientic), using the operating conditions outlined in Table 4.7.
Standard sample and skimmer cones, cyclonic spray chamber and PFA nebuliser with a
ow rate of ∼100 µL min−1 (Elemental Scientic Inc., USA) were used for all Cu isotopic
measurements made in this thesis.
e analyses were carried out by static multi-collection with ve Faraday cups
(Figure 4.5) to monitor masses 60, 61, 62 for Ni and 63, 65 for Cu (Larner et al., 2011).
Data acquisition was performed over three blocks of 20 cycles of four seconds integration
each, with an idle time of 3 s. An amplier baseline was performed before every block,
and a routine instrumental sensitivity of ∼35 V ppm−1 for 63Cu was achieved. e
measurements were corrected for mass discrimination through a combination of internal
correction with the admixed Ni applying Russell’s exponential law (Baxter et al., 2006)
and external normalisation using a standard sample bracketing approach, as described in
Nielsen et al. (2004) and Zhu et al. (2000). e measured 65Cu/63Cu isotope ratios were
tested for outliers, ≥ two standard deviations from the mean (2SD).
e typical measurement repeatability of a NIST SRM-976 standard solution was
δ65CuERM-AE633 -0.04± 0.01‰ (2SE; n = 350) (Figure 4.6), which is in good agreement with
published values (Moeller et al., 2012). It has to be noted that the measurement precision
is dependent on the measurement sensitivity and maintenance of the instrument. In
Figure 4.6, it is shown that an observed decrease in measurement sensitivity led to an
increase in measurement variability (aer the 94th standard analysis), which could be
compensated through ne tuning of the machine and the later replacement of the low
resolution slit (aer the 193rd standard analysis).
Currently no biological reference material certied for Cu isotope measurements
exists. Several materials have been analysed with good reproducibility across dierent
laboratories. Here, the certied reference material (CRM) DORM-2 (see appendix B.2)
was utilised as it was a commonly used CRM for trace metal analysis. Table 4.6 shows that
the recovery of metals was within the recommended guidelines. As for the Cu isotopic
composition, the material does not appear to demonstrate the same homogeneity as for




































































































homogenisation of the sample during manufacturing, the data suggests a heterogeneous
distribution of Cu isotopes in the sample. is could stem from varying contributions
of dierent muscle tissues, diet and sex of the sh used, which are all factors known to
contribute to the heterogeneous distribution of isotope ratios in biological tissue (Balter
et al., 2013; Balter and Vigier, 2014; Balter and Zazzo, 2011; Balter et al., 2010). e analysis
certicate for the DORM-2 does not elaborate on these parameters. As this large spread
of Cu isotope ratios (∼4‰) was not observed in repeat samples of chicken liver aliquots
(Figure 4.12) and other samples (Section 4.4.4 and Chapters 5, 6 and 7), or between samples
processed in one batch (Figure 4.7), it was concluded that the reference material was the
source of the observed variability, rather than it being a method-induced artefact.
e typical total procedure blank over three years of analysis was determined to be
1.4 ± 2.7 ng (2SD; n = 26), with a mean δ65CuERM-AE633 value of 14‰. Blank contribution
was typically less than 0.3%, which is in good agreement with results reported in other
studies (see Section 4.4.1).
4.4 METHOD VALIDATION
4.4.1 Blanks
In tracemetal isotope analysis it is crucial that blank concentrations are reduced asmuch as
possible (Albarede and Beard, 2004). To achieve this goal, themethod was setup to include
a resin wash step before every conditioning step with 3mL (6 column volumes) of 8MHCl
(Table 4.2). Processing total procedure blanks alongside the pseudosamples 3 and 4 for
the development of the automated method, under clean room conditions, monitored the
average procedural blank of the method. e average blank contribution was 0.5 ± 0.3 ng
Cu (2SD; n = 11), equivalent to ≤0.1% of the amount of Cu processed for sample analysis
(∼333 – 990 ng). is is at the lower end of the reported range for blank contributions
in other studies, which is between 0.021 – 3% (Aramendı́a et al., 2013; Costas-Rodŕıguez
et al., 2015; Larner et al., 2011; Maréchal et al., 1999; Van Heghe et al., 2012).
L3 L2 L1 C H2
1011Ω 1011Ω 1012Ω 1011Ω 1011Ω
60Ni 61Ni 62Ni 63Cu 65Cu
















































































































DORM-2 biological reference material
1 5 10 15 20 25 30 35
Figure 4.7: Repeatability of measurement of DORM-2 biological reference material, mean on top
of yellow (0.79 ± 0.17‰) and blue (0.79 ± 1.04‰) shaded regions indicating the 2SE and 2SD
condence intervals, respectively (n = 39). e dierent colours indicate sample batches. Samples
with the same colour were processed together.
When testing samples in series of pseudosamples 1 and 2, blank contribution was on
average slightly higher than the total procedure blanks processed with pseudosamples 3
and 4, the latter processed under clean room conditions (see above); pseudosample 1:
1.8 ± 3.1 ng Cu (2SD; n = 50) (Figure 4.8A and B); pseudosample 2: 1.5 ± 1.3 ng Cu (2SD;
n = 18) (Figure 4.8C). ese samples were processed and measured under regular
laboratory conditions without clean room facilities. Considering this, the blank
contribution for the amount Cu loaded in pseudosamples 1 and 2 was
acceptable at ≤0.2%.
4.4.2 Carry over
Reusing the chromatographic column for high precision isotope ratios requires that
carry over from previous samples is negligible. To assess carry over, method blanks were
interspersed between samples and processed systematically in every run. Insignicant Cu
is retained on the column aer the elution as shown above (see Section 4.4.1). Blank and
carry over concentrations were not signicant and did not aect isotopic ratios for Cu
concentrations observed in the samples (Figure 4.8).
4.4.3 Column yield and column life
Copper can fractionate during the ion exchange process and this is most likely to occur
during sample loading or elution o the column (Maréchal and Albarède, 2002; Zhu
et al., 2002). High yields ensure that all the Cu is retained and released by the resin
at the appropriate time, thereby eliminating any potential fractionation. e yield was
determined as 97 ± 3% (2SD) (Table 4.4) across all tested sample matrices, which is in
good agreement with Cu yields from commonly applied methods: 100 ± 6% (Maréchal
et al., 1999) and 100 ± 2% (Larner et al., 2011). e yield remained high across dierent
pseudosample matrices and no apparent systematic change in Cu isotope ratios was























































Figure 4.8: Assessment of carry over on the Cu column. Ten samples of pseudosample 2
were processed, with ve blanks interspersed between each. Panel A shows the recovered Cu,
demonstrating low carry over between samples. Panel B shows the % recovery of Cu for each of the
samples; for the 10 pseudosample aliquots processed, a Cu recovery of 99 ± 2% was achieved. Panel
C shows a lower resolution repetition using pseudosample 1, where 8 samples were processed





















y = 0.00075x –0.093
R2 = -0.004
Figure 4.9: Scatterplot showing no correlation of Cu yield and Cu isotope measurements of
pseudosamples 3 and 4.
does not readily fractionate on the column to induce systematic changes in the isotopic
composition of the eluant. Hypothetically, yields of less than 90% could be suitable to
produce high precision isotopic measurements, though further testing is necessary to
conrm this.
It is recommended to only process samples through the chromatography which have
been digested with methods able to completely drive o the organic carbon present
in biological samples (e.g., microwave digestion methods). Initial experiments with a
digestion method using small vessels in a household microwave (Matos et al., 2009)
resulted in partial digestions. Attempts to process these samples via the chromatography
procedure led to rapid resin degradation and low yields. is problem was resolved
through the application of the more rigorous microwave digestion method. Incomplete
digestion can lead to:
1) Cu being complexed in the matrix and therefore not readily held on the resin,
resulting in low yields, and potential Cu fractionation; and
2) incompletely digested organic matter accumulating on the column. e
accumulation of organic matter could lead to a reduction of available binding sites
and associated reduction in the resin’s capacity.
It was found following the application of partially digested samples that repeated
ushing of the column with 8 M HCl and 15 M HNO3 did not result in the visual removal
of the accumulated organic matter retained on the resin, with yields remaining low, even
for pure standard solutions. us the resin had to be discarded.
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Continuously high Cu yields and lack of observed Cu isotope fractionation from the
various sample types indicated no evidence of resin degradation for the processing of the
samples subjected to microwave digestion (n > 50). It is expected that column end-of-life-
behaviour will result in a reduction in Cu yields. It is not clear at this point whether a
reduction in Cu yields leads to fractionation of Cu on the column. It is recommended
that column performance is monitored by systematically processing a pure synthetic
pseudosample doped with an isotopic reference material every ve to ten samples. By
doing so, column quality parameters, such as Cu recovery, matrix removal, and isotope
fractionation due to resin exhaustion are systematically monitored.
4.4.4 Repeatability of isotope ratio values
ERM-AE633:
A pure 250 ng g−1 ERM-AE633 solution was repeatedly processed and analysed to test
the overall accuracy, precision, and reproducibility of the chromatography procedure. A
δ65Cu value (-0.01 ± 0.01‰ (2SE; n = 20)) for 20 consecutive replicates processed on the
same column (Figure 4.10), was determined to be in accordance with recommended
values (Moeller et al., 2012). e mean value of the measurements demonstrates high
accuracy, while the low standard error indicates high precision and reproducibility.
Pseudosamples:
Matrix eects were investigated with pseudosamples that approximate samples of
biological origin. Pseudosamples 3 and 4 were spiked with the isotopic reference material
(∼990 ng CuERM-AE633) and processed ve times each. No fractionation during the
automated chromatography process was observed (Tables 4.8 and 4.4, and Figure 4.11),
with very good precision for pseudosample 3 (δ65Cu = -0.01 ± 0.02‰; 2SE) and
pseudosample 4 (δ65Cu = -0.03 ± 0.02‰; 2SE). ese results show that organic carbon
free matrix samples are easily processed with high precision and accuracy by the
chromatography procedure.
Biological samples:
e optimised method was tested for its suitability to process real biological samples
of unknown isotopic composition. Seven subsamples of two separate aliquots of chicken
liver were processed, interspersed with two aliquots of pseudosample 4, and the Cu isotope
composition of these samples analysed (Figure 4.12) in a random order. e results of
the pseudosample indicate that the between-batch variability is negligible compared to
previous analyses and that the repeatability of Cu isotopic measurements within the two
batches of liver tissue was very good. Batch 1 and 2 yielded average δ65Cu of 0.51 ± 0.02‰
(2SE; n = 3) and 1.06 ± 0.01‰ (2SE; n = 4), respectively (Table 4.8). e precision for
the analysis of biological samples is similar to or better than previously published values
(Larner et al., 2011, 2013; Larner et al., 2015; Jaouen et al., 2013; Télouk et al., 2015). Metals
and metal isotopes have been shown to be heterogeneously distributed in organ tissues
(Balter et al., 2013; Hare et al., 2012; Kindness, 2003; Moynier et al., 2013), suggesting that
the dierence measured between the two batches can be explained by natural variability




















Isotopic measurement of standard solution
Sample
Accepted value: 0.00 ± 0.05‰
Figure 4.10: Reproducibility of a pure 250 ng g−1 CuERM-AE633 solution spiked with Ni aer
processing through the column (accepted value, as reported by Moeller et al. (2012)).
Cu yield of PS3
Cu yield of PS4
Isotopic measurement of PS3




























Figure 4.11: Repeatability of Cu isotope measurements and yield of Cu recovery for a sequence of
randomly ordered analyses of pseudosamples 3 and 4 (PS3, PS4), demonstrating a high degree of
repeatability. Pseudosamples contained Cu from the ERM-AE633 certied reference material with
an expected δ65CuERM-AE633 of 0.00 ± 0.05‰ (Moeller et al., 2012).
Table 4.8: Cu isotope data obtained for pure standard solutions, pseudosamples and biological
samples (‰, 2SE); it is indicated if the sample was processed through the chromatography.
Sample type Standard n 65Cu (‰) 2SE processed
250 ng g−1 NIST-976 ERM-AE633 73 −0.06 0.01 N
250 ng g−1 ERM-AE633 ERM-AE633 20 −0.01 0.01 Y
Pseudosample 3 ERM-AE633 5 −0.01 0.02 Y
Pseudosample 4 ERM-AE633 5 −0.03 0.02 Y
Chicken liver aliquot 1 ERM-AE633 3 0.51 0.02 Y


























Chicken liver aliquot 1 Chicken liver aliquot 2
0.51±0.02‰ 1.06±0.02‰
Isotopic measurement of aliquot 1
Isotopic measurement of aliquot 2
Figure 4.12: Reproducibility of Cu isotope measurements for a sequence of randomly ordered
analyses of chicken liver aliquot samples.
local butcher, it was not possible to control for potential general sources of heterogeneity
of the samples such as sex, age or diet of the chickens. e concentrations of Cu in the
samples from both aliquots did not vary signicantly (Batch 1: 16.2 ± 0.4 µg g−1; Batch 2:
17.5 ± 3.3 µg g−1; p = 0.129). Comparison with published measurements of sheep and
mouse livers show a similarly large spread of Cu isotope compositions: mouse δ65Cu
0.05 to 0.79‰ (n = 10) and sheep δ65Cu -1.38 to -0.75‰ (n = 4) with a reproducibility of
<0.05‰ (Balter et al., 2013).
4.5 CONCLUSION
A new automated chromatography method was developed that enables quick and ecient
separation of Cu from biological material, resulting in a clean Cu fraction in a discrete
volume.emethod results in high Cu yields from a variety of pseudo- and real biological
samples, and the method did not induce fractionation of Cu isotopes.
Compared to previously described, manually-executed methods (Larner et al., 2011;
Maréchal et al., 1999) this automated approach has several distinct advantages:
1) by utilising the prepFAST-MCTM automated platform, it enables the unsupervised
processing of over 30 samples per 24 h, and at the same time reduces user-induced
errors.is presents amajor step forward in terms of sample throughput, as manual
methods typically enable only 10 - 30 samples to be processed per week;
2) the application of a highly specic Cu resin removes the need to rely on
reducing/oxidation agents (Larner et al., 2011; Maréchal et al., 1999), to retain Cu
on the resin;
3) there is no requirement of a cleaning step (for example with HClO4 (Larner et al.,
2011) to remove residual organic matter from the introduced reducing agent.
e automated approach is characterised by low blank contribution and high sample
throughput with very good precision and repeatability of Cu isotope ratio measurements
of biological samples. It is recommended that in order to enable easier comparison of
future development and renement of Cu chromatography methods, an international
biological reference material should be characterised.
e method presented herein represents an important milestone with regards to the
automation of chromatography procedures for the application of isotope ratio analysis
in biological samples. Future application and renement of the method will facilitate a
new area of biomedical research as a result of the ability to process very large sample sets





All animals are equal, but some animals
are more equal than others.
[George Orwell - Animal Farm]
❧
CHAPTER 5
LONGITUDINAL ASSESSMENT OF METAL
CONCENTRATIONS AND COPPER ISOTOPE
RATIOS IN THE G93A SOD1 MOUSE MODEL
OF AMYOTROPHIC LATERAL SCLEROSIS
Data used to generate gures for this chapter can be found in Appendix A.3.
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5.1 STUDY RATIONALE
Current research has not been able to attribute a single metal to be exclusively responsible
for MN deterioration in ALS. In the cerebrospinal uid (CSF) of patients with ALS,
signicantly elevated concentrations of Mn, Al, Cd, Co, Cu, Zn, Pb, V and U (Roos et al.,
2013), as well as Mg, Fe, Cu and Zn (Hozumi et al., 2011) have been observed, compared
to healthy controls, suggesting an accumulation process. However, combinations or
synergistic eects between metals may provide explanations to the neurodegeneration in
ALS that cannot be attributed to one single metal (Roos et al., 2013).
In the G93A mouse model of ALS, the diseased animals have been described to have
signicantly elevated concentrations of Cu in the spinal cord (Tokuda et al., 2014, 2013,
2008, 2015), and this concentration may increase over time with the progression of the
disease (Tokuda et al., 2009, 2007). A recent study was not able to conrm this nding
in the G37R mouse model of ALS, showing no signicant dierence in spinal cord Cu
concentrations between healthy and diseased tissues (Hilton et al., 2016). e increase
observed in Cu concentration in the G93A mouse model of ALS was hypothesised to
be the result of a mSOD1-dependent shi in intracellular Cu homeostasis toward Cu
accumulation in the spinal cord during disease progression: Cu inux increases, Cu
chaperones are up-regulated, and Cu eux decreases (Tokuda et al., 2009). is proposed
dysregulation within spinal MNs was associated with an age-dependent increase in Cu ion
concentrations in the spinal cord (Tokuda et al., 2009). When testing the hypothesis that
Cu concentrations increase in an age-dependent manner using mice expressing various
SOD1 mutants (SODG93A, SOD1G127X, SOD1G85R, and SOD1D90A), it was found that the
amount of Cu bound to the SOD1 active site varied considerably between the mutants.
Overall though Cu concentrations were, in every case, signicantly increased compared to
healthy controls (Tokuda et al., 2013). In another in vivo study using mice over-expressing
various SOD1 mutants (SODA4V, SOD1G37R, SOD1H80R, and SOD1D125H), it was found
that the SOD1 present in protein aggregates was metal decient, irrespective of the ability
of the mutant SOD1 isoforms to bind Cu (Bourassa et al., 2014). ese results suggest a
misbalance between the availability and demand for Cu in the cell. In the ventral horn
of the spinal cord of the SOD1G85R mouse, Fe and Zn are increased in the grey matter,
while there is no dierence in Cu concentration between white and grey matter (Bourassa
and Miller, 2012). While observations in the G37R mouse model of ALS showed a subtle
increase in Cu concentration between SOD1G37R and non-transgenic litter mates (WT)
brain samples (Hilton et al., 2016), no signicant dierence was found in SOD1G93A and
non-transgenic litter mates (WT) brain (Lelie et al., 2011; Li et al., 2006; Tokuda et al.,
2009, 2007). Further, a subtle redistribution between the grey and white matter of the
spinal cord was observed, with areas of higher Cu concentration correlating to areas of
high SOD1 expression, relative to surrounding cells (Lelie et al., 2011).
In an ALS context, there is currently no consensus concerning Zn concentrations in
the spinal cord and brain. When comparing spinal cord concentrations of Zn in tissue
from the G93A SOD1 mouse and WT mice, elevation (Li et al., 2006; Tokuda et al., 2013),
depletion (Tokuda et al., 2008) and no dierence (Lelie et al., 2011) in concentration have
been reported. In nervous system tissues (brain and spinal cord) from SOD1G37R mice,
elevated Zn concentrations compared to non-transgenic littermates have been reported
(Hilton et al., 2016). Tokuda et al. (2007) showed that Zn concentrations decreased over
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time in the spinal cord of diseased mice but remained constant in the brain. Contrastingly,
Tokuda et al. (2013) found elevated Zn concentrations in diseased spinal cord tissue
compared to transgenic WT animals, which over-express wild type SOD1 rather than the
mSOD1, while the concentrations of Mg, Ca, Al, Mn and Fe were not elevated. Other
work indicated a disease-specic increase of Zn in the brain (white matter) of mice
expressing mutant SOD1 (SOD1G93A, SOD1G37R, SOD1H46R/SOD1H48Q) (Lelie et al., 2011).
In a mTDP-43A315T mouse model of frontotemporal lobar degeneration and ALS, elevated
concentrations of Zn, Cu andMn were found in the spinal cord of diseased animals, while
concentrations of these metals in the brain remained unaected (Dang et al., 2014).
Ironmetabolism has been previously studied inALS patients, resulting in observations
of elevated levels of serum ferritin (Goodall et al., 2008; Ikeda et al., 2012; Nadjar et al.,
2012; Su et al., 2015) and reduced levels of serum transferrin (Nadjar et al., 2012), indicating
high overall Fe concentrations in the body. Magnetic resonance imaging of ALS patients
indicates abnormal Fe accumulation in the motor cortex (Ignjatović et al., 2013; Kwan
et al., 2012; Langkammer et al., 2010), which could be responsible for inammation and
oxidative damage. Further ndings of elevated Fe concentrations in human CSF (Hozumi
et al., 2011) and the presence of elevated Fe capable of promoting free-radical generation
(Ignjatović et al., 2012) contribute to the hypothesis that a variety of disturbances in Fe
metabolism may contribute to the aetiology of ALS (Oshiro et al., 2011). Surprisingly,
ndings in the SOD1G93A mouse model revealed no apparent changes to Fe metabolism
(Gajowiak et al., 2016).
It has been hypothesised that Cu isotopic ratios in blood and various organs should
reect the eciency of overall body Cu metabolism (Harvey et al., 2005; Lyon and Fell,
1990; Lyon et al., 1996; Turnlund et al., 1989, 1982), but only recently have tools to test this
been available. e naturally occurring stable isotopes of Cu (65Cu/63Cu) are expected to
distribute as a function of coordination and bond energy. Heavy isotopes are anticipated to
be enriched in the strongest bonds, since the vibrational energy decreases at higher isotope
mass (Albarède, 2015; Bigeleisen and Mayer, 1947). Hence, at the cellular level, it is likely
that the Cu isotopic ratio is inuenced by Cu-specic cell ligands (Balter et al., 2013, 2015).
e potential of medical isotope metallomics as a diagnostic tool has been reviewed
for a variety of conditions (Costas-Rodŕıguez et al., 2016). In this study it was tested
whether there is a detectable longitudinal ALS-signal in metal (Cu, Zn, Fe)
concentrations and Cu isotope ratios in keystone tissues (brain, spinal cord, muscle tissue
and whole blood) involved in the pathogenesis of ALS in the SOD1G93A mouse model.
ese longitudinal results were collected to improve our understanding of the
involvement of transition metals in the development of ALS and the potential for Cu
isotopes to serve as a prognostic/diagnostic tool for the disease.
5.2 SAMPLES
Transgenic mice in this study expressed the G93A mutant form of human SOD1 (B6SJL-
Tg(SOD1*G93A)1Gur/J; Jackson Laboratory, USA) (Gurney et al., 1994), from here on
referred to as ‘SOD1G93A’. Healthy controls were non-transgenic litter mates (WT). e
mice were bred under specic conditions in accordance with Australian animal ethics laws
















Figure 5.1:Overview of samples taken from mice, a blood sample was also collected.
animal ethics committee approved all experimental procedures (Ethics Number: AE14/28;
see Appendix C.1). All animals had free access to a uniform diet and water, and were held
on a regulated 12 hours day-night light cycle. Mice were euthanised by CO2 asphyxiation,
immediately dissected to collect blood and various tissue samples (Figure 5.1), which
were snap frozen in liquid nitrogen. For this study, brain, spinal cord, muscle tissue and
blood samples were processed. All mice were female to avoid gender dierences in the
data. Mice were 30, 60, 90 or 120 days old (±2 days) to capture the characteristic disease
progression typical for this mouse model (Olsen et al., 2001). Samples of the mouse
food were randomly collected from various locations at the breeding facility (Australian
Bioresources). Samples of DORM-2 dogsh muscle, certied reference material of the
National Research Council Canada (CRM, NRCC), were used to test the completeness
and accuracy of the sample digestion protocol.
5.3 ANALYTICAL AND STATISTICAL METHODS
All samples for this study were processed following the procedure previously described in
Chapter 4, using themicrowave digestionmethod (Section 4.3.3) for theMARS 6 digestion
system (CEM Corporation, USA). e samples were then analysed for their elemental
concentrations (see Section 4.3.5.1) and Cu isotopic composition (see Section 4.3.5.2).
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To assess the results from the measured data set, statistical analysis was performed.
All statistical analyses were conducted using the statistical program R v3.3.1 (R Core
Team, 2018). Prior to analysis, outliers were removed using the median average deviation
(3*mad). Any measurements outside 3*mad were considered to be measurement artefacts
or the result of contamination. Data were analysed through a linear regression model
for each organ type with disease state and time used as independent variables and the
measurements of Cu, Fe, Zn, Ni and Co21, as well as Cu isotope ratios, as dependent
variables. Timewas treated as a continuous variable. Likelihood ratio tests (Barr et al., 2013)
were used to determine which independent variables were signicant. e assumptions
of the linear regression model were checked, including normality tests for residuals. A
signicance level of α= 0.05 was used.
5.4 RESULTS
5.4.1 Metal concentrations
e results for Ni and Co measurements were very inconsistent, and largely discarded
due to the fact that concentrations in the measured samples were below detection limit
(0.01 ng g−1 for both elements). Besides the lack of an apparent physiological relevance of
Ni in higher organisms (Zambelli and Ciurli, 2013) and limited relevance of Co in human
health (Yamada, 2013), no statistically signicant trends were detected in either of these
elements for disease state nor for time in any of the analysed tissues (Figure 5.2). e
following results therefore focus on the Cu, Fe, Zn and Cu isotope results.
Spinal cord
In spinal cord tissues, Cu, Zn and Fe concentrations do not vary considerably
between SOD1G93A and WT samples (Table 5.1, 5.3 and Figure 5.3 A). Temporal
behaviours of all three metals are similar in that they increase until 90 days (d) and then
decrease, with the exception of Zn in the SOD1G93A tissue, where concentrations keep
increasing until 120 d (Fig. 5.3 A, D and G). Furthermore, Zn concentrations show
unexpectedly high values and large variability at 90 d.
Brain
Similar to the spinal cord tissues, brain tissues do not display a signicant variation
between SOD1G93A andWT for any of the assessed metals (Tables 5.1, 5.3). All three metals
show similar trends with age, in both SOD1G93A andWT, whereby concentrations increase
until 60 or 90 d and then decrease. ese trends appear more pronounced for Cu and
Fe (Table 5.1 and Figure 5.3 B, E and H), but only reach statistical signicance for Cu
(p = 0.004).
21Ni was chosen for its lack of physiological relevance in mammals. A potentially general
mechanism of accumulation could have been identied through this element. Co was chosen as
it was previously shown to be potentially implicated in ALS (Ingre et al., 2015; Roos et al., 2013).
Both metals had to be corrected for asymmetry of the data set, due to large spread as a result of
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Figure 5.2:Nickel (A – C) and Co (D – F) concentrations in brain, spinal cord and muscle tissue
(µg g−1 of dry tissue) as a function of time (days). All data are presented as box (median ±95% CI)
and whisker (maximum and minimum) plots n ≥ 3.
Muscle
Dierent to the other tissues, concentrations in muscle tissue do vary signicantly,
when grouped together, between SOD1G93A and WT mice: Cu (p < 0.0005), Zn
(p < 0.0005) and Fe (p = 0.004) (Tables 5.1, 5.3 and Figure 5.3 C, F and I). e dierence
in Cu concentration between the SOD1G93A and WT mice appears to be a
pre-symptomatic feature, trailing the development of symptoms (i.e., 60 d) in Zn and Fe
(Figure 5.3 F and I). e concentrations of all three metals increase until 90 d in the SOD1
tissue and then slightly decrease. In WT mice Cu, Zn and Fe concentrations are relatively
constant over time (Figure 5.3 C, F and I), while the concentrations of Zn show a larger
variability at 60 d.
Whole blood
In whole blood, none of the analysed metals vary signicantly between SOD1G93A and
WTmice (Table 5.1, Figure 5.4). Iron concentrations demonstrated a signicant trend over
time (p = 0.05), where concentrations from both populations appear to remain steady











































































































































































































































































































































































Table 5.1:Mean metal concentrations (µg g−1) and δ65Cu values (‰) for spinal cord, brain and
muscle tissues, and whole blood.⋆
State n 30 d n 60 d n 90 d n 120 d
Spinal cord
Cu
SOD1G93A 6 9 ± 7 6 21 ± 12 5 19 ± 12 6 16 ± 14
WT 7 12 ± 12 6 15 ± 10 6 18 ± 8 6 12 ± 11
SOD1G93A 6 52 ± 28 6 83 ± 49 5 87 ± 60 6 89 ± 65
Zn
WT 7 56 ± 43 6 53 ± 31 6 97 ± 59 5 45 ± 46
Fe
SOD1G93A 6 56 ± 55 6 100 ± 80 5 104 ± 72 6 95 ± 69
WT 7 90 ± 110 6 80 ± 54 6 109 ± 58 5 64 ± 21
SOD1G93A 6 1.7 ± 0.8 6 1.4 ± 1.1 6 1.7 ± 1.2 6 1.6 ± 0.7
δ65Cu
WT 7 1.7 ± 0.7 6 2.1 ± 0.7 6 1.2 ± 0.6 6 1.5 ± 1.1
Brain
Cu
SOD1G93A 6 14 ± 2 6 27 ± 13 5 29 ± 14 6 25 ± 7
WT 7 16 ± 6 6 28 ± 12 6 27 ± 19 6 23 ± 3
SOD1G93A 6 87 ± 40 6 121 ± 50 6 94 ± 98 6 97 ± 38
Zn
WT 7 76 ± 47 6 110 ± 45 6 108 ± 80 6 78 ± 18
Fe
SOD1G93A 6 73 ± 18 6 122 ± 34 6 110 ± 120 6 94 ± 39
WT 7 80 ± 25 6 128 ± 46 6 120 ± 84 6 102 ± 24
SOD1G93A 6 1.8 ± 0.4 6 1.3 ± 0.8 6 1.5 ± 0.4 6 1.3 ± 0.4
δ65Cu
WT 7 1.8 ± 0.8 6 1.6 ± 0.8 6 0.9 ± 2.2 6 1.4 ± 0.8
Muscle
Cu
SOD1G93A 6 7 ± 5 6 17 ± 8 6 24 ± 15 6 13 ± 5
WT 6 5 ± 4 6 7 ± 5 5 6 ± 3 6 4 ± 1
SOD1G93A 6 48 ± 20 6 97 ± 64 5 117 ± 63 6 95 ± 47
Zn
WT 6 42 ± 19 6 68 ± 56 5 49 ± 24 6 37 ± 14
Fe
SOD1G93A 6 47 ± 18 6 74 ± 26 5 1146 ± 23 6 120 ± 96
WT 6 50 ± 26 6 74 ± 42 5 65 ± 37 6 47 ± 6
SOD1G93A 6 2.2 ± 1.8 6 1.0 ± 2.0 6 0.7 ± 0.9 6 0.5 ± 1.3
δ65Cu
WT 6 2.0 ± 1.6 6 1.7 ± 1.9 6 1.1 ± 2.2 6 0.7 ± 0.6
Blood
Cu
SOD1G93A 6 5 ± 3 7 3 ± 3 7 3 ± 4 8 4 ± 3
WT 8 4 ± 2 8 3 ± 3 7 3 ± 4 8 3 ± 1
SOD1G93A 7 25 ± 10 7 31 ± 21 7 35 ± 27 8 33 ± 19
Zn
WT 9 23 ± 14 8 31 ± 27 7 34 ± 34 8 26 ± 7
Fe
SOD1G93A 7 2100 ± 1800 7 1700 ± 1900 7 1600 ± 2500 8 2900 ± 1700
WT 9 2200 ± 1700 8 1800 ± 2300 8 1800 ± 2700 8 3000 ± 500
SOD1G93A 7 1.1 ± 0.7 8 0.7 ± 1.7 8 0.8 ± 1.2 8 1.3 ± 1.2
δ65Cu
WT 9 1.1 ± 0.8 8 0.9 ± 1.0 8 0.6 ± 0.9 8 1.2 ± 1.3
⋆Concentrations are presented for the diseased (SOD1G93A) and healthy, non-transgenic (WT) samples
against time (in days; d). Errors shown are 2 standard deviations of the repeat measurements.
Table 5.2:Metal concentrations (Cu, Fe, Zn) (µg g−1 ± 2SD) and δ65Cu values (‰ ± 2SD) in
mouse faeces
Age State δ65Cu Cu Fe Zn n
30
SOD1G93A 0.89 ± 0.42 53 ± 34 1210 ± 540 350 ± 170 3
WT 0.67 ± 0.09 57 ± 10 1270 ± 310 357 ± 8 3
SOD1G93A 0.85 ± 0.29 85 ± 33 1470 ± 160 400 ± 51 3
60
WT 0.94 ± 0.87 60 ± 21 1280 ± 210 320 ± 85 3
90
SOD1G93A 1.19 ± 1.16 88 ± 18 1600 ± 5300 410 ± 62 3
WT 0.66 ± 0.33 90 ± 51 1600 ± 400 450 ± 33 3
SOD1G93A 0.73 ± 0.35 90 ± 39 2000 ± 1500 400 ± 76 3
120
WT 0.77 ± 0.24 61 ± 11 1620 ± 230 500 ± 570 3
Food and faeces
Mouse food samples show Cu, Zn and Fe concentrations of 13.7 ± 0.5, 76 ± 5 and
340 ± 30 µg g−1, respectively (2SE, n = 6). In faeces, there is no signicant dierence in
metal concentrations between SOD1G93A and WT samples, and no trends over the age of
the mice (Tables 5.3 and 5.2).
5.4.2 Cu isotope ratios
Spinal cord
In the spinal cord, δ65Cu values vary between 0.83 and 2.44‰ for SOD1G93A mice,
and between 0.65 and 2.46‰ for WT mice (Figure 5.6 A, Table 5.3), with the dierence
only being signicant at 60 d (p = 0.0328) as a result of unusually heavy Cu isotope
compositions in the WT tissue, compared to the other measurements in the tissue. Over
time, no systematic variation was observed in either population.
Brain
In brain tissue, the δ65Cu values vary between 0.9 and 2.2‰ for SOD1G93A, and
between -1.3 to 2.2‰ for WT mice (Figure 5.6 B, Table 5.3) with the dierence not
reaching statistical signicance. Across time, in both groups the δ65Cu values decrease
from 1.8‰ at 30 d, to 1.3 – 1.4‰ at 120 d (Table 5.1; p = 0.011).
Muscle
In muscle tissue, the Cu isotope composition varies between -0.2 and 2.4‰ for
SOD1G93A mice, and between -0.4 to 3.3‰ for WT animals (Fig. 5.6 C). Similar to the
trends observed in brain tissue, the δ65Cu values decrease between 30 – 120 d, but this























































































































Table 5.3:Maximum and minimum metal concentrations (µg g−1) and δ65Cu values (‰) for
spinal cord, brain and muscle tissues, and whole blood, across all time points
SOD1G93A WT
Min Max Min Max
Spinal cord
Cu 4 24 4 24
Zn 27 122 20 142
Fe 35 183 46 195
δ65Cu 0.8 2.4 0.8 2.5
Brain
Cu 13 38 9 38
Zn 15 140 34 156
Fe 18 216 41 169
δ65Cu 0.9 2.2 −1.3 2.2
Muscle
Cu 4 39 3 11
Zn 15 140 34 156
Fe 37 205 38 102
δ65Cu −0.2 3.9 0.4 3.3
Blood
Cu 1 8 1 6
Zn 18 60 16 53
Fe 51 4008 48 4166
δ65Cu −0.3 2.4 −0.1 2.2
Faeces
Cu 36 104 50 115
Zn 257 442 273 835
Fe 1011 2771 1099 1781
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Figure 5.5: δ65Cu values in whole blood and faeces against time (d), including food (grey line;
0.84 ± 0.03‰; ± 2SE). Box plots (A) show median values (solid horizontal line, 50th percentile
(box outline) and 90th percentile (whiskers); (n ≥ 7). Results in plot (B) show mean ± 2SE (n = 3
per time point and disease state).
Whole blood
In whole blood the δ65Cu values vary between 0.6 and 1.9‰ for SOD1G93A, and
between 0.5 and 1.4‰ for WT mice. ese δ65Cu values uctuate around 0.83‰, which is
the same as the isotope ratio of food (see below; Figure 5.5 A). Overall there is no
signicant dierence between SOD1G93A and WT mice.
Food and faeces
Mouse food samples have a δ65Cu value of 0.84 ± 0.03‰ (2SE, n = 5), which is at the
lower end of the observed values and similar to those observed in blood (Figure 5.5 A).
e average δ65Cu value of all mouse faecal samples is also 0.84 ± 0.59‰ (2SD, n = 24),
while SOD1G93A mouse faeces average at 0.92 ± 0.66‰ (2SD, n = 12) and WT mouse
faeces at 0.77 ± 0.48‰ (2SD, n = 12) (Figure 5.5 B). ere is no signicant dierence
between the two populations or changes with time (Table 5.2).
5.5 DISCUSSION
5.5.1 Accumulation of metals
It has been previously hypothesised that changes in Cu and Zn concentrations play an
important role in the gain-of-toxic function associated with mSOD1 (Borchelt et al., 1994;
Hilton et al., 2015). is has been supported by ndings that:
1) Cu chelators, such as D-penicillamine and Trientine, can prolong survival of



























































































































































































































































































































































































































































































































































































2) the ATPase ATP7B, a Cu transporter, is down regulated in the spinal cord of SOD1
transgenic mice (G93A) (Olsen et al., 2001),
3) delivery of Cu via the blood-brain-barrier permeable complex
Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) to
Cu-decient SOD1 converted it to stable holo-SOD1 in the SOD1G37R mouse
model, prolonging survival (Hilton et al., 2017; Williams et al., 2016; Roberts et al.,
2014), suggesting a therapeutic target for increased Cu concentrations, and
4) Zn decient mSOD1 can induce motor neuron apoptosis via peroxynitrite
-mediated tyrosine nitration (Estévez et al., 1999).
Apart from these ndings, Cu and Zn have an antagonistic interaction (Davies, 1974),
meaning that dyshomeostasis of one could prevent the proper utilisation of the other
(Tokuda et al., 2013). Over-expression of mSOD1 (e.g., the SOD1G93A mouse model of ALS
used in this work) was proposed to lead to increased Cu concentrations in spinal cord
tissue, due to a proposed increased anity ofmSOD1 for Cu,making it an eective Cu sink
(Tokuda and Furukawa, 2016). However, a recent review (Hilton et al., 2015) concluded
that partially metalated intermediate SOD1 species may account for the observed SOD1
toxic-gain of function. Taking this into account with an overall increased concentration
of the mSOD1 in the SOD1G93A model, Cu concentrations in ALS aected tissues are
therefore expected to increase, compared to healthy controls.
5.5.1.1 Spinal cord
Overall, all metals (Cu, Zn, Fe) show a similar behaviour: aer a marked increase of Cu
concentration from 30 – 60 d, the concentrations peak at 90 d, and decrease towards
120 d, without signicant dierences between healthy and diseased tissues
(Figure 5.3 A, D and G). Lelie et al. (2011) found a redistribution of Cu between the grey
and white spinal cord matter of SOD1G93A mice, which may not be reected in bulk
analyses as performed in this study. Zinc concentrations are an exception as in the
SOD1G93A mouse they were found to keep increasing until 120 d (Figure 5.3 D).
Furthermore, the WT tissue shows a marked rise from 60 – 90 d with an unexpected
high concentration of Zn at 90 d and then a decrease at 120 d, which remains
unexplained. Recent ndings (Wright et al., 2016) suggest that the interaction between
the Cu chaperone (CCS) and SOD1 is perturbed, such that, during the metalation and
maturation of SOD1, the Zn atom is not incorporated properly into its structure. is
would negatively impact disulphide formation and Cu activation of SOD1.
Previous work (Dang et al., 2014; Tokuda et al., 2009, 2014, 2013, 2007, 2008, 2015)
has found signicantly elevated Cu concentrations in spinal cord tissue of several mouse
models of ALS, which was suggested to be the result of mSOD1 in the SOD1G93A mouse
having a higher anity to bind Cu ions, leading to increased Cu in spinal cord tissue
compared to WT mice (Tokuda et al., 2009). However, recent work (Hilton et al., 2016)
did not nd a signicant dierence between non transgenic WT and SOD1G37R spinal
cord tissue, similar to ndings presented here (Figure 5.3 A). e previous observations
of increased Cu concentrations, particularly in mouse models of ALS that involve over-
expression of SOD1,may therefore be reective of the increased amount of SOD1 expressed
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in these mice. Furthermore, it is possible that this signal indicates the presence of free,
but not bioavailable, Cu, rather than a side eect of an increased binding anity (Tokuda
and Furukawa, 2016), as previously proposed. A recent review highlighted the increasing
evidence for the involvement of partially metalated SOD1 in ALS development (Hilton
et al., 2015), which is supported by work with SOD1G37R mice whereby Cu was delivered
directly to spinal cord mSOD1 via CuII(atsm) (McAllum et al., 2013; Roberts et al., 2014).
is direct delivery decreased the amount of metal decient SOD1, while it improved
the amount of fully metalated-SOD1 present (Roberts et al., 2014), as well as the ALS
phenotype. Previous work has found mixed results of reduced Zn concentrations (Tokuda
et al., 2007, 2008), no dierence (Lelie et al., 2011) and increased concentrations (Hilton
et al., 2016; Li et al., 2006; Tokuda et al., 2013), in various mSOD1mouse models compared
to controls. A lack of variation in Fe concentrations in the spinal cord in SOD1G93A andWT
over time and between one another is in agreement with prior ndings (Li et al., 2006).
5.5.1.2 Brain
e SOD1G93A and WT tissues had similar trends in all three metals, but no signicant
dierence between these two groups (Figure 5.3 B, E and H). A dramatic increase from
30 to 60 d, was followed by a slow decrease in Cu, Zn and Fe. e lack of dierence
between the SOD1G93A and WT tissues suggests that these trends may be the result of
ageing, which is only signicant for Cu concentrations. While higher concentrations of
Cu and Zn in brain tissue were previously found in the SOD1G37R mouse model (Hilton
et al., 2016), our ndings are in accordance with other work using mSOD1 mouse models
(G37R, G93A, H46R/H48Q), where no dierences were observed between the mutant
and healthy controls (Lelie et al., 2011; Li et al., 2006; Tokuda et al., 2007). is lack of
increased concentrations could be the result of a lack of an ALS-related up-regulation of
Cu tracking to the cerebellum (Tokuda et al., 2009), and that only a small area of the
brain is aected, which may be dicult to detect whenmeasuring the metal concentration
in the whole brain.
5.5.1.3 Muscle
Muscle tissue from diseased mice consistently demonstrated higher metal concentrations
than WT samples in accordance with previous ndings (Hilton et al., 2016), with
increases in Cu and Zn concentrations preceding the establishment of symptoms
(Figure 5.3 C and F) and Fe trailing them (Figure 5.3 I). Skeletal muscle is one of the
largest organs in the human body, comprising ∼40% of the whole body lean mass;
muscles and bones together contain ∼50% of total body Cu (Evans, 1973). Muscle tissue
provides a source of amino acids during stress and forms a crucial part of whole body
metabolism and homeostasis (Neel et al., 2013), while also being suggested to contain a
surplus of SOD (Linder, 1991). In ALS, muscle tissue (Gonzalez de Aguilar et al., 2008;
Luo et al., 2013; Xiao et al., 2015), and other (neighbouring) cell types (Boillée, Vande
Velde and Cleveland, 2006) may play a signicant role in pathology development.
Distinct and rapid muscle atrophy caused by MN death is a pathologic hallmark of ALS.
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e accumulation of excess Cu and Zn in muscle observed in this study could be
the consequence of the over-expression of the mSOD1 protein in the SOD1G93A mouse,
whereby the increased concentrations reect an increased requirement for Cu and Zn
by the partially metalated protein, similar to previous ndings in the SOD1G37R mouse
model (Hilton et al., 2016). However, if the increases are not a consequence of the over-
expression of SOD1 in this mouse model, they may indicate a causal pathologic feature
of ALS, whereby accumulation of Cu and Zn in muscle could be toxic, resulting in MN
death. is would support the dying-back-hypothesis of ALS (Kiernan et al., 2011): ALS
may be a dying back motor neuropathy whereby distal axonal degeneration occurs and
this precedes neuronal degeneration (Fischer et al., 2004; Frey et al., 2000). e axon and
neuromuscular junction are aected at an earlier stage prior to the onset of symptoms and
neurodegeneration, which may indicate that intrinsic defects in the muscle occur early,
promoting or contributing to withdrawal of the motor axon (Zhou et al., 2015). Signalling
between the muscle and the neuron is important for axonal growth and management
of the neuromuscular junction (Nguyen et al., 2000), while the loss of signal from the
neuron to the muscle leads to atrophy. It is also possible that muscle defects may be
independent of axonal withdrawal (Zhou et al., 2015), leading to the assumption that
skeletal muscle is likely to be one of the primary targets of ALS-associated mutations.
While the origin of the here-observed accumulating metals remains unknown, Cu isotope
analyses (see Section 5.5.2) suggest that the Cu could originate from a dietary, exogenic Cu
source. However, the direction and magnitude of changes (increase of inux vs decrease
of eux vs changes to recycling processes) are unclear.
5.5.1.4 Whole blood
ere were no signicant trends inmetal concentrations of Cu and Zn in whole blood over
time or between the SOD1G93A andWT samples. Iron concentrations were an exception, as
they followed a trend over time such that the concentration decreased between 30 – 60 d
and then increased until 120 d (Figure 5.4 C). Mixed results have been documented for Cu
concentrations in blood serum and ceruloplasmin: concentrations have been reported to
be decreased in ALS patients, compared to healthy controls (Domza l and Radzikowska,
1983; Kapaki et al., 1997), or to not be signicantly dierent (Pamphlett et al., 2001), similar
to the data presented here. is could be a side eect of the short residence time of these
metals in blood (e.g., 7 – 14 d for Cu in mice (Cabrera et al., 2008)), robust excretion
mechanisms (Cabrera et al., 2008), and low Cu concentrations compared to humans
(Cabrera et al., 2008; Montaser et al., 1992). ese may therefore account for the lack
of positive association with disease progression. One study on human blood reported a
positive association betweenCu concentrations andALS,while Znwas inversely associated
(Peters et al., 2016).
5.5.1.5 Faeces
Faeces did not demonstrate a dierence between SOD1G93A andWT samples, for any of the
assessed metals. e lack of a disease signal and observation of a time dependent increase
in Fe and Cu concentrations indicate that most likely the higher dietary requirement of
the older, and therefore larger mice leads to changes in faeces metal composition. is is
120
possibly a compression function whereby more food is consumed and excreted with a
higher density, leading to slightly increased concentrations in the older mice. Overall, no
disease dependent anomalies of metal uptake or excretion were detected.
5.5.2 Copper isotope ALS signal
e Cu isotopes display a scattered pattern for spinal cord tissue without any clear trends
(Figure 5.6 A). Brain (Figure 5.6 B) and muscle tissue (Figure 5.6 C) follow a similar
time-dependent trend, whereby the δ65Cu values start at a heavier levels at 30 d and then
shi towards lighter levels. e same trend was observed in SOD1G93A and WT tissues. In
blood (Figure 5.5 A) no signicant dierence was detected between SOD1G93A and WT.
It was observed, however, that the blood and faeces δ65Cu values (Figure 5.5) uctuated
around 0.84‰, i.e., the δ65Cu value of food, indicating that the isotope signal is more a
reection of the diet than the disease. Overall, the δ65Cu values from tissues from the
SOD1G93A mouse model of ALS presented here indicate that there is no presence of a clear
ALS-associated Cu isotope signal.
It has been postulated that stable isotope ratios can inform about previous oxidation
conditions in geological and biological systems (Schauble, 2004). Isotope ratios of Cu
(Balter et al., 2015; Bondanese et al., 2016; Télouk et al., 2015) and Zn (Larner et al.,
2015) change in association with cancer development and Cu isotope ratios with liver
cirrhosis (Costas-Rodŕıguez et al., 2015) (see Section 3.1 for review). In the example of
cancer, hypoxic (reducing) conditions within the tumour’s environment can impair the
metabolism of Cu and change the metal’s redox state. is is the consequence of the
binding ability of specic molecules, inducing isotopic fractionation, which is measurable
(Balter et al., 2015).
A variety of neurodegenerative diseases have been associated with excessive oxidative
stress (Ferrante et al., 2002; Gordillo et al., 1989; Matés and Sánchez-Jiménez, 1999; Sayre
et al., 2001; Stadtman, 1990) including ALS where oxidative stress has been identied to
be of great importance (Niebrój-Dobosz et al., 2004), in both humans and rodent models
(Ferraiuolo et al., 2011). Twomechanisms have been identied to induce oxidative stress in
cells in relation to Cu: 1) a Fenton-like reaction that can directly catalyse reactive oxygen
species (ROS) generation (Prousek, 2007), 2) exposure to elevated concentrations of Cu,
which signicantly decreases the levels of glutathione (GSH) (Mattie and Freedman, 2004;
Speisky et al., 2009). A decrease in GSH limits the cell’s antioxidant ability, contributing
to shiing the redox balance towards more oxidising conditions (Jomova and Valko, 2011;
Linder, 1991). is may also enhance the cytotoxicity of ROS and allow Cu to be more
catalytically active, resulting in the production of even more ROS (Ahuja et al., 2015).
In ALS, mitochondrial dysfunction was reportedly responsible for increases in the free
radical generation (Sayre et al., 2001; Siklós et al., 1998; Swerdlow et al., 2000), followed
by oxidative stress and associated calcium toxicity following glutamate receptor activation
(Swerdlow et al., 2000). Interestingly, recent results have demonstrated that Cu isotope
fractionation can be induced in a liver cancer cell line (HepG2) through application of
oxidative stress (Flórez et al., 2018). e greatest amount of fractionation was observed
in those cells that were exposed to the largest amount of stress. Isotopic fractionation
was proposed as the result of preferential discharge of 63Cu from the cells as a protective
mechanism (Flórez et al., 2018). Following these results, it was expected that there should
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be a direct correlation between disease progression and the development of oxidative
stress (Barber et al., 2006; Barber and Shaw, 2010), leading to Cu isotope fractionation,
and an ALS-associated Cu isotope signal.
e observed lack of a Cu isotope signal in the SOD1G93A mouse model of ALS may be
the result of several factors:
1) ROS production does increase as a function of time (ageing-eect) in SOD1
transgenic mice (Liu et al., 1998), which would require ROS to be relatively more
increased to be able to be traced as a deviation of the signal that arises from ageing
alone,
2) in the spinal cord of the SOD1G93A mice two metallothionein-I/II (MT-I/II)
isoforms were previously found to be signicantly elevated, which act as Cu
chaperones, sequestering free Cu (Prohaska and Gybina, 2004) as a compensatory
reaction to Cu-mediated oxidative stress, even at pre-symptomatic stages
(Tokuda et al., 2007). It was later found that over-expression of MT-I in the
SOD1G93A mouse model prolongs survival and restores Cu dyshomeostasis
(Tokuda et al., 2014), which suggests that ROS production could be regulated and
a resulting Cu isotope signal dampened, and
3) it is widely accepted that it is not the loss of antioxidant function of mSOD1 that
leads to the development of pathology, but rather a separate toxic gain-of-function
(Bruijn, 1998). While this toxic gain-of-function was conrmed by transgenic mice
over-expressing mSOD1, where the level of mSOD1-expression was proportional
to the onset and severity of symptoms (Gurney et al., 1994; Henriques et al., 2010;
Wong and Martin, 2010; Wong et al., 1995), it has proved dicult to elucidate the
specicmechanisms ofmSOD1 toxicity (Hilton et al., 2015). Given that the ALS-like
phenotype of the SOD1G93A mice used in this study is driven by the expression of
the mSOD1 and to a lesser extent its over-expression, it is reasonable to assume that
the inferred oxidative stress would not be reected in a changed isotope signature
in the target tissues. is becomes clear, when taking into account that in brain
and spinal cord tissue there is little to no dierence in Cu concentrations between
SOD1G93A andWT tissue (Figure 5.3 A and D).is suggests that in addition to the
tight control of Cu inux through the blood-brain-barrier (Choi and Zheng, 2009;
Linder, 1991), the binding of Cu to various proteins/binding sites does not alter as
a result of the disease. Moreover, the alteration may be too subtle to be detected
using stable isotope techniques at the currently available resolution. Changes in
Cu concentration in tissues may be attributable to the overall higher concentration
of mSOD1 in the transgenic mice or the up-regulation of cupro-proteins as a side
eect of mSOD1 over-expression, possibly leading to cell specic deciencies of
Cu, resulting in no change to the isotope ratio in the tissue.
e signicantly elevated Cu concentrations in SOD1G93A muscle tissue (Figure 5.3 C)
oer a slightly dierent picture: muscle tissue, compared to central nervous system tissues,
is subject to less stringent regulation of Cu transport (Linder, 1991). Muscle tissue in
general was noted to be a major repository of metals, and contains a surplus of SOD
(Linder, 1991). A tracer study using 64Cu observed that young (neonates, 10 – 12 d)
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mice retained signicantly more Cu than adult counterparts in muscle tissue (Mann
et al., 1979). rough the current research it is hypothesised that muscle tissue may, at
least in part, serve as a reservoir for exogenic, dietary Cu, and its natural Cu isotope
signature may, therefore, alter to become more similar to that of the food source over
time (30 – 90 d) (Figure 5.6 C). Further to the assimilation, it is plausible to assume that
recycling processes can further enhance the preferential uptake and retention of the lighter
Cu isotope over time, indicating that Cu may accumulate in the weaker bonds (Albarède,
2015; Bigeleisen and Mayer, 1947). While there is overall more Cu in the SOD1G93A muscle
tissue (Figure 5.3 C), it binds to the same protein binding sites as in the WT controls.
is is supported by the δ65Cu values measured in this work (Figure 5.6 C) whereby the
ratios move in the same direction in SOD1G93A and WT mice. However, SOD1G93A tissue
appears to follow a steeper decline towards the δ65Cu value of food (0.84‰), suggesting
that cupro-proteins, using weaker bonds, may be up-regulated and accumulate Cu, as
previously suggested for several other tissues (Roos et al., 2013; Tokuda et al., 2009). is
accumulation of Cu could then lead to a dying back process, in the form of a distal motor
neuropathy (Redler and Dokholyan, 2012; Wong and Martin, 2010).
5.5.3 Cu isotope ageing signal
e δ65Cu values for muscle and brain tissue in this study demonstrate a similar age-
dependent trend, which is independent of disease state. e δ65Cu values are positive
at 30 d (∼2‰) and then decreased over time (Figure 5.6 B and C). A similar ageing
trend was recently observed in a study by Sauzéat et al. (2018) in long-lived C. elegans
nematodes, accompanied in a reduction of Cu concentration over time. Compared to
controls, the long-lived worms had a far elevated Cu concentration at 2 days of age which
then decreased over time, while controls with a regular-length life-span started out with a
lower Cu concentration and increased over time. e observed Cu isotope fractionation
was attributed to the production of ROS via the Haber-Weiss reaction (see Section 2.3
page 35), following the oxidisation of Cu+ to Cu2+ in a high Cu environment.e presence
of ROS then accelerates ageing within the cell. Following ab initio calculations, Cu+
compounds are expected to preferentially bind the light isotope of Cu, meaning that the
formation of ROS would result in the creation of 63Cu2+ compounds, while fractionating
Cu in the process. e resulting in-utilised pool of 65Cu could then be preferentially
excreted from the cell resulting in the observed enrichment in δ65Cu in these organisms.
is hypothesis does though not serve to explain the observed trends fully. A potential
exists for the excretion mechanism responsible for the removal of Cu from the long-lived
worms to also provide a protective function. Future work has to explore these mechanisms
in more detail.
Concerning the here-observed trends, it is well known that organisms accumulate
certain metals in various tissues and uids over the course of their lifespan (Basun et al.,
1991; Hare et al., 2013; Zecca et al., 2001). As the oldest mice tested in this study were 120 d
old (still comparatively young, equivalent to ≈20 – 30 y in humans (Flurkey et al., 2007)),
it is surprising that a Cu isotope ageing-signal may already be present. e downward





























Figure 5.7:Uptake of Cu into the foetus via the placenta. Ceruloplasmin, and other low molecular
copper-compounds, predominantly [Cu2+(His)2], accumulate the heavy isotope 65Cu.is Cu
then accumulates in the liver of the foetus aer crossing the foetal endothelium, enriching it
in 65Cu.
dierent rates of metabolism in these dierent organs, as observed in humans, where
female breast tissue ages faster than other organs (Horvath, 2013). A precise assessment of
ageing in individual organs remains dicult.
To determine whether the signal observed here is indicative of ageing, it is important
to control for any potential age-related changes in Cu absorption that may aect the signal.
In men and women between 20 and 83 y, there is no signicant change in Cu absorption
over time (Johnson et al., 1992) and Cu absorption is tightly regulated as a function of
available dietary Cu (Turnlund, 1998; Turnlund et al., 1998). As the mice used in this
study (and their parents before them) were given a uniform and standardised diet, it is
reasonable to assume that trends over time are a true expression of ageing, rather than
the result of variability in diet with age.
It is well known that during mammalian pregnancy, metals (nutrients) are
transported from the mother across the placenta to the foetus, where they cross the foetal
endothelium and enter circulation (Figure 5.7) (Gambling et al., 2003). ese metals
(e.g., Fe and Cu) are then stored in the foetal liver and are rapidly liberated to facilitate
growth aer birth (Donley et al., 2002; Linder, 1991; Uauy et al., 1998). Copper transport
to the foetus increases in the last trimester and is chaperone specic (Tong and McArdle,
1995). e Cu accumulates in the placenta in the form of ceruloplasmin, CuHis2, or other
low molecular complexes (McArdle and van den Berg, 1992). In the absence of
ceruloplasmin, Cu transport is not inhibited, highlighting the potential importance of the
CuHis2 pathway in the transport (Gambling et al., 2003). Based on ab initio calculations,
histidine containing compounds, such as ceruloplasmin and CuHis2 [Cu2+(His)2] have
previously been hypothesised to concentrate the heavier isotope of Cu (Balter et al., 2013).
In this study, more positive δ65Cu values (accumulation of heavier isotopes) in brain and
muscle samples (Figure 5.6 B and C) were found at 30 d. ese results suggest the
presence of a ‘starting pool’ of ‘heavy’ Cu received from the mother, which is then diluted,
recycled or changed over time through exogenic, dietary Cu and endogenic metabolic Cu











































































Figure 5.8: Conceptual model for the presence of a ‘starting pool’ of heavy Cu received from the
mother and accumulated in the foetal liver (A). is Cu is an initial source for the fast neonatal
growth phase, distributing 65Cu throughout the tissues. e commencement of ingestion of
external non-maternal food (lighter Cu isotopic composition) meets the high nutrient requirement
of juvenile growth (B). is dilutes the pre-existing heavy Cu pool. e dilution continues until
adult hood, at which point growth stops and Cu isotope ratios stabilise, reecting the food’s isotope
ratio (C). At this point, localised recycling processes with endogenic and exogenic Cu are possible
and could potentially result in further fractionation.
the observations here were made in both groups of mice and are independent of
potentially increased levels of oxidative stress due to ALS, it seems unlikely that a similar
mechanism as proposed by Sauzéat et al. (2018).
5.6 CONCLUSION
e assessment of metal concentrations in tissues from healthy and ALS mice yielded
contrasting results. Brain and blood samples showed no denitive trends between diseased
and healthy tissues, while Zn concentrations in spinal cord and muscle tissue, and Cu
concentrations in muscle tissue were elevated at pre-symptomatic stages in the diseased
tissues. An increase in Fe concentrations in muscle trailed the development of symptoms.
Observed pre-symptomatic changes in metal concentrations in the results from muscle
tissue may support the dying-back hypothesis as a function of toxicity induced by the
accumulation. is warrants further investigation into the potential applicability of metal
concentrations as biomarkers for ALS. Copper isotope ratios revealed no clear disease-
based signal in any of the tissues. When considering the higher Cu concentrations and
changes in isotope ratios in the SOD1 mouse muscle, it could suggest that either the
association of Cu with specic binding sites does not change or that possible changes in
the association of Cu with other binding sites is below the detection limit of the applied
method. Future studies should consider overcoming the limitations of the mSOD1 over-
expression models by using transgenic mice that over-express wild type SOD1 as controls.
is would account for any eects induced by the increased expression of SOD1 alone.
In muscle and brain tissue, changes in isotope composition over time were observed,
suggesting the presence of an ageing signal. is potentially presents a new way of looking
at the concept of metabolic ageing, whereby the speed of ageing can be determined by turn-
over rates of recycling and accumulation processes of Cu in certain tissues, as a deviation
from the foetal Cu pool. Mice currently present one of the best model organisms to
study ALS and ageing. A promising direction for future studies is the application of metal
concentration and Cu isotope measurements to human samples, including blood plasma
and potential muscle biopsies, and to specic cell types, to understand the involvement of
Cu and other metals in the aetiology of ALS.
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6.1 STUDY RATIONALE
Findings in the G93Amouse model of ALS indicate that there is a pathologic perturbation
in Cu metabolism. While the accumulation and/or depletion of metals in dierent tissues
reported in the literature are inconsistent, overall there appears to be accumulation in
tissues of diseased mice. Tissues associated with the autonomic nervous system (ANS)
was demonstrated to accumulate Cu and Zn (Hilton et al., 2016), with muscle tissue
shown in in Section 5.5.1.3to demonstrate pre-symptomatic increases in concentrations.
Results from central nervous system (CNS) tissues in Sections 5.5.1.1 and 5.5.1.2, indicate
accumulation of Cu in the spinal cord (Li et al., 2006; Tokuda et al., 2014, 2013, 2008, 2015)
at single time points, as well as over time (Tokuda et al., 2009, 2007). Brain tissue showed a
similarly varied behavior with studies reporting both elevated concentrations (Hilton et al.,
2016), or no change to healthy controls (Lelie et al. (2011); Li et al. (2006); Tokuda et al.
(2009, 2007). ese are based on either reducing the general availability of Cu through
the application of Cu chelators (i.e. Trietine or D-penicillamine), which has been shown
to prolong survival of SOD1G93A mice (Hottinger et al., 1997; Nagano et al., 2003); or the
application of a synthetic Cu chaperone (CuII-atsm) to transport Cu across the blood-
brain-barrier, which prolongs survival in SOD1G37R and SOD1G93A mice (Hilton et al.,
2017; McAllum et al., 2013; Roberts et al., 2014; Soon et al., 2011; Williams et al., 2016).
In SOD1, Cu and Zn ions are crucial for its function: Zn provides structural stability,
while Cu is essential for the protein’s catalytic activity. In SOD1 mouse models of ALS,
mutant SOD1 accumulates in a Cu-decient form (Lelie et al., 2011; Roberts et al., 2014;
Williams et al., 2016). is partially metalated SOD1 is proposed to lead to aggregation
and toxicity (Bruijn, 1998; Gurney et al., 1994; Roberts et al., 2014). Treatment of mice
with the synthetic Cu-containing therapeutic agent CuII(atsm) converts the partially
metalated SOD1 into holo SOD1 through the delivery of Cu (Roberts et al., 2014),
improving the phenotype signicantly (Lelie et al., 2011; Roberts et al., 2014; Williams et
al., 2016). is points towards a misbalance of bioavailability and demand for Cu in the
CNS (Hilton et al., 2017).
e potential role of metals as well as muscle tissue (Gonzalez de Aguilar et al., 2008;
Luo et al., 2013; Xiao et al., 2015) in ALS pathology has recently gathered further attention.
In addition to the involvement of metals in binding to SOD1, results presented in Chapter 5
suggested that toxic accumulation of metals in muscle tissue may also play a role in ALS
pathology. With pathological hallmarks that include the destruction of the neuromuscular
junction (NMJ) and axonal retraction preceding MN death (Zhou et al., 2015), ALS could
be described as a distal motor neuropathy (Fischer et al., 2004; Frey et al., 2000; Kiernan
et al., 2011) (see Section 5.5.2).
In this study concentrations of transition metals in transgenic mutant SOD1G93A
mice and non-transgenic controls were assessed. rough the longitudinal comparison of
diseased and healthy CNS and non-CNS tissues, this research sought to expand current
knowledge on the role and presence of transition metals in the pathology of ALS.
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6.2 SAMPLES
is study used two types of transgenic over-expression models, SOD1G93A and SOD1WT;
only female mice were used in this work. e SOD1G93A mouse model of ALS expressed
the G93A mutant form of human SOD1 (B6SJL-Tg(SOD1*G93A)1Gur/J)(Gurney et al.,
1994) (Jackson Laboratory, ME, USA), backcrossed onto a black 6 background. Healthy
controls for thesemice were non-transgenic litter-mates (NTGUOW).esemice were bred
at Australian Bioresources (Mossvale, AU) in accordance with the approved University of
Wollongong ethics clearance (AE14/28). At ages 30, 60, 90 and 120 (±2) days, capturing
the characteristic disease progression (Olsen et al., 2001), mice were euthanised by CO2
asphyxiation blood collected via puncturing of the le ventricle. e mice were not
perfused and following blood collection immediately dissected and tissue samples (brain,
spinal cord, liver, intestine, heart and muscle) were snap frozen in liquid nitrogen. Muscle
tissue was samples of Quadriceps femoris from both legs and intestine samples were 2 cm
sections immediately following the stomach.
e second type of mouse model used was SOD1WT mice, which over-express the non
mutated form of human SOD1 (B6SJL-Tg(SOD1)2Gur/J) (Gurney et al., 1994) (Jackson
laboratories). Healthy controls were non-transgenic litter-mates (NTGUCL). Mice were
bred at University College London - Biological Services (London, UK) in accordance with
the Guide for the Care and Use of Laboratory Animals as adopted by the US National
Instituted of Health and under license from the UK Government (Animals and Scientic
procedures) Act 1986 (Amended Regulations 2012), following ethical approval from the
University College London Institute of Neurology. e samples taken from this mouse
model were brain, spinal cord and muscle tissue (Quadriceps femoris) samples. ese
samples were collected at 60 and 90 d to assess if the previously observed increase in Cu
concentration in diseased tissue (Section 5.4.1) is the result of the over-expression of the
mSOD1 or presents a pathologic feature, independent of mSOD1 over-expression.
6.3 ANALYTICAL TECHNIQUES
All samples for this study were processed following the procedure previously described in
Chapter 4, using themicrowave digestionmethod (Section 4.3.3) for theMARS 6 digestion
system (CEM Corporation, USA). e samples were then analysed for their elemental
concentrations (see Section 4.3.5.1). Liver, heart and intestinal tissue were additionally
analysed for their Cu isotopic composition (see Section 4.3.5.2).
Statistical analysis was conducted using the statistical program R v3.4.2 (R Core Team,
2018). Prior to analysis, outliers were removed using themedian average deviation (3*mad).
Any measurements outside 3*mad were considered to be measurement artefacts or the
result of contamination. Transgenic SODWT muscle samples were analysed qualitatively,
due to the low sample number. Data were analysed using linear regression models with
disease state and time used as independent variables and Cu, Fe, Zn and Se concentrations,
as well as Cu isotope ratios, as dependent variables. Likelihood ratio tests were used to
determine which independent variables were signicant (Barr et al., 2013). A signicance




Tissues controlled by the ANS, i.e. the liver, intestine and heart, demonstrate a signicant
dierence in Cu concentration (p < 0.0005) between the SOD1G93A and healthy controls
(Figure 6.1 A – C), which is evident starting at 30 d, with concentrations in heart and liver
increasing over time in the diseased tissues, while they remained relatively constant in
the intestine. Zinc concentrations show a similar behaviour to Cu: they vary signicantly
between SOD1G93A and healthy controls in heart and liver tissues (p < 0.0005), and
intestine (p = 0.03) (Figure 6.1 D – F) starting at 30 d. In heart and liver, the Zn
concentrations increase over time, while concentrations in intestine remain largely
constant. In contrast to Cu and Zn concentrations, Fe concentrations only vary
signicantly between the diseased and healthy liver (p = 0.05) and the intestine
(p = 0.006) tissue (Figure 6.2 A – C), and over time in liver (p < 0.0005) and intestine
(p = 0.001). Concerning Se concentrations, only intestine was found to show a signicant
dierence between healthy and diseased tissue (p = 0.04), while Se concentrations in
heart (p = 0.002), liver and intestine (p = 0.0005) changed over time (Figure 6.2 D – F).
Concerning Cu isotope ratios, no signicant dierences were observed between the
SOD1G93A and healthy tissues.
6.4.2 Other tissues
Muscle tissue (Quadriceps)
As shown in Section 5.4.1, Cu (p < 0.0005), Zn (p < 0.0005) and Fe (p = 0.004)
are signicantly dierent between SOD1G93A and NTGUOW mice (Figure 6.4). Muscle
tissues from mice that over-express the SOD1WT were collected at 60 d and 90 d and
tissues from non-transgenic litter-mates from the same colony were collected at 90 d
of age (Figure 6.4). e concentrations of Cu, Zn and Fe in the SOD1WT samples are in
agreement with results from muscle tissue collected from non-transgenic mice from a
dierent colony (NTGUOW) (Section 5.4.1). e metal concentrations in SOD1WT tissues
match well these found in NTGUOW non-transgenic controls (Figure 6.4).
Central nervous system tissues
In Section 5.4.1 it was shown that there is no signicant dierence between brain and
spinal cord tissue from SOD1G93A and NTGUOW mice in Cu, Zn and Fe concentrations.
Samples from mice over-expressing SOD1WT and non-transgenic littermates from the
same colony (NTGUCL) were collected at 60 and 90 d of age, and are in general agreement
with previously presented results of SOD1G93A and NTGUOW mice from a dierent colony





















































































































































































































































































































































































































Days (d) Days (d) Days (d)
30 60 90 120
State: SOD1G93A NTG
pre-symptomatic symptomatic pre-symptomatic symptomatic pre-symptomatic symptomatic
Figure 6.2: Iron (A – C), Se (D – F) concentrations in peripheral tissues (heart, liver and intestine)
(µg g−1 of dry tissue) as a function of time (days). All data are presented as box (median ±95% CI)




























Days (d) Days (d) Days (d)
30 60 90 120
Heart Liver Intestine
State: SOD1 WT
pre-symptomatic symptomatic pre-symptomatic symptomatic pre-symptomatic symptomatic
Figure 6.3: δ65Cu values (A – C) in peripheral tissues (heart, liver and intestine) as a function
of time (days). All data are presented as box (median ±95% CI) and whisker (maximum and





























































































































































































































































































































































































































































































































Days (d) Days (d)
30 60 90 120
SOD1G93A NTGUOWNTGUCL SOD1WT
pre-symptomatic symptomaticpre-symptomatic symptomatic
Figure 6.5: Copper and Zn concentrations (µg g−1 of dry tissue) in brain and spinal cord tissue
as a function of time (days). Boxplots (median ±95% CI) show values for SOD1G93A mice and
non-transgenic littermates (n ≥ 5). NTGUOW and SOD1G93A values were taken from Chapter 5,
Section 5.4.1. Triangles and circles depict additional samples of SOD1WT mice and non-transgenic
littermates (see legend).
6.5 DISCUSSION
6.5.1 Copper isotope ratios in tissues controlled by the ANS
In Chapter 5, Section 5.5.3 it was discussed that Cu isotope ratios in brain andmuscle tissue
may assimilate to that of the diet over time. is was particularly noticeable in muscle
tissue, leading to a proposed model in which a ‘heavy’ Cu pool instilled by the mother into
the neonate mice is diluted over time through exogenic Cu intake (Figure 5.8, page 125).
When comparing the results in brain and muscle tissue to heart tissue (Figure 6.3 A), the
trends over time in the heart are not statistically signicant (p = 0.415), and relatively
variable within the dataset. is could be an expression of a less pronounced expression
of a similar mechanism as brain and muscle tissue, or it could be a side-eect of the free
perfusion of the heart. On the one hand, this is dierent to the brain, as its exposure to
metals is tightly controlled by the blood-brain-barriers (Choi and Zheng, 2009). Muscle
on the other hand represents an important metabolic end point (Neel et al., 2013) and
storage unit (Linder, 1991).
Liver and intestine tissue do not demonstrate this trend. While this may be expected
for the intestine, it is a surprising in the liver. It is the key-tissue in which the preferentially
heavy Cu from the mother is accumulated and then liberated to fuel rapid growth aer
birth. ere it would be expected that a particularly steep decrease and assimilation of
the Cu isotope ratios to the dietary Cu source would be present. e lack of the ageing
Cu isotope signal is therefore, while surprising, likely the result of the tested time points
between 30 and 120 d: as essentially all dietary Cu passes through the liver before it is
distributed to the peripheral tissues, the turnover is very fast, and the assimilation likely
occurs before the earliest tested time point of 30 d in this study. is may likely be during
the infant stage of up to 21 d of age, which is not captured by the samples here. Concerning
the observation in the intestine, the Cu isotope ratios seem systematically enriched in
heavier Cu, compared to the food source. is observation seems at odds with ndings
by Cadiou et al. (2017), who found that cellular Cu uptake preferentially fractionates
towards lighter isotope ratios (Figure 3.3, page 62). e systematic enrichment with heavy
isotopes observed could represent a specic uptake signal resultant from the Cu uptake
pathway via DMT1, which has the ability to transport both, Cu2+ and Cu+ across the
apical plasma membrane (Figure 2.1, page 39). More work is needed to understand this
systematic isotopic enrichment in the intestinal tissue.
6.5.2 Accumulation of Cu and Zn in tissues controlled by the
ANS
Tissues controlled by the ANS play an as yet unknown role in the development of ALS.e
accumulation of Cu in the heart and liver could either be pathological and driven by ALS,
or the result of the over-expression of SOD1 in the mouse model. As the mouse model of
ALS over-expresses (20 – 24 times) human SOD1 (hSOD1) harbouring the G93Amutation
(Gurney et al., 1994), over-expression of the protein could result in it acting as a Cu sink
(Tokuda and Furukawa, 2016). However, if this were the case, a uniform oset with regards
to the Cu concentration in tissues from SOD1G93A mice compared to the non-transgenic
mice would be expected (similar to that observed for the intestine where concentrations
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did not change signicantly over time). A lack of increases of SOD1 concentration with
time in spinal cord and brain of variousmousemodels of ALS was observed and attributed
to relatively high-level steady-states (Jonsson et al., 2006), though work by Turner et al.
(2003) has shown age-dependent accumulation of hSOD1 in the lumbar spinal cord, the
sciatic nerve, and the gastrocnemiusmuscle. In previous work shown here (Chapter 5.5.1.3),
it was acknowledged that dierences in Cu and Zn concentration between the SOD1G93A
and non-transgenic mice in muscle tissue could be due to over-expression of hSOD1. Here,
observations of a lack of elevated concentrations in Fe and Se (Figure 6.2) point towards a
great contribution of over-expressed SOD1 to the Cu accumulation.is accumulationwas
also reported in previous work (Tokuda et al., 2013): in spinal cord tissue of SOD1WT mice
(over-expression of wild-type SOD1) and SOD1G93Amice Cu concentrations were elevated
(up to 3.2-fold) compared to non-transgenic controls. Furthermore, Cu concentrations in
spinal cordwere signicantly elevated in SOD1G93A samples compared to SOD1WT samples
(Tokuda, 2017). is indicates that at least part, if not all of the accumulation of Cu and
Zn in these tissues could be attributable to SOD1 over-expression. However, the distinct
accumulation of Cu in heart and liver over time (Figure 6.1) compared to controls may
represent disease pathology: previously it was found that in SOD1G93A spinal cord tissue,
Cu was bound to copper-binding proteins other than SOD1 and this increased over time
(Tokuda et al., 2013). Accumulation of Cu in cupro-proteins besides SOD1 may therefore
contribute to the observed signal. e observation of a subtle age-dependent increase
of hSOD1 in the gastrocnemius muscle (Turner et al., 2003) could indicate that a large
proportion, if not all of the observed metal accumulation is a result of SOD1 accumulation
with age. e lack of SOD1 concentration measurements here presents a limitation to
the conclusions that can be drawn. Without tissue-matched measurements from mice
that over-express SOD1WT, or determination of SOD1 concentrations, estimation of how
much of the observed increase in Cu concentration is attributable to the over-expression
of SOD1 in peripheral system tissues remains uncertain.
Zinc concentrations were found to be signicantly elevated in all three tissues (liver,
heart and intestine) and their concentrations in heart and liver increase over time
(Figure 6.1 D – F). Similar to Cu, increased concentration of Zn in heart and liver of
SOD1G93A mice are likely to be related to the over-expression of SOD1, as other elements
(Fe and Se) were not increased (Figure 6.2). Another factor may also contribute: work
using spinal cord tissue from SOD1G93A mice showed an accumulation of Zn not only in
the zinc-binding site of SOD1, but also suggested an increase of Zn binding in other Zn
binding proteins (Tokuda et al., 2013). e increase in Zn concentration was also
statistically signicant in the intestine.
While the accumulation of Cu and Zn in these tissues precede disease pathology
and symptoms, coinciding with initial protein aggregation at 30 d (Gould et al., 2006)
(Table 6.1), the specic binding of the metal(s) to SOD1 has to be further scrutinised.
6.5.3 Lack of up-regulation of Cu transport into CNS
Previously no increase in Cu and Zn concentration was found in the CNS (see Chapter 5,
Section 5.4.1 and Figure 6.5); however, here it is shown these do increase in non-CNS
tissues (Figures 6.1). is could be the result of the non-uniform expression of mSOD1 in
various tissues. Results in humans (Human Protein Atlas, 2017) as well as in the SOD1G37R
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Table 6.1: Typical ALS symptoms and features in transgenic SOD1 mice
Feature/symptom Average time of onset (d) Reference
Initial protein aggregation 30 Gould et al. 2006
Selective neuromuscular junction degeneration 47 Fischer et al. 2004
Maximum running speed reduced 52 Veldink et al. 2003
Reduction of blood ow through the spinal cord 60 Zhong et al. 2008
Axonal loss prominent 80 Fischer et al. 2004
Signicant motor neuron loss 100 Fischer et al. 2004
Onset of paralysis 100 Chiu et al. 1995
(Hilton et al., 2016) and SOD1G93A (Gajowiak et al., 2016) mouse models have shown that
SOD1 protein expression varies between tissues; SOD1G37R CNS tissues expressed much
greater amounts of SOD1 compared to peripheral nervous system tissues (Hilton et al.,
2016). In tissues from SOD1G93A mice, higher amounts of SOD1 were reported in spinal
cord compared to liver and muscle (Gastrocnemius) (Gajowiak et al., 2016). us, if Cu
and Zn concentrations reect the amount of SOD1 present, it would be expected that
CNS tissues would have higher concentrations of Cu and Zn compared to other tissues.
e origin for the discrepancy in Cu and Zn concentrations between CNS and non-CNS
tissues is therefore more likely to be the response of the blood-CNS barriers. While an
increased Cu requirement in the CNS, due to the SOD1 over-expression, may not be met
(Hilton et al., 2016), it is unclear why Zn concentrations are not elevated.
e results presented here show an accumulation of Cu and other metals in the heart
and liver tissue compared to the CNS similar to previously reported results (Hilton et al.,
2016) and those reported in Chapter 5. Blood of ALS patients was shown to not accumulate
Cu and Zn (Garzillo et al., 2014; Kapaki et al., 1997; Nagata et al., 1985; Pamphlett et al.,
2001; Roos et al., 2013). is agrees with the previous ndings in the SOD1G93A mouse
presented in Chapter 5. Blood carries a large amount of the total body Cu, which can be
regarded as a theoretically innite pool for the individual compartments. e observed
increases in tissue concentration, such as heart and liver in the SOD1G93A mice, despite
no change observed in blood (Section 5.4.1), suggests that acquisition of Cu from the liver
into the blood does not vary. Overall the increased demand for Cu in the organism due
to higher mSOD1 levels in these tissues is satised. Copper concentrations in the heart,
liver and intestine may therefore serve as an additional proxy for disease in the SOD1G93A
mouse model of ALS.
e lack of an increase in Cu concentration in the CNS may reect a disconnect
between the rate of Cu uptake and Cu requirement (Hilton et al., 2016) as a response
to the over-expression of mSOD1. Recent results have shown that the amount of Cu in
both brain and spinal cord tissue of the SOD1G37R mouse model is disproportionately
small compared to the amount of SOD1 protein expressed (Hilton et al., 2016). is
indicates that as well as a generally slower turnover, Cu transport into the CNS is not
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accumulation of Cu and other metals in the PNS
No increase in Cu
concentration in blood
No increase of Cu into 
the CNS via blood brain barrier
Mutant SOD1 being ‘starved’
steady
[Cu]
Figure 6.6: Generalized model of Cu transport by the blood-brain-barrier (BBB) and blood-
cerebrospinal uid-barrier (BCB). Free Cu ions are transported, predominantly via the BBB,
into the CNS, where they distribute following a concentration gradient. e removal of Cu from
the CNS is currently not well understood but appears to occur via the BCB. In the SOD1G93A
mouse model of ALS, a general accumulation of Cu is observed in peripheral nervous system
tissues in response to the over-expression of mSOD1. Besides this increase, no other compartment
demonstrates an increase in Cu concentration, indicating that there is no up regulation of Cu
transport from blood into the central nervous system, resulting in ‘starvation’ of the over-expressed
mSOD1. Modied from Zheng and Monnot (2012).
up-regulated to satisfy the increased Cu requirement due to mSOD1 over-expression.
is eectively ‘starves’ the over-expressed mSOD1 (Figure 6.6) (Hilton et al., 2016). As a
result, the protein could be destabilised, making it aggregation-prone (Lelie et al., 2011).
e result could be MN death through direct toxicity of the partially metalated SOD1
(Gil-Bea et al., 2017; Roberts et al., 2014).
6.5.4 Pathological accumulation of Cu in muscle tissue may
contribute to ALS development
Muscle tissue (Gonzalez de Aguilar et al., 2008; Luo et al., 2013; Xiao et al., 2015), and
other (neighbouring) cell types (Boillée, Vande Velde and Cleveland, 2006) may play a
signicant role in the development of ALS pathology. Distinct and rapid muscle atrophy
caused by MN death is a pathologic feature of ALS. Skeletal muscle comprises ∼40% of
whole body lean mass and, combined with bone, makes up ∼50% of total body Cu in
humans (Evans, 1973). Results reported in Section 5.4.1 showed consistently elevated metal
concentrations in SOD1G93A muscle tissue compared to samples from non-transgenic
animals, in accordance with previous ndings (Hilton et al., 2016). ese increases of Cu
and Zn concentrations precede the onset of disease symptoms (Figure 6.4 A – B), while
Fe trails them (Figure 6.4 C). We hypothesised that this observed accumulation could
be the result of the over-expression of mSOD1 in the SOD1G93A mouse model and that
further testing involving tissues from mice that over-express SOD1WT was necessary to
determine whether a pathologic accumulation of Cu occurred in muscle tissue.
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Here, Cu, Zn and Fe concentrations measured in samples from mice over-expressing
wild type SOD1 were similar to those found in tissues from non-transgenic controls
(Figure 6.4 A – C). is is in agreement with results from a previous study comparing
Cu in spinal cord tissues from mice over-expressing wild-type SOD1 and non-transgenic
controls (Tokuda et al., 2009). Since the accumulation of these metals in muscle tissue is
not related to SOD1 over-expression, we contend that it represents a pathological feature
of ALS that warrants further investigation, particularly as the accumulation of Cu is
pre-symptomatic (Figure 6.4 A). While the methodology applied here does not enable us
to determine the origin of the accumulation, several options regarding its involvement in
ALS pathology are presented below:
First, as proposed in Chapter 5, Cu accumulationmay result in toxicity at the NMJ and
the onset of ALS as a distal motor neuropathy that proceeds via a ‘dying-back’ mechanism
(Fischer et al., 2004; Frey et al., 2000; Kiernan et al., 2011). In this case distal axonal
degeneration precedes neuronal degeneration, whereby axons and NMJs are aected
early and the MN withdraws due to perturbations arising from muscle tissue (Zhou et al.,
2015). e axonal degeneration may be the result of retrograde axonal transport of metals
from the muscle via the NMJ. is process has previously been demonstrated for Hg,
which leaked into the synaptic cles from blood vessels in muscle tissue, where it got
transported up the motor neuron (Arvidson, 1992). In a scenario as demonstrated here,
where the muscle tissue continues to accumulate Cu, it is not unlikely for Cu to leak into
the synaptic cle in a similar fashion to Hg, resulting then in a pathway that could bypass
the BBB (Arvidson, 1994) and induce the proposed pathway of toxicity. is contrasts
the toxic-gain-of-function and ‘dying-forward’ hypotheses in which denervation results
from the CNS. To understand the potential role of muscular Cu as a trigger for axonal
denervation, its location within the tissue must be considered: the Cu may reside in the
cytosol or extracellular space. In the cytosol, it could lead to increased reactive oxygen
species (ROS)-related stress and, ultimately cellular damage and apoptosis (Linder, 1991).
However, Cu is unlikely to be present as a free ion, as this would trigger an anti-oxidant
response, through SOD1 and other protective mechanisms, in order to reduce its impact.
Mechanisms to protect against Cu toxicity include the intrinsic stress response of the heat
shock proteins (e.g., heat shock protein 70) (Urani et al., 2001), which can be triggered
by sub-lethal concentrations of Cu. Additionally, the metal-responsive transcription
factor 1 (MTF-1) (Balamurugan and Schaner, 2006) acts under both high and low Cu
concentrations to control the expression of metallothioneins and other components (Cu
importer/transporter 2) that control Cu homeostasis. Cu in the extracellular space can
bind to a variety of proteins, including ceruloplasmin, extracellular SOD1, extracellular
metallothionein and albumin (Linder and Hazegh-Azam, 1996). e work presented here
is limited to organ-level resolution and therefore does not provide any further insight into
how Cu accumulates in tissues, including whether it is located inside or outside cells, or
both.
Second, the accumulation of Cu in muscle tissue may be the consequence of
hyper-metabolism. Increases in energy expenditure are intrinsically linked to ALS
progression, preceding axonal retraction and denervation (Dupuis and Loeer, 2009;
Dupuis et al., 2004; Ferri and Coccurello, 2017). Even though previous work has shown
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that mitochondrial defects precede the onset of MN loss (Basun et al., 1991; Jaarsma et al.,
2000; Kong and Xu, 1998), specic mechanisms and causal links between
hyper-metabolism and mitochondrial dysfunction remain largely unknown.
Mitochondrial respiration produces electrons, which may escape the electron
transport chain to induce the formation of reactive oxygen species (ROS) (Adam-Vizi
and Chinopoulos, 2006; Liemburg-Apers et al., 2015; Murphy, 2009). Mitochondrial
dysfunction, including muscle tissue, has been identied as one of the key features of ALS
(Leclerc et al., 2001). Aggregated, swollen, vacuolated and fragmented mitochondria, as a
possible result of mSOD1 interaction (Pickles et al., 2016), are able to explain other
pathological features such as oxidative stress, glutamate excitotoxicity and apoptosis
(Abel et al., 2012; Faes and Callewaert, 2011; Martin, 2011; Smith et al., 2017). It was
suggested that dysregulation of Cu homeostasis may play a substantial role in the
development of the mitochondrial defects associated with ALS (Son et al., 2007).
e observed Cu accumulation in muscle tissue may be the result of more than one
mechanism, whereby initially it is increased due to a currently unknown process that
increases ROS production. Increases in ROS could stimulate glucose uptake, which in
return could stimulate ROS production leading to a malignant cycle (Liemburg-Apers
et al., 2015). Simultaneously, Cu transport into mitochondria could be up regulated to
meet the demand of cellular respiration, resulting in the observed hyper-metabolism and
overall accumulation of Cu in the tissue.
6.5.5 An updated view on the role of Cu in muscle tissue in ALS
e specic role of accumulated Cu in muscle tissue associated with ALS pathology
remains unclear. e data presented here shows an increase in metal concentrations
in muscle tissues of the SOD1G93A mouse model over time. is suggests that this is a
pathological process (Figure 6.7 C), which may result in both a toxic-gain-of-function
(partiallymetalated SOD1 aggregates that are toxic and lead to axonal retraction) and dying-
back (e.g., accumulation of insoluble mSOD1 aggregates and glutamate toxicity result
in ALS presenting as a distal axonal retraction that precedes death of MNs [see Dadon-
Nachum et al. 2011 for a comprehensive review]) mechanism of ALS onset and progression.
e unifying element in both these mechanisms is Cu. We therefore propose that both the
toxic-gain-of-function and the dying-back hypotheses to explain the mechanisms of ALS
pathology should not be considered as separate, but rather occur in parallel (Figure 6.7 C).
e relative proportion to which each process contributes to the end result of muscular
denervation remains unclear.
e model proposed here combines ndings of general Cu accumulation in
peripheral tissues, specically muscle tissue, and lack of up-regulation of Cu in the CNS.
It is proposed that there are separate processes (Figure 6.7 A and B) associated with Cu
(either as a trigger or consequence), whose specic distribution on an organ level we have
tested (Figure 6.7 C). is specic distribution may contribute to the development of
ALS in these mice (see Section 6.5.4). Furthermore, the model explains why Cu chelators
(Hottinger et al., 1997; Nagano et al., 2003), as well as synthetic Cu-containing therapeutic
agents (Roberts et al., 2014) likely act to prolong the survival of SOD1 mouse models. In
addition to the transformation of labile intermediate forms of SOD1 into apo-SOD1,
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Figure 6.7: Generalised and simplied schematic of pathological processes in ALS. (A) Dying
forward hypothesis: Together with mitochondrial dysfunction and overall increased oxidative
stress, demetalated mSOD1, lacking Cu, aggregates (1) and results in a toxic-gain-of-function (2),
which leads to axonal retraction and denervation (3). (B) Dying back hypothesis: (1) mitochondrial
dysfunction, glutamate toxicity, accumulation of insoluble mSOD1 and neurolaments, as well as
selective neuromuscular synapsis vulnerability, lead to (2) pathological changes in nerve terminals
and axonal retraction, resulting (3) in muscular denervation.
In a revised model, including the latest ndings of Cu concentrations in the SOD1G93A mouse
model (C), it is proposed that in addition to the toxic gain-of-function (2), accumulation of Cu
in muscle tissue contributes to axonal retraction (2) either via direct toxicity or a more complex
mechanisms (e.g., oxidative stress-induced mitochondrial dysfunction), leading to (3) muscular
denervation. Possible intervention options including Cu chelators to remove excessive Cu from
muscle tissue and Cu chaperones to deliver Cu to SOD1, are also highlighted.
(Roberts et al., 2014) Cu chelators may also remove some generally available Cu to
prevent its accumulation in tissues. Simultaneously, the synthetic Cu-containing
therapeutic agent CuII(atsm), which is able to readily cross the BBB, was found to deliver
Cu to mSOD1 so it is in a (stable) holo-SOD1 state (Hilton et al., 2017; Soon et al., 2011;
Williams et al., 2016). Prolonged survival (>20%) in G93A mice treated with CuII(atsm)
has been reported, however this lifespan is greatly extended in G93A mice co-expressing
the human copper chaperone for superoxide dismutase (CCS) (G93A×CCS) and treated
transdermally from prenatal stages (Williams et al., 2016). Even though this presents a
very important milestone in nding a feasible treatment option for ALS, it is not a cure as
all mice developed typical end stage motor neuron disease. Furthermore, G93A×CCS
mice removed from treatment aer 21 days had the same life span as SOD1G93A mice
(Williams et al., 2016). is indicates that at least part of the toxic-gain-of-function of
SOD1 resides in mSOD1 being metal decient, while pathological Cu accumulation in
muscle tissue may also contribute.
Based on the model we have proposed here (Figure 6.7), a treatment combining a
specic Cu chelator (to prevent Cu accumulation in non-CNS tissues), and a synthetic
Cu-containing therapeutic agent (to deliver Cu to the CNS) could be most benecial to
treat ALS in the here assessed G93A mouse model. An application to humans with SOD1
familial ALS, and potentially other genotypes, could be benecial as well; even though
studies on human tissue samples did not observe Cu accumulation in neither liver or
kidneys (Smitt et al., 1992), nor in brain (Gellein et al., 2003) of ALS patients compared to
controls. e lack of general accumulation of Cu in human ALS patients is inconclusive
at this point due to the overall limited number of studies available. Future studies should
systematically assess Cu concentrations in human ALS patient organs, including muscle
tissues, target tissues of ALS. Furthermore, Cu accumulation in ALS models has to further
be examined as it may serve as a biomarker of disease.
6.6 CONCLUSION
e assessment of metal concentrations in several tissues from control and ALS mice
showed accumulation of Cu in tissues controlled by the PNS compared to tissues of the
CNS. is accumulation was identied to be pre-symptomatic. Muscle tissue showed
accumulation of Cu, which was not driven by over-expression of SOD1, as previously
concluded in Chapter 5, but rather was associated with disease pathology in SOD1G93A
mice and was evident at pre-symptomatic stages. e results further indicate that there
is a lack of Cu uptake into the brain despite the higher Cu requirement due to mSOD1
over-expression in the SOD1G93A mouse model of ALS. e observed pre-symptomatic
changes in metal concentrations in tissues controlled by the PNS provide further evidence
for a role of metals, in particular Cu, in the development of ALS pathology.
e accumulation of Cu in muscle tissue leads us to propose a revised model of the
mechanisms underpinning ALS pathology, which unites the toxic-gain-of-function and
dying-back hypotheses. Our model oers another explanation to elucidate the axonal
retraction of MNs in ALS, a process potentially underpinned by Cu accumulation. Further
investigation into the potential applicability of metal concentrations as biomarkers for
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ALS is therefore warranted. Future studies should expand to study human tissues, and
further establish in disease models the location and binding of Cu in ANS tissues to help
further elucidate the role that Cu plays in the aetiology of ALS.
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Alice:Would you tell me, please, which way I ought to go from here?
e Cheshire Cat: That depends a good deal on where you want to get to.
Alice: I don’t much care where.
e Cheshire Cat: Then it doesn’t much matter which way you go.
Alice: . . . So long as I get somewhere.
e Cheshire Cat: Oh, you’re sure to do that, if only you walk long enough.
[Lewis Carroll - Alice in Wonderland]
•
CHAPTER 7
COMPARISON OF HUMAN BLOOD PLASMA
FROM MOTOR NEURON DISEASE AND
HEALTHY COHORTS USING COPPER
ISOTOPE METALLOMICS
Data used to generate gures for this chapter can be found in Appendix A.4.
Portions of this chapter were previously published in:
Enge, T.G., Ecroyd, H., Jolley, D.F., Dawber, J.P., Chung R.S., Crouch, P.J., Turner, S.P.,
Dosseto, A., 2018. Comparison of human blood from motor neuron disease and healthy
cohorts using copper isotope metallomics.Metallomics.
Author Contributions: TGE, HE, DFJ and AD designed the experimental setup. RSC,
PJC and SPT provided access to samples. TGE processed and analysed the samples,
and interpreted the results. JPD performed the statistical analysis. HE, DFJ and AD




Metals in whole blood (Bocca et al., 2015; Fang et al., 2010; Forte et al., 2017; Kamel
et al., 2005, 2002; Oggiano et al., 2018; Pamphlett et al., 2001; Peters et al., 2016; Stober
et al., 1983), serum (Garzillo et al., 2014; Kapaki et al., 1997), plasma (Conradi et al., 1978;
Pamphlett et al., 2001; Ronnevi et al., 1982; Roos et al., 2012, 2013; Stober et al., 1983) and red
blood cells (Nagata et al., 1985; Pamphlett et al., 2001; Vinceti et al., 2002) of ALS patients
have been previously evaluated to assess if metal exposure could be an environmental
trigger of disease, or whether metal concentrations vary within the disease context (see
Table 2.7, page 51). ere is no clear and consistent association in the literature between
metal exposure and/or metal concentration in blood with MND, including ALS. For
example, concentrations of Cu in blood of MND patients have been reported to be lower
(Kapaki et al., 1997), higher (Forte et al., 2017; Oggiano et al., 2018; Peters et al., 2016;
Vinceti et al., 2002) or not dierent (Pamphlett et al., 2001; Roos et al., 2013) to healthy
controls. is suggests that a Cu signal associated with perturbations in Cu metabolism
in ALS is not resolved by conventional bulk concentration analysis methods. Interestingly,
ndings from mouse models of ALS indicate the presence of a pathologic perturbation in
Cumetabolism. For example, tissues associated with the autonomic nervous system (ANS)
have been shown in to accumulate Cu and Zn (Hilton et al., 2016) Chapter 6, with muscle
tissue demonstrating pre-symptomatic increases in concentrations (Section 5.4.1). Results
from central nervous system (CNS) tissues indicate accumulation of Cu in the spinal cord
(Li et al., 2006; Tokuda et al., 2014, 2013, 2008, 2015). Brain tissue showed a similarly varied
behaviour with studies reporting both elevated concentrations (Hilton et al., 2016), or no
change (Lelie et al., 2011; Li et al., 2006; Tokuda et al., 2009) to healthy controls, as shown
in Chapter 5, Section 5.4.1. ese changes in Cu concentrations have been postulated to
play an important role in the gain-of-toxic function associated with disease-associated
mutant forms of SOD1 (mSOD1) (Borchelt et al., 1994; Hilton et al., 2015).
Copper isotope metallomics was also applied in Chapters 5 and 6 to SOD1G93A mice,
which develop ALS-like symptoms as a result of the over-expression of mutant G93A
SOD1. It was shown that there is no discernible dierence in δ65Cu values between central
nervous system (CNS) tissues, brain and spinal cord and whole blood between SOD1G93A
mice and non-transgenic controls. e absence of an ALS signal in blood was largely
explained by the short residence time of Cu in blood and robust excretion mechanisms.
e observation that blood and food had the same Cu isotope ratio suggested that any
potential disease signal was masked by the isotope ratio of food.is was attributed to the
small size of mice and small area aected by the disease (motor neurons in the spinal cord
and brain), therefore not altering the mass balance to produce a measurable Cu isotope
signal in blood.
is study addressed whether there is a detectable ALS-signal in metal (Cu, Zn, Fe, Se)
concentrations or Cu isotope ratios in blood plasma of ALS patients. Blood plasma samples
were chosen for their general availability from blood banks, generous sample volumes and
good understanding of the matrix. While it is proposed that cerebro spinal uid samples
would be the more optimal choice, they were not chosen, due to their low availability,
small sample volume, diculty in the provision of reference samples and high degree of
molecular complexity. is study on blood plasma samples was performed in order to
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improve our understanding of the involvement of transition metals in the development of
ALS and the potential for these analytes to serve as a prognostic/diagnostic tool for the
disease in humans.
7.2 SAMPLES
Human samples, including samples from identical twins were accessed from two
institutions: Melbourne University, Australia (Melbourne) and Macquarie University,
Australia (Sydney). Blood plasma collected in Sydney was collected via venipuncture into
10 mL EDTA tubes, centrifuged at 2,100 × g for 10 min with slow breaking. Following
this, sample aliquots of 750 µL were separated and stored at -80 ºC in the Macquarie
University Neurodegenerative Disease Biobank. e Macquarie University ethics
committee approved all procedures (5201600387); samples from Melbourne were
acquired from the University of Melbourne brain bank and provided by PJC (University
of Melbourne Human Research Ethics Committee approval #1238124.2). e
characteristics of the samples provided from each institute are presented in Tables 7.1 and
7.2. Given that the sample types only dier in the inclusion of the clotting factors, and
have been shown to vary little (Versieck and Cornelis, 1980), they are
merged for this work.
7.3 ANALYTICAL AND STATISTICAL TECHNIQUES
All samples for this study were processed following the previously described procedures
in Chapter 4, using the microwave digestion method for the MARS 6 digestion system
(Section 4.3.3).e samples were then analysed for their elemental concentrations
(see Section 4.3.5.1) and Cu isotopic composition (see Section 4.3.5.2).
To assess any statistical signicance, all samples, with the exception of the identical
twin samples, were combined. All MND related diagnoses (ALS, sporadic ALS, familial
ALS, fail limb, PLS) were paired into one group, herein referred to as ‘MND’. Additionally,
all control samples were paired into the group ‘Control’. e aim of this analysis was
to determine any signicant dierences between the Control and MND groups, while
controlling for age, sex and sample collection location (Melbourne vs Sydney). is was
done using a linear regression model with the concentrations for each of the four elements
(Cu, Fe, Zn, Se) and Cu isotope ratios used separately as response variables. Before the
models were t, the response variable was transformed appropriately and outliers were
removed. Observations were deemed to be outliers if they were outside the interval of three
times the median absolute deviation (MAD) from the median. e t of the regression
models were assessed using diagnostic plots to ensure the model assumptions were met.
A statistical signicance level of 0.05 was used.
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Table 7.1: Characteristics of the human samples
Dataset
Melbourne Sydney
Total (n) 30 132
Age (mean ± 1SD) 56 ± 10 59 ± 16
MND patients (n) 15 114
MND type sALS
fALS, sALS, PLS, Flail-
limb
sex (f/m) 10/5 42/72
Controls (n) 15 18
Control type
Age and sex matched, non-
related
Mixture of obligate careers
and unrelated controls
sex (f/m) 10/5 11/7









MND samples (%) Type of MND
Pair 1 Male 4 69 – 70 2 50 PLS
Pair 2 Female 16 43 – 45 9 56 sALS
Pair 3 Male 6 80 3 50 Flail limb
7.4 RESULTS
Appropriate regression models that did not violate the model assumptions (linearity,
normality and homoscedasticity), were found for all ve-response variables. A square
root transformation was applied to all elements, except Se where a natural log (loge =
ln) transformation was preferable. For the datasets of Se concentrations and Cu isotope
ratios, which included values <1, a constant was added to ensure all values were positive
following the transformation. All ve response variables required outliers to be removed,
with 15 (9%), 17 (10%), 4 (2%), 19 (14%), 6 (4%) outliers respectively for Cu, Zn, Fe, Se and
δ65Cu values. e unusually large number of outliers observed for Se stems from the large
scatter within the dataset, related to sporadic ALS (see below).
ere was no signicant dierence found in the concentration of Cu between the
MND and healthy controls (p = 0.098). ere was a statistically signicant dierence
found in the concentration of Cu in blood betweenmales and females, with women having
higher Cu concentrations (p = 0.001; Figure 7.1 C) compared tomen. Additionally, samples
collected in Melbourne have lower Cu concentrations compared to samples collected in
Sydney (p = 0.015; Figure 7.1 B). No signicant changes were observed with age (p = 0.129;
Figure 7.1 D). When assessing Zn concentrations, there was no signicant dierence
between MND patients and controls (p = 0.489; Figure 7.1 E). A signicant dierence
was observed in relation to where the samples were collected: samples fromMelbourne
having higher Zn concentrations that samples collected in Sydney (p = 0.021; Figure 7.1 F).
No signicant dierence was observed between women and men (p = 0.632; Figure 7.1 G)
nor with age (p = 0.053; Figure 7.1 H). Iron concentrations (Figure 7.1 I – L) showed no
signicant dierences between MND and control groups (p = 0.712), sampling location
(p = 0.224), sex (p = 0.551) or age (p = 0.242). Similarly, δ65Cu values (Figure 7.2 A – D)
showed no signicant dierences between the disease states (p = 0.053), sampling location
(p = 0.912), sex (p = 0.380) or age (p = 0.058). Selenium concentrations (Figure 7.2 E – G),
which were only assessed in samples from the Macquarie dataset, did not show any
signicant dierences between MND and control samples (p = 0.424), sex (p = 0.243) or
age (p = 0.932).
In the twin dataset (Figure 7.3 A – E), qualitative analysis was performed due to the
low sample numbers. Copper concentrations remained constant over time in all pairs
of identical twins, but appear slightly elevated in the MND twin of pair 2 (Figure 7.3
A). While Zn concentrations appear to slightly decrease over time, Fe concentrations
remained relatively constant (Figure 7.3 B – C). Selenium concentrations were variable
within pair 2. Concentrations of Se in the twin with MND in pair 3 were consistently
higher, compared to the healthy twin (Figure 7.3 D).ere were no apparent dierences in
Cu isotope ratios between the diseased and healthy twins, outside of the expected natural
variability. However, pair 2 demonstrated a change from one steady state to another with






















































































































n = 26 n = 122 n = 24 n = 124 n = 57 n = 91
n = 32 n = 114 n = 26 n = 120 n = 59 n = 87
n = 34 n = 125 n = 30 n = 129 n = 63 n = 96
Figure 7.1: Box plots of metal concentrations in human blood. Metals assessed were Cu (A – D),
Zn (E – H) and Fe (I – L). Plots are shown for dierences between MND patients and controls (A,
E and I), sampling location (B, F and J) and sex (C, G and K). Additional plots (D, H and L) show
the distribution against age (years). Data are presented following the correction for the statistical
analysis (sqrt = square root), as box (median ±95% CI) and whisker (maximum and minimum)
plots. Signicance: *** p < 0.001; * p < 0.05. For plots of the raw, uncorrected data, please see





























































































































† Se only measured in 
SYD samples
n = 33 n = 124 n = 30 n = 127 n = 62 n = 95
n = 19 n = 95 n = 47 n = 67
Control MND Female Male
n = 19 n = 114 n = 52 n = 79
Figure 7.2: Box plots of δ65Cu values (‰) (A – D) and Se concentrations (E – J). Plots are shown
for dierences between MND patients and controls (A, E and I), sampling location (B, F and J)
and sex (C, G and K). Additional plots (D, H and L) show the distribution against age (years).
Data are presented following the correction for the statistical analysis (sqrt = square root; ln =
logarithm base e), as box (median ±95% CI) and whisker (maximum and minimum) plots. Panels
H – J present uncorrected data to demonstrate the high variance of Se concentrations in MND
patients (Colours in panel H indicate the diagnosis associated with the specic outlier values). Se
was only measured in the Sydney dataset. For plots of the raw, uncorrected data of δ65Cu values,
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Figure 7.3:e evolution of metal concentrations (Cu, Zn, Fe and Se) and δ65Cu values in blood
plasma, in the twin dataset against time.Grey areas in panelDhighlight increased Se concentrations
in the MND twin from pair 3 compared to the control. e grey area in panel E indicates the
change in Cu isotope ratio of twin pair 2 from one steady state to a second one over the span of
several months, between Sep 2015 – Feb 2016. is shi is proposed to be the result of a change in
diet.
7.5 DISCUSSION
7.5.1 Metal concentrations in ALS blood
Across all metals analysed (Cu, Zn, Fe and Se), no signicant dierences in
concentrations were detected in the blood of MND patients compared to healthy controls
(Figures 7.1 and 7.2). is is in general agreement with the literature whereby no specic
metal has been distinctly associated with the development of MND; however, reported
results for concentrations of metals in human blood vary considerably (see Table 2.7,
page 51). is variability may be the result of various factors: for example, blood Cu
concentrations are aected by age, sex, diet, pregnancy and usage of contraceptives
(Rahmanian et al., 2014; van den Berghe and Klomp, 2009). Additionally, females have a
faster Cu metabolism than men, which results in higher ceruloplasmin (CP) and Cu
plasma concentrations (Johnson et al., 1992), and menstruation aects plasma Cu
concentrations (Michos et al., 2010). e data here agrees well with these ndings: higher
Cu concentrations were observed in female serum compared to men (Figure 7.1 C), and
in younger women (pre-menopausal, <40 y) compared to older ones
(menopausal, 40 – 60 y and post-menopausal, >60 y) (de Bruin et al., 2001) (p = 0.018;
Figure 7.4).
e dierence in Cu concentrations between sampling locations is likely the result of
the varying size and distribution of the data sets (Figure 7.5). While the Sydney dataset
contained samples from 18 females below the age of 40 y (representing 14% of the total
samples analysed from this site), theMelbourne dataset contained none.eobservation of
higher Cu concentrations in female samples, particularly those <40 y, is likely to accounts
for the dierence in Cu concentration between the two datasets (Sydney and Melbourne).
Large variance was observed in Se concentrations in the MND samples (Figure 7.2 H).
is large variance, as well as the elevated Se concentration in the MND twin (pair 3)
(Figure 7.3 D) may be related to the severity of the disease, and/or represent a specic
feature of Flail Limb. Selenium may be involved in a protective mechanism, which has
been observed to be inversely related with the severity of the disease (Oggiano et al., 2018):
less severe ALS cases had signicantly higher Se concentrations in blood compared to
more severe cases, but were not statistically dierent from controls. Although information
on disease severity is not available for the samples examined, the large variance could
represent a spectrum of Se concentrations in response to ALS progression (Figure 7.2 H).
Further experiments are required in order to conrm this proposal.
7.5.2 Copper isotope ratios in MND blood plasma
ere was no signicant dierence measured in the Cu isotope ratios between MND
patients and healthy controls. Furthermore, no trends relating to age, sex, or sampling
location were observed. In the G93A mouse model of ALS, disease onset is triggered as a
function of mutant SOD1 over-expression (Gurney et al., 1994). In this model organism it
was proposed in Chapter 5 that a blood-based ALS Cu isotope signal could be present
as a result of excessive oxidative stress, a key pathological features of ALS (Ferraiuolo
et al., 2011; Niebrój-Dobosz et al., 2004). Copper isotope ratios are sensitive to changes
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Figure 7.4: Box plots of Cu concentrations in female samples, divided by age into <40 and >40 y,
corresponding to pre- and post-menopausal (de Bruin et al., 2001). Data are presented following the
correction for statistical analysis as box (median ±95% CI) and whisker (maximum andminimum)
plots. Signicance: * p < 0.05.
would change as a result of ALS-induced oxidative stress. Dierences in coordination
environment and oxidation state result in natural variations in the isotopic composition
of transition metals in organisms, which are usually small. In the case of Cu, the heavy
isotope (65Cu) favours hard bonds, i.e., with N or O, while the light isotope (δ65Cu)
preferentially bonds to so ligands (S) (Albarède et al., 2011). Surprisingly, the work in
Chapters 5 and 6 showed no signicant variation of the Cu isotope ratio in whole blood or
tissues (heart, liver, intestine, brain, spinal cord, muscle) of the G93A SOD1 mouse over
time. is was attributed to four possible key factors (Chapter 5):
1) oxidative stress, particularlywithin the spinal cord, ismitigated by the up-regulation
of metallothionein (Tokuda et al., 2007), binding excess Cu potentially creating
a pool of light Cu. As this was not observed in measurements of the spinal cord,
there may be further processes regulating this scavenged Cu, possibly removing it,
reducing the potential size of the pool of Cu,
2) a signal due to oxidative stress associated with disease may be masked by
endogenous reactive oxygen species (ROS), the levels of which increase over time
in G93A SOD1 mice (Liu et al., 1998). us to detect a disease-related oxidative
stress signal would require a large increase in ROS,
3) a Cu isotope signal associated with ALS may be masked by the Cu in food due to
the rapid turnover of Cu in the mouse body (7 – 14 d) (Cabrera et al., 2008) and
tight control of Cu inux and eux in the CNS; indeed the isotope ratios measured
in whole blood, faeces and liver reected that of food, as reported in Chapters 5
and 6, and
4) as ALS is modelled by the over-expression of a G93A mutant form of SOD1 in
these mice, the Cu bindings sites are not altered. While it is expected that Cu
concentrations would be higher in the G93A mouse model (as a function of SOD1
over-expression) (see Chapter 5.5.2), no associated changes in Cu-binding, which
could alter the Cu isotope ratio, are expected.
While mice do not provide a straightforward metabolic analogue for humans, the
G93Amouse model displays symptoms that closely mimic human ALS (McGoldrick et al.,
2013). Humans are ∼2,300 times larger than mice (average Australian man, 25 – 34 y:
68,700 g (Australian Bureau of Statistics, 2015); average adult male B6 mouse, 17 w: 30 g
(e Jackson Laboratory, 2018)). e mass specic metabolic rate can be calculated from




is indicates that humans have a metabolism ∼7 times slower compared to that of
mice. Concerning Cu metabolism, whole body Cu turnover in mice has been estimated
to take 7 – 14 d (Cabrera et al., 2008), while it is ∼6 weeks in humans (Albarede et al.,
2016). Given that Cu metabolism appears to scale well with general metabolism, it may
be plausible that the lack of a measurable Cu isotope disease signal in human serum
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Figure 7.5:Histograms showing the distribution of samples against age in years.e yellow shaded
area indicates the age range of potential onset of menopause in females (40 – 60 y). MEL =
Melbourne dataset; SYD = Sydney dataset.
and plasma could be the result of similar mechanisms as those discussed in Section 5.5.2.
However, one of the key factors dictating whether a disease Cu isotope signal can be
measured in the body is the ability of the disease mechanism to impart a substantial
change in δ65Cu values.
All MND cases included in this study display key pathological features centred around
the CNS, specically the spinal cord. Assuming that MND modies the δ65Cu of the
cerebrospinal uid (CSF), then for blood to carry a detectable change in δ65Cu associated
with the disease it needs to receive a steady and signicant inux of Cu from the CNS
of a dierent isotopic composition to the one typically found in blood. In this scenario,
several issues arise:
A) Fluxes of Cu from the CNS are tightly regulated by the blood-brain-barrier (BBB)
and blood-cerebrospinal uid-barrier (BCB) (Zheng and Monnot, 2012). Copper
concentrations in the CSF range from 9 – 24 µg L−1 (Forte et al., 2004; Joergstuerenburg
et al., 1999; Melø et al., 2003), i.e., orders of magnitude lower than that in blood plasma
(1130 µg L−1, Linder 1991). Since the choroid plexus produces the CSF (Orešković et al.,
2017) and has a large capacity to hold Cu within the CNS (Manto, 2014), it could be
expected that the uptake and excretion of Cu into the CSF is also large. Surprisingly, the
rate of Cu entering the choroid plexus is ∼1300 times greater than that into the CSF (Choi
and Zheng, 2009), indicating that Cu is taken up into the brain via the BBB and then
diuses from the interstitial uid into the CSF (Fu et al., 2014).
e whole mass of Cu in human CSF is ∼1.6 µg, which is less than 0.05% of the ∼4 mg
of Cu in blood plasma. To estimate the contribution of CSF Cu to plasma Cu, the mass of
Cu euxed from the CSF to blood has to be approximated, as currently no measurements
exist (see Appendix A.5.1). Here, two eux scenarios weremodelled : amaximum scenario
(MAX), where all CSF Cu is euxed with the turn-over of the CSF.e general production
rate of CSF is 0.35 mL min−1 (Cutler et al., 1968), amounting to ∼500 mL d−1, meaning
that the entire volume of CSF (150 mL) would need to be turned over about 3 – 4 times
per day; at this rate, the daily Cu eux from the CSF to the blood would be ∼6.5 µg. is
is likely a gross over-estimation, as it disregards any separation, storage and recycling
mechanisms when transported via the choroid plexus. A second model was constructed
(CONS) for which daily Cu eux was estimated to be 10% of the total mass of Cu in the
CSF, in the author’s opinion a more realistic scenario compared to the rst one. In this
scenario, 0.19 µg of Cu are euxed daily from the CSF into the blood.
A mass balance model was constructed to assess the general relationship between CSF
Cu eux and δ65Cu in blood plasma (see Appendix A.5.1). Based on the above CONS
CSF Cu eux model, for a change in plasma δ65Cu isotopic composition of 0.05‰ to
be detectable aer one day, the CSF would have to have a δ65Cu of 1059‰, which is
beyond the ∼3‰ range observed in biological material (Balter and Zazzo, 2011): even
when considering the maximum potential Cu eux of 6.5 µg d−1, as proposed in the
MAX model, the CSF isotope ratio necessary to impart a blood δ65Cu signature is still
one order of a magnitude larger (∼31‰) than the natural biological range to impart the
necessary isotope ratio in the blood. erefore it is unlikely that an isotopic signature
can be imparted (Figure 7.6. Conversely, assuming that CSF Cu does not exceed a 3‰ Cu
isotope ratio, 67 µg of Cu would have to be eux from the CSF into the blood plasma per
day in order for a detectable this signal to occur in blood, which far exceeds any estimation
of the available CSF Cu pool.
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Figure 7.6: Conceptual model illustrating the potential relationship between eux of Cu from
the CSF and its impact on the isotope ratio of blood, modelled for one day, assuming all CSF Cu
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Time needed to achieve δ65Cu change of 0.05‰ 
in blood with different rates of potential accumulation:  
10% accumulation: 130 d
0.1% accumulation: 10262 d ≈ 28 y
1% accumulation: 1162 d ≈ 3 y
50% accumulation: 17 d
100% accumulation: 6 d 
Figure 7.7: Conceptual models illustrating the potential relationship between eux of Cu from
the CSF and its impact on the isotope ratio of blood over time. e relationship was estimated
using calculations presented in Appendix A.5.1. (A) and (B) present the relationship in Figure
7.6 modelled over time: (A) the conservative model (CONS) with a Cu eux of 0.19 µg d−1 and
(B) the maximum model (MAX) with a Cu eux of 6.5 µg d−1. In both (A) and (B), coloured
functions represent linear accumulation of dierent fractions (0.1 – 100%) of CSF Cu within the
blood.
Modifying the original model to accommodate a time and accumulation factor (see
Appendix A.5.1), enables assessment of the relationship between CSF Cu eux and δ65Cu
in blood plasma over time, adding the general assumption of accumulation of all or a
fraction of the CSF Cu (Figure 7.7). e models indicate that there is a possibility for CSF
Cu to impart a specic signature on the blood plasma δ65Cu ratio, though the proportion
of accumulation would have to be high for this to occur: if 50% or 10% of the CSF Cu
is retained within the body (i.e., in liver), in the CONS model (Figure 7.7 A) it would
require 3 and 10 years respectively for CSF with a δ65Cu ratio of 3‰ to impart a Cu isotope
signature of 0.05‰ in blood plasma. In the MAX model, these times are signicantly
reduced to 17 and 130 d, respectively (Figure 7.7 B). ese estimates do not allow for
the general turnover of Cu in blood or the liver, which would signicantly extend the
period of time required for a Cu isotope signal arising from CSF Cu to reach measurable
levels in blood. Further, it has to be noted that the MAX model represents a physiological
impossibility and the generally high rate constants of accumulation of isotopically heavier
CSF Cu assumed by the models are rather unrealistic and would lead to a linear increase
of liver isotope ratios with time. is has not been observed in G93A mice (Section 6.5.1).
It is thus concluded that perturbations in the CNS that result in a CSFCu isotope signal
are unlikely to be detected in blood serum and plasma (Figures 7.6 and 7.7). Moreover, it
is unlikely that perturbations in Cu metabolism associated with MND would lead to such
large isotope fractionation, particularly as the ∼60,000 motor neurons only make up a
very small fraction of all neurons in the spinal cord, which is estimated to be ∼1 billion in
humans (Williams and Herrup, 1988). Focus should be placed on the evaluation of CSF
as a target for the application of Cu isotope metallomics in MND patients, as selective
recycling of Cu via the choroid plexus may create a highly localised, isotopically dierent
Cu pool. Although these recycling processes are yet to be shown experimentally, work
on the CSF of ALS patients may support their existence: while Cu concentrations in CSF
were found to be elevated compared to controls, blood Cu concentrations were similar
across the two groups (Roos et al., 2013).
B) Human production of biological uids is dynamic: the general turnover of Cu
in the human body is variable and modulated by the Cu uptake rate: increased dietary
uptake results in increased turnover and vice versa (Turnlund, 1998). Variability may also
be introduced by the time point of sampling, as CSF production follows a circadian cycle,
increasing during sleep (Nilsson et al., 1992). erefore, the relative contribution of any
Cu euxed from the CSF to blood changes continuously, adding complication to the
sampling strategy and reliability of the potential isotope marker. Given the small overall
volume and mass of Cu euxed from the CNS to blood, the likelihood of a Cu-related
MND-isotope signal developing in blood is very low.
C) Dietary sources of Cu may also impart an isotopic signal that could mask any
signal arising as a result of disease. As noted above, Cu plasma concentrations change in
response to dietary uptake of Cu. In Chapter 5, it was shown that in mice the Cu isotope
ratio of blood reects that of food. To date, this phenomenon has not been described
in human blood, although it has been identied in human bones and teeth (Jaouen and
Pons, 2017). Mice provide a particularly good organism to test the potential contribution
of dietary Cu to the blood isotope signature, as their diet is uniform and can be easily
manipulated. In contrast, most humans have a variable omnivorous diet, which would
lead to a variable isotopic signature. While it remains to be tested how a dietary Cu isotope
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signature translates into blood, results from one set of twins (No. 2) show a shi from one
steady state to another over the course of several months in both healthy and MND twins
(Figure 7.3 E). is shi could be the result of either a substantial change in diet, or be
related to menopause, as at the time of sample donation these females were 45 y of age
(see discussion below).
7.5.3 Cu isotope ratios: sex and age
e samples analysed in this work do not show any trends of δ65Cu with age or sex. e
lack of dierence between sexes can be explained by the mean age of the patients. Previous
studies comparing the Cu isotope ratio in a variety of blood samples of women and men
of various ages made a couple of key observations:
1) whole blood and red blood cells were Cu isotopically lighter in young female,
compared to young male subjects (n = 50) (Albarède et al., 2011);
2) red blood cells from pre-menopausal women had a dierent δ65Cu to that of men,
while post-menopausal women were similar to men (Jaouen and Balter, 2014);
3) whole blood from non-menstruating women due tomenopause, and those using an
intra-uterine anti-contraceptive device showed no δ65Cu dierences (Van Heghe
et al., 2014);
4) whole blood fromnon-menstruatingwomenhad a signicantly dierentCu isotope
ratio compared to menstruating women (Van Heghe et al., 2014), and
5) whole blood of non-menstruating women showed similar δ65Cu values to that of
men (Van Heghe et al., 2014).
In contrast, the above patterns were not found in the blood of Siberian Yakut females
comparing pre- and post-menopausal women and men. Rather, δ65Cu values decreased
with age (17 – 74 y) likely due to diet ormetabolic and ethnical specicity of this population,
rather than menopause (Jaouen et al., 2013).
In the work presented here, the subjects’ ages are 52 ± 15 y in women (1SD; n = 64) and
63 ± 14 y in men (1SD; n = 99). As most females here were >40 y and therefore likely to be
either experiencing or have experienced menopause (de Bruin et al., 2001), no signicant
dierence between the populations is expected. However, it is worth pointing out that Cu
concentrations in female samples analysed here were signicantly greater than those in
men (Figure 7.1 C). is could illustrate metabolic dierences between women and men
(Johnson et al., 1992), or reect the observed dierence between pre- and post-menopausal
women (Figure 7.4).
e female identical twins (Pair 2, 45 y), show a distinctive shi in plasma δ65Cu
towards isotopically heavier values over the course of the longitudinal study. is shi
could be associated with menopause as previously reported (Van Heghe et al., 2014);
however, this is unlikely given the short sampling period of 21months. A substantial dietary
shi is more likely to result in the observed Cu isotope signal (Figure 7.3 E). However,
evidence indicates that the frequency as well as duration of menstruation increases (Tae
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andDennerstein, 2002a) over the course of several months (Tae andDennerstein, 2002b),
towards the point of the ‘nalmenstrual period’, dened as the starting point ofmenopause
by the World Health Organization (1996). It would therefore be expected that menopause
would lead to increasingly light δ65Cu values, reaching a minimum at the time of the
nal menstrual period. e δ65Cu values would then start to transition to heavier values,
towards those of men, as menstruation ceases. Interestingly, at the beginning of the time
series, isotopic ratios for these female twins are initially similar to those of the male
twins (Figure 7.3 E), and then shi towards heavier values, which is likely the result of
variability in the dietary baseline.is shi indicates that the relative enrichment occurred
from a dierent isotopic origin. Diet was unfortunately not controlled for in this study.
e potentially dierent dietary backgrounds could osets the females’ blood isotope
signature, indicating that the shi and trend observed could be entirely diet-induced,
independent of menopause altogether. Further, the isotope signature does not follow the
above proposed trends, which could be a function of sampling resolution. More work is
needed to better understand the correlation between isotopic shis, menopause and diet.
7.5.4 Why does the application of Cu isotope metallomics work
in liver cancer?
It is relatively dicult to argue that Cu isotope ratios in human blood could be used as
a disease biomarker of MND, as discussed above. Conversely, it has been shown that
Cu isotopes in blood may indicate cancer progression and severity (Costas-Rodŕıguez
et al., 2015; Télouk et al., 2015). Serum of liver cancer patients was found to be enriched
in light Cu isotopes compared to controls (Balter et al., 2015; Costas-Rodŕıguez et al.,
2015). In the case of liver cancer, the contribution of Cu to overall Cu metabolism is more
straightforward than in the MND scenario. e liver exchanges Cu readily with the blood
through the production of ceruloplasmin, which carries 70 – 90% of the blood Cu. As
the liver cancer grows, it replaces the healthy liver, damages its function, and contributes
signicantly to the overall amount of Cu in blood.
ere are some unique properties in relation to liver cancer that are likely to explain the
distinct Cu isotope ratios found in blood:
i) Cu may be immobilised in cysteine-rich metallothionein, which is released and
therefore able to enrich blood with the lighter isotope (Balter et al., 2015);
ii) heavy Cu may be chelated by lactate as a byproduct of cellular respiration within
the tumour (Télouk et al., 2015);
iii) the presence of hypoxic conditions in the tumour favours the uptake of heavy Cu,
due to an unknownmechanism, and therefore depletes blood, leaving it isotopically
lighter (Bondanese et al., 2016);
iv) physiological dysfunction of the liver, as indicated by inammation may result in
isotope fractionation (Costas-Rodŕıguez et al., 2015).
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It is likely that the tumour specic interaction with the liver and blood, paired with
its relatively large size result in the observed Cu isotope ratio in blood. is indicates that
certain conditions have to be met for Cu isotope ratios to have the potential for application
as a biomarker:
1) the exchange of Cu has to be signicant between the diseased tissue and blood,
restricting the application to large organs, such as liver, kidneys, etc.;
2) Cu metabolism within the tissue that is aected by disease has to be altered in a
way that favours isotope fractionation;
3) the induced isotope fractionation has to either take place at the level of
transmembrane uptake as previously described (Cadiou et al., 2017), or be the
result of signicant immobilisation or release of Cu from storage proteins, which
should be up-regulated too, due to pathological processes.
7.5.5 A metal-based ALS blood biomarker?
A biomarker should act as an indicator of biological and pathogenic processes (Bowser
et al., 2012; Strimbu and Tavel, 2010). In the case of MND, it is attractive to pursue the idea
of an ‘MND signature’, which could lead to early diagnosis and potentially preventative
intervention. However, challenges are posed by the clinical and genetic heterogeneity of
MNDs and identication of appropriate at-risk populations. is understanding is crucial
for a meaningful interpretation of any biomarker (Bowser et al., 2012).
Due to MND’s complex nature, an important question to answer is which biological
uid or tissue to use to capture the sine qua non feature ofMND: the degeneration ofmotor
neurons. Easily accessible samples, such as blood are distant from the proposed locus of
disease onset and demonstrate signicant heterogeneity. Currently, it seems unlikely that
metal concentrations or Cu isotope ratios have the general ability to detect MND-related
pathological processes in blood. Metals require a well-dened disease framework and
physiochemical rationale to be applied and understood properly. is rationale should
indicate a reason for either metal accumulation or depletion, or isotope fractionation as a
result of the disease. e high degree of localisation and complexity of the Cu metabolic
perturbation associated with MND presents a particular challenge. e limitations that
blood presents may likely be overcome by sampling CSF. Its proximity to the pathology
and isolation from any other circulation, may reect and concentrate subtle perturbations
in Cumetabolism: previously, elevated concentrations of select metals have been observed
in the CSF of ALS patients (Roos et al., 2013). However, collecting and working with CSF
comes with its own challenges: it is not an easily accessible biological uid, uctuations in
volume over the course of the day may require multiple samples to be taken. us, more
work is required to evaluate its potential as a carrier of a metal-based MND-biomarker.
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7.6 CONCLUSION
e concept of a metal-based MND biomarker in human blood has been pursued and
tested for the past 40 years. is search has proven dicult, due not only to the inherent
complexity of metal metabolism, but also due to factors such as sex, age and diet all
signicantly impacting metal metabolism. Even tests performed on blood of identical
twins, which largely eliminate these factors, revealed no MND-related dierences in the
metal concentration or Cu isotope ratio in blood, with the exception of Se concentrations
in the twin pair aected by Flail limb disease. An interesting result of this study was the
identication of a potential dietary Cu isotope signal in one set of twins. While the signal
could arise due to menopause, its magnitude and speed was rather abrupt and rapid. is
raises concerns over the potential impact of dietary sources on Cu isotope measurements
in blood. Given the particularly signicant potential short-term impact, it warrants future
investigation.
It is concluded that it is unlikely for blood metal concentrations or Cu isotope ratios
to change signicantly due to the pathological processes that underpin in MND. e
modelling approach utilised here yielded a quantitative assessment of Cu mass balances
which indicate that the highly localised nature of the disease pathology in the CNS
and limited eux of Cu from the CNS into the blood, so that it is unlikely to result in
a detectable CNS metal signal. Physiologically impossible conditions are necessary to
produce a long-term MND Cu isotope ratio in blood that is detectable. Over short time
frames, the blood metal pool, in particular for Cu, is too large and turns over too rapidly.
Direct sampling of CSF may enable detection of a metal-based MND signal, however,
sampling this uid is painful, laborious and challenging. With regards to Cu isotope
ratios in blood serum and plasma, the results presented here suggest that it is unlikely
that it could be used as a blood biomarker of MND. It is suggested that application of
medical isotope metallomics should focus on diseases and conditions with a clear and
distinct pathway, able to result in isotope fractionation. is includes cancers and several
non-cancer conditions (see Chapter 3.1.5), such as for example liver cirrhosis. In fact it is
not to be excluded that some observations made in cancer patients may well be an adverse




The important thing is not to stop questioning. Curiosity has its own reason for
existence. One cannot help but be in awe when he contemplates the mysteries of
eternity, of life, of the marvelous structure of reality. It is enough if one tries merely




CONCLUSIONS, LIMITATIONS, AND FUTURE
RESEARCH
e application of transition-metal concentration measurements and Cu isotope
metallomics in various mouse and human tissues, to evaluate the potential for
development of an (early) disease biomarker for amyotrophic lateral sclerosis (ALS) was
assessed in this thesis. e conclusions broadly fall into three major categories: 1) those
concerning the development of an automated Cu chromatography method (Chapter 4),
2) those based on ndings in the G93A mouse model of ALS (Chapters 5 and 6), and 3)
those discussing ndings in the human blood plasma samples (Chapter 7). Major
conclusions, limitations and future outlook of the work presented here are
discussed below.
8.1 DEVELOPMENT OF AN AUTOMATED AND HIGH-
THROUGHPUT CU CHROMATOGRAPHY
Currently, the application of Cu isotope metallomics to medical questions has a major
limitation. It is traditionally a slow process, restricted by the general ability and skill level
of the analyst, and overall capacity of the specic method applied.emedical community
expects large datasets to evaluate the value and applicability of isotope ratios in a medical
context, overcome noise present in the sampling population due to heterogeneity and
to validate it against exiting biomarkers. In order to tackle this issue, an automated
chromatography system for the rapid separation of Cu from biological material for Cu
isotope ratio analysis was successfully developed and presented in Chapter 4.is method
is characterised by several key abilities:
1) It is a relatively high-throughput method, which has the ability to process
unsupervised ∼30 samples in 24 h. is surpasses any previously developed
manual methods. is level of productivity is independent of the
technician’s/analyst’s skills and presents a great advantage to other manual
chromatography methods.
2) e method can be easily modied to process samples of various degrees of
complexity. Owing to the selective Cu retention on the high capacity Cu resin
used, the matrix wash step of the chromatography can be exibly adjusted to
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accomodate more complex samples (Figure 4.3 on page 86). e opposite is also
true for less complex samples: the wash step can be shortened, decreasing sample
processing time and increasing productivity.
3) Owing to the modular construction of the prepFAST-MCTM, a secondary column
to remove other excess metals, e.g., Fe, can be installed in situations where simply
increasing the matrix wash is not sucient to remove excess Fe. A sample can be
pre-processed to selectively retain Fe, while eluting other elements, or be added
aer the Cu elution to remove any remaining Fe.is gives the Cu chromatography
method presented here great potential for future customisability.
4) e method does not rely on oxidising agents to make the Cu available to the resin.
is reduces not only processing time prior to sample loading onto the column but
also removes the need for excessive cleaning procedures to remove the introduced
oxidising agents.
e Cu chromatography method presented and applied here is an important
developmental step towards the future routine application of Cu isotope ratio analysis
within a medical context. Limitations of the approach arise from its a) partial-automation
and therefore still relatively slow sample throughput, and b) high degree of complexity
and specialisation of the analysis of Cu isotope ratios viaMC-ICP-MS in the separated
Cu fractions. To overcome some of the outlined limitations, the following suggestions for
future development are made:
a) Future iterations of automated Cu chromatography approaches should be more
advanced in their level of automation, or be fully automated. is should not only
include focus on the chromatography method itself, making it faster and more
ecient, but also the steps leading up to it and those following it.is could include
an automated dry down and reux of digested samples, prior to processing on
the column and then the dry down and reux of the eluants to continue with the
measurement of the samples. If and when such a high level of automation can
be achieved is unclear. Such integration of automation would minimise the time
lost due to human intervention, as the machine has the ability to process samples
independently for 24 h. is would also further remove the need for a high degree
of specialisation of the user, and would make the method more suitable for e.g., a
hospital setting to process samples routinely.
b) Following the successful optimisation of sample processing through the Cu
chromatography, a major hurdle is the measurement of the Cu isotope ratios via
MC-ICP-MS. is is not a standard method and restricted to specialised
mass-spectrometer facilities. For isotope metallomics to become a more widely
used approach that has the ability to complement and/or rival conventional
biochemical disease biomarkers, eorts have to be invested into automating,
simplifying and optimising the mass spectrometers that are able to measure the
small dierences observed in natural isotope abundances. is could for example
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include decreasing their size and cost, more ecient beam handling so that several
dierent isotope systems can be measured simultaneously, or the introduction of a
specialist type of MC-ICP-MS that is restricted in its abilities and developed to
automatically measure specic isotope ratios.
Once these issues are overcome, Cu isotopes and other metal isotopes could serve as
biomarkers for a variety of conditions as elaborated on in Chapter 3. While it is hard to
estimate when such changes could or would be developed, the advances presented in this
thesis have contributed towards this ultimate goal.
8.2 METAL ALS SIGNAL IN THE G93AMOUSEMODEL
OF ALS
e second primary aim of this work was to establish if there is an ALS signal in transition
metal concentrations and Cu isotope ratios in key organs relevant to ALS progression
in the SOD1G93A mouse model of ALS, as reported in Chapters 5 and 6. e conclusions
from this work are summarised below.
8.2.1 Metal concentrations in the G93A mouse model of ALS
Metals have been associated and hypothesised to play a major role in the development of
ALS. As reported in Chapters 5 and 6, overall there appears to be a general mechanism that
leads to metal accumulation over time; elevated concentrations were also observed with
disease state in tissues of the SOD1G93A mouse tissues compared to healthy controls. e
ndings of metal accumulation across the tested tissues can be split into two categories: 1)
no accumulation in brain and spinal cord was observed, and 2) accumulation in muscle,
heart, liver and intestinal tissue was found compared to healthy controls.
Cu,Zn superoxide dismutase 1 (SOD1) is a ubiquitously expressed protein. In the
SOD1G93A mouse model of ALS, a mutant form of SOD1 is over-expressed ∼20 times.
erefore it was assumed that if the expression of ALS does not impact on the metal
concentrations, at least Cu and Zn metal concentrations should be elevated uniformly
in all tissues, to depict the overall over-expression of the protein. at a lack of metal
accumulation was observed in the CNS tissues (brain and spinal cord) is therefore an
interesting observation. Given the over-expression of the protein in those tissues, these
results conrm previous ndings by e.g., Hilton et al. (2016) that there may be an apparent
lack of up-regulation of Cu metabolism into the CNS. is could eectively ‘starve’ the
SOD1 present in those tissues and may be one reason for its propensity to aggregate,
triggering the toxic-gain-of-function associated with the onset of ALS.
e observation of elevated Cu and Zn concentrations in the tissues (heart, liver and
intestine) controlled by the autonomic nervous system (ANS), primarily the were partly
attributed to SOD1 over-expression. e fact that accumulation was observed over time
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in both in heart, and liver could represent a pathological feature; Cu may be accumulating
in proteins other than SOD1. However, the work presented here was not able to draw any
denitive conclusions, whether this is the case since total SOD1 protein levels were not
measured in the tissues.
Muscle tissue (Quadriceps femoris) from G93A mice was observed to have elevated
Cu, Zn and Fe concentrations, of which Cu and Zn precede the onset of disease
symptoms, while Fe trails them, compared to healthy controls. To answer the question of
whether this observed accumulation is indeed a result of ALS or an artefact of the SOD1
over-expression, the Cu and Zn concentrations in muscle tissue from non-transgenic
healthy controls and mice over-expressing wild type SOD1 (WTSOD1) were compared.
is comparison could have had two plausible outcomes: 1) there could be elevated Cu
and Zn concentrations in the WTSOD1 (over-expressing the non-mutated form of SOD1)
samples, indicating that over-expression of the protein alone drives the observed
accumulation in Cu and Zn concentrations, or 2) there could be no dierence compared
to non transgenic controls, indicating that the observed accumulation in the SOD1G93A
tissue is driven by the pathology rather than the over-expression of the protein. e
ndings reported here (Section 6.5.4, page 140) demonstrate that over-expression of
SOD1 does not drive the observed accumulation of Cu and Zn, conrming that Cu may
play a bigger than so far assumed role in the developed of ALS pathology, particularly in
muscle tissue.
Together, the ndings concerning metal concentrations in the SOD1G93A mouse led
to a model that elegantly updates the view on the role of Cu in ALS, with a particular
focus on muscle tissue. It is proposed that the observed lack of up-regulation of Cu into
the CNS tissues leads to a starving modus of the over-expressed SOD1 as previously
proposed by Hilton et al. (2016). Metals accumulate in the peripheral tissues (controlled
by the autonomous nervous system) and, in particular muscle tissue, long before the
onset of symptoms in heart, liver and intestinal tissue.is accumulation further precedes
the onset of accumulation in muscle tissue. erefore, it is proposed that two parallel
occurring mechanisms lead to the observed metal concentration distributions. ese
two mechanisms act on the motor neuron from opposite directions. On the one side
there is the dying forwardmechanism: partly metallated SOD1 aggregates and develops
a toxic-gain-of-function resulting in a cascading eect leading to axonal retraction and
nally motor neuron death; on the other side is the dying back mechanism, which is
characterised by pathological metal (Cu) accumulation in the muscle tissue with the
potential to trigger a cascading eect via the development of Cu-mediated mitochondrial
dysfunction, leading to axonal retraction (Figure 6.7, page 143).
e here-performed evaluation of metal concentrations has shown that an ALS signal
exists in key-organs aected by the disease as well as in unaected organs. While the
ndings suggest a role for Cu and Zn, as well as potentially other metals in ALS, a couple
of fundamental limitations have to be mentioned in this context:
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1) e presented work has focused on the measurement of metal concentrations
in bulk tissue and organs. Bulk analysis is characterised by an averaging eect,
as the whole organ (in the case of mice) or large parts of the organ (in the case
of larger animals) are processed, and analysed at once. is leads to a loss in
spatial resolution; subtle deviations within a tissue are lost by averaging across
the whole organ.
2) e work presented here was not accompanied by protein concentration
measurements. As pointed out above, metal concentrations could change as a
result of the over-expression of the SOD1. Rather than having specic tissue
matched wild-type over-expression mice (as done here), the total concentration of
SOD1 tissue could be measured in each of the tissues. is would have enabled the
calculation of Cu concentration per unit protein available, providing an indication
of how much the over-expression of SOD1 contributes to the observed metal
concentration signal, and how much of it was purely pathological.
Future studies of metal concentrations in an ALS context should focus on the
accumulation of metals, in particular of Cu in the muscle tissue. Methods such as Laser
ablation-ICP-MS could aid in resolving the location of the accumulation within
particular tissues; it would be particularly interesting to resolve if the accumulation that
was observed here is located close to the neuromuscular junction, or more generally
within muscle tissue. Such spatial information could provide valuable clues to further
inform how Cu contributes to the axonal retraction characteristic of ALS. Further,
protein assays should accompany metal analyses to resolve any up-regulation or binding
of Cu with specic proteins, or even isoforms. In a disease model like the SODG93A ALS
mouse, several mouse specic isoforms of proteins exist. To have the greatest chance of
translating discoveries in mice into viable treatment approaches in humans, dierences
between mice and humans should be controlled for.
8.3 COPPER ISOTOPE RATIO SIGNAL IN THE G93A
MOUSE MODEL OF ALS
Copper isotope ratios were determined simultaneously from the same longitudinal
samples as the above described metal concentrations. e overall results revealed no
distinct Cu isotope ratio signal associated with ALS in any of the tested mouse tissues.
Otherwise noteworthy ndings were 1) that blood, food and faeces uctuate around the
δ65Cu value of the food source, suggesting a direct relationship between them (Figure 5.5,
page 116), and 2) longitudinal assessment of Cu isotope ratios in muscle and brain tissue
demonstrated an age-dependent trend, independent of the general disease state and
progression (Figure 5.6, page 117).
e general lack of a Cu isotope signal associated with ALS development and
progression in the mouse tissues was attributed to the various protein binding sites of Cu
not being altered as a result of the disease: it is unlikely that Cu binds dierently to the
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mSOD1 protein vs its wild-type form. is is supported by the fact that the disease
pathology is mainly driven by the expression of mSOD1, rather than its over-expression
(the over-expression is mainly associated with disease onset and progression occurring
more rapidly). Given that the mSOD1 in the G93A mice is over-expressed ∼20 times, it is
expected that any isotope signal as a result of altered binding of Cu to the mSOD1 would
be magnied and measurable. As no such signal was observed, any potential alteration
that may take place may be too subtle to be detected using stable isotope techniques at
the currently available resolution.
In contrary to the expected Cu isotope ALS signal, an ageing signal was observed in
brain and muscle tissue where the δ65Cu ratios developed from a heavier composition
to a lighter one over time (Figure 5.6, page 117). is was identied as a enrichment of
bodily Cu pools with dietary Cu. It is hypothesised that initially, the foetal liver is enriched
with heavy Cu from the mother, which is transported via the placenta. is metal pool
fuels rapid growth following birth and is then diluted with dietary Cu and as a result of
endogenic metabolic recycling processes (Figure 5.8, page 125).
Limitations to these results arise from the limited theoretical and experimental data
available concerning Cu isotope fractionation within a whole organism context. While
ab initio calculations serve to predict how certain types of bonds result in theoretical Cu
isotope fractionation, the calculation models available are still very limited. So far only
single bond interactions and small/low molecular weight molecules have been modelled.
With the advent of quantum computing and overall better availability of computing power,
more complex models can be used to better inform and study the phenomena leading to
isotope fractionation. Experimental data have to accompany the theoretical assessment
since both compliment each another. Concerning experimental data, the Cu isotope ratio
measurements have largely been applied to disease contexts whereCu isotope fractionation
was predicted to exist due to a specic pathologic process which favours one isotope over
another. Few studies have explored natural isotope fractionation as a concept, making
the interpretation of results dicult and oen speculative. Future work should focus not
only on improving our mathematical understanding of Cu isotope fractionation and the
resulting isotope ratios, but also explore molecular and cellular isotope fractionation, as
well as larger scale (e.g., organ-level) interactions. For example, it would be most benecial
to compare the binding anities and interactions between Cu and dierent amino acids
(e.g., histidine and cysteine, which oen coexist at metal binding sites of proteins) in
single, as well as mixed-batch experiments, and compare SOD1 mutants to assess if the
mutation does or does not induce isotope fractionation. Further, multi protein assays,
simulating real life conditions inside common cells, could serve as control experiments
where dierent ratios of metal-binding proteins can be explored. ese would also enable
processes such as storage, transport and redox-chemistry pathways of Cu to be explored,
expanding on the work of Cadiou et al. (2017) within yeast.
In addition to the fundamental experimental work, focus should also be placed on
the here-observed ageing-signal. Current markers that describe metabolic ageing, rather
than chronological or physiological ageing are rare and hard to dene. e Cu isotope
signal observed here appears to be sensitive to an intrinsic rate of metabolic turn-over
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within a specic organ.is rate can be determined as a deviation from the diet and could
therefore serve to facilitate new insight into metabolic changes with age and over time
within certain tissues or tissue types.
8.4 A METAL MND SIGNATURE IN HUMAN BLOOD
PLASMA
Results presented in Chapter 7 revealed no dierences in metal concentrations and Cu
isotope ratios between human serum samples of a MND cohort22 and healthy controls.
While no overall trends were observed, females had higher Cu concentrations compared
to men. In addition to the MND and healthy cohorts, serum samples from three pairs
of twins were qualitatively analysed for their metal concentrations and Cu isotope ratio
composition.ese samples were particularly interesting as one of the twins had developed
an MND while the other did not. Two observations were made in these rather restricted
samples: 1) in one of the pairs of twins, the MND twin (diagnosed with Flail limb MND)
had systematically elevated Se concentrations, while 2) in another pair of twins, Cu
isotope ratios evolved from one steady state to a second one over the span of several
months (Figure 7.3, page 154). e elevated Se concentrations could represent a protective
mechanism of Se in the Flail limbMND,while the Cu isotope ratio change likely represents
a change in diet, due to the short time frame the change occurred over. e apparent lack
of a measurable MND-δ65Cu signal in the general as well as twin dataset is hypothesised
to be the result of an imbalanced mass balance, where the amount of Cu euxing from
the CSF is negligible compared to the large transient blood Cu pool (Figure 7.6, page
160). is means that any potential Cu signal is diluted. erefore it is unlikely that a
MND blood serum biomarker based on metal concentration or natural isotope ratio
can be developed.
Limitations to this approach arisemainly from the chosen sample type. It is impractical
for blood serum/plasma to carry a metal-based disease signal from a pathology that is
based in the CNS. ese diculties primarily arise from the way this potential signal is
exchanged between the CNS tissues and the blood: any exchange of metals to and from
the CNS and CSF is very tightly regulated and varies with the circadian rhythm, while
unknown recycling processes via the choroid plexus contribute to the maintenance of a
continuous Cu concentration in the CSF. Additionally, the results of a modelling approach
to estimate the exchange between the CSF Cu and blood Cu (Chapter 7) demonstrated that
it is unlikely that enoughCu is euxed from theCSF per day to lead to ameasurable disease
signal. e model also tested for various amounts of accumulation of CSF derived Cu.
As there is no evidence for a general and selective retention of heavy Cu by either the
liver or the body in general, it is unlikely that any accumulation is signicant in a real
life context. It is thus concluded that perturbations in the CNS that result in a CSF
Cu isotope signal are unlikely to be detected in blood serum. Moreover, it is highly
22eMND cohort consisted of various MND pathologies, including familiar and sporadic ALS.
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unlikely that perturbations in Cu metabolism associated with MND would lead to a large,
detectable isotope fractionation, in particular as the ∼60,000 motor neurons only make
up a very small fraction of the neurons in the spinal cord. A nal limitation that has to
be considered when sampling and analysing human blood is the noise and variability
introduced into the dataset by the human test subjects. is results from variable dietary
Cu uptake and variability in clinical expression of the MNDs. Dierent to the mouse
tissues studied, which have been inbred and are housed in a controlled environment,
consuming a uniform diet for generations, humans do the exact opposite. Environmental
factors, genetic variability and dietary variability introduce noise that likely has a masking
eect on any existing signal.
Future developments should evaluate dierent sources of clinical and genetic
heterogeneity within the sample cohorts of MND. A clearer understanding of such
limiting factors and their impact can inform sampling strategies and improve future
work. To overcome some of the issue found with blood, CSF should be sampled instead
of blood; it is very close to the primary locus of the pathology and more likely to carry a
MND Cu isotope signal, as selective recycling of Cu via the choroid plexus may create a
highly localised, isotopically enriched Cu pool. However, collecting and working with
CSF comes with its own challenges: it is not an easily accessible biological uid,
uctuations in volume over the course of the day may require multiple samples to be
taken, and more work is required to evaluate its potential as a general MND-biomarker.
Further, other tissues which can be biopsied should be considered to extend our
understanding into the distribution of metals and Cu isotopic compositions within the
MND context in humans.
8.5 CONCLUDING REMARKS
Metals have been hypothesised to play an important role in the development of ALS
and MNDs in general. To-date, a metal concentration-based biomarker for MND in
human blood has been extensively pursued. While single metals have been associated
with MND/ALS, no particular metal or mixture thereof has been conclusively identied
to trigger the disease. While it is concluded here that it is unlikely a MNDmetal signal
exists in human blood, the results presented signicantly contribute to our understanding
of how metals may contribute to the ALS pathology. e pathophysiological relevance
of metals should now be accepted, and a particular focus placed on their localisation
within muscle tissue and association with protein aggregates. is will contribute to
the potential development of remediation strategies to correct perturbations to metal
metabolism within ALS. Concerning the application of Cu isotope ratio measurements,
their application should be considered in conditions and environments that provide a
theoretical framework for isotope fractionation to occur. While preliminary results have
shown the method’s great potential, it is unlikely that isotopic biomarkers will be available
in the near future. However, the approach has opened up new avenues of thinking about
metal metabolism and cellular metallomics.
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‘Now, that the patient is no longer here, we can
and must speak amongst ourselves in total frankness.
The most varied remedies with the most logical bases
will be entirely impotent to slow the progressive
advance of this disease. It is sad to say, but it is true.
However, for the doctor, whether it is sad or not is not
the issue: truth is the issue. Let us keep looking in spite
of everything. Let us keep searching for it is indeed the
best method for nding. And perhaps, thanks to our
eorts, the verdict we will give such a patient
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Maréchal, C. and Albarède, F., 2002. Ion-exchange fractionation of copper and zinc isotopes.
Geochimica et Cosmochimica Acta, 66(9), 1499–1509. doi: 10.1016/S0016-7037(01)00815-8.
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van den Berghe, P. V. E., Folmer, D. E., Malingré, H. E. M., van Beurden, E., Klomp, A. E. M., et al.,
2007. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates
cellular copper uptake. Biochemical Journal, 407(1), 49–59. doi: 10.1042/BJ20070705.
van den Berghe, P. V. and Klomp, L. W., 2009. New developments in the regulation of intestinal
copper absorption. Nutrition Reviews, 67(11), 658–672. doi: 10.1111/j.1753-4887.2009.00250.x.
Van Heghe, L., Delanghe, J., Van Vlierberghe, H. and Vanhaecke, F., 2013.e relationship between
the iron isotopic composition of human whole blood and iron status parameters.Metallomics,
5(11), 1503. doi: 10.1039/c3mt00054k.
Van Heghe, L., Deltombe, O., Delanghe, J., Depypere, H. and Vanhaecke, F., 2014. e inuence of
menstrual blood loss and age on the isotopic composition of Cu, Fe and Zn in human whole
blood. J. Anal. At. Spectrom., 29(3), 478–482. doi: 10.1039/C3JA50269D.
Van Heghe, L., Engström, E., Rodushkin, I., Cloquet, C. and Vanhaecke, F., 2012. Isotopic analysis
of the metabolically relevant transition metals Cu, Fe and Zn in human blood from vegetarians
and omnivores using multi-collector ICP-mass spectrometry. Journal of Analytical Atomic
Spectrometry, 27(8), 1327. doi: 10.1039/c2ja30070b.
van Rheenen, W., Shatunov, A., Dekker, A. M., McLaughlin, R. L., Diekstra, F. P., et al., 2016.
Genome-wide association analyses identify new risk variants and the genetic architecture of
amyotrophic lateral sclerosis. Nature Genetics, 48(9), 1043–1048. doi: 10.1038/ng.3622.
220
van Zundert, B., Peuscher, M. H., Hynynen, M., Chen, A., Neve, R. L., et al., 2008. Neonatal
neuronal cuircuitry shows hyperexcitable disturbance in a mouse model of the adult-onset
neurodegenerative disease amyotrophic lateral sclerosis. Journal of Neuroscience, 28(43), 10864–
10874. doi: 10.1523/JNEUROSCI.1340-08.2008.
Vandamme, T. F., 2014. Use of rodents as models of human diseases. Journal of Pharmacy and
Bioallied Sciences, 6(1), 2–9. doi: 10.4103/0975-7406.124301.
Vander Heiden, M. G., Cantley, L. C. andompson, C. B., 2009. Understanding the Warburg
Eect: e Metabolic Requirements of Cell Proliferation. Science, 324(5930), 1029–1033. doi:
10.1126/science.1160809.
Veldink, J., Bär, P., Joosten, E., Otten,M.,Wokke, J., et al., 2003. Sexual dierences in onset of disease
and response to exercise in a transgenic model of ALS. Neuromuscular Disorders, 13(9), 737–743.
doi: 10.1016/S0960-8966(03)00104-4.
Veldink, J. H., van den Berg, L. H., Cobben, J. M., Stulp, R. P., De Jong, J. M., et al., 2001.
Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic
ALS. Neurology, 56(6), 749–752.
Versieck, J. and Cornelis, R., 1980. Normal levels of trace elements in human blood plasma or
serum. Analytica Chimica Acta, 116(2), 217–254. doi: 10.1016/S0003-2670(01)95205-5.
Vinceti, M., Bergomi, M., Nacci, G., Pietrini, V., Ferrari, A., et al., 2002. Erythrocyte zinc, copper,
and copper/zinc superoxide dismutase and risk of sporadic amyotrophic lateral sclerosis: A
population-based case-control study. Amyotrophic Lateral Sclerosis and Other Motor Neuron
Disorders, 3(4), 208–214. doi: 10.1080/146608202760839006.
Vinceti, M., Bottecchi, I., Fan, A., Finkelstein, Y. and Mandrioli, J., 2012. Are environmental
exposures to selenium, heavymetals, and pesticides risk factors for amyotrophic lateral sclerosis?
Reviews on Environmental Health, 27(1), 19–41. doi: 10.1515/reveh-2012-0002.
Vinceti, M., Filippini, T., Mandrioli, J., Violi, F., Bargellini, A., et al., 2017. Lead, cadmium
and mercury in cerebrospinal uid and risk of amyotrophic lateral sclerosis: A case-
control study. Journal of Trace Elements in Medicine and Biology, 43(2016), 121–125. doi:
10.1016/j.jtemb.2016.12.012.
von Blanckenburg, F., Noordmann, J. and Guelke-Stelling, M., 2013. e Iron Stable Isotope
Fingerprint of the Human Diet. Journal of Agricultural and Food Chemistry, 61(49), 11893–11899.
doi: 10.1021/jf402358n.
Walczyk, T. and von Blanckenburg, F., 2005. Deciphering the iron isotope message of
the human body. International Journal of Mass Spectrometry, 242(2-3), 117–134. doi:
10.1016/j.ijms.2004.12.028.
Walczyk, T. and von Blanckenburg, F., 2002. Natural Iron Isotope Variations in Human Blood.
Science, 295(5562), 2065–2066. doi: 10.1126/science.1069389.
Walker, E., Cuttitta, F. and Senle, F., 1958. Some natural variations in the relative abundance
of copper isotopes. Geochimica et Cosmochimica Acta, 15(3), 183–194. doi: 10.1016/0016-
7037(58)90056-5.
221
Walpole, S. C., Prieto-Merino, D., Edwards, P., Cleland, J., Stevens, G., et al., 2012. e weight of
nations: An estimation of adult human biomass. BMC Public Health, 12(1), 439. doi: 10.1186/1471-
2458-12-439.
Walsh, C. T., Sandstead, H. H., Prasad, A. S., Newberne, P. M. and Fraker, P. J., 1994. Zinc: Health
eects and research priorities for the 1990s. Environmental Health Perspectives, 102(Suppl 2), 5–
46. doi: 10.1289/ehp.941025.
Wang, Q., Johnson, J. L., Agar, N. Y. and Agar, J. N., 2008. Protein aggregation and protein
instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biology, 6(7), e170.
doi: 10.1371/journal.pbio.0060170.
Warita, H., Itoyama, Y. and Abe, K., 1999. Selective impairment of fast anterograde axonal transport
in the peripheral nerves of asymptomatic transgenic mice with a G93A mutant SOD1 gene.
Brain Research, 819(1-2), 120–131. doi: 10.1016/S0006-8993(98)01351-1.
West, G. B., 1997. A general model for the origin of allometric scaling laws in biology. Science,
276(5309), 122–126. doi: 10.1126/science.276.5309.122.
White, M. A. and Sreedharan, J., 2016. Amyotrophic lateral sclerosis. Current Opinion in Neurology,
29(5), 557–564. doi: 10.1097/WCO.0000000000000367.
Wiedau-Pazos, M., Goto, J. J., Rabizadeh, S., Gralla, E. B., Roe, J. A., et al., 1996. Altered reactivity
of superoxide dismutase in familial amyotrophic lateral sclerosis. Science, 271(5248), 515–518.
doi: 10.1126/science.271.5248.515.
Williams, A. H., Valdez, G., Moresi, V., Qi, X., McAnally, J., et al., 2009. MicroRNA-206 delays
ALS progression and promotes regeneration of neuromuscular synapses in mice. Science,
326(5959), 1549–1554. doi: 10.1126/science.1181046.
Williams, J. R., Trias, E., Beilby, P. R., Lopez, N. I., Labut, E. M., et al., 2016. Copper delivery to the
CNS by CuATSM eectively treats motor neuron disease in SODG93A mice co-expressing the
Copper-Chaperone-for-SOD. Neurobiology of Disease, 89, 1–9. doi: 10.1016/j.nbd.2016.01.020.
Williams, K. L., Topp, S., Yang, S., Smith, B., Fita, J. A., et al., 2016. CCNF mutations in
amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 7, 11253.
doi: 10.1038/ncomms11253.
Williams, R. W. and Herrup, K., 1988. e Control of Neuron Number. Annual Review of
Neuroscience, 11(1), 423–453. doi: 10.1146/annurev.ne.11.030188.002231.
Williamson, T. L. and Cleveland, D. W., 1999. Slowing of axonal transport is a very early event in
the toxicity of ALS-linked SOD1 mutants to motor neurons. Nature Neuroscience, 2(1), 50–56.
doi: 10.1038/4553.
Wirth, P. L. and Linder, M. C., 1985. Distribution of copper among components of human serum.
Journal of the National Cancer Institute, 75(2), 277–284.
Wong, M. and Martin, L. J., 2010. Skeletal muscle-restricted expression of human SOD1 causes
motor neuron degeneration in transgenic mice. Human Molecular Genetics, 19(11), 2284–2302.
doi: 10.1093/hmg/ddq106.
222
Wong, P. C., Pardo, C. a., Borchelt, D. R., Lee, M. K., Copeland, N. G., et al., 1995. An adverse
property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized
by vacuolar degeneration of mitochondria. Neuron, 14(6), 1105–1116. doi: 10.1016/0896-
6273(95)90259-7.
World Health Organization, 1996. Research on the menopause:report of a WHO scientic group.
Technical reportWorld Health Organization Geneva.
Wright, G. S. A., Antonyuk, S. V. and Hasnain, S. S., 2016. A faulty interaction between SOD1 and
hCCS in neurodegenerative disease. Scientic Reports, 6(1), 27691. doi: 10.1038/srep27691.
Wroe, R., Wai-Ling Butler, A., Andersen, P. M., Powell, J. F. and Al-Chalabi, A., 2008. ALSOD:e
Amyotrophic Lateral Sclerosis Online Database. Amyotrophic Lateral Sclerosis, 9(4), 249–250.
doi: 10.1080/17482960802146106.
Wu, C.-h., Fallini, C., Ticozzi, N., Keagle, P. J., Sapp, P. C., et al., 2012. Mutations in the
prolin 1 gene cause familial amyotrophic lateral sclerosis. Nature, 488(7412), 499–503. doi:
10.1038/nature11280.
Xiao, Y., Ma, C., Yi, J., Wu, S., Luo, G., et al., 2015. Suppressed autophagy ux in skeletal muscle of
an amyotrophic lateral sclerosis mouse model during disease progression. Physiological Reports,
3(1), e12271. doi: 10.14814/phy2.12271.
Xu, Z., 2000. Mechanism and treatment of motoneuron degeneration in ALS: What have SOD1
mutants told us? Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1(4), 225–234.
doi: 10.1080/14660820050515052.
Yamada, K., 2013. Cobalt: Its Role in Health and Disease. in A. Sigel, H. Sigel and R. K. O. Sigel
(eds), Interrelations between Essential Metal Ions and Human Diseases, Springer Netherlands,
London chapter 9, pp. 295–320.
Yamanaka, K., Chun, S. J., Boillee, S., Fujimori-Tonou, N., Yamashita, H., et al., 2008. Astrocytes
as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nature
Neuroscience, 11(3), 251–253. doi: 10.1038/nn2047.
Yang, Y., Hentati, A., Deng, H.-X., Dabbagh, O., Sasaki, T., et al., 2001. e gene encoding alsin,
a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of
recessive amyotrophic lateral sclerosis. Nature Genetics, 29(2), 160–165. doi: 10.1038/ng1001-160.
Yerbury, J. J., Ooi, L., Dillin, A., Saunders, D. N., Hatters, D. M., et al., 2016. Walking the tightrope:
Proteostasis and neurodegenerative disease. Journal of Neurochemistry, 137(4), 489–505. doi:
10.1111/jnc.13575.
Yim, M. B., Kang, J. H., Yim, H. S., Kwak, H. S., Chock, P. B., et al., 1996. A gain-of-function of an
amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement
of free radical formation due to a decrease in Km for hydrogen peroxide. Proceedings of the
National Academy of Sciences, 93(12), 5709–5714. doi: 10.1073/pnas.93.12.5709.
Young, E. D., Galy, A. and Nagahara, H., 2002. Kinetic and equilibrium mass-dependent isotope
fractionation laws in nature and their geochemical and cosmochemical signicance.Geochimica
et Cosmochimica Acta, 66(6), 1095–1104. doi: 10.1016/S0016-7037(01)00832-8.
223
Yu, Y., Su, F.-C., Callaghan, B. C., Goutman, S. A., Batterman, S. A., et al., 2014. Environmental
risk factors and amyotrophic lateral sclerosis (ALS): A case-control study of ALS in Michigan.
PLoS ONE, 9(6), e101186. doi: 10.1371/journal.pone.0101186.
Zambelli, B. and Ciurli, S., 2013. Nickel and Human Health. in A. Sigel, H. Sigel and R. K. O. Sigel
(eds), Interrelations between Essential Metal Ions and Human Diseases, Springer Netherlands,
London chapter 10, pp. 321–357.
Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., et al., 2001. Iron,
neuromelanin and ferritin content in the substantia nigra of normal subjects at dierent ages:
Consequences for iron storage and neurodegenerative processes. Journal of Neurochemistry,
76(6), 1766–1773. doi: 10.1046/j.1471-4159.2001.00186.x.
Zheng, G., Chen, J. and Zheng, W., 2012. Relative contribution of CTR1 and DMT1 in
copper transport by the blood–CSF barrier: Implication in manganese-induced neurotoxicity.
Toxicology and Applied Pharmacology, 260(3), 285–293. doi: 10.1016/j.taap.2012.03.006.
Zheng, W., 2018. Personal Communication.
Zheng, W. andMonnot, A., 2012. Regulation of brain iron and copper homeostasis by brain barrier
systems: Implication in neurodegenerative diseases. Pharmacology &erapeutics, 133(2), 177–
188. doi: 10.1016/j.pharmthera.2011.10.006.Regulation.
Zhong, Z., Deane, R., Ali, Z., Parisi, M., Shapovalov, Y., et al., 2008. ALS-causing SOD1 mutants
generate vascular changes prior to motor neuron degeneration. Nature Neuroscience, 11(4), 420–
422. doi: 10.1038/nn2073.
Zhou, H., Chen, G., Chen, C., Yu, Y. and Xu, Z., 2012. Association between extremely low-frequency
electromagnetic elds occupations and amyotrophic lateral sclerosis: A meta-analysis. PLoS
ONE, 7(11), e48354. doi: 10.1371/journal.pone.0048354.
Zhou, J., Yi, J. and Bonewald, L., 2015. Muscle-bone crosstalk in amyotrophic lateral sclerosis.
Current Osteoporosis Reports, 13(5), 274–279. doi: 10.1007/s11914-015-0281-0.
Zhu, X., Guo, Y., Williams, R., O’Nions, R., Matthews, A., et al., 2002. Mass fractionation
processes of transition metal isotopes. Earth and Planetary Science Letters, 200(1-2), 47–62. doi:
10.1016/S0012-821X(02)00615-5.
Zhu, X., O’Nions, R., Guo, Y., Belshaw, N. and Rickard, D., 2000. Determination of natural Cu-
isotope variation by plasma-source mass spectrometry: Implications for use as geochemical
tracers. Chemical Geology, 163(1-4), 139–149. doi: 10.1016/S0009-2541(99)00076-5.
Zischka, H. and Lichtmannegger, J., 2014. Pathological mitochondrial copper overload in livers
of Wilson’s disease patients and related animal models. Annals of the New York Academy of
Sciences, 1315(1), 6–15. doi: 10.1111/nyas.12347.
224

Estimated amount of glucose used by an adult human brain each day,
expressed in M&Ms: 250








































n = 26 n = 122 n = 24 n = 124 n = 57 n = 91







































Figure A.1: Box plots of metal concentrations in human blood (raw data). Metals assessed were
Cu (A – D) and Zn (E – H). Plots are shown for dierences between MND patients and controls
(A and E), sampling location (B and F) and sex (C and G). Additional plots (D and H) show the
distribution against age (years).
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Figure A.2: Box plots of Fe concentrations (A – D) and δ65Cu values (‰) (E – H) . Plots are shown
for dierences between MND patients and controls (A and E), sampling location (B and F) and
sex (C and G). Additional plots (D and H) show the distribution against age (years).
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Table A.1.2:Data for Figure 4.3, page 86;main gure
Recovery of elements during Cu chromatography (%)
Method step Fraction (mL) 63Cu 65Cu Fe Na Mg K Ca Mn Zn
Load 1 0.1 0.1 29.6 32.3 32.2 31.4 33 31.2 32.8
Load 2 0.1 0.1 29.6 32.3 32.2 31.4 33 31.2 32.8
Matrix wash 1 0.1 0 31.1 35 35.2 36.8 33.4 37 33.9
Matrix wash 2 0.1 0.1 0.5 0.2 0.2 0.2 0.2 0.2 0.2
Matrix wash 3 0 0 0.2 0 0 0 0 0 0
Matrix wash 4 0 0 0.2 0 0 0.1 0 0 0
Cu elution 1 95.5 95.7 8.7 0.1 0.1 0.1 0.1 0.1 0.1
Cu elution 2 3.8 3.9 0.1 0 0 0 0.1 0.1 0.1
Cu elution 3 0.1 0.1 0.1 0 0 0 0 0.1 0
Cu elution 4 0.1 0.1 0 0 0 0 0 0 0
Sum 99.9 100.1 100.1 99.9 99.9 100 99.8 99.9 99.9
Table A.1.3:Data for Figure 4.3, page 86; inset
Recovery (%) Cumulative (%)
Elution Volume 63Cu 65Cu 63Cu
0.25 12.46 12.46 12.46
0.5 77.59 77.60 90.05
0.75 8.23 8.24 98.29
1 1.43 1.43 99.72
1.25 0.07 0.07 99.79
1.5 0.09 0.09 99.88
1.75 0.05 0.05 99.94
2 0.03 0.03 99.97
2.25 0.03 0.03 100.00
233
Table A.1.4:Data for Figure 4.6, page 94; repeat measurements of NIST-976 solutions
# δ65Cu⋆ 2SE Session Outlier # δ65Cu⋆ 2SE Session Outlier
1 −0.04 0.03 4 N 35 −0.11 0.02 8 N
2 −0.03 0.03 4 N 36 −0.06 0.02 8 N
3 −0.03 0.03 4 N 37 0.03 0.02 8 N
4 −140.99 18.28 4 Y 38 −0.03 0.02 8 N
5 −0.03 0.03 4 N 39 −0.06 0.03 8 N
6 −0.08 0.03 4 N 40 −0.06 0.02 9 N
7 0.90 0.03 4 Y 41 −0.06 0.02 9 N
8 −0.10 0.03 4 N 42 −0.04 0.03 9 N
9 −0.10 0.03 4 N 43 −0.04 0.02 9 N
10 −0.03 0.03 4 N 44 −0.04 0.02 9 N
11 −0.08 0.03 5 N 45 −0.04 0.02 9 N
12 −0.05 0.03 5 N 46 −0.02 0.02 9 N
13 −0.06 0.03 5 N 47 −0.07 0.02 9 N
14 −0.02 0.04 5 N 48 −0.06 0.03 10 N
15 −0.02 0.03 6 N 49 −0.10 0.02 10 N
16 −0.03 0.04 6 N 50 −0.10 0.03 10 N
17 −0.07 0.04 6 N 51 −0.05 0.02 10 N
18 −0.08 0.03 6 N 52 −0.07 0.02 10 N
19 −0.06 0.03 6 N 53 −0.03 0.02 10 N
20 −0.01 0.03 7 N 54 −0.02 0.02 10 N
21 −0.02 0.03 7 N 55 −0.07 0.02 10 N
22 −0.03 0.03 7 N 56 −0.04 0.02 10 N
23 −0.01 0.03 7 N 57 −0.07 0.03 11 N
24 −0.06 0.03 7 N 58 −0.06 0.03 11 N
25 −0.06 0.03 7 N 59 −0.09 0.03 11 N
26 −0.05 0.03 7 N 60 −0.06 0.02 11 N
27 −0.02 0.03 7 N 61 −0.05 0.02 11 N
28 −0.03 0.03 7 N 62 −0.06 0.03 11 N
29 −0.06 0.03 7 N 63 −0.04 0.02 11 N
30 −0.03 0.02 8 N 64 −0.03 0.02 11 N
31 −0.04 0.02 8 N 65 −0.06 0.03 11 N
32 −0.06 0.02 8 N 66 −0.10 0.03 11 N




Table A.1.4 continued: Data for Figure 4.6
#⋆ δ65Cu† 2SE Session Outlier #⋆ δ65Cu† 2SE Session Outlier
34 −0.09 0.03 8 N 68 237.43 201.25 11 Y
69 −14.74 506.46 11 Y 102 −0.12 0.05 13 N
70 −633.30 386.28 11 Y 103 −0.03 0.09 14 N
71 −0.09 0.03 11 N 104 0.02 0.10 14 N
72 −0.11 0.03 11 N 105 −0.04 0.06 14 N
73 −0.06 0.02 11 N 106 0.00 0.10 14 N
74 −0.04 0.02 11 N 107 −0.21 0.08 14 Y
75 −0.07 0.03 11 N 108 −0.15 0.08 14 N
76 −0.11 0.03 11 N 109 −0.13 0.10 14 N
77 −0.06 0.03 11 N 110 0.02 0.09 14 N
78 −0.05 0.03 12 N 111 −0.15 0.11 14 N
79 −0.09 0.03 12 N 112 −0.06 0.05 15 N
80 −0.03 0.03 12 N 113 −0.13 0.08 15 N
81 −0.02 0.03 12 N 114 0.00 0.07 15 N
82 −0.01 0.03 12 N 115 −0.12 0.11 15 N
83 −0.01 0.03 12 N 116 −0.10 0.12 15 N
84 0.00 0.03 12 N 117 −0.15 0.12 16 N
85 −0.03 0.03 12 N 118 −0.14 0.11 16 N
86 0.03 0.03 12 N 119 −0.17 0.06 16 N
87 −0.02 0.03 12 N 120 −0.08 0.09 16 N
88 −0.05 0.03 12 N 121 −0.08 0.07 16 N
89 −0.06 0.03 12 N 122 −0.07 0.07 16 N
90 −0.08 0.03 12 N 123 −0.04 0.06 16 N
91 −0.10 0.03 12 N 124 −0.17 0.10 16 N
92 −0.02 0.03 12 N 125 −0.29 0.18 16 Y
93 −0.09 0.03 12 N 126 −0.27 0.20 16 N
94 −0.06 0.04 12 N 127 −0.01 0.05 17 N
Drop in sensitivity 128 0.00 0.06 17 N
95 −0.15 0.06 13 N 129 0.00 0.07 17 N
96 −0.09 0.06 13 N 130 −0.04 0.05 17 N
97 −0.03 0.05 13 N 131 −0.03 0.06 17 N
98 −0.06 0.05 13 N 132 −0.03 0.06 18 N




Table A.1.4 continued: Data for Figure 4.6
#⋆ δ65Cu† 2SE Session Outlier #⋆ δ65Cu† 2SE Session Outlier
100 −0.05 0.04 13 N 134 −0.08 0.05 18 N
101 −0.12 0.04 13 N 135 −0.02 0.05 18 N
136 −0.06 0.06 18 N 170 −0.05 0.08 20 N
137 −0.08 0.06 18 N 171 −0.04 0.07 20 N
138 0.00 0.05 18 N 172 −0.06 0.07 20 N
139 −0.09 0.08 18 N 173 −0.08 0.07 20 N
140 −0.04 0.07 18 N 174 −0.09 0.09 20 N
141 −0.06 0.07 18 N 175 −0.05 0.14 20 N
142 −0.07 0.07 18 N 176 −0.21 0.10 20 N
143 −0.09 0.06 18 N 177 −0.12 0.11 20 N
144 −0.05 0.06 18 N 178 0.05 0.06 20 N
145 −0.03 0.08 18 N 179 0.12 0.05 20 N
146 −126.19 5.78 18 Y 180 0.04 0.11 20 N
147 −0.09 0.06 19 N 181 0.00 0.10 20 N
148 −0.02 0.06 19 N 182 0.65 0.05 20 Y
149 −0.04 0.06 19 N 183 1.59 0.05 20 Y
150 −0.01 0.05 19 N 184 0.57 0.12 20 Y
151 −0.01 0.04 19 N 185 −0.61 0.15 20 Y
152 −0.06 0.04 19 N 186 0.19 0.06 20 Y
153 −0.03 0.04 19 N 187 −0.07 0.08 20 N
154 −0.03 0.05 19 N 188 0.00 0.05 20 N
155 −0.07 0.04 19 N 189 −0.09 0.07 20 N
156 −0.07 0.05 19 N 190 −0.07 0.06 20 N
157 0.01 0.05 19 N 191 −0.34 0.12 20 N
158 −0.07 0.05 19 N 192 0.33 0.05 20 Y
159 −0.05 0.05 19 N 193 −0.14 0.12 20 N
160 −0.08 0.06 19 N 194 0.03 0.04 20 N
161 -0.03 0.06 19 N Installation of new LR slit
162 0.00 0.06 19 N 195 −0.08 0.05 21 N
163 0.01 0.07 19 N 196 −0.06 0.05 21 N
164 0.02 0.04 19 N 197 −0.06 0.05 21 N
165 −0.01 0.07 19 N 198 0.00 0.05 21 N




Table A.1.4 continued: Data for Figure 4.6
#⋆ δ65Cu† 2SE Session Outlier #⋆ δ65Cu† 2SE Session Outlier
167 −0.12 0.10 20 N 200 0.01 0.05 21 N
168 −0.07 0.12 20 N 201 −0.06 0.05 21 N
169 −0.10 0.07 20 N 202 −0.06 0.05 21 N
203 −0.04 0.06 21 N 237 −0.01 0.08 22 N
204 −0.04 0.05 21 N 238 −0.02 0.09 22 N
205 −0.03 0.05 21 N 239 −0.12 0.07 22 N
206 0.01 0.05 21 N 240 −0.04 0.06 22 N
207 −0.07 0.05 21 N 241 −0.07 0.09 22 N
208 0.00 0.06 21 N 242 −0.03 0.08 22 N
209 −0.03 0.06 21 N 243 −0.07 0.09 22 N
210 −0.01 0.05 21 N 244 −0.07 0.07 22 N
211 −0.04 0.05 21 N 245 0.01 0.10 22 N
212 −0.07 0.06 21 N 246 0.02 0.08 22 N
213 −0.09 0.05 21 N 247 0.09 0.09 26 N
214 −0.09 0.07 21 N 248 0.12 0.12 26 N
215 −0.05 0.06 21 N 249 0.03 0.13 26 N
216 −0.10 0.06 21 N 250 −0.13 0.11 26 N
217 −0.10 0.06 21 N 251 −0.01 0.11 26 N
218 −0.01 0.05 21 N 252 −0.12 0.09 26 N
219 0.00 0.05 21 N 253 0.02 0.10 26 N
220 −0.05 0.06 21 N 254 −0.08 0.11 26 N
221 0.00 0.10 21 N 255 0.10 0.13 26 N
222 −0.12 0.12 21 N 256 0.11 0.12 26 N
223 −0.03 0.08 21 N 257 −0.03 0.11 26 N
224 −0.07 0.10 21 N 258 −0.04 0.12 26 N
225 −0.08 0.11 21 N 259 0.00 0.08 26 N
226 −0.19 0.11 21 N 260 0.13 0.13 26 N
227 0.00 0.11 21 N 261 0.16 0.12 26 N
228 −0.05 0.06 22 N 262 −0.06 0.12 26 N
229 −0.09 0.06 22 N 263 −0.08 0.14 26 N
230 −0.04 0.06 22 N 264 −0.01 0.13 26 N
231 −0.05 0.08 22 N 265 −0.06 0.12 26 N




Table A.1.4 continued: Data for Figure 4.6
#⋆ δ65Cu† 2SE Session Outlier #⋆ δ65Cu† 2SE Session Outlier
233 −0.07 0.07 22 N 267 −0.04 0.10 26 N
234 −0.05 0.08 22 N 268 0.02 0.12 26 N
235 −0.06 0.09 22 N 269 −0.07 0.09 26 N
236 −0.13 0.06 22 N 270 −0.02 0.12 26 N
271 −0.14 0.08 26 N 304 0.04 0.07 27 N
272 0.03 0.07 26 N 305 −0.03 0.06 27 N
273 −0.05 0.07 26 N 306 −0.07 0.08 27 N
274 −0.05 0.06 26 N 307 −0.07 0.08 27 N
275 −0.04 0.08 26 N 308 −0.03 0.09 27 N
276 −0.08 0.11 26 N 309 −0.02 0.11 27 N
277 −0.07 0.10 26 N 310 −0.05 0.05 27 N
278 −0.10 0.09 26 N 311 −0.05 0.04 27 N
279 −0.03 0.14 26 N 312 −0.03 0.04 27 N
280 0.02 0.16 26 N 313 −0.09 0.04 27 N
Replacement of skimmer cone 314 −0.05 0.04 27 N
281 0.04 0.05 27 N 315 −0.03 0.04 27 N
282 −0.04 0.05 27 N 316 −0.03 0.06 27 N
283 −0.03 0.03 27 N 317 −0.07 0.05 27 N
284 −0.01 0.04 27 N 318 0.01 0.05 27 N
285 −0.01 0.04 27 N 319 0.00 0.05 28 N
286 −0.06 0.04 27 N 320 −0.10 0.04 28 N
287 −0.06 0.04 27 N 321 −0.04 0.05 28 N
288 −0.03 0.06 27 N 322 −0.04 0.05 28 N
289 −0.07 0.04 27 N 323 −0.05 0.05 28 N
290 −0.04 0.04 27 N 324 −0.03 0.04 28 N
291 −0.02 0.05 27 N 325 −0.04 0.05 28 N
292 −0.04 0.05 27 N 326 −0.02 0.05 28 N
293 0.02 0.04 27 N 327 −0.02 0.05 28 N
294 −0.02 0.05 27 N 328 −0.02 0.04 28 N
295 0.00 0.04 27 N 329 −0.02 0.04 28 N
296 −0.05 0.04 27 N 330 0.02 0.05 28 N
297 −0.02 0.05 27 N 331 −0.03 0.04 28 N




Table A.1.4 continued: Data for Figure 4.6
#⋆ δ65Cu† 2SE Session Outlier #⋆ δ65Cu† 2SE Session Outlier
299 −0.06 0.04 27 N 333 −0.02 0.03 28 N
300 −0.02 0.05 27 N 334 −0.03 0.04 28 N
301 −0.03 0.04 27 N 335 0.02 0.04 28 N
302 −0.09 0.07 27 N 336 −0.03 0.05 28 N
303 −0.04 0.06 27 N 337 −0.03 0.05 28 N
338 0.00 0.05 28 N 355 −0.07 0.05 28 N
339 −0.02 0.04 28 N 356 −0.06 0.04 28 N
340 −0.08 0.06 28 N 357 0.03 0.05 28 N
341 0.03 0.04 28 N 358 0.01 0.04 28 N
342 −0.06 0.05 28 N 359 −0.09 0.04 28 N
343 −0.05 0.04 28 N 360 −0.07 0.05 28 N
344 −0.01 0.05 28 N 361 −0.08 0.04 28 N
345 −0.01 0.05 28 N 362 −0.01 0.05 28 N
346 −0.10 0.04 28 N 363 −0.04 0.04 28 N
347 −0.01 0.05 28 N 364 −0.03 0.05 28 N
348 −0.05 0.05 28 N 365 −0.05 0.04 28 N
349 0.03 0.05 28 N 366 −0.03 0.05 28 N
350 −0.05 0.04 28 N 367 −0.02 0.05 28 N
351 −0.02 0.04 28 N 368 0.00 0.04 28 N
352 0.04 0.05 28 N 369 −0.05 0.04 28 N
353 −0.06 0.05 28 N 370 −0.05 0.04 28 N




Table A.1.5:Data for Figure 4.7, page 95
Sample type #⋆ δ65Cu† 2SE Batch # Sample type #⋆ δ65Cu† 2SE Batch #
DORM-2 1 1.03 0.16 1 DORM-2 21 1.89 0.29 11
DORM-2 2 1.06 0.12 1 DORM-2 22 1.05 0.31 11
DORM-2 3 0.47 0.07 2 DORM-2 23 1.36 0.11 11
DORM-2 4 0.76 0.15 2 DORM-2 24 0.36 0.08 11
DORM-2 5 0.90 0.19 3 DORM-2 25 1.08 0.17 12
DORM-2 6 0.87 0.12 3 DORM-2 26 0.29 0.24 12
DORM-2 7 0.09 0.08 4 DORM-2 27 0.86 0.20 13
DORM-2 8 0.06 0.07 4 DORM-2 28 1.19 0.16 13
DORM-2 9 0.09 0.07 5 DORM-2 29 0.83 0.09 14
DORM-2 10 0.25 0.06 5 DORM-2 30 0.86 0.09 14
DORM-2 11 0.25 0.06 6 DORM-2 31 1.20 0.30 15
DORM-2 12 0.13 0.06 6 DORM-2 32 1.25 0.27 15
DORM-2 13 1.58 0.05 7 DORM-2 33 0.57 0.33 16
DORM-2 14 1.48 0.03 7 DORM-2 34 0.75 0.07 16
DORM-2 15 1.86 0.11 8 DORM-2 35 1.05 0.16 16
DORM-2 16 1.76 0.14 8 DORM-2 36 0.09 0.05 17
DORM-2 17 0.48 0.06 9 DORM-2 37 0.01 0.05 17
DORM-2 18 0.72 0.07 9 DORM-2 38 0.65 0.05 18
DORM-2 19 0.41 0.08 10 DORM-2 39 0.82 0.05 18





















1 Blank 0.27 5.3 31 Blank 0.19 3.7
2 Blank 0.14 2.7 32 Blank 0.04 0.8
3 Blank 0.03 0.7 33 Blank 0.03 0.6
4 Blank 0.05 0.9 34 Blank 0.03 0.5
5 Blank 0.02 0.4 35 Blank 0.03 0.6
6 PS 2 99.7 1976.6 36 PS 2 99.7 1975.6
7 Blank 0.22 4.3 37 Blank 0.23 4.5
8 Blank 0.10 1.9 38 Blank 0.05 0.9
9 Blank 0.22 4.4 39 Blank 0.08 1.7
10 Blank 0.03 0.5 40 Blank 0.03 0.6
11 Blank 0.03 0.5 41 Blank 0.02 0.5
12 PS 2 105.3 2087.8 42 PS 2 97.4 1930.4
13 Blank 0.17 3.3 43 Blank 0.19 3.7
14 Blank 0.04 0.8 44 Blank 0.05 1.0
15 Blank 0.03 0.7 45 Blank 0.05 1.0
16 Blank 0.02 0.4 46 Blank 0.02 0.4
17 Blank 0.03 0.6 47 Blank 0.14 2.8
18 PS 2 101.5 2012.4 48 PS 2 98.8 1958.3
19 Blank 0.16 3.2 49 Blank 0.19 3.8
20 Blank 0.06 1.2 50 Blank 0.21 4.3
21 Blank 0.02 0.5 51 Blank 0.19 3.9
22 Blank 0.03 0.5 52 Blank 0.04 0.7
23 Blank 0.06 1.1 53 Blank 0.19 3.8
24 PS 2 98.6 1954.1 54 PS 2 100.7 1994.9
25 Blank 0.17 3.4 55 Blank 0.23 4.6
26 Blank 0.05 1.0 56 Blank 0.05 1.0
27 Blank 0.04 0.8 57 Blank 0.03 0.6
28 Blank 0.03 0.6 58 Blank 0.03 0.6
29 Blank 0.15 3.0 59 Blank 0.06 1.1
30 PS 2 98.3 1949.2 60 PS 2 99.9 1980.7
⋆PS = Pseudosample
†Yield calculated to Cu loaded: 1982 (ng)
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1 Blank 0.18 1.8
2 Blank 0.13 1.2
3 PS 1 105.0 1029.0
4 Blank 0.22 2.2
5 Blank 0.09 0.8
6 PS 1 102.7 1006.0
7 Blank 0.20 1.9
8 Blank 0.07 0.6
9 PS 1 88.8 869.9
10 Blank 0.22 2.1
11 Blank 0.06 0.6
12 PS 1 102.8 1007.0
13 Blank 0.17 1.7
14 Blank 0.09 0.9
15 PS 1 101.3 992.7
16 Blank 0.18 1.8
17 Blank 0.07 0.7
18 PS 1 100.5 984.8
19 Blank 0.22 2.2
20 Blank 0.09 0.9
21 PS 1 100.6 986.0
22 Blank 0.21 2.0
23 Blank 0.23 2.3
24 PS 1 98.4 964.6
25 Blank 0.13 1.3
26 Blank 0.26 2.5
⋆PS = Pseudosample
†Yield calculated to Cu loaded: 980 (ng)
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Table A.1.8:Data for Figure 4.9, page 97 and Figure 4.11, page 99
Sample type⋆ δ65Cu† SE Cu yield (%)
PS 3 −0.05 0.01 95.2
PS 3 −0.02 0.01 91.7
PS 3 0.01 0.01 93.8
PS 3 0.02 0.01 94.5
PS 3 −0.01 0.01 98.9
PS 4 −0.05 0.01 89.8
PS 4 −0.01 0.01 94.5
PS 4 −0.02 0.01 97.7
PS 4 0.00 0.01 98.8




Table A.1.9:Data for Figure 4.10, page 99; reproducibility of ERM-AE633 solution
Sample type Sample # δ65Cu⋆ SE
ERM-AE633 1 0.03 0.02
ERM-AE633 2 0.02 0.02
ERM-AE633 3 0.01 0.02
ERM-AE633 4 0.00 0.02
ERM-AE633 5 −0.04 0.02
ERM-AE633 6 −0.02 0.02
ERM-AE633 7 −0.04 0.02
ERM-AE633 8 −0.04 0.02
ERM-AE633 9 0.01 0.02
ERM-AE633 10 −0.03 0.01
ERM-AE633 11 0.00 0.01
ERM-AE633 12 −0.03 0.02
ERM-AE633 13 −0.01 0.01
ERM-AE633 14 0.07 0.01
ERM-AE633 15 −0.03 0.01
ERM-AE633 16 −0.04 0.01
ERM-AE633 17 −0.02 0.01
ERM-AE633 18 −0.01 0.01
ERM-AE633 19 −0.02 0.01
ERM-AE633 20 −0.02 0.01
⋆δ65Cu values (‰)
Table A.1.10:Data for Figure 4.12, page 100; reproducibility of chicken samples
Sample type Aliquot # Sample # δ65Cu⋆ SE
Chicken liver 1 1 0.50 0.01
1 2 0.50 0.01
1 3 0.52 0.01
Chicken liver 2 1 1.07 0.01
2 2 1.06 0.01
2 3 1.05 0.01
2 4 1.07 0.01
⋆δ65Cu values (‰)
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A.3 DATA, CHAPTER 5
Table A.2.1:Data for Figure 5.2, page 110
Animal ID Tissue Time (d) State Ni (µg/g)⋆ Co (µg/g)⋆
1481 brain 30 SOD1 <LOD <LOD
1482 brain 30 SOD1 <LOD <LOD
1562 brain 30 SOD1 4.3 20.1
1634 brain 30 SOD1 8.0 14.1
1636 brain 30 SOD1 <LOD 17.3
1653 brain 30 SOD1 6.4 19.5
1563 brain 30 WTUOW <LOD 5.9
1564 brain 30 WTUOW <LOD 4.3
1565 brain 30 WTUOW 4.7 15.9
1566 brain 30 WTUOW 5.0 18.5
1567 brain 30 WTUOW 38.2 6.1
1571 brain 30 WTUOW 88.1 23.3
1602 brain 30 WTUOW 6.9 21.7
1018 brain 60 SOD1 183.9 42.5
1189 brain 60 SOD1 46.0 37.3
1195 brain 60 SOD1 21.4 36.4
1197 brain 60 SOD1 58.4 35.8
1198 brain 60 SOD1 16.6 38.2
1208 brain 60 SOD1 <LOD 16.3
1009 brain 60 WTUOW 23.6 39.2
1194 brain 60 WTUOW 33.0 43.9
1196 brain 60 WTUOW 110.0 102.6
1218 brain 60 WTUOW 63.8 49.2
1219 brain 60 WTUOW 37.8 44.4
1241 brain 60 WTUOW 6.5 25.9
928 brain 90 SOD1 1.3 60.4
930 brain 90 SOD1 25.3 35.7
931 brain 90 SOD1 27.3 38.0
937 brain 90 SOD1 177.4 68.9
938 brain 90 SOD1 32 315.7 42 862.9
1145 brain 90 SOD1 13.1 24.3
997 brain 90 WTUOW 10.4 16.4
⋆<LOD = below limit of detection (0.01 ng/g); concentrations determined in dry tissues.
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Table A.2.1 continued: Data for Figure 5.2
Animal ID Tissue Time (d) State Ni (µg/g)⋆ Co (µg/g)⋆
998 brain 90 WTUOW 19.7 49.8
1000 brain 90 WTUOW 18.4 41.5
1003 brain 90 WTUOW 46.0 50.3
1004 brain 90 WTUOW 14.9 61.9
1173 brain 90 WTUOW <LOD <LOD
854 brain 120 SOD1 <LOD <LOD
855 brain 120 SOD1 1.5 <LOD
863 brain 120 SOD1 94 823.6 60 710.2
865 brain 120 SOD1 6.3 28.7
870 brain 120 SOD1 8.0 34.3
877 brain 120 SOD1 <LOD 1.0
1074 brain 120 WTUOW <LOD 35.8
1078 brain 120 WTUOW <LOD 33.7
1084 brain 120 WTUOW 26.5 40.6
1160 brain 120 WTUOW 100.7 31.7
1223 brain 120 WTUOW <LOD 8.1
1225 brain 120 WTUOW 23.6 33.1
1481 muscle 30 SOD1 <LOD <LOD
1482 muscle 30 SOD1 <LOD 36.5
1483 muscle 30 SOD1 120.0 62.9
1562 muscle 30 SOD1 21.7 41.6
1634 muscle 30 SOD1 44.2 49.3
1636 muscle 30 SOD1 6.7 28.4
1563 muscle 30 WTUOW 843.0 <LOD
1564 muscle 30 WTUOW <LOD <LOD
1566 muscle 30 WTUOW 57.8 22.0
1567 muscle 30 WTUOW 17.6 46.0
1571 muscle 30 WTUOW 1.0 23.4
1602 muscle 30 WTUOW 62.0 49.9
1189 muscle 60 SOD1 213.4 <LOD
1195 muscle 60 SOD1 1.2 <LOD
1197 muscle 60 SOD1 73.5 <LOD
1198 muscle 60 SOD1 6.3 <LOD
1208 muscle 60 SOD1 47.3 53.0
⋆<LOD = below limit of detection (0.01 ng/g); concentrations determined in dry tissues.
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Table A.2.1 continued: Data for Figure 5.2
Animal ID Tissue Time (d) State Ni (µg/g)⋆ Co (µg/g)⋆
1209 muscle 60 SOD1 5.8 34.1
1009 muscle 60 WTUOW 41.3 105.2
1194 muscle 60 WTUOW 26.4 <LOD
1196 muscle 60 WTUOW 147.1 <LOD
1218 muscle 60 WTUOW 137.4 37.2
1219 muscle 60 WTUOW 46.5 <LOD
1241 muscle 60 WTUOW 26.4 26.7
928 muscle 90 SOD1 104.2 35.3
929 muscle 90 SOD1 147.1 241.9
930 muscle 90 SOD1 29.5 <LOD
931 muscle 90 SOD1 <LOD <LOD
937 muscle 90 SOD1 522.8 203.6
938 muscle 90 SOD1 311.0 31.3
997 muscle 90 WTUOW 105.5 23.7
998 muscle 90 WTUOW 171.5 60.4
1000 muscle 90 WTUOW 149.9 95.1
1004 muscle 90 WTUOW 178.8 28.3
1173 muscle 90 WTUOW 4.5 <LOD
854 muscle 120 SOD1 <LOD <LOD
855 muscle 120 SOD1 <LOD <LOD
863 muscle 120 SOD1 132.8 0.5
870 muscle 120 SOD1 26.2 21.6
877 muscle 120 SOD1 50.8 102.6
892 muscle 120 SOD1 11.0 133.5
1074 muscle 120 WTUOW 3.3 <LOD
1078 muscle 120 WTUOW 2.2 <LOD
1084 muscle 120 WTUOW 22.1 <LOD
1159 muscle 120 WTUOW 2.5 17.6
1225 muscle 120 WTUOW 101.5 24.4
2818 muscle 120 WTUOW 54.4 32.4
1481 spinalcord 30 SOD1 <LOD <LOD
1482 spinalcord 30 SOD1 <LOD <LOD
1483 spinalcord 30 SOD1 59.7 16.1
1562 spinalcord 30 SOD1 <LOD 15.8
⋆<LOD = below limit of detection (0.01 ng/g); concentrations determined in dry tissues.
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Table A.2.1 continued: Data for Figure 5.2
Animal ID Tissue Time (d) State Ni (µg/g)⋆ Co (µg/g)⋆
1634 spinalcord 30 SOD1 <LOD <LOD
1653 spinalcord 30 SOD1 29.6 9.4
865 spinalcord 30 WTUOW 17.7 0.7
1563 spinalcord 30 WTUOW <LOD <LOD
1564 spinalcord 30 WTUOW <LOD <LOD
1566 spinalcord 30 WTUOW <LOD 1.3
1567 spinalcord 30 WTUOW 42.5 <LOD
1571 spinalcord 30 WTUOW <LOD <LOD
1602 spinalcord 30 WTUOW 40.3 26.5
1018 spinalcord 60 SOD1 1160.6 43.3
1189 spinalcord 60 SOD1 117.3 32.5
1195 spinalcord 60 SOD1 255.1 147.7
1197 spinalcord 60 SOD1 193.0 47.9
1198 spinalcord 60 SOD1 155.3 27.7
1208 spinalcord 60 SOD1 <LOD <LOD
1009 spinalcord 60 WTUOW 155.1 35.7
1194 spinalcord 60 WTUOW 181.8 66.5
1196 spinalcord 60 WTUOW 164.8 1635.4
1212 spinalcord 60 WTUOW <LOD <LOD
1219 spinalcord 60 WTUOW 298.7 31.6
1653 spinalcord 60 WTUOW 29.6 27.1
928 spinalcord 90 SOD1 14.3 8.2
929 spinalcord 90 SOD1 140.5 12.3
930 spinalcord 90 SOD1 244.5 41.3
931 spinalcord 90 SOD1 102.4 23.5
937 spinalcord 90 SOD1 674.0 16.5
938 spinalcord 90 SOD1 13 340 653.7 323 916.4
997 spinalcord 90 WTUOW 140.2 44.6
998 spinalcord 90 WTUOW 74.8 31.3
1000 spinalcord 90 WTUOW 779.0 42.0
1003 spinalcord 90 WTUOW 259.6 39.6
1004 spinalcord 90 WTUOW 147.0 30.1
1173 spinalcord 90 WTUOW 43.6 13.6
854 spinalcord 120 SOD1 36.1 21.6
⋆<LOD = below limit of detection (0.01 ng/g); concentrations determined in dry tissues.
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Table A.2.1 continued: Data for Figure 5.2
Animal ID Tissue Time (d) State Ni (µg/g)⋆ Co (µg/g)⋆
855 spinalcord 120 SOD1 60.9 32.9
863 spinalcord 120 SOD1 113 566.6 424 341.7
870 spinalcord 120 SOD1 130.9 89.4
877 spinalcord 120 SOD1 <LOD <LOD
1565 spinalcord 120 SOD1 10.7 26.5
1074 spinalcord 120 WTUOW 0.6 <LOD
1078 spinalcord 120 WTUOW 122.5 11.7
1084 spinalcord 120 WTUOW 8.6 24.2
1160 spinalcord 120 WTUOW <LOD <LOD
1225 spinalcord 120 WTUOW 8.2 3.0
2139 spinalcord 120 WTUOW <LOD <LOD
⋆<LOD = below limit of detection (0.01 ng/g); concentrations determined in dry tissues.
Table A.2.2:Data for Figure 5.3, page 111
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Fe (µg/g)⋆ Zn (µg/g)⋆
1481 brain 30 SOD1 14.0 77.4 113.2
1482 brain 30 SOD1 14.5 61.9 112.2
1562 brain 30 SOD1 14.3 74.2 73.0
1634 brain 30 SOD1 12.5 69.1 65.5
1636 brain 30 SOD1 13.2 88.2 85.7
1653 brain 30 SOD1 12.6 68.8 75.0
1563 brain 30 WTUOW 18.4 104.1 99.3
1564 brain 30 WTUOW 18.8 75.0 104.5
1565 brain 30 WTUOW 16.7 76.0 66.4
1566 brain 30 WTUOW 15.7 71.4 63.3
1567 brain 30 WTUOW 12.4 63.5 34.2
1571 brain 30 WTUOW 19.8 86.3 84.4
1602 brain 30 WTUOW 13.1 81.2 78.3
1018 brain 60 SOD1 29.0 132.1 132.3
1189 brain 60 SOD1 30.8 116.9 126.1
1195 brain 60 SOD1 27.5 122.1 120.0
1197 brain 60 SOD1 33.1 126.2 139.6
1198 brain 60 SOD1 29.0 143.4 135.8
⋆Concentrations determined in dry tissues.
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Table A.2.2 continued: Data for Figure 5.3
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Fe (µg/g)⋆ Zn (µg/g)⋆
1208 brain 60 SOD1 15.0 89.2 71.4
1009 brain 60 WTUOW 35.3 146.8 131.5
1194 brain 60 WTUOW 31.7 139.9 120.7
1196 brain 60 WTUOW 30.7 145.1 119.5
1218 brain 60 WTUOW 26.9 125.7 111.2
1219 brain 60 WTUOW 26.5 129.0 108.1
1241 brain 60 WTUOW 18.2 83.2 66.0
928 brain 90 SOD1 27.6 108.6 116.1
930 brain 90 SOD1 29.6 122.8 130.8
931 brain 90 SOD1 32.3 126.6 133.7
937 brain 90 SOD1 52.3 215.7 214.7
938 brain 90 SOD1 38.3 17.6 14.7
1145 brain 90 SOD1 19.1 88.5 77.0
997 brain 90 WTUOW 9.0 41.0 34.7
998 brain 90 WTUOW 24.3 139.4 114.3
1000 brain 90 WTUOW 29.2 115.8 99.3
1003 brain 90 WTUOW 30.2 134.2 155.7
1004 brain 90 WTUOW 37.6 168.7 133.2
1173 brain 90 WTUOW 30.7 121.1 110.5
854 brain 120 SOD1 25.0 97.8 101.6
855 brain 120 SOD1 18.1 67.0 72.9
863 brain 120 SOD1 28.9 124.3 119.8
865 brain 120 SOD1 23.1 88.1 78.3
870 brain 120 SOD1 25.3 106.5 91.2
877 brain 120 SOD1 26.8 81.8 117.2
1074 brain 120 WTUOW 25.1 120.0 86.8
1078 brain 120 WTUOW 24.0 112.4 80.4
1084 brain 120 WTUOW 23.1 101.3 76.8
1160 brain 120 WTUOW 22.2 96.2 69.9
1223 brain 120 WTUOW 20.8 92.2 88.5
1225 brain 120 WTUOW 20.8 89.2 65.6
1481 muscle 30 SOD1 4.4 42.8 53.8
1482 muscle 30 SOD1 7.1 36.5 63.1
1483 muscle 30 SOD1 8.1 48.1 47.4
⋆Concentrations determined in dry tissues.
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Table A.2.2 continued: Data for Figure 5.3
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Fe (µg/g)⋆ Zn (µg/g)⋆
1562 muscle 30 SOD1 10.4 55.3 43.0
1634 muscle 30 SOD1 4.1 39.3 33.7
1636 muscle 30 SOD1 8.7 60.4 46.0
1563 muscle 30 WTUOW 3.9 51.3 56.6
1564 muscle 30 WTUOW 3.0 38.1 44.2
1566 muscle 30 WTUOW 4.3 44.2 28.0
1567 muscle 30 WTUOW 6.3 75.2 42.5
1571 muscle 30 WTUOW 4.9 44.4 35.4
1602 muscle 30 WTUOW 9.1 44.4 44.7
1189 muscle 60 SOD1 17.3 74.6 122.8
1195 muscle 60 SOD1 17.6 62.3 91.7
1197 muscle 60 SOD1 20.5 90.4 135.9
1198 muscle 60 SOD1 21.1 90.3 115.2
1208 muscle 60 SOD1 11.7 61.1 59.2
1209 muscle 60 SOD1 13.0 67.9 59.5
1009 muscle 60 WTUOW 8.2 99.2 82.9
1194 muscle 60 WTUOW 5.8 64.3 65.2
1196 muscle 60 WTUOW 4.5 64.7 51.3
1218 muscle 60 WTUOW 5.6 64.7 58.1
1219 muscle 60 WTUOW 10.7 101.9 115.7
1241 muscle 60 WTUOW 4.6 48.7 34.1
928 muscle 90 SOD1 18.3 130.3 87.5
929 muscle 90 SOD1 19.6 153.7 101.6
930 muscle 90 SOD1 27.7 160.5 170.8
931 muscle 90 SOD1 38.8 223.2 273.7
937 muscle 90 SOD1 20.7 141.8 114.0
938 muscle 90 SOD1 20.5 146.1 108.9
997 muscle 90 WTUOW 5.6 64.2 48.5
998 muscle 90 WTUOW 7.9 94.5 68.8
1000 muscle 90 WTUOW 5.8 66.9 49.0
1004 muscle 90 WTUOW 4.3 54.1 35.6
1173 muscle 90 WTUOW 4.0 44.5 43.6
854 muscle 120 SOD1 10.4 98.9 103.9
855 muscle 120 SOD1 11.3 104.1 98.4
⋆Concentrations determined in dry tissues.
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Table A.2.2 continued: Data for Figure 5.3
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Fe (µg/g)⋆ Zn (µg/g)⋆
863 muscle 120 SOD1 12.1 108.0 102.6
870 muscle 120 SOD1 15.0 56.3 56.8
877 muscle 120 SOD1 12.4 205.1 83.3
892 muscle 120 SOD1 17.8 124.7 127.8
1074 muscle 120 WTUOW 4.1 46.2 45.5
1078 muscle 120 WTUOW 4.6 48.8 41.2
1084 muscle 120 WTUOW 4.0 45.2 40.8
1159 muscle 120 WTUOW 3.2 41.8 28.5
1225 muscle 120 WTUOW 4.1 49.2 31.0
1481 spinalcord 30 SOD1 5.2 34.8 58.6
1482 spinalcord 30 SOD1 6.6 37.4 62.3
1483 spinalcord 30 SOD1 6.2 38.1 28.9
1562 spinalcord 30 SOD1 11.4 68.3 50.5
1634 spinalcord 30 SOD1 8.6 50.1 44.0
1653 spinalcord 30 SOD1 15.0 106.9 68.2
865 spinalcord 30 WTUOW 10.0 54.7 35.4
1563 spinalcord 30 WTUOW 9.5 50.6 65.6
1564 spinalcord 30 WTUOW 6.7 195.0 65.3
1566 spinalcord 30 WTUOW 8.6 45.7 31.2
1567 spinalcord 30 WTUOW 24.5 143.1 91.7
1571 spinalcord 30 WTUOW 9.5 55.9 38.2
1602 spinalcord 30 WTUOW 12.4 83.6 61.2
1018 spinalcord 60 SOD1 28.9 182.5 112.3
1189 spinalcord 60 SOD1 20.0 81.3 80.6
1195 spinalcord 60 SOD1 20.0 86.8 74.0
1197 spinalcord 60 SOD1 20.7 87.4 75.2
1198 spinalcord 60 SOD1 23.9 122.5 109.8
1208 spinalcord 60 SOD1 10.8 64.0 46.5
1009 spinalcord 60 WTUOW 17.7 81.8 63.5
1194 spinalcord 60 WTUOW 18.0 94.1 58.6
1196 spinalcord 60 WTUOW 20.5 115.5 68.5
1212 spinalcord 60 WTUOW 8.7 46.9 28.4
1219 spinalcord 60 WTUOW 17.0 91.7 61.5
1653 spinalcord 60 WTUOW 8.5 47.6 38.0
⋆Concentrations determined in dry tissues.
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Table A.2.2 continued: Data for Figure 5.3
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Fe (µg/g)⋆ Zn (µg/g)⋆
928 spinalcord 90 SOD1 12.4 67.9 51.4
929 spinalcord 90 SOD1 12.5 101.9 59.6
930 spinalcord 90 SOD1 21.3 163.2 122.0
931 spinalcord 90 SOD1 25.4 104.5 109.0
937 spinalcord 90 SOD1 22.4 79.9 92.4
938 spinalcord 90 SOD1 128.8 505.1 549.0
997 spinalcord 90 WTUOW 18.7 164.3 142.0
998 spinalcord 90 WTUOW 11.6 97.4 81.9
1000 spinalcord 90 WTUOW 22.5 108.5 93.7
1003 spinalcord 90 WTUOW 20.2 109.9 122.5
1004 spinalcord 90 WTUOW 20.0 101.2 81.6
1173 spinalcord 90 WTUOW 15.0 75.1 60.3
854 spinalcord 120 SOD1 20.0 92.6 92.5
855 spinalcord 120 SOD1 20.0 96.5 100.1
863 spinalcord 120 SOD1 24.3 120.0 117.1
870 spinalcord 120 SOD1 14.3 146.2 116.0
877 spinalcord 120 SOD1 16.1 65.7 78.4
1565 spinalcord 120 SOD1 4.0 50.1 27.4
1074 spinalcord 120 WTUOW 17.1 73.1 356.2
1078 spinalcord 120 WTUOW 17.1 75.6 50.1
1084 spinalcord 120 WTUOW 16.1 64.2 80.9
1160 spinalcord 120 WTUOW 8.7 50.2 27.6
1225 spinalcord 120 WTUOW 3.6 2635.9 20.4
2139 spinalcord 120 WTUOW 11.6 56.6 46.4
⋆Concentrations determined in dry tissues.
Table A.2.3:Data for Figure 5.4, page 114
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Fe (µg/g)⋆ Zn (µg/g)⋆
877 blood 30 SOD1 6.2 2306.8 30.2
1481 blood 30 SOD1 3.8 2516.5 28.3
1483 blood 30 SOD1 6.6 2584.0 24.5
1562 blood 30 SOD1 5.9 2553.6 23.5
1634 blood 30 SOD1 2.9 2464.7 17.7
⋆Concentrations determined in dry tissues.
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Table A.2.3 continued: Data for Figure 5.4
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Fe (µg/g)⋆ Zn (µg/g)⋆
1636 blood 30 SOD1 4.5 2457.4 20.1
1653 blood 30 SOD1 9.8 50.5 31.1
1563 blood 30 WTUOW 3.3 2593.9 27.8
1564 blood 30 WTUOW 3.2 2647.1 28.1
1565 blood 30 WTUOW 11.5 48.4 37.9
1567 blood 30 WTUOW 3.2 2605.1 17.4
1571 blood 30 WTUOW 5.1 2742.2 21.8
1572 blood 30 WTUOW 3.3 1810.3 16.1
1602 blood 30 WTUOW 5.1 2761.4 22.8
1603 blood 30 WTUOW 2.8 2120.2 17.6
1604 blood 30 WTUOW 2.8 2359.4 18.1
1018 blood 60 SOD1 4.7 819.5 38.2
1189 blood 60 SOD1 0.7 1473.1 41.6
1195 blood 60 SOD1 14.2 11 035.8 100.2
1197 blood 60 SOD1 2.4 968.5 37.2
1198 blood 60 SOD1 5.8 437.6 41.5
1208 blood 60 SOD1 3.7 2727.1 20.2
1209 blood 60 SOD1 3.4 2576.5 20.8
1211 blood 60 SOD1 2.9 2518.2 19.9
1009 blood 60 WTUOW 5.1 685.1 42.2
1187 blood 60 WTUOW 2.5 2449.0 17.5
1194 blood 60 WTUOW 2.1 933.9 53.0
1196 blood 60 WTUOW 2.3 1159.9 34.4
1212 blood 60 WTUOW 2.2 2414.7 17.1
1218 blood 60 WTUOW 0.9 1000.0 15.7
1219 blood 60 WTUOW 3.1 1633.9 31.9
1241 blood 60 WTUOW 4.4 4165.8 39.8
928 blood 90 SOD1 3.8 2732.0 30.6
929 blood 90 SOD1 3.7 2719.0 40.8
930 blood 90 SOD1 1.5 172.7 38.0
931 blood 90 SOD1 1.5 268.0 37.8
937 blood 90 SOD1 7.9 273.9 60.2
938 blood 90 SOD1 539.3 0.0 3856.6
1145 blood 90 SOD1 3.0 2422.0 20.3
⋆Concentrations determined in dry tissues.
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Table A.2.3 continued: Data for Figure 5.4
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Fe (µg/g)⋆ Zn (µg/g)⋆
1145 blood 90 SOD1 2.6 2570.0 19.6
997 blood 90 WTUOW 1.8 605.9 37.0
998 blood 90 WTUOW 4.4 1137.2 43.4
1000 blood 90 WTUOW 6.1 226.7 51.9
1003 blood 90 WTUOW 8.6 3829.4 152.7
1004 blood 90 WTUOW 2.2 459.6 37.5
1166 blood 90 WTUOW 2.7 2732.7 20.3
1167 blood 90 WTUOW 2.4 2477.6 17.7
1173 blood 90 WTUOW 3.3 3150.8 30.6
854 blood 120 SOD1 2.3 1673.6 26.1
855 blood 120 SOD1 2.5 1808.7 24.6
863 blood 120 SOD1 5.5 3471.8 42.1
865 blood 120 SOD1 4.6 3371.8 44.6
870 blood 120 SOD1 5.2 4007.6 40.9
877 blood 120 SOD1 5.7 3433.7 37.1
892 blood 120 SOD1 3.8 2609.8 22.5
902 blood 120 SOD1 3.1 2432.2 21.2
1074 blood 120 WTUOW 3.6 3230.4 26.3
1078 blood 120 WTUOW 3.2 3043.2 27.4
1084 blood 120 WTUOW 3.8 3371.2 29.6
1158 blood 120 WTUOW 2.9 2617.4 22.1
1159 blood 120 WTUOW 2.6 2656.2 19.7
1160 blood 120 WTUOW 3.7 3268.9 27.9
1223 blood 120 WTUOW 3.7 3054.8 30.2
1225 blood 120 WTUOW 3.8 3050.7 26.9
⋆Concentrations determined in dry tissues.
Table A.2.4:Data for Figure 5.6, page 117
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1481 brain 30 SOD1 2.20 0.06
1482 brain 30 SOD1 2.12 0.05
1562 brain 30 SOD1 1.67 0.05
1634 brain 30 SOD1 1.84 0.10
⋆δ65Cu values (‰)
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Table A.2.4 continued: Data for Figure 5.6
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1636 brain 30 SOD1 1.65 0.07
1653 brain 30 SOD1 1.82 0.06
1563 brain 30 WTUOW 2.33 0.06
1564 brain 30 WTUOW 2.23 0.05
1565 brain 30 WTUOW 1.70 0.07
1566 brain 30 WTUOW 1.38 0.06
1567 brain 30 WTUOW 1.67 0.05
1571 brain 30 WTUOW 1.91 0.06
1602 brain 30 WTUOW 1.27 0.05
1018 brain 60 SOD1 0.93 0.04
1189 brain 60 SOD1 1.37 0.05
1195 brain 60 SOD1 1.95 0.12
1197 brain 60 SOD1 1.37 0.04
1198 brain 60 SOD1 0.88 0.03
1208 brain 60 SOD1 1.61 0.07
1009 brain 60 WTUOW 1.50 0.04
1194 brain 60 WTUOW 1.23 0.04
1196 brain 60 WTUOW 2.24 0.13
1218 brain 60 WTUOW 1.25 0.05
1219 brain 60 WTUOW 1.30 0.06
1241 brain 60 WTUOW 1.88 0.07
928 brain 90 SOD1 1.29 0.04
930 brain 90 SOD1 1.42 0.03
931 brain 90 SOD1 1.53 0.03
937 brain 90 SOD1 1.36 0.04
938 brain 90 SOD1 1.80 0.04
1145 brain 90 SOD1 1.40 0.08
997 brain 90 WTUOW 1.97 0.04
998 brain 90 WTUOW 1.02 0.03
1000 brain 90 WTUOW −1.34 0.02
1003 brain 90 WTUOW 1.32 0.02
1004 brain 90 WTUOW 0.97 0.04
1173 brain 90 WTUOW 1.37 0.04
854 brain 120 SOD1 1.18 0.04
⋆δ65Cu values (‰)
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Table A.2.4 continued: Data for Figure 5.6
Animal ID Tissue Time (d) State δ65Cu⋆ SE
855 brain 120 SOD1 1.11 0.04
863 brain 120 SOD1 1.10 0.01
865 brain 120 SOD1 1.64 0.06
870 brain 120 SOD1 1.28 0.09
877 brain 120 SOD1 1.34 0.04
1074 brain 120 WTUOW 1.15 0.04
1078 brain 120 WTUOW 1.57 0.05
1084 brain 120 WTUOW 1.86 0.04
1160 brain 120 WTUOW 0.74 0.67
1223 brain 120 WTUOW 1.53 0.06
1225 brain 120 WTUOW 1.61 0.09
1481 muscle 30 SOD1 3.90 0.66
1482 muscle 30 SOD1 2.12 0.09
1483 muscle 30 SOD1 1.48 0.07
1562 muscle 30 SOD1 1.66 0.09
1634 muscle 30 SOD1 2.12 0.07
1636 muscle 30 SOD1 1.65 0.05
1563 muscle 30 WTUOW 3.09 0.14
1564 muscle 30 WTUOW 2.92 0.15
1566 muscle 30 WTUOW 1.57 0.08
1567 muscle 30 WTUOW 1.09 0.06
1571 muscle 30 WTUOW 1.57 0.07
1602 muscle 30 WTUOW 1.60 0.08
1189 muscle 60 SOD1 2.37 0.11
1195 muscle 60 SOD1 2.19 0.08
1197 muscle 60 SOD1 0.47 0.08
1198 muscle 60 SOD1 0.48 0.07
1208 muscle 60 SOD1 0.47 0.06
1209 muscle 60 SOD1 0.09 0.06
1009 muscle 60 WTUOW 0.49 0.08
1194 muscle 60 WTUOW 3.15 0.15
1196 muscle 60 WTUOW 2.22 0.21
1218 muscle 60 WTUOW 2.02 0.11
1219 muscle 60 WTUOW 0.72 0.06
⋆δ65Cu values (‰)
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Table A.2.4 continued: Data for Figure 5.6
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1241 muscle 60 WTUOW 1.69 0.16
928 muscle 90 SOD1 0.46 0.05
929 muscle 90 SOD1 1.21 0.13
930 muscle 90 SOD1 1.25 0.06
931 muscle 90 SOD1 0.37 0.06
937 muscle 90 SOD1 0.41 0.07
938 muscle 90 SOD1 0.29 0.07
997 muscle 90 WTUOW 0.67 0.06
998 muscle 90 WTUOW 0.58 0.06
1000 muscle 90 WTUOW 0.60 0.06
1004 muscle 90 WTUOW 3.31 0.17
1173 muscle 90 WTUOW 0.95 0.05
854 muscle 120 SOD1 0.31 0.05
855 muscle 120 SOD1 0.25 0.05
863 muscle 120 SOD1 0.29 0.04
870 muscle 120 SOD1 1.74 0.07
877 muscle 120 SOD1 −0.22 0.08
892 muscle 120 SOD1 0.33 0.05
1074 muscle 120 WTUOW 0.47 0.05
1078 muscle 120 WTUOW 0.74 0.07
1084 muscle 120 WTUOW 0.66 0.08
1159 muscle 120 WTUOW 1.16 0.06
1225 muscle 120 WTUOW 0.46 0.05
2818 muscle 120 WTUOW 0.40 0.06
1481 spinalcord 30 SOD1 2.37 0.09
1482 spinalcord 30 SOD1 1.73 0.05
1483 spinalcord 30 SOD1 1.13 0.07
1562 spinalcord 30 SOD1 1.97 0.09
1634 spinalcord 30 SOD1 1.53 0.07
1653 spinalcord 30 SOD1 1.63 0.07
865 spinalcord 30 WTUOW 1.74 0.06
1563 spinalcord 30 WTUOW 1.99 0.05
1564 spinalcord 30 WTUOW 2.42 0.05
1566 spinalcord 30 WTUOW 1.41 0.07
⋆δ65Cu values (‰)
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Table A.2.4 continued: Data for Figure 5.6
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1567 spinalcord 30 WTUOW 1.55 0.05
1571 spinalcord 30 WTUOW 1.65 0.07
1602 spinalcord 30 WTUOW 1.38 0.08
1018 spinalcord 60 SOD1 1.08 0.08
1189 spinalcord 60 SOD1 2.24 0.05
1195 spinalcord 60 SOD1 1.89 0.03
1197 spinalcord 60 SOD1 0.84 0.04
1198 spinalcord 60 SOD1 0.83 0.02
1208 spinalcord 60 SOD1 1.41 0.07
1009 spinalcord 60 WTUOW 2.35 0.12
1194 spinalcord 60 WTUOW 2.34 0.05
1196 spinalcord 60 WTUOW 2.24 0.03
1212 spinalcord 60 WTUOW 1.35 0.08
1219 spinalcord 60 WTUOW 2.36 0.04
1653 spinalcord 60 WTUOW 2.00 0.09
928 spinalcord 90 SOD1 1.39 0.15
929 spinalcord 90 SOD1 1.40 0.07
930 spinalcord 90 SOD1 1.32 0.02
931 spinalcord 90 SOD1 1.32 0.02
937 spinalcord 90 SOD1 2.44 0.06
938 spinalcord 90 SOD1 2.12 0.04
997 spinalcord 90 WTUOW 0.73 0.07
998 spinalcord 90 WTUOW 1.28 0.03
1000 spinalcord 90 WTUOW 0.80 0.04
1003 spinalcord 90 WTUOW 1.44 0.02
1004 spinalcord 90 WTUOW 1.32 0.02
1173 spinalcord 90 WTUOW 1.44 0.05
854 spinalcord 120 SOD1 1.44 0.05
855 spinalcord 120 SOD1 1.39 0.04
863 spinalcord 120 SOD1 2.15 0.02
870 spinalcord 120 SOD1 1.25 0.07
877 spinalcord 120 SOD1 1.99 0.05
1565 spinalcord 120 SOD1 1.57 0.07
1074 spinalcord 120 WTUOW 1.30 0.04
⋆δ65Cu values (‰)
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Table A.2.4 continued: Data for Figure 5.6
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1078 spinalcord 120 WTUOW 1.34 0.04
1084 spinalcord 120 WTUOW 1.46 0.04
1160 spinalcord 120 WTUOW 1.57 0.07
1225 spinalcord 120 WTUOW 0.65 0.07
2139 spinalcord 120 WTUOW 2.46 0.06
⋆δ65Cu values (‰)
Table A.2.5:Data for Figure 5.5, page 116
Animal ID Tissue Time (d) State δ65Cu⋆ SE
877 blood 30 SOD1 1.30 0.06
1481 blood 30 SOD1 1.25 0.06
1483 blood 30 SOD1 0.76 0.06
1562 blood 30 SOD1 0.94 0.06
1634 blood 30 SOD1 0.73 0.09
1636 blood 30 SOD1 0.91 0.06
1653 blood 30 SOD1 1.74 0.09
1563 blood 30 WTUOW 1.62 0.07
1564 blood 30 WTUOW 1.43 0.08
1565 blood 30 WTUOW 1.55 0.08
1567 blood 30 WTUOW 1.24 0.10
1571 blood 30 WTUOW 0.92 0.06
1572 blood 30 WTUOW 0.64 0.08
1602 blood 30 WTUOW 0.83 0.06
1603 blood 30 WTUOW 1.09 0.08
1604 blood 30 WTUOW 0.56 0.07
1018 blood 60 SOD1 −0.19 0.20
1189 blood 60 SOD1 0.33 0.14
1195 blood 60 SOD1 0.82 0.12
1197 blood 60 SOD1 0.66 0.11
1198 blood 60 SOD1 −0.28 0.05
1208 blood 60 SOD1 2.42 0.27
1209 blood 60 SOD1 1.01 0.09
1211 blood 60 SOD1 0.70 0.05
⋆δ65Cu values (‰)
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Table A.2.5 continued: Data for Figure 5.5
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1009 blood 60 WTUOW 1.87 0.08
1187 blood 60 WTUOW 0.99 0.08
1194 blood 60 WTUOW 0.29 0.13
1196 blood 60 WTUOW 0.60 0.11
1212 blood 60 WTUOW 1.03 0.07
1218 blood 60 WTUOW 1.16 0.09
1219 blood 60 WTUOW 0.72 0.07
1241 blood 60 WTUOW 0.42 0.06
928 blood 90 SOD1 0.49 0.08
929 blood 90 SOD1 1.97 0.10
930 blood 90 SOD1 −0.12 0.05
931 blood 90 SOD1 0.31 0.14
937 blood 90 SOD1 0.65 0.24
938 blood 90 SOD1 0.69 0.06
1145 blood 90 SOD1 1.18 0.06
1145 blood 90 SOD1 1.05 0.10
997 blood 90 WTUOW 0.30 0.06
998 blood 90 WTUOW 1.10 0.12
1000 blood 90 WTUOW 0.63 0.06
1003 blood 90 WTUOW 0.32 0.18
1004 blood 90 WTUOW −0.10 0.07
1166 blood 90 WTUOW 1.04 0.07
1167 blood 90 WTUOW 1.09 0.08
1173 blood 90 WTUOW 0.58 0.06
854 blood 120 SOD1 0.34 0.06
855 blood 120 SOD1 1.97 0.09
863 blood 120 SOD1 2.04 0.10
865 blood 120 SOD1 1.73 0.09
870 blood 120 SOD1 1.10 0.06
877 blood 120 SOD1 1.33 0.09
892 blood 120 SOD1 0.55 0.05
902 blood 120 SOD1 1.05 0.07
1074 blood 120 WTUOW 2.20 0.09
1078 blood 120 WTUOW 0.46 0.05
⋆δ65Cu values (‰)
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Table A.2.5 continued: Data for Figure 5.5
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1084 blood 120 WTUOW 2.03 0.10
1158 blood 120 WTUOW 0.99 0.08
1159 blood 120 WTUOW 1.26 0.07
1160 blood 120 WTUOW 0.65 0.04
1223 blood 120 WTUOW 0.89 0.06
1225 blood 120 WTUOW 0.79 0.05
1481 faeces 30 SOD1 0.91 0.11
1482 faeces 30 SOD1 0.66 0.15
1634 faeces 30 SOD1 1.09 0.10
1564 faeces 30 WTUOW 0.63 0.06
1606 faeces 30 WTUOW 0.68 0.08
1607 faeces 30 WTUOW 0.72 0.12
1018 faeces 60 SOD1 0.69 0.07
1195 faeces 60 SOD1 0.86 0.08
1197 faeces 60 SOD1 0.98 0.10
1009 faeces 60 WTUOW 0.83 0.07
1194 faeces 60 WTUOW 0.56 0.18
1196 faeces 60 WTUOW 1.42 0.17
928 faeces 90 SOD1 0.91 0.14
930 faeces 90 SOD1 0.81 0.08
931 faeces 90 SOD1 1.86 0.17
997 faeces 90 WTUOW 0.67 0.11
998 faeces 90 WTUOW 0.49 0.09
1003 faeces 90 WTUOW 0.82 0.07
855 faeces 120 SOD1 0.57 0.09
863 faeces 120 SOD1 0.91 0.07
877 faeces 120 SOD1 0.72 0.12
1074 faeces 120 WTUOW 0.89 0.20
1078 faeces 120 WTUOW 0.66 0.05
1152 faeces 120 WTUOW 0.74 0.11
⋆δ65Cu values (‰)
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A.4 DATA, CHAPTER 6
Table A.3.1:Data for Figure 6.1, page 133
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Zn (µg/g)⋆
1481 heart 30 SOD1 43.6 90.8
1482 heart 30 SOD1 40.5 84.6
1483 heart 30 SOD1 43.8 92.4
1562 heart 30 SOD1 46.6 97.5
1634 heart 30 SOD1 26.3 70.1
1636 heart 30 SOD1 39.0 83.2
1563 heart 30 WTUOW 27.0 71.3
1564 heart 30 WTUOW 27.2 72.2
1565 heart 30 WTUOW 28.8 72.3
1566 heart 30 WTUOW 28.6 72.3
1567 heart 30 WTUOW 27.6 70.1
1571 heart 30 WTUOW 26.6 65.6
1018 heart 60 SOD1 49.5 97.3
1188 heart 60 SOD1 47.4 91.6
1189 heart 60 SOD1 45.1 95.7
1197 heart 60 SOD1 45.7 91.1
1198 heart 60 SOD1 48.8 94.7
1208 heart 60 SOD1 37.6 75.9
1009 heart 60 WTUOW 26.7 65.9
1194 heart 60 WTUOW 27.3 70.1
1196 heart 60 WTUOW 27.6 70.9
1196 heart 60 WTUOW 24.2 62.8
1212 heart 60 WTUOW 26.3 68.7
1218 heart 60 WTUOW 27.1 72.1
928 heart 90 SOD1 46.6 89.5
929 heart 90 SOD1 51.8 98.5
930 heart 90 SOD1 48.6 91.8
931 heart 90 SOD1 50.7 97.1
937 heart 90 SOD1 45.2 89.6
938 heart 90 SOD1 48.6 89.9
997 heart 90 WTUOW 28.6 69.2
998 heart 90 WTUOW 27.5 69.4
⋆Concentrations determined in dry tissues.
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Table A.3.1 continued: Data for Figure 6.1
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Zn (µg/g)⋆
1000 heart 90 WTUOW 28.0 70.6
1003 heart 90 WTUOW 46.8 90.2
1004 heart 90 WTUOW 26.4 65.9
1173 heart 90 WTUOW 26.8 67.5
854 heart 120 SOD1 50.0 92.7
855 heart 120 SOD1 50.5 93.9
863 heart 120 SOD1 51.2 94.1
865 heart 120 SOD1 43.7 82.4
870 heart 120 SOD1 51.8 94.7
877 heart 120 SOD1 53.0 94.9
1074 heart 120 WTUOW 27.6 69.6
1078 heart 120 WTUOW 28.0 68.9
1084 heart 120 WTUOW 23.6 60.1
1160 heart 120 WTUOW 25.6 65.3
1223 heart 120 WTUOW 27.3 67.6
1225 heart 120 WTUOW 25.5 64.6
1481 intestine 30 SOD1 21.3 107.2
1482 intestine 30 SOD1 21.3 110.9
1483 intestine 30 SOD1 21.1 123.3
1562 intestine 30 SOD1 21.5 114.2
1635 intestine 30 SOD1 20.5 115.2
1636 intestine 30 SOD1 16.1 99.5
1563 intestine 30 WTUOW 44.6 88.4
1564 intestine 30 WTUOW 11.5 105.3
1565 intestine 30 WTUOW 17.7 111.4
1566 intestine 30 WTUOW 14.1 103.7
1567 intestine 30 WTUOW 12.9 107.3
1571 intestine 30 WTUOW 10.3 85.8
1018 intestine 60 SOD1 24.9 116.5
1189 intestine 60 SOD1 22.7 117.3
1195 intestine 60 SOD1 21.2 107.5
1197 intestine 60 SOD1 24.7 119.9
1198 intestine 60 SOD1 20.6 102.3
1208 intestine 60 SOD1 22.8 117.1
⋆Concentrations determined in dry tissues.
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Table A.3.1 continued: Data for Figure 6.1
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Zn (µg/g)⋆
1009 intestine 60 WTUOW 11.9 94.2
1194 intestine 60 WTUOW 11.4 99.4
1212 intestine 60 WTUOW 10.2 96.3
1218 intestine 60 WTUOW 12.6 95.6
1219 intestine 60 WTUOW 10.4 180.9
928 intestine 90 SOD1 21.4 105.8
929 intestine 90 SOD1 22.5 108.6
930 intestine 90 SOD1 23.0 125.6
931 intestine 90 SOD1 23.9 121.2
937 intestine 90 SOD1 22.0 113.1
938 intestine 90 SOD1 20.7 106.4
997 intestine 90 WTUOW 11.9 107.9
998 intestine 90 WTUOW 10.5 91.4
1000 intestine 90 WTUOW 13.3 111.0
1003 intestine 90 WTUOW 20.9 110.7
1004 intestine 90 WTUOW 13.4 107.7
1173 intestine 90 WTUOW 11.4 98.1
854 intestine 120 SOD1 20.8 107.3
855 intestine 120 SOD1 26.6 114.5
863 intestine 120 SOD1 21.2 110.2
865 intestine 120 SOD1 21.7 109.4
870 intestine 120 SOD1 24.1 120.1
1074 intestine 120 WTUOW 11.4 85.4
1078 intestine 120 WTUOW 42.9 102.2
1084 intestine 120 WTUOW 12.7 101.8
1160 intestine 120 WTUOW 11.8 97.3
1223 intestine 120 WTUOW 10.8 97.3
1225 intestine 120 WTUOW 10.1 97.2
1481 liver 30 SOD1 64.0 191.8
1482 liver 30 SOD1 33.7 103.1
1483 liver 30 SOD1 35.7 110.1
1562 liver 30 SOD1 45.5 129.1
1635 liver 30 SOD1 30.9 104.7
1636 liver 30 SOD1 30.9 105.7
⋆Concentrations determined in dry tissues.
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Table A.3.1 continued: Data for Figure 6.1
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Zn (µg/g)⋆
1563 liver 30 WTUOW 17.7 102.3
1564 liver 30 WTUOW 16.5 96.5
1565 liver 30 WTUOW 17.1 95.7
1566 liver 30 WTUOW 17.4 98.4
1567 liver 30 WTUOW 18.3 96.8
1571 liver 30 WTUOW 18.3 96.2
1018 liver 60 SOD1 42.9 126.2
1189 liver 60 SOD1 40.6 127.5
1195 liver 60 SOD1 48.6 134.0
1197 liver 60 SOD1 40.6 122.6
1198 liver 60 SOD1 48.1 133.5
1208 liver 60 SOD1 40.6 120.4
1009 liver 60 WTUOW 15.4 94.5
1194 liver 60 WTUOW 16.8 102.9
1196 liver 60 WTUOW 14.3 89.8
1212 liver 60 WTUOW 15.9 94.6
1218 liver 60 WTUOW 14.0 87.0
1219 liver 60 WTUOW 15.2 93.0
928 liver 90 SOD1 39.5 121.4
929 liver 90 SOD1 45.8 135.8
930 liver 90 SOD1 45.1 138.2
931 liver 90 SOD1 44.9 133.5
937 liver 90 SOD1 47.3 132.2
938 liver 90 SOD1 51.1 147.4
997 liver 90 WTUOW 16.5 104.6
998 liver 90 WTUOW 15.8 99.6
1000 liver 90 WTUOW 15.1 97.1
1003 liver 90 WTUOW 36.7 119.0
1004 liver 90 WTUOW 16.1 98.7
1173 liver 90 WTUOW 15.0 91.9
854 liver 120 SOD1 43.3 130.0
855 liver 120 SOD1 50.3 139.4
863 liver 120 SOD1 47.7 138.3
865 liver 120 SOD1 41.7 124.5
⋆Concentrations determined in dry tissues.
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Table A.3.1 continued: Data for Figure 6.1
Animal ID Tissue Time (d) State Cu (µg/g)⋆ Zn (µg/g)⋆
870 liver 120 SOD1 53.2 141.4
877 liver 120 SOD1 51.8 142.3
1074 liver 120 WTUOW 16.4 103.5
1078 liver 120 WTUOW 16.3 99.4
1084 liver 120 WTUOW 15.3 93.3
1160 liver 120 WTUOW 14.8 91.8
1223 liver 120 WTUOW 14.3 95.0
1225 liver 120 WTUOW 14.9 96.5
⋆Concentrations determined in dry tissues.
Table A.3.2:Data for Figure 6.2, page 134
Animal ID Tissue Time (d) State Fe (µg/g)⋆ Se (ng/g)⋆
1481 heart 30 SOD1 459.6 1199
1482 heart 30 SOD1 552.2 998
1483 heart 30 SOD1 439.2 1014
1562 heart 30 SOD1 399.9 602
1634 heart 30 SOD1 428.0 940
1636 heart 30 SOD1 474.4 1187
1563 heart 30 WTUOW 531.7 1025
1564 heart 30 WTUOW 467.8 1093
1565 heart 30 WTUOW 343.1 1170
1566 heart 30 WTUOW 505.5 1250
1567 heart 30 WTUOW 392.4 875
1571 heart 30 WTUOW 384.1 980
1018 heart 60 SOD1 452.0 1161
1188 heart 60 SOD1 475.7 1233
1189 heart 60 SOD1 416.7 1061
1197 heart 60 SOD1 585.0 1320
1198 heart 60 SOD1 403.3 950
1208 heart 60 SOD1 744.2 1549
1009 heart 60 WTUOW 761.2 1096
1194 heart 60 WTUOW 567.2 1059
1196 heart 60 WTUOW 424.4 1054
⋆Concentrations determined in dry tissues.
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Table A.3.2 continued: Data for Figure 6.2
Animal ID Tissue Time (d) State Fe (µg/g)⋆ Se (ng/g)⋆
1196 heart 60 WTUOW 749.1 1076
1212 heart 60 WTUOW 682.6 1230
1218 heart 60 WTUOW 696.2 1359
928 heart 90 SOD1 591.5 1297
929 heart 90 SOD1 529.5 1191
930 heart 90 SOD1 603.9 1296
931 heart 90 SOD1 593.7 1013
937 heart 90 SOD1 580.6 1315
938 heart 90 SOD1 564.8 1176
997 heart 90 WTUOW 481.0 1092
998 heart 90 WTUOW 523.2 1453
1000 heart 90 WTUOW 636.5 1280
1003 heart 90 WTUOW 562.8 1569
1004 heart 90 WTUOW 529.5 1154
1173 heart 90 WTUOW 646.7 1158
854 heart 120 SOD1 599.0 1264
855 heart 120 SOD1 556.3 1097
863 heart 120 SOD1 546.6 1070
865 heart 120 SOD1 682.6 1599
870 heart 120 SOD1 665.5 1545
877 heart 120 SOD1 484.5 1136
1074 heart 120 WTUOW 592.1 1010
1078 heart 120 WTUOW 576.7 1106
1084 heart 120 WTUOW 878.4 1643
1160 heart 120 WTUOW 854.7 1224
1223 heart 120 WTUOW 529.7 1142
1225 heart 120 WTUOW 635.7 1210
1481 intestine 30 SOD1 386.7 1770
1482 intestine 30 SOD1 583.4 1554
1483 intestine 30 SOD1 597.8 2104
1562 intestine 30 SOD1 233.2 1949
1635 intestine 30 SOD1 396.1 1921
1636 intestine 30 SOD1 361.9 1692
1563 intestine 30 WTUOW 573.3 1298
⋆Concentrations determined in dry tissues.
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Table A.3.2 continued: Data for Figure 6.2
Animal ID Tissue Time (d) State Fe (µg/g)⋆ Se (ng/g)⋆
1564 intestine 30 WTUOW 308.7 1970
1565 intestine 30 WTUOW 291.0 1608
1566 intestine 30 WTUOW 291.0 1930
1567 intestine 30 WTUOW 248.9 2123
1571 intestine 30 WTUOW 299.7 1486
1018 intestine 60 SOD1 679.8 2019
1189 intestine 60 SOD1 470.5 2159
1195 intestine 60 SOD1 421.4 1887
1197 intestine 60 SOD1 413.4 2229
1198 intestine 60 SOD1 484.4 1766
1208 intestine 60 SOD1 514.4 2029
1009 intestine 60 WTUOW 347.3 2002
1194 intestine 60 WTUOW 361.2 2054
1212 intestine 60 WTUOW 422.2 1861
1218 intestine 60 WTUOW 385.2 1916
1219 intestine 60 WTUOW 439.3 2018
928 intestine 90 SOD1 666.5 2048
929 intestine 90 SOD1 491.6 2030
930 intestine 90 SOD1 537.7 2109
931 intestine 90 SOD1 478.3 2572
937 intestine 90 SOD1 673.5 2155
938 intestine 90 SOD1 424.6 2120
997 intestine 90 WTUOW 549.5 2118
998 intestine 90 WTUOW 455.6 1898
1000 intestine 90 WTUOW 398.9 2243
1003 intestine 90 WTUOW 685.6 2171
1004 intestine 90 WTUOW 597.1 2120
1173 intestine 90 WTUOW 390.4 2150
854 intestine 120 SOD1 537.4 1993
855 intestine 120 SOD1 565.2 2252
863 intestine 120 SOD1 550.8 2478
865 intestine 120 SOD1 546.9 2135
870 intestine 120 SOD1 428.0 2374
1074 intestine 120 WTUOW 345.4 1848
⋆Concentrations determined in dry tissues.
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Table A.3.2 continued: Data for Figure 6.2
Animal ID Tissue Time (d) State Fe (µg/g)⋆ Se (ng/g)⋆
1078 intestine 120 WTUOW 302.3 2192
1084 intestine 120 WTUOW 344.2 2083
1160 intestine 120 WTUOW 483.5 1971
1223 intestine 120 WTUOW 391.9 1609
1225 intestine 120 WTUOW 859.8 1966
1481 liver 30 SOD1 596.7 5040
1482 liver 30 SOD1 263.3 2959
1483 liver 30 SOD1 265.2 2962
1562 liver 30 SOD1 311.3 3812
1635 liver 30 SOD1 375.2 3073
1636 liver 30 SOD1 386.7 3415
1563 liver 30 WTUOW 287.8 4285
1564 liver 30 WTUOW 343.6 3793
1565 liver 30 WTUOW 328.6 3896
1566 liver 30 WTUOW 103.4 3950
1567 liver 30 WTUOW 324.4 3909
1571 liver 30 WTUOW 241.8 3480
1018 liver 60 SOD1 347.8 4290
1189 liver 60 SOD1 351.7 4601
1195 liver 60 SOD1 375.5 4603
1197 liver 60 SOD1 342.0 4129
1198 liver 60 SOD1 388.7 4413
1208 liver 60 SOD1 331.3 4339
1009 liver 60 WTUOW 144.4 4541
1194 liver 60 WTUOW 362.1 4590
1196 liver 60 WTUOW 333.6 4172
1212 liver 60 WTUOW 385.6 4325
1218 liver 60 WTUOW 376.6 3535
1219 liver 60 WTUOW 349.7 3816
928 liver 90 SOD1 441.5 4445
929 liver 90 SOD1 499.5 5007
930 liver 90 SOD1 445.1 5148
931 liver 90 SOD1 472.6 4809
937 liver 90 SOD1 419.8 4846
⋆Concentrations determined in dry tissues.
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Table A.3.2 continued: Data for Figure 6.2
Animal ID Tissue Time (d) State Fe (µg/g)⋆ Se (ng/g)⋆
938 liver 90 SOD1 389.8 4975
997 liver 90 WTUOW 398.7 4764
998 liver 90 WTUOW 361.6 4919
1000 liver 90 WTUOW 447.1 4692
1003 liver 90 WTUOW 408.3 4267
1004 liver 90 WTUOW 402.8 4545
1173 liver 90 WTUOW 447.8 4206
854 liver 120 SOD1 608.1 4782
855 liver 120 SOD1 535.5 5152
863 liver 120 SOD1 710.5 4960
865 liver 120 SOD1 448.6 4795
870 liver 120 SOD1 530.0 5055
877 liver 120 SOD1 646.7 5375
1074 liver 120 WTUOW 489.0 4875
1078 liver 120 WTUOW 465.9 4575
1084 liver 120 WTUOW 423.3 4213
1160 liver 120 WTUOW 418.4 4011
1223 liver 120 WTUOW 439.8 4255
1225 liver 120 WTUOW 533.1 4356
⋆Concentrations determined in dry tissues.
Table A.3.3:Data for Figure 6.3, page 134
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1481 heart 30 SOD1 1.23 0.09
1482 heart 30 SOD1 1.06 0.07
1483 heart 30 SOD1 1.40 0.11
1562 heart 30 SOD1 1.68 0.12
1634 heart 30 SOD1 0.78 0.15
1636 heart 30 SOD1 1.30 0.11
1563 heart 30 WTUOW 2.11 0.11
1564 heart 30 WTUOW 2.09 0.10
1565 heart 30 WTUOW 1.24 0.11
1566 heart 30 WTUOW 2.24 0.16
⋆δ65Cu values (‰)
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Table A.3.3 continued: Data for Figure 6.3
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1567 heart 30 WTUOW 1.02 0.10
1571 heart 30 WTUOW 2.60 0.16
1018 heart 60 SOD1 1.67 0.13
1188 heart 60 SOD1 1.44 0.12
1189 heart 60 SOD1 1.34 0.12
1197 heart 60 SOD1 1.88 0.13
1198 heart 60 SOD1 1.22 0.11
1208 heart 60 SOD1 0.47 0.10
1009 heart 60 WTUOW 1.57 0.13
1194 heart 60 WTUOW 0.68 0.12
1196 heart 60 WTUOW 1.59 0.14
1196 heart 60 WTUOW 1.45 0.11
1212 heart 60 WTUOW 0.88 0.13
1218 heart 60 WTUOW 1.47 0.12
928 heart 90 SOD1 0.47 0.07
929 heart 90 SOD1 0.54 0.11
930 heart 90 SOD1 1.32 0.10
931 heart 90 SOD1 1.29 0.11
937 heart 90 SOD1 0.75 0.11
938 heart 90 SOD1 1.35 0.13
997 heart 90 WTUOW 0.67 0.10
998 heart 90 WTUOW 1.71 0.13
1000 heart 90 WTUOW 0.92 0.10
1003 heart 90 WTUOW 1.61 0.11
1004 heart 90 WTUOW 0.97 0.11
1173 heart 90 WTUOW 1.00 0.11
854 heart 120 SOD1 0.51 0.11
855 heart 120 SOD1 0.58 0.11
863 heart 120 SOD1 1.10 0.14
865 heart 120 SOD1 1.76 0.15
870 heart 120 SOD1 0.85 0.13
877 heart 120 SOD1 2.74 0.14
1074 heart 120 WTUOW 4.08 0.75
1078 heart 120 WTUOW 0.38 0.16
⋆δ65Cu values (‰)
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Table A.3.3 continued: Data for Figure 6.3
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1084 heart 120 WTUOW 1.65 0.11
1160 heart 120 WTUOW 0.90 0.11
1223 heart 120 WTUOW 1.80 0.12
1225 heart 120 WTUOW 0.54 0.09
1481 intestine 30 SOD1 1.86 0.11
1482 intestine 30 SOD1 0.64 0.10
1483 intestine 30 SOD1 1.03 0.10
1562 intestine 30 SOD1 1.32 0.10
1635 intestine 30 SOD1 0.98 0.11
1636 intestine 30 SOD1 1.13 0.11
1563 intestine 30 WTUOW 1.61 0.14
1564 intestine 30 WTUOW 0.99 0.12
1565 intestine 30 WTUOW 1.01 0.16
1566 intestine 30 WTUOW 1.89 0.18
1567 intestine 30 WTUOW 2.06 0.15
1571 intestine 30 WTUOW 0.62 0.10
1018 intestine 60 SOD1 0.90 0.12
1189 intestine 60 SOD1 0.91 0.14
1195 intestine 60 SOD1 1.29 0.18
1197 intestine 60 SOD1 1.51 0.14
1198 intestine 60 SOD1 1.73 0.12
1208 intestine 60 SOD1 1.16 0.36
1009 intestine 60 WTUOW 1.96 0.13
1194 intestine 60 WTUOW 1.18 0.15
1212 intestine 60 WTUOW 0.85 0.15
1218 intestine 60 WTUOW −0.22 0.20
1219 intestine 60 WTUOW 1.70 0.13
928 intestine 90 SOD1 1.20 0.12
929 intestine 90 SOD1 1.20 0.17
930 intestine 90 SOD1 0.95 0.12
931 intestine 90 SOD1 1.83 0.17
937 intestine 90 SOD1 1.65 0.13
938 intestine 90 SOD1 1.42 0.12
997 intestine 90 WTUOW 1.01 0.13
⋆δ65Cu values (‰)
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Table A.3.3 continued: Data for Figure 6.3
Animal ID Tissue Time (d) State δ65Cu⋆ SE
998 intestine 90 WTUOW 0.50 0.11
1000 intestine 90 WTUOW 1.65 0.12
1003 intestine 90 WTUOW 0.94 0.10
1004 intestine 90 WTUOW 1.65 0.14
1173 intestine 90 WTUOW 1.72 0.15
854 intestine 120 SOD1 1.21 0.17
855 intestine 120 SOD1 1.39 0.11
863 intestine 120 SOD1 1.82 0.19
865 intestine 120 SOD1 0.60 0.12
870 intestine 120 SOD1 1.44 0.13
1074 intestine 120 WTUOW 1.49 0.12
1078 intestine 120 WTUOW 1.26 0.09
1084 intestine 120 WTUOW 1.64 0.20
1160 intestine 120 WTUOW 4.21 0.28
1223 intestine 120 WTUOW 1.09 0.21
1225 intestine 120 WTUOW 1.54 0.24
1481 liver 30 SOD1 0.75 0.18
1482 liver 30 SOD1 0.77 0.09
1483 liver 30 SOD1 0.68 0.16
1562 liver 30 SOD1 1.04 0.28
1635 liver 30 SOD1 1.13 0.17
1636 liver 30 SOD1 0.70 0.13
1563 liver 30 WTUOW 1.04 0.17
1564 liver 30 WTUOW 0.77 0.17
1565 liver 30 WTUOW 0.84 0.14
1566 liver 30 WTUOW 1.07 0.22
1567 liver 30 WTUOW 1.34 0.18
1571 liver 30 WTUOW 0.96 0.17
1018 liver 60 SOD1 1.11 0.21
1189 liver 60 SOD1 0.68 0.17
1195 liver 60 SOD1 0.90 0.26
1197 liver 60 SOD1 0.79 0.13
1198 liver 60 SOD1 0.69 0.16
1208 liver 60 SOD1 0.67 0.18
⋆δ65Cu values (‰)
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Table A.3.3 continued: Data for Figure 6.3
Animal ID Tissue Time (d) State δ65Cu⋆ SE
1009 liver 60 WTUOW 0.76 0.18
1194 liver 60 WTUOW 1.00 0.21
1196 liver 60 WTUOW 0.29 0.23
1212 liver 60 WTUOW 0.98 0.09
1218 liver 60 WTUOW 0.91 0.11
1219 liver 60 WTUOW 1.12 0.18
928 liver 90 SOD1 1.01 0.20
929 liver 90 SOD1 0.76 0.21
930 liver 90 SOD1 0.72 0.25
931 liver 90 SOD1 1.01 0.15
937 liver 90 SOD1 0.88 0.15
938 liver 90 SOD1 0.60 0.21
997 liver 90 WTUOW 0.90 0.17
998 liver 90 WTUOW 1.09 0.13
1000 liver 90 WTUOW 0.93 0.09
1003 liver 90 WTUOW 1.09 0.17
1004 liver 90 WTUOW 1.23 0.19
1173 liver 90 WTUOW 1.00 0.21
854 liver 120 SOD1 1.08 0.22
855 liver 120 SOD1 0.73 0.18
863 liver 120 SOD1 1.26 0.18
865 liver 120 SOD1 0.60 0.20
870 liver 120 SOD1 0.84 0.21
877 liver 120 SOD1
1074 liver 120 WTUOW
1078 liver 120 WTUOW 0.60 0.28
1084 liver 120 WTUOW 0.87 0.16
1160 liver 120 WTUOW 0.80 0.11
1223 liver 120 WTUOW −0.74 0.22
1225 liver 120 WTUOW 0.59 0.17
⋆δ65Cu values (‰)
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Table A.3.4:Data for Figure 6.4, page 135
Animal ID Tissue⋆ Time (d) State† Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡
1481 quadriceps 30 SOD1UOW 4.4 42.8 53.8
1482 quadriceps 30 SOD1UOW 7.1 36.5 63.1
1483 quadriceps 30 SOD1UOW 8.1 48.1 47.4
1562 quadriceps 30 SOD1UOW 10.4 55.3 43.0
1634 quadriceps 30 SOD1UOW 4.1 39.3 33.7
1636 quadriceps 30 SOD1UOW 8.7 60.4 46.0
1563 quadriceps 30 NTGUOW 3.9 51.3 56.6
1564 quadriceps 30 NTGUOW 3.0 38.1 44.2
1566 quadriceps 30 NTGUOW 4.3 44.2 28.0
1567 quadriceps 30 NTGUOW 6.3 75.2 42.5
1571 quadriceps 30 NTGUOW 4.9 44.4 35.4
1602 quadriceps 30 NTGUOW 9.1 44.4 44.7
1189 quadriceps 60 SOD1UOW 17.3 74.6 122.8
1195 quadriceps 60 SOD1UOW 17.6 62.3 91.7
1197 quadriceps 60 SOD1UOW 20.5 90.4 135.9
1198 quadriceps 60 SOD1UOW 21.1 90.3 115.2
1208 quadriceps 60 SOD1UOW 11.7 61.1 59.2
1209 quadriceps 60 SOD1UOW 13.0 67.9 59.5
1009 quadriceps 60 NTGUOW 8.2 99.2 82.9
1194 quadriceps 60 NTGUOW 5.8 64.3 65.2
1196 quadriceps 60 NTGUOW 4.5 64.7 51.3
1218 quadriceps 60 NTGUOW 5.6 64.7 58.1
1219 quadriceps 60 NTGUOW 10.7 101.9 115.7
1241 quadriceps 60 NTGUOW 4.6 48.7 34.1
928 quadriceps 90 SOD1UOW 18.3 130.3 87.5
929 quadriceps 90 SOD1UOW 19.6 153.7 101.6
930 quadriceps 90 SOD1UOW 27.7 160.5 170.8
931 quadriceps 90 SOD1UOW 38.8 223.2 273.7
937 quadriceps 90 SOD1UOW 20.7 141.8 114.0
⋆quadriceps = Quadriceps Femoris = muscle tissue
†SOD1UOW = SOD1G93A tissue harvested at UOW; referred to as SOD1 previously;
NTGUOW = wild-type tissues harvested at UOW; referred to asWT previously;
SOD1WT =WT SOD1 over-expression tissues harvested at University College London;
NTGUCL = wild-type tissues harvested at University College London
‡Concentrations determined in dry tissues
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Table A.3.4 continued: Data for Figure 6.4
Animal ID Tissue⋆ Time (d) State† Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡
938 quadriceps 90 SOD1UOW 20.5 146.1 108.9
997 quadriceps 90 NTGUOW 5.6 64.2 48.5
998 quadriceps 90 NTGUOW 7.9 94.5 68.8
1000 quadriceps 90 NTGUOW 5.8 66.9 49.0
1004 quadriceps 90 NTGUOW 4.3 54.1 35.6
1173 quadriceps 90 NTGUOW 4.0 44.5 43.6
854 quadriceps 120 SOD1UOW 10.4 98.9 103.9
855 quadriceps 120 SOD1UOW 11.3 104.1 98.4
863 quadriceps 120 SOD1UOW 12.1 108.0 102.6
870 quadriceps 120 SOD1UOW 15.0 56.3 56.8
877 quadriceps 120 SOD1UOW 12.4 205.1 83.3
892 quadriceps 120 SOD1UOW 17.8 124.7 127.8
1074 quadriceps 120 NTGUOW 4.1 46.2 45.5
1078 quadriceps 120 NTGUOW 4.6 48.8 41.2
1084 quadriceps 120 NTGUOW 4.0 45.2 40.8
1159 quadriceps 120 NTGUOW 3.2 41.8 28.5
1225 quadriceps 120 NTGUOW 4.1 49.2 31.0
2818 quadriceps 120 NTGUOW 4.1 48.5 31.8
UCL 30 quadriceps 60 SOD1WT 6.2 59.3 47.8
UCL 31 quadriceps 60 SOD1WT 6.0 72.3 58.9
UCL 32 quadriceps 60 SOD1WT 6.0 80.1 53.4
UCL 33 quadriceps 90 SOD1WT 8.4 69.4 45.2
UCL 34 quadriceps 90 SOD1WT 8.6 63.4 58.0
UCL 27 quadriceps 90 NTGUCL 7.7 86.2 50.3
UCL 28 quadriceps 90 NTGUCL 5.4 65.5 39.2
UCL 29 quadriceps 90 NTGUCL 9.4 103.1 56.1
⋆quadriceps = Quadriceps Femoris = muscle tissue
†SOD1UOW = SOD1G93A tissue harvested at UOW; referred to as SOD1 previously;
NTGUOW = wild-type tissues harvested at UOW; referred to asWT previously;
SOD1WT =WT SOD1 over-expression tissues harvested at University College London;
NTGUCL = wild-type tissues harvested at University College London
‡Concentrations determined in dry tissues
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Table A.3.5:Data for Figure 6.5, page 136
Animal ID Tissue⋆ Time (d) State† Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡
1481 brain 30 SOD1UOW 14.0 77.4 113.2
1482 brain 30 SOD1UOW 14.5 61.9 112.2
1562 brain 30 SOD1UOW 14.3 74.2 73.0
1634 brain 30 SOD1UOW 12.5 69.1 65.5
1636 brain 30 SOD1UOW 13.2 88.2 85.7
1653 brain 30 SOD1UOW 12.6 68.8 75.0
1563 brain 30 NTGUOW 18.4 104.1 99.3
1564 brain 30 NTGUOW 18.8 75.0 104.5
1565 brain 30 NTGUOW 16.7 76.0 66.4
1566 brain 30 NTGUOW 15.7 71.4 63.3
1567 brain 30 NTGUOW 12.4 63.5 34.2
1571 brain 30 NTGUOW 19.8 86.3 84.4
1602 brain 30 NTGUOW 13.1 81.2 78.3
1018 brain 60 SOD1UOW 29.0 132.1 132.3
1189 brain 60 SOD1UOW 30.8 116.9 126.1
1195 brain 60 SOD1UOW 27.5 122.1 120.0
1197 brain 60 SOD1UOW 33.1 126.2 139.6
1198 brain 60 SOD1UOW 29.0 143.4 135.8
1208 brain 60 SOD1UOW 15.0 89.2 71.4
UCL 30 brain 60 SOD1WT 30.7 144.2 172.2
UCL 31 brain 60 SOD1WT 25.4 132.8 129.6
UCL 32 brain 60 SOD1WT 20.7 126.5 87.6
1009 brain 60 NTGUOW 35.3 146.8 131.5
1194 brain 60 NTGUOW 31.7 139.9 120.7
1196 brain 60 NTGUOW 30.7 145.1 119.5
1218 brain 60 NTGUOW 26.9 125.7 111.2
1219 brain 60 NTGUOW 26.5 129.0 108.1
1241 brain 60 NTGUOW 18.2 83.2 66.0
⋆quadriceps = Quadriceps Femoris = muscle tissue
†SOD1UOW = SOD1G93A tissue harvested at UOW; referred to as SOD1 previously;
NTGUOW = wild-type tissues harvested at UOW; referred to asWT previously;
SOD1WT =WT SOD1 over-expression tissues harvested at University College London;
NTGUCL = wild-type tissues harvested at University College London
‡Concentrations determined in dry tissues
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Table A.3.5 continued: Data for Figure 6.5
Animal ID Tissue⋆ Time (d) State† Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡
UCL 27 brain 90 NTGUCL 24.6 111.4 84.6
UCL 28 brain 90 NTGUCL 24.3 107.6 85.3
UCL 29 brain 90 NTGUCL 22.6 110.5 87.0
928 brain 90 SOD1UOW 27.6 108.6 116.1
930 brain 90 SOD1UOW 29.6 122.8 130.8
931 brain 90 SOD1UOW 32.3 126.6 133.7
937 brain 90 SOD1UOW 52.3 215.7 214.7
938 brain 90 SOD1UOW 38.3 17.6 14.7
1145 brain 90 SOD1UOW 19.1 88.5 77.0
UCL 33 brain 90 SOD1WT 24.4 147.7 86.1
UCL 34 brain 90 SOD1WT 29.5 126.9 131.8
997 brain 90 NTGUOW 9.0 41.0 34.7
998 brain 90 NTGUOW 24.3 139.4 114.3
1000 brain 90 NTGUOW 29.2 115.8 99.3
1003 brain 90 NTGUOW 30.2 134.2 155.7
1004 brain 90 NTGUOW 37.6 168.7 133.2
1173 brain 90 NTGUOW 30.7 121.1 110.5
854 brain 120 SOD1UOW 25.0 97.8 101.6
855 brain 120 SOD1UOW 18.1 67.0 72.9
863 brain 120 SOD1UOW 28.9 124.3 119.8
865 brain 120 SOD1UOW 23.1 88.1 78.3
870 brain 120 SOD1UOW 25.3 106.5 91.2
877 brain 120 SOD1UOW 26.8 81.8 117.2
1074 brain 120 NTGUOW 25.1 120.0 86.8
1078 brain 120 NTGUOW 24.0 112.4 80.4
1084 brain 120 NTGUOW 23.1 101.3 76.8
1160 brain 120 NTGUOW 22.2 96.2 69.9
⋆quadriceps = Quadriceps Femoris = muscle tissue
†SOD1UOW = SOD1G93A tissue harvested at UOW; referred to as SOD1 previously;
NTGUOW = wild-type tissues harvested at UOW; referred to asWT previously;
SOD1WT =WT SOD1 over-expression tissues harvested at University College London;
NTGUCL = wild-type tissues harvested at University College London
‡Concentrations determined in dry tissues
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Table A.3.5 continued: Data for Figure 6.5
Animal ID Tissue⋆ Time (d) State† Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡
1223 brain 120 NTGUOW 20.8 92.2 88.5
1225 brain 120 NTGUOW 20.8 89.2 65.6
1481 spinalcord 30 SOD1UOW 5.2 34.8 58.6
1482 spinalcord 30 SOD1UOW 6.6 37.4 62.3
1483 spinalcord 30 SOD1UOW 6.2 38.1 28.9
1562 spinalcord 30 SOD1UOW 11.4 68.3 50.5
1634 spinalcord 30 SOD1UOW 8.6 50.1 44.0
1653 spinalcord 30 SOD1UOW 15.0 106.9 68.2
865 spinalcord 30 NTGUOW 10.0 54.7 35.4
1563 spinalcord 30 NTGUOW 9.5 50.6 65.6
1564 spinalcord 30 NTGUOW 6.7 195.0 65.3
1566 spinalcord 30 NTGUOW 8.6 45.7 31.2
1567 spinalcord 30 NTGUOW 24.5 143.1 91.7
1571 spinalcord 30 NTGUOW 9.5 55.9 38.2
1602 spinalcord 30 NTGUOW 12.4 83.6 61.2
1018 spinalcord 60 SOD1UOW 28.9 182.5 112.3
1189 spinalcord 60 SOD1UOW 20.0 81.3 80.6
1195 spinalcord 60 SOD1UOW 20.0 86.8 74.0
1197 spinalcord 60 SOD1UOW 20.7 87.4 75.2
1198 spinalcord 60 SOD1UOW 23.9 122.5 109.8
1208 spinalcord 60 SOD1UOW 10.8 64.0 46.5
midrule UCL 30 spinalcord 60 SOD1WT 16.7 93.8 100.0
UCL 31 spinalcord 60 SOD1WT 13.5 167.1 52.7
UCL 32 spinalcord 60 SOD1WT 17.3 128.8 88.3
1009 spinalcord 60 NTGUOW 17.7 81.8 63.5
1194 spinalcord 60 NTGUOW 18.0 94.1 58.6
⋆quadriceps = Quadriceps Femoris = muscle tissue
†SOD1UOW = SOD1G93A tissue harvested at UOW; referred to as SOD1 previously;
NTGUOW = wild-type tissues harvested at UOW; referred to asWT previously;
SOD1WT =WT SOD1 over-expression tissues harvested at University College London;
NTGUCL = wild-type tissues harvested at University College London
‡Concentrations determined in dry tissues
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Table A.3.5 continued: Data for Figure 6.5
Animal ID Tissue⋆ Time (d) State† Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡
1196 spinalcord 60 NTGUOW 20.5 115.5 68.5
1212 spinalcord 60 NTGUOW 8.7 46.9 28.4
1219 spinalcord 60 NTGUOW 17.0 91.7 61.5
1653 spinalcord 60 NTGUOW 8.5 47.6 38.0
UCL 27 spinalcord 90 NTGUCL 19.2 235.0 69.9
UCL 28 spinalcord 90 NTGUCL 13.5 143.6 76.0
UCL 29 spinalcord 90 NTGUCL 14.2 158.7 61.5
928 spinalcord 90 SOD1UOW 12.4 67.9 51.4
929 spinalcord 90 SOD1UOW 12.5 101.9 59.6
930 spinalcord 90 SOD1UOW 21.3 163.2 122.0
931 spinalcord 90 SOD1UOW 25.4 104.5 109.0
937 spinalcord 90 SOD1UOW 22.4 79.9 92.4
938 spinalcord 90 SOD1UOW 128.8 505.1 549.0
UCL 33 spinalcord 90 SOD1WT 18.0 198.4 57.6
UCL 34 spinalcord 90 SOD1WT 19.2 125.0 78.0
997 spinalcord 90 NTGUOW 18.7 164.3 142.0
998 spinalcord 90 NTGUOW 11.6 97.4 81.9
1000 spinalcord 90 NTGUOW 22.5 108.5 93.7
1003 spinalcord 90 NTGUOW 20.2 109.9 122.5
1004 spinalcord 90 NTGUOW 20.0 101.2 81.6
1173 spinalcord 90 NTGUOW 15.0 75.1 60.3
854 spinalcord 120 SOD1UOW 20.0 92.6 92.5
855 spinalcord 120 SOD1UOW 20.0 96.5 100.1
863 spinalcord 120 SOD1UOW 24.3 120.0 117.1
870 spinalcord 120 SOD1UOW 14.3 146.2 116.0
877 spinalcord 120 SOD1UOW 16.1 65.7 78.4
⋆quadriceps = Quadriceps Femoris = muscle tissue
†SOD1UOW = SOD1G93A tissue harvested at UOW; referred to as SOD1 previously;
NTGUOW = wild-type tissues harvested at UOW; referred to asWT previously;
SOD1WT =WT SOD1 over-expression tissues harvested at University College London;
NTGUCL = wild-type tissues harvested at University College London
‡Concentrations determined in dry tissues
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Table A.3.5 continued: Data for Figure 6.5
Animal ID Tissue⋆ Time (d) State† Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡
1565 spinalcord 120 SOD1UOW 4.0 50.1 27.4
1074 spinalcord 120 NTGUOW 17.1 73.1 356.2
1078 spinalcord 120 NTGUOW 17.1 75.6 50.1
1084 spinalcord 120 NTGUOW 16.1 64.2 80.9
1160 spinalcord 120 NTGUOW 8.7 50.2 27.6
1225 spinalcord 120 NTGUOW 3.6 2635.9 20.4
2139 spinalcord 120 NTGUOW 11.6 56.6 46.4
⋆quadriceps = Quadriceps Femoris = muscle tissue
†SOD1UOW = SOD1G93A tissue harvested at UOW; referred to as SOD1 previously;
NTGUOW = wild-type tissues harvested at UOW; referred to asWT previously;
SOD1WT =WT SOD1 over-expression tissues harvested at University College London;
NTGUCL = wild-type tissues harvested at University College London
‡Concentrations determined in dry tissues
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A.5 DATA, CHAPTER 7
e following table provides an overview of the human plasma samples that were analysed
for Chapter 7.
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Table A.4.1:Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
02/09 MEL ALS MND 34 F 12.8 14.5 5.9 0.93 0.10
23/09 MEL ALS MND 50 F 16.4 12.9 13.1 1.15 0.19
19/09 MEL ALS MND 55 F 10.2 8.8 14.5 1.41 0.11
12/09 MEL ALS MND 59 F 14.3 11.4 14.1 1.10 0.11
16/09 MEL ALS MND 75 F 26.3 25.5 23.9 2.07 0.12
07/09 MEL ALS MND 44 M 13.5 13.6 10.6 1.45 0.15
26/09 MEL ALS MND 45 M 14.8 17.0 22.6 0.92 0.08
09/09 MEL ALS MND 50 M 10.3 10.3 10.3 0.58 0.09
25/09 MEL ALS MND 54 M 7.8 9.6 8.3 1.07 0.13
13/09 MEL ALS MND 59 M 10.3 9.0 7.4 0.88 0.11
29/09 MEL ALS MND 61 M 13.6 13.4 15.3 0.83 0.21
24/09 MEL ALS MND 62 M 10.0 10.4 10.0 1.46 0.16
15/09 MEL ALS MND 64 M 7.4 5.7 3.8 0.88 0.13
08/09 MEL ALS MND 66 M 11.4 12.1 11.8 0.99 0.16
06/09 MEL ALS MND 66 M 9.8 12.4 12.5 1.09 0.15
32/09 MEL Control Control 31 F 20.9 6.3 18.0 −0.27 0.07
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
33/09 MEL Control Control 48 F 17.0 9.2 13.1 0.68 0.11
30/09 MEL Control Control 58 F 11.9 7.8 11.9 0.58 0.11
41/09 MEL Control Control 59 F 15.9 9.1 15.7 1.00 0.08
40/09 MEL Control Control 68 F 42.2 14.4 34.2 1.03 0.12
37/09 MEL Control Control 43 M 9.8 8.8 19.3 0.04 0.06
43/09 MEL Control Control 47 M 6.0 6.4 12.8 1.60 0.28
42/09 MEL Control Control 50 M 7.1 7.1 15.9 0.79 0.24
35/09 MEL Control Control 53 M 12.9 9.2 13.7 0.97 0.09
44/09 MEL Control Control 58 M 11.3 7.5 11.3 1.18 0.14
39/09 MEL Control Control 61 M 25.8 8.4 11.8 1.28 0.18
34/09 MEL Control Control 62 M 18.5 16.9 17.7 1.53 0.12
01/10 MEL Control Control 64 M 13.8 10.1 12.4 1.00 0.19
36/09 MEL Control Control 65 M 3.6 3.5 5.0 1.00 0.17
31/09 MEL Control Control 66 M 16.5 14.7 27.6 −0.09 0.05
MQ160068 SYD ALS-familial MND 25 F 24.4 7.8 11.8 1.3 −0.76 0.06
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ160188 SYD ALS-familial MND 26 F 15.4 8.5 12.1 1.2 −0.70 0.05
MQ140283 SYD ALS-familial MND 31 F 14.5 10.1 17.7 1.4 0.55 0.07
MQ140299 SYD ALS-familial MND 32 F 14.7 9.3 12.6 1.5 −2.05 0.05
MQ160321 SYD ALS-familial MND 34 F 14.1 6.6 2.3 1.8 0.20 0.05
MQ160054 SYD ALS-familial MND 38 F 20.3 9.3 11.1 1.3 1.45 0.05
MQ160260 SYD ALS-familial MND 38 F 20.9 9.2 9.6 1.3 1.29 0.06
MQ170001 SYD ALS-familial MND 38 F 17.9 8.6 1.8 1.2 1.02 0.05
MQ150119 SYD ALS-familial MND 52 F 12.7 7.6 29.1 1.0 1.52 0.07
MQ140210 SYD ALS-familial MND 52 F 13.4 7.6 3.2 1.3 2.45 0.06
MQ160145 SYD ALS-familial MND 54 F 12.0 10.1 14.5 1.2 2.04 0.05
MQ150078 SYD ALS-familial MND 57 F 12.7 7.4 8.8 1.0 1.80 0.05
MQ150228 SYD ALS-familial MND 57 F 13.9 8.5 15.2 2.8 1.73 0.25
MQ160036 SYD ALS-familial MND 58 F 15.5 8.3 9.6 1.2 1.40 0.06
MQ160218 SYD ALS-familial MND 58 F 17.5 11.3 11.7 1.5 0.55 0.07
MQ170059 SYD ALS-familial MND 59 F 16.5 12.4 23.7 1.4 2.73 0.06
MQ140292 SYD ALS-familial MND 63 F 14.9 9.1 9.4 1.0 1.21 0.06
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ150049 SYD ALS-familial MND 31 M 11.9 8.9 5.1 1.0 1.27 0.06
MQ160242 SYD ALS-familial MND 33 M 13.7 8.9 9.7 1.5 0.41 0.07
MQ160345 SYD ALS-familial MND 33 M 2.9 2.2 3.2 0.3 −0.04 0.05
MQ140232 SYD ALS-familial MND 44 M 12.3 8.4 6.6 0.8 0.37 0.07
MQ160196 SYD ALS-familial MND 54 M 15.4 8.9 3.6 1.4 0.15 0.06
MQ150157 SYD ALS-familial MND 66 M 14.4 7.2 12.3 1.7 1.32 0.08
MQ160015 SYD ALS-familial MND 74 M 12.4 8.7 21.1 1.2 0.42 0.08
MQ160168 SYD ALS-familial MND 74 M 12.1 9.6 12.7 1.3 1.65 0.08
MQ160308 SYD ALS-familial MND 75 M 12.8 10.5 17.4 1.3 0.33 0.06
MQ160268 SYD ALS-sporadic MND 23 F 15.6 5.9 2.6 0.9 0.77 0.05
MQ140303 SYD ALS-sporadic MND 31 F 14.7 6.2 16.6 3.5 0.41 0.06
MQ150220 SYD ALS-sporadic MND 31 F 14.2 8.2 25.7 1.3 0.46 0.07
MQ160207 SYD ALS-sporadic MND 32 F 16.1 129.2 18.7 1.5 0.51 0.06
MQ150215 SYD ALS-sporadic MND 34 F 15.2 8.4 24.6 4.3 −0.13 0.05
MQ160217 SYD ALS-sporadic MND 35 F 17.3 15.8 17.6 4.0 0.02 0.06
MQ150234 SYD ALS-sporadic MND 59 F 14.3 8.6 7.7 1.4 0.83 0.06
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ160085 SYD ALS-sporadic MND 59 F 15.4 6.9 11.5 1.3 0.81 0.06
MQ150074 SYD ALS-sporadic MND 60 F 16.4 7.3 16.1 1.5 0.51 0.05
MQ150226 SYD ALS-sporadic MND 61 F 15.0 6.7 32.4 1.3 1.01 0.07
MQ160184 SYD ALS-sporadic MND 62 F 18.1 10.0 32.3 1.6 0.69 0.05
MQ150166 SYD ALS-sporadic MND 63 F 14.9 9.5 23.8 1.5 0.75 0.06
MQ160007 SYD ALS-sporadic MND 64 F 16.7 10.5 17.8 1.5 1.32 0.05
MQ140214 SYD ALS-sporadic MND 64 F 13.9 7.6 10.3 1.2 0.01 0.05
MQ160209 SYD ALS-sporadic MND 64 F 14.8 7.8 10.6 1.6 0.64 0.05
MQ150141 SYD ALS-sporadic MND 71 F 12.6 7.1 14.6 1.5 1.29 0.08
MQ150284 SYD ALS-sporadic MND 71 F 11.5 7.7 15.3 1.7 0.66 0.08
MQ150178 SYD ALS-sporadic MND 72 F 13.5 7.6 20.2 1.1 −0.13 0.06
MQ160134 SYD ALS-sporadic MND 72 F 15.1 7.1 10.5 1.4 0.82 0.06
MQ140183 SYD ALS-sporadic MND 32 M 10.7 9.0 26.6 1.1 −2.59 0.06
MQ150291 SYD ALS-sporadic MND 33 M 13.2 14.0 18.8 1.5 2.19 0.05
MQ160172 SYD ALS-sporadic MND 34 M 13.3 8.2 13.1 1.5 1.61 0.06
MQ150164 SYD ALS-sporadic MND 52 M 10.8 6.9 12.9 6.5 −0.07 0.06
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ160052 SYD ALS-sporadic MND 52 M 14.1 13.5 16.8 5.9 0.03 0.07
MQ150105 SYD ALS-sporadic MND 54 M 12.0 12.8 9.3 1.6 −0.08 0.06
MQ150296 SYD ALS-sporadic MND 55 M 15.0 397.0 8.1 1.7 0.45 0.05
MQ160106 SYD ALS-sporadic MND 55 M 11.9 14.2 15.9 1.5 0.46 0.06
MQ150219 SYD ALS-sporadic MND 58 M 14.2 13.0 13.9 2.1 −0.77 0.05
MQ160038 SYD ALS-sporadic MND 58 M 12.3 12.6 18.1 1.5 4.21 0.06
MQ160179 SYD ALS-sporadic MND 59 M 17.8 8.1 −1.6 1.4 1.38 0.06
MQ150066 SYD ALS-sporadic MND 60 M 12.3 12.5 16.6 5.2 −0.13 0.06
MQ150276 SYD ALS-sporadic MND 61 M 12.0 6.6 12.7 4.9 −0.26 0.06
MQ160137 SYD ALS-sporadic MND 62 M 12.3 7.5 16.8 3.5 −0.31 0.06
MQ140298 SYD ALS-sporadic MND 63 M 11.7 16.4 18.2 3.0 0.36 0.05
MQ150273 SYD ALS-sporadic MND 63 M 13.3 7.4 18.6 4.1 0.11 0.05
MQ160247 SYD ALS-sporadic MND 64 M 14.4 8.3 44.6 3.8 0.05 0.05
MQ140247 SYD ALS-sporadic MND 67 M 10.7 7.6 7.1 1.5 0.91 0.07
MQ150257 SYD ALS-sporadic MND 68 M 13.8 10.1 12.0 1.3 2.95 0.06
MQ150257 SYD ALS-sporadic MND 68 M 13.9 9.1 19.1 2.1 1.06 0.08
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ140253 SYD ALS-sporadic MND 70 M 15.0 9.8 18.7 1.8 −0.12 0.07
MQ160272 SYD ALS-sporadic MND 70 M 19.7 7.8 7.3 1.2 0.88 0.07
MQ150259 SYD ALS-sporadic MND 71 M 14.3 8.6 18.1 1.5 0.12 0.05
MQ140255 SYD ALS-sporadic MND 71 M 12.8 7.4 10.3 1.2 0.85 0.07
MQ160122 SYD ALS-sporadic MND 71 M 16.6 9.6 13.5 1.5 −0.18 0.06
MQ140266 SYD ALS-sporadic MND 72 M 10.7 6.6 8.7 1.3 0.49 0.05
MQ150272 SYD ALS-sporadic MND 72 M 12.6 7.0 10.4 1.2 1.31 0.05
MQ150224 SYD ALS-sporadic MND 72 M 13.5 8.3 11.2 1.1 2.05 0.07
MQ160174 SYD ALS-sporadic MND 73 M 13.6 6.3 13.0 1.4 1.79 0.07
MQ160075 SYD ALS-sporadic MND 73 M 15.3 8.9 14.0 1.0 1.10 0.06
MQ150248 SYD ALS-sporadic MND 73 M 12.0 11.3 6.1 1.1 1.24 0.07
MQ160143 SYD ALS-sporadic MND 73 M 9.8 13.0 91.7 1.0 −1.39 0.05
MQ150140 SYD ALS-sporadic MND 78 M 11.0 7.5 10.9 1.6 1.44 0.05
MQ150292 SYD ALS-sporadic MND 78 M 13.4 10.6 18.4 1.5 2.33 0.05
MQ160159 SYD ALS-sporadic MND 79 M 13.6 7.7 8.6 1.4 0.31 0.05
MQ140202 SYD ALS-sporadic MND 81 M 13.5 8.1 1.0 1.1 1.68 0.05
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ150060 SYD ALS-sporadic MND 82 M 14.7 7.0 21.9 1.2 1.45 0.06
MQ160030 SYD ALS-sporadic MND 83 M 11.3 6.2 18.0 1.0 3.08 0.05
MQ150035 SYD ALS-sporadic MND 86 M 12.8 6.7 3.8 1.1 6.09 0.06
MQ150218 SYD ALS-sporadic MND 87 M 12.0 10.9 12.2 1.2 0.71 0.08
MQ160163 SYD ALS-sporadic MND 87 M 11.9 8.0 8.2 1.1 2.36 0.08
MQ150028 SYD ALS-sporadic MND 91 M 14.5 7.8 15.5 1.5 0.60 0.07
MQ160039 SYD ALS-sporadic MND 92 M 6.4 4.0 7.6 0.6 −0.44 0.06
MQ150120 SYD At risk control Control 34 F 11.8 9.7 14.1 1.5 1.24 0.07
MQ150121 SYD At risk control Control 62 F 14.5 10.4 10.7 1.1 1.06 0.05
MQ160037 SYD At risk control Control 63 F 18.1 8.0 8.1 1.3 1.70 0.06
MQ150280 SYD Control (unrelated) Control 32 F 32.2 10.7 9.3 1.3 1.27 0.05
MQ160243 SYD Control (unrelated) Control 32 F 35.0 9.6 2.7 1.3 1.17 0.06
MQ150088 SYD Control (unrelated) Control 50 F 12.7 8.4 16.8 1.3 1.24 0.06
MQ140233 SYD Control (unrelated) Control 51 F 12.9 10.0 6.6 1.2 1.25 0.05
MQ160069 SYD Control (unrelated) Control 26 M 12.7 9.7 21.8 1.5 0.62 0.06
MQ140268 SYD Control (unrelated) Control 31 M 26.2 8.6 4.3 1.2 1.59 0.06
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ160261 SYD Control (unrelated) Control 41 M 18.9 11.2 14.7 1.6 0.93 0.07
MQ140293 SYD Control (unrelated) Control 46 M 18.9 7.4 4.5 1.1 0.31 0.05
MQ150079 SYD Control (unrelated) Control 54 M 13.5 9.4 11.1 1.1 0.66 0.05
MQ140212 SYD Control (unrelated) Control 56 M 13.9 10.3 24.3 1.6 1.27 0.05
MQ140300 SYD Control (unrelated) Control 78 M 13.1 7.7 12.5 1.5 0.26 0.05
MQ150080 SYD Flail Limb MND 61 F 12.8 10.3 4.4 1.0 0.02 0.06
MQ150258 SYD Flail Limb MND 61 F 10.7 9.8 3.9 1.8 0.62 0.05
MQ160139 SYD Flail Limb MND 62 F 15.3 23.0 5.4 1.3 0.70 0.07
MQ140188 SYD Flail Limb MND 65 M 10.0 12.5 11.5 1.4 0.63 0.05
MQ150191 SYD Flail Limb MND 66 M 11.5 8.0 18.6 1.6 0.81 0.06
MQ160161 SYD Flail Limb MND 67 M 10.5 9.1 7.1 1.1 0.42 0.06
MQ150223 SYD Flail Limb MND 69 M 5.3 3.4 4.2 0.5 0.68 0.05
MQ160073 SYD Flail Limb MND 70 M 12.5 18.5 9.9 1.4 0.69 0.06
MQ160270 SYD Flail Limb MND 73 M 11.9 8.2 9.9 1.2 1.59 0.06
MQ150112 SYD Flail Limb MND 78 M 11.5 7.0 13.7 1.2 2.24 0.05
MQ160078 SYD Flail Limb MND 79 M 13.5 8.1 30.7 1.4 0.80 0.05
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ160262 SYD Flail Limb MND 79 M 11.9 4.8 18.2 3.8 0.28 0.05
MQ160287 SYD obligate carrier Control 26 F 15.5 7.6 7.2 1.2 2.33 0.05
MQ150050 SYD obligate carrier Control 53 F 13.0 11.0 2.4 1.2 6.33 0.08
MQ140211 SYD obligate carrier Control 57 F 14.4 8.0 10.8 1.0 2.07 0.06
MQ160286 SYD obligate carrier Control 60 F 11.6 8.4 9.2 1.1 2.52 0.05
MQ150011 SYD obligate carrier Control 72 F 11.4 9.8 9.8 1.4 3.28 0.06
MQ140228 SYD PLS MND 71 F −0.21 0.06
MQ150185 SYD PLS MND 72 F 2.8 2.1 4.6 −0.24 0.08
MQ160224 SYD PLS MND 73 F 12.8 8.6 22.9 2.7 −0.31 0.08
MQ150124 SYD PLS MND 53 M 11.6 14.6 6.6 1.2 2.15 0.06
MQ150261 SYD PLS MND 54 M 12.7 7.9 6.0 1.6 1.23 0.07
MQ160138 SYD PLS MND 54 M 12.7 6.4 4.4 1.3 2.40 0.06
MQ150269 SYD PLS MND 56 M 11.9 27.2 19.1 1.4 0.45 0.06
MQ160201 SYD PLS MND 57 M 12.6 7.4 20.4 1.7 1.22 0.05
MQ150001 SYD PLS MND 68 M 13.1 17.3 36.5 1.4 1.16 0.05
MQ150245 SYD PLS MND 69 M 16.6 17.6 15.8 1.4 2.78 0.05
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)
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Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ160140 SYD PLS MND 70 M 13.5 11.6 11.7 1.4 0.44 0.05
MQ150026 SYD PLS MND 70 M 14.6 58.7 9.9 1.3 0.16 0.06
MQ160035 SYD PLS MND 71 M 13.7 6.6 9.9 1.3 0.32 0.06
MQ160240 SYD PLS MND 72 M 14.4 5.5 7.8 1.4 0.23 0.05
MQ140216 SYD TWINS ALS-sporadic MND 43 F 19.4 12.0 5.0 1.4 −0.15 0.12
MQ150044 SYD TWINS ALS-sporadic MND 44 F 21.7 8.0 11.5 1.3 −0.29 0.08
MQ150098 SYD TWINS ALS-sporadic MND 44 F 18.5 7.6 9.6 2.5 −0.32 0.07
MQ150188 SYD TWINS ALS-sporadic MND 44 F 20.7 8.4 10.8 1.2 −0.26 0.07
MQ150252 SYD TWINS ALS-sporadic MND 45 F 21.0 8.7 14.7 1.1 0.21 0.08
MQ150298 SYD TWINS ALS-sporadic MND 45 F 23.0 8.3 8.9 1.2 0.36 0.10
MQ160048 SYD TWINS ALS-sporadic MND 45 F 20.3 7.9 11.4 1.5 0.73 0.14
MQ160107 SYD TWINS ALS-sporadic MND 45 F 25.3 7.9 12.5 1.2 0.60 0.12
MQ160156 SYD TWINS ALS-sporadic MND 45 F 24.6 8.7 7.5 1.4 0.68 0.09
MQ150045 SYD TWINS At risk control Control 44 F 19.9 8.8 14.8 1.3 −0.54 0.10
MQ150100 SYD TWINS At risk control Control 44 F 20.9 7.0 17.9 1.2 −0.47 0.11
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.
aSe only analysed in samples from SYD datasets.
bδ65Cu values (‰)295
Table A.4.1 continued: Overview over human plasma samples assessed in Chapter 7
Sample ID Dataset Diagnosis Classication⋆ Age† Sex Cu (µg/g)‡ Fe (µg/g)‡ Zn (µg/g)‡ Se (µg/g)‡a δ65Cub SE
MQ150189 SYD TWINS At risk control Control 44 F 17.0 9.0 28.0 136.9 −0.23 0.12
MQ150254 SYD TWINS At risk control Control 45 F 19.6 8.4 10.3 2.1 −0.32 0.09
MQ150299 SYD TWINS At risk control Control 45 F 20.4 8.1 101.3 1.1 0.09 0.10
MQ160050 SYD TWINS At risk control Control 45 F 18.3 8.8 21.3 1.2 0.59 0.11
MQ160109 SYD TWINS At risk control Control 45 F 20.2 7.4 9.9 1.3 0.25 0.08
MQ150039 SYD TWINS At risk control Control 69 M 13.1 9.8 12.1 1.3 −0.43 0.09
MQ150242 SYD TWINS At risk control Control 70 M 12.0 9.5 7.1 1.4 −0.54 0.08
MQ160059 SYD TWINS At risk control Control 80 M 11.1 8.2 19.6 1.2 −0.16 0.15
MQ160113 SYD TWINS At risk control Control 80 M 11.3 8.0 17.6 1.3 −0.09 0.11
MQ160208 SYD TWINS At risk control Control 80 M 11.7 7.2 59.9 1.5 −0.19 0.12
MQ160057 SYD TWINS Flail Limb MND 80 M 11.6 8.5 13.4 1.8 −0.13 0.14
MQ160111 SYD TWINS Flail Limb MND 80 M 11.8 18.3 16.8 1.9 −0.13 0.14
MQ160219 SYD TWINS Flail Limb MND 80 M 11.5 6.4 11.4 2.1 −0.33 0.11
MQ150038 SYD TWINS PLS MND 69 M 13.0 10.0 6.2 1.3 −0.64 0.11
MQ150241 SYD TWINS PLS MND 70 M 12.8 7.9 7.7 1.1 −0.30 0.08
⋆Classication used in statistical analysis.
†Age at sample donation.
‡Concentrations determined in dry samples.




A.5.1 Mass balance calculations referred to in Chapter 7
Mass balance calculations based on average 25 year old male human (all values used in these
calculation are conservative):
Table A.4.2:Data and constants used in mass balance calculations
Name Symbol⋆ Values Reference
Mean Cu concentration 0.2 µmol/L = 0.2 nmol/mL; 0.2 nmol/mL (Pall et al., 1987)
in CSF
[Cu]CSF
× 63.546 g/mol† = 12.7 ng/mL
Mean Volume of CSF VCSF 150 mL (Sakka et al., 2011)
Production rate of CSF PCSF 0.35 mL/min (Cutler et al., 1968)
Times turnover of CSF 0.35 mL/min/d × 1440 min = 504 mL/d
per day
RCSF→PL
504 mL/d / 150 mL = 3.4 1/d
Total mass of Cu in CSF mCuCSF 150 mL × 12.7 ng/mL = 1905 ng = 1.9 µg
Mean Cu concentration
in blood plasma
[Cu]PL 1.13 µg/mL (Linder, 1991)
Blood volume in human
male (∼25 y)
VPL 6234 mL (Davy and Seals, 1994)
Blood plasma is ∼55% of
blood
6234 mL × 0.55 = 3429 mL ≈ 3.5 L
Total mass of Cu in
plasma
mCuPL 3500 mL × 1.13 µg/mL = 3955 µg ≈ 4 mg
Proportion of Cu in CSF
relative to plasma
1.9 µg / 3955 µg × 100 ≈ 0.05%
Density of CSF 1.00059 g/mL (Lui et al., 1998)
Mass of CSF in human mCSFhuman 150 mL × 1.00059 g/mL = 150.1 g ≈ 150 g
⋆ CSF = cerebrospinal uid; PL = blood plasma
† Molecular weight of Cu
To perform the mass balance calculations, two estimates of Cu eux rates (E) from the
CSF to the blood are going to be used (Equations A.1 and A.2).
Maximum Cu eux in 24 h from the CSF into the blood⋆ (MAX scenario):
ECuCSF→PL,MAX = m
Cu
CSF × RCSF→PL ≈ 6.5 µg/d (A.1)
⋆NOTE: this value is used here as a maximum estimation of the potential Cu eux from
the CSF to blood, assuming that all Cu from the CSF is euxed at the same rate that CSF
turns over. is estimate is likely not adequate, disregarding processes that separate, store
and recycle Cu back into the CNS via the choroid plexus (Zheng, 2018).
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Conservative (CON scenario) estimate of Cu eux in 24 h from the CSF into blood,
calculated as 10% of mCuPL⋆⋆:
ECuCSF→PL,CON = (m
Cu
CSF × 0.1)/d ≈ 0.19 µg/d = 190 ng/g (A.2)
⋆⋆NOTE: this conservative estimate is not based on empirical evidence and was set to
crease a contrast to the above estimated maximum eux rate.
e daily contribution of CSF Cu to the blood Cu pool can be calculated with
ECSF→PL / mCuPL × 100. is yields a contribution of 0.16 and 0.005%/d for the maximum
and conservative eux scenarios respectively.
Isotopic calculations
Current uncertainty on Cu isotopic measurements:
δ65Cu = 0.05‰
Determine what isotopic composition CSF would have to have to reach 0.05‰:
Setup the mass balance equation:
mmix = mplasma +mCSF
δmix = isotope ratio of plasma and CSF mixed, here 0.05‰
mplasma = mass of Cu in plasma measured
δplasma = arbitrary Cu isotope ratio of blood plasma, here 0‰
mCSF = mass ux of Cu from CSF, calculated as ECuCSF→PL × X × T
X = relative retention of specic CSF Cu in the plasma pool in percent
T = unit time over which the mass balance is calculated in days
Basic mass balance equation (Equation A.3)
mmix × δmix = (mplasma × δplasma +mCSF × δCSF) (A.3)
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Solving the equation for δCSF (Equation A.4)
δCSF =
mmix × δmix −mplasma × δplasma
mCSF
(A.4)
Fill in the place holders (Equation A.5 and A.6)
δCSF =




(mplasma + ECuCSF→PL × T × X) × δmix −mplasma × δplasma
ECuCSF→PL × T × X
(A.6)
Notes
Note 1 It is assumed that the total blood plasma mass of Cu (mmix) contains the euxed
Cu of the CSF.
Note 2 Following on from Note 1, a factor assuming the selective retention of CSF Cu in
the metabolic system (liver/blood), can be introduced. is accumulation could be
possibly found in the liver. is relative contribution of CSF Cu to the blood Cu
pool increases in a linear fashion with the introduction of an accumulation factor
X over time period T (X is percent retention per unit time; T is a whole number in
days). is factor is over-simplied and does not account for recycling processes
and relative discharge of some proportions of CSF Cu via the excretion pathways
over time.
Note 3 Here the contribution of CSF Cu is calculated to an arbitrary Cu isotope ratio of
blood plasma. In this case it is set to 0‰for simplicity.
Note 4 δmix represents the isotope ratio that is to be achieved (0.05‰).
Example calculation Example calculation using Equation A.6 for the contribution of CSF
Cu aer 100 days, assuming 0.1%/d accumulation in the maximum eux scenario. this
mean that 99.9% of the CSF Cu signal is lost due to excretion pathways:
δmix = 0.05‰
mplasma = 4 mg
δplasma = 0‰
ECuCSF→PL = 6.5 µg/d
X = 0.1%
T = 100 d
300
δCSF =
(4000µg + 6.5µg/d × 100d × 0.01) × 0.05‰ − 4000µg × 0‰






e CSF Cu δ65Cu value would have to be 30.82‰ to produce a measurable 0.05‰output
aer 100 days’ worth of contribution to the blood pool with a retention of 0.1% in the
maximum eux scenario. When calculating the relationship for the conservative scenario,
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All following pages are an integral part of the certificate. 
Page 1 of 3 
 
JOINT RESEARCH CENTRE 
Institute for Reference Materials and Measurements 
 
CERTIFICATE OF ANALYSIS 
ERM®- AE633 
Cu in 1 M nitric acid  
 Certified value (1) Uncertainty (2) 
amount content mol (63Cu) · g-1 (solution) 5.998 · 10-6 0.036 · 10-6 
amount ratio n(65Cu)/n(63Cu) 0.445 63 0.000 42 
1) The values reported in this certificate result from measurements performed at IRMM. The isotope amount content value is 
traceable to the SI via measurements carried out at IRMM, the value of the isotope amount ratio is traceable to SI via the 
values of the Cu isotope ratio of the isotopic reference material NIST SRM 976. 
2) Estimated expanded uncertainty U with a coverage factor k=2, corresponding to a level of confidence of about 95 %, as 
defined in the Guide to the Expression of Uncertainty in Measurement (GUM), ISO, 1995. 
 
This certificate is valid for three years after purchase. 
Sales date: 
The material can be regarded as a homogenous solution. 
 
Accepted as CRM, Geel, November 2002 Signed:  
 
Dr. Philip Taylor 
Unit for Isotope Measurements 
EC-DG JRC-IRMM 
Retieseweg 111 
B-2440 Geel, Belgium 
 
 
Accepted as an ERM®, Geel, June 2004  
Latest revision: November 2013 
Signed:  
Prof. Dr. Hendrik Emons 
European Commission 
Joint Research Centre 
Institute for Reference Materials and Measurements 
Retieseweg 111 
B-2440 Geel, Belgium 
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NOTE 
European Reference Material ERM®-AE633 was originally certified as IRMM-633. It was produced and certified 
under the responsibility of the IRMM according to the principles laid down in the technical guidelines of the 
European Reference Materials® co-operation agreement between BAM-IRMM-LGC. Information on these 
guidelines is available on the Internet (http://www.erm-crm.org). A detailed technical report on the certification 
procedure can be found in IRMM Internal Report GE/R/IM/22/00, available from IRMM on explicit request. 
 
DESCRIPTION OF THE SAMPLE 
The Spike Isotopic Reference Material ERM®-AE633 is supplied with a certified isotope amount content of 
63Cu and certified amount ratios of Cu. The samples are supplied in flame-sealed glass ampoules containing 
about 34 µmol of copper in 4 mL of nitric acid solution. 
From the certified values, the following amount and mass contents, the isotopic composition of Cu and the 
molar mass Cu in this Reference Material are derived: 
  
Certified value Uncertainty (1) 
amount content mol (Cu) · g-1 (solution) 8.671 · 10-6 0.052 · 10-6 
mass content g (63Cu) · g-1 (solution) 3.774 · 10-4 0.023 · 10-4 
 g (Cu) · g-1 (solution) 5.510 · 10-4 0.033 · 10-4 
















molar mass Cu in this sample   63.545 57 g·mol-1 0.000 40 
1 Estimated expanded uncertainty U with a coverage factor k=2, corresponding to a level of confidence of about 95 %, as 
defined in the Guide to the Expression of Uncertainty in Measurement (GUM), ISO, 1995. 
 
Atomic masses used for calculation of the derived values:* 
* G. Audi and A.H. Wapstra, The 1993 atomic mass evaluation, Nucl Phys A565 (1993) 1-65. 
 
Isotope g · mol-1 Uncertainty (1) 
63Cu 
65Cu 
62.929 600 7 
64.927 793 8 
0.000 003 0 
0.000 003 8 
1 Estimated expanded uncertainty U with a coverage 
factor k=2, corresponding to a level of confidence of 
about 95 %, as defined in the Guide to the Expression 
of Uncertainty in Measurement (GUM), ISO, 1995. 
 
ANALYTICAL METHOD USED FOR CERTIFICATION 
The copper mass fraction has been determined by Isotope Dilution Mass Spectrometry. 
PARTICIPANTS 
In cooperation with the Federal Institute for Material Research and Testing (BAM), Berlin, Germany. 
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SAFETY INFORMATION 
Not applicable     
INSTRUCTIONS FOR USE 
Using this spike isotopic reference material, the copper content in an unknown sample can be determined by 
Species-Specific Isotope Dilution, through a measurement of the isotope amount ratio R(B) = 
n(63Cu)/n(65Cu)  in a blend. It should be calculated with the aid of the following equation, which enables an 
easy quantification of the uncertainty sources in the procedure: 
 
























)(XR  = amount ratio n(63Cu)/n(65Cu) in the unknown sample material X 
)(YR  =  amount ratio n(63Cu)/n(65Cu) in the spike material Y 
∑ )(XRi  = sum of all amount ratios in the unknown sample material X 
∑ )(YRi  = sum of all amount ratios in the spike material Y 
m X( )  = mass of unknown sample used in the measurement 
)(Ym  = mass of the sample of spike solution used in the measurement 
( )XCuc ,  = amount content of Cu · g-1 sample material 






Neither the European Commission, its contractors nor any person acting on their behalf: 
(a) make any warranty or representation, express or implied, that the use of any information, material, apparatus, 
method or process disclosed in this document does not infringe any privately owned intellectual property rights;  
or 
(b) assume any liability with respect to, or for damages resulting from, the use of any information, material, 
apparatus, method or process disclosed in this document save for loss or damage arising solely and directly 
from the negligence of the Institute for Reference Materials and Measurements of the European Commission's 




European Commission - Joint Research Centre 
Institute for Reference Materials and Measurements (IRMM) 
Retieseweg 111, B - 2440  Geel (Belgium) 
Telephone: +32-14-571.722 - Telefax: +32-14-590.406 
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National Research        Conseil national
Council Canada            de recherches Canada
The following table shows those elements for which certified values have
been established for the dogfish (Squalus acanthias) reference material.
Certified values are based on results of determinations by at least two
independent methods of analysis. The uncertainties represent 95 percent
tolerance limits for an individual sub-sample of 250 mg or greater.
TRACE ELEMENTS (milligrams/kilogram)
Aluminum (d,g,i) 10.9 ± 1.7
Arsenic (d,g,h,x) 18.0 ± 1.1
Cadmium (g,p) 0.043 ± 0.008
Cobalt (d,g) 0.182 ± 0.031
Chromium (g,i,p) 34.7 ± 5.5
Copper (g,i,p,x) 2.34 ± 0.16
Iron (g,i,p,x) 142 ± 10
Lead (g,p) 0.065 ± 0.007
Manganese (d,g,i) 3.66 ± 0.34
Mercury (c,p) 4.64 ± 0.26
Nickel (g,i,p) 19.4 ± 3.1
Selenium (g,p) 1.40 ± 0.09
Silver (g,p) 0.041 ± 0.013
Thallium (p) (0.004)*
Tin (p) (0.023)*
Zinc (f,g,i,p) 25.6 ± 2.3
Methylmercury
(as Hg) (e,t) 4.47 ± 0.32
Arsenobetaine
(as As) (l,m) 16.4 ± 1.1
Tetramethylarsonium
(as As) (l) 0.248 ± 0.054
* information value only
DORM-2
 Dogfish Muscle Certified Reference Material for Trace Metals
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Coding
The coding refers only to the ultimate method
of analyte determination. No mention is made
here regarding the various methods of sample
preparation, decomposition and possible
analyte separation prior to determination within
each coded method.
c - Cold vapour atomic absorption
spectrometry.
d - Inductively coupled plasma mass
spectrometry (ICPMS)
e - Cold vapour microwave induced plasma
atomic emission spectrometry
f - Flame atomic absorption spectrometry.
g -Graphite furnace atomic absorption
spectrometry.
h - Hydride generation atomic absorption
spectrometry.
i - Inductively coupled plasma atomic
emission spectrometry.
I - High-performance liquid chromatography
ICPMS
m-Ionspray mass spectrometry
p - Isotope dilution inductively coupled plasma
mass spectrometry.
t - Gas chromatography - electron capture
detection
x - X-ray fluorescence spectrometry
This reference material is primarily intended for
use in the calibration of procedures and the
development of methods used for the analysis
of marine animals and materials with a similar
matrix.
There appear to be elevated concentrations of
iron, chromium and nickel in DORM-2
indicating the possible contamination of this
material by stainless steel during its
preparation. The mercury concentration of this
certified reference material (CRM) is also
relatively high but it is almost all
organomercury and was probably in the
dogfish muscle to start with.
Storage and Sampling
This material should be kept tightly closed in
the original bottle and should be stored in a
cool location, away from any intense radiation
sources such as ultraviolet lamps and sunlight.
The bottle should be well mixed by rotation and
shaking prior to use, and tightly closed immedi-
ately thereafter.
Homogeneity
This material was tested for homogeneity at
the National Research Council (NRC) in Ot-
tawa. Also, randomly selected bottles were
used for the analytical determinations by the
NRC laboratory and the collaborating laborato-
ries.
Results from different bottles indicated no
significant differences compared to results
from sub-samples within bottles. It is as-
sumed, then, that all bottles of this material is
essentially of the same composition. The
homogeneity is warranted by NRC for samples
of 250 mg weight and above for the elements
listed on the first page. There is other evidence
which supports homogeneity for some of the
analytes down to the level of 25 mg samples.
Instructions for Drying
DORM-2 can be dried to constant weight by:
(1) drying at reduced pressure (e.g. 50
mm Hg) at room temperature in a
vacuum desiccator over magnesium
perchlorate for 24 hours.
(2) vacuum drying (about 0.5 mm Hg) at
room temperature for 24 hours.
Both of these methods were used to obtain a
conversion factor to produce the “dry weight”
results listed on the first page.
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Preparation of Materials
This reference material was processed at the
Canadian Institute for Fisheries Technology,
Technical University of Nova Scotia, Halifax.
The preparation scheme is described below in
the schematic drawing.
The procedure does not result in totally defatted




















Comments, information and inquiries
should be addressed to:
Également disponible en français sur demande.
Stability
The predecessor CRM, DORM-1 has been
periodically analyzed for more than fifteen years
and has been both physically and chemically
stable over that time. We expect similar
behaviour from DORM-2.
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Updates
It is anticipated that as more data become avail-
able the established values may be updated and
reliable values assigned to more elements.
Our web site at  http://inms-ienm.nrc-cnrc.gc.ca/
calserv/chemical_metrology_e.html will contain
any new information.
 Date of issue: January 1993
organoarsenic compounds certified: September 1999
Date of expiry: January  2010
Dr. R.E. Sturgeon
National Research Council of Canada
Institute for National Measurement Standards
M-12, Montreal Road




The results listed in this certificate are traceable to
the SI through gravimetrically prepared standards of
established purity and international measurement
intercomparisons.  As such, they serve as suitable
reference materials for laboratory quality assurance
programs, as outlined in ISO/IEC 17025. This CRM
is registered at the Bureau International des Poids
et Mesures (BIPM) in Appendix C of the Comité
International des Poids et Mesures database listing
Calibration and Measurement Capabilities accepted
by signatories to the Mutual Recognition Arrange-






Animal research authority; approval AE14/28, University of Wollongong
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Addition of Mahlea Ryan as a research assistant to the ethics protocol
314
Final extension of research period for the animal ethics approval
 
Ethics Unit, Research Services Office 
University of Wollongong NSW 2522 Australia 
Telephone  (02) 4221 3386  Facsimile  (02) 4221 4338 




In reply please quote:   AE14/28 




9 January 2017 
 
 
A/Professor Heath Ecroyd 




Dear A/Professor Ecroyd 
 
AE14/28 Determination of the significance of copper levels in the body for the 
development of ALS in an ALS-mouse model 
     
 
The Animal Ethics Executive Committee has approved the following amendment to the 
above protocol subject to ratification at the next Committee meeting: 
 
1. Extension of the protocol to 31 January 2018. 
 
Names of Researchers: A/ Professor Heath Ecroyd, Dr Justin Yerbury, Gabriel 
Enge, Dr Tracy Maddocks, A/ Professor Dianne Jolley, 
Kate Roberts, Martin Engel, Maria Catacouzinos, Carlee 
Coombes, Mahlea Ryan 
 
Amendment Approval Date:  9 January 2017 
 
Monitoring Report Due: 31 December 2016 
 
Numbers of Animals: 96 G39A SOD1 Mice 
 96 C57GL/6 (B6) Mice 
 
It will be necessary to inform the Committee of any changes to the research protocol and 





Dr Malcolm France 
Chair, Animal Ethics Committee  
 
cc:  A/Professor James Wallman, Head of Biological Sciences 
 Dr Sarah Toole, Animal Welfare Officer 
 Ms Linda Deitch, IHMRI 
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FEBRUARY 2017  
Gabriel Enge 
Has undertaken mandatory refresher training in Animal 
Welfare and Ethics via an online moodle module. 
Topics included:- 
• The Australian code for the care and use of animals for scientific 
purposes 8th Edition 2013. 
• Researchers responsibilities when undertaking animal research. 
• Reporting and licencing requirements 
• The UOW, Animal Ethics Committee reporting and operational 
guidelines. 
Dr Sarah Toole BVSc(Hons) 
 Animal Welfare Officer.  
316
C.2 HUMAN-ETHICS
Human ethics fromMacquarie University for samples provided for chapter 7.
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Faculty	  of	  Medicine	  &	  Health	  Sciences	  
F10A	  Building	  




Macquarie	  University	  	  
Neurodegenerative	  Disease	  
Biobank	  
Project	  Request	  Form	  
	  
Date	  of	  Request:	  24/7/17	  
Project	  Title:	  	  
A. Investigator	  Information	  	  
	  
Principle	  Investigator	  	  
Name	   Email	  
Roger	  Chung	   Roger.chung@mq.edu.au	  
	  
	  
MQ	  Lab	  Based	  Researcher	  	  
Name	   Email	  
Albert	  Lee	   Albert.lee@mq.edu.au	  
Hannah	  Suddull	   Hannah.suddull@mq.edu.au	  
Christoph	  Krisp	   Christoph.krisp@mq.edu.au	  
Mark	  Molloy	   Mark.molloy@mq.edu.au	  
	  
	  
Additional	  Investigator	  	  
Name	   Affiliation	   Will	  samples	  be	  sent	  externally	  to	  
investigator?	  
A/Prof	  Anthony	  Dossetto	   University	  of	  Wollongong	   yes	  
Gabriel	  Enge	  (PhD	  student)	   University	  of	  Wollongong	   yes	  
	   	   	  
Add	  extra	  lines	  as	  required	  
	  
B.	  Research	  Project	  
	  
1. Project	  Approval	  
	  
Biobank	  Project	  Number	  	  
(Include	  if	  amending	  existing	  application,	  
otherwise	  for	  committee	  use)	  
RC001	  
Biobank	  HREC	  Number	  	   5201600387	  
External	  Affiliation	  Ethics	  Details	   	  
Grant	  Information	  and	  Number	   NHMRC	  Dementia	  Teams	  Grant	  (APP1095215)	  
MNDRIA	  grant-­‐in-­‐aid	  (GIA1610)	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Macquarie	  University	  	  
Neurodegenerative	  Disease	  
Biobank	  
Project	  Request	  Form	  
	  
2. Application	  Process	  
	  
I. Grant	  Applications:	  Prior	  to	  submitting	  a	  grant	  application	  for	  a	  project	  that	  will	  utilise	  biobank	  
samples	  and	  clinical	  data	  researchers	  must	  speak	  to	  the	  biobank	  manager	  to	  ensure	  feasibility	  of	  
the	  project	  in	  terms	  of	  available	  samples	  and	  clinical	  data.	  The	  grant	  application	  and	  project	  
request	  form	  (step	  2)	  should	  be	  completed	  in	  parallel.	  Pilot	  studies	  without	  related	  grant	  
applications	  are	  also	  welcomed	  in	  which	  case	  the	  application	  will	  occur	  after	  the	  pilot	  provides	  
strong	  data	  to	  support	  the	  hypothesis.	  
II. Project	  Request	  Form:	  The	  form	  must	  be	  sent	  to	  the	  biobank	  manager	  for	  review	  and	  editing.	  
Once	  the	  form	  is	  completed	  to	  a	  satisfactory	  standard,	  the	  request	  will	  be	  added	  to	  the	  agenda	  of	  
the	  next	  scheduled	  biobank	  meeting.	  
III. Biobank	  Committee:	  The	  principle	  investigator	  and/or	  main	  contact	  on	  the	  project	  form	  will	  be	  
invited	  to	  the	  meeting	  to	  discuss	  the	  project	  and	  answer	  any	  questions.	  Following	  which	  the	  
committee	  will	  come	  to	  a	  formal	  agreement.	  Projects	  are	  reviewed	  on	  scientific	  merit,	  and	  sample	  
and	  clinical	  data	  availability.	  Researchers	  should	  provide	  power	  calculations	  so	  the	  biobank	  can	  
determine	  availability	  of	  samples	  to	  allow	  the	  project	  to	  have	  adequate	  statistical	  power.	  The	  
review	  outcome	  will	  be	  either;	  approval,	  revision,	  request	  for	  more	  supporting	  data	  or	  rejection.	  
IV. Documents	  for	  External	  Collaborations:	  If	  the	  project	  involves	  sending	  samples	  to	  external	  
collaborators,	  additional	  documents	  must	  be	  provided.	  The	  researcher	  must	  attain	  an	  MTA	  and	  a	  
HREC	  approval	  letter	  for	  each	  external	  institution	  receiving	  samples.	  Relevant	  documents	  can	  be	  
provided	  by	  biobank	  manager	  
V. MQ	  HREC:	  The	  biobank	  manager	  will	  send	  the	  project	  request	  form,	  MTA	  and	  external	  site	  HREC	  
approval	  letter	  to	  MQ	  HREC	  for	  review	  and	  approval.	  
VI. Obtaining	  Samples	  and	  Clinical	  Data:	  Once	  the	  project	  is	  fully	  approved,	  biobank	  samples	  and	  
clinical	  data	  will	  be	  given	  to	  the	  main	  contact	  on	  the	  request	  form.	  
3. Project	  Summary	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Macquarie	  University	  	  
Neurodegenerative	  Disease	  
Biobank	  
Project	  Request	  Form	  
	  
Please	  provide	  a	  summary	  with	  the	  aims,	  hypothesis	  and	  research	  plan	  of	  the	  project	  in	  which	  the	  samples	  will	  be	  used.	  
Include	  justification	  for	  the	  amount/number/type	  of	  samples	  requested	  and	  how	  they	  will	  be	  used.	  Please	  also	  include	  
proposed	  dates	  or	  whether	  this	  is	  an	  on-­‐going	  project.	  If	  this	  is	  a	  pilot	  project	  please	  outline	  requirements	  for	  both	  pilot	  
and	  full	  project.	  
	  
	  
As	  per	  original	  application:	  
	  
Project	  Aims	  and	  hypotheses:	  We	  will	  use	  a	  new	  proteomic	  technique	  to	  screen	  for	  the	  presence	  of	  robust	  
protein	  biomarkers	  that	  can	  be	  used	  in	  future	  for	  early	  diagnosis	  of	  ALS	  and	  for	  tracking	  the	  prognosis	  of	  
patients.	  We	  hypothesize	  that	  low-­‐abundance	  plasma	  biomarkers	  are	  present	  that	  will	  be	  informative	  of	  
disease	  status	  and	  severity	  (Study	  1,	  2).	  	  Secondly,	  we	  predict	  that	  proteomic	  biomarkers	  in	  patient-­‐derived	  
cells/tissue	  will	  provide	  insight	  into	  disease	  origins	  and	  biomolecular	  mechanisms	  of	  neurodegeneration	  
(Study	  3).	  
	  
Study	  1:	  Unbiased	  protein	  profiling	  of	  plasma	  from	  cohorts	  of	  familial	  ALS	  patients	  displaying	  disease	  
discordance.	  
Study	  2:	  Validation	  of	  potential	  proteomic	  biomarkers	  in	  a	  cohort	  of	  sporadic	  ALS	  patients.	  
Study	  3:	  Unbiased	  proteomic	  profiling	  of	  patient-­‐derived	  cells/tissue	  from	  ALS	  patients.	  
	  
Research	  Plan:	  	  We	  will	  screen	  patient	  plasma	  and	  cell/tissue	  samples	  using	  the	  APAF	  SWATH-­‐MS	  technology	  
and	  subsequent	  western	  blotting	  validation.	  	  This	  will	  be	  undertaken	  in	  a	  proof-­‐of-­‐concept	  manner,	  designed	  
to	  validate	  the	  use	  of	  these	  approaches	  for	  biomarkers	  studies	  in	  ALS.	  	  	  
	  
Patient	  cohorts:	  	  This	  project	  will	  use	  plasma	  samples	  from	  four	  patient	  cohorts.	  	  All	  of	  the	  samples	  have	  
already	  been	  collected	  and	  stored	  in	  the	  Macquarie	  ALS	  biobank.	  
	  
Cohort	  1,	  discordant	  identical	  twins:	  	  We	  have	  two	  sets	  of	  genetically	  identical	  twins	  with	  only	  one	  sibling	  
presenting	  with	  ALS.	  	  We	  have	  longitudinally	  collected	  plasma	  samples	  from	  these	  twins	  over	  the	  past	  2	  years	  
(5	  visits).	  	  Total	  of	  20	  samples.	  
	  
Cohort	  2,	  discordant,	  multi-­‐generational	  ALS	  families:	  	  CI	  Blair	  has	  access	  to	  several	  large	  families	  that	  display	  
dominant	  inheritance	  of	  ALS	  across	  multiple	  generations.	  	  	  Over	  the	  past	  two	  years,	  we	  have	  collected	  plasma	  
samples	  from	  affected	  and	  unaffected	  family	  members.	  	  For	  this	  study,	  we	  will	  use	  a	  discordant	  pair	  of	  siblings	  
(ALS	  and	  unaffected)	  from	  three	  families,	  with	  up	  to	  4	  longitudinal	  samples	  per	  person	  (where	  available).	  
Total	  of	  up	  to	  24	  samples.	  
	  
Cohort	  3,	  sporadic	  ALS	  patients	  (validation	  cohort	  1):	  	  We	  have	  collected	  plasma	  samples	  from	  over	  100	  
patients	  (and	  their	  spouses)	  presenting	  with	  sporadic	  ALS	  in	  the	  past	  two	  years.	  	  We	  will	  divide	  samples	  into	  
four	  clinically-­‐defined	  sub-­‐groups;	  1)	  control	  (30	  participants),	  2)	  sporadic	  ALS	  (bulbar	  presentation,	  10	  
patients),	  3)	  sporadic	  ALS	  (lumbar	  presentation,	  10	  patients),	  and	  4)	  PLS	  (10	  patients).	  At	  this	  stage	  we	  do	  not	  
have	  preliminary	  data	  to	  allow	  us	  to	  perform	  power	  calculations	  to	  determine	  the	  minimum	  cohort	  size	  for	  
each	  disease	  subtype.	  	  We	  will	  not	  apply	  exclusion	  criteria	  (ie:	  age,	  gender,	  ethnic	  background	  etc)	  because	  
we	  expect	  the	  number	  of	  available	  patients	  for	  some	  of	  the	  subtype	  groups	  to	  be	  quite	  small,	  and	  because	  we	  
predict	  that	  the	  severe	  clinical	  phenotype	  will	  mask	  the	  effect	  of	  these	  exclusion	  criteria.	  We	  will	  use	  4	  
longitudinal	  samples	  per	  person.	  	  Total	  of	  240	  samples.	  
	  
Cohort	  4,	  sporadic	  ALS	  patients	  (validation	  cohort	  2):	  	  We	  will	  use	  plasma	  samples	  available	  through	  the	  MQ	  
MND	  biobank,	  that	  have	  not	  been	  used	  as	  part	  of	  the	  earlier	  Cohorts.	  	  These	  may	  be	  a	  variety	  of	  familial	  and	  
sporadic	  cases,	  across	  different	  age/gender/ethnic	  backgrounds.	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New	  for	  this	  modification	  request:	  
	  
Overview:	  	  We	  have	  made	  excellent	  progress	  with	  the	  proteomic	  profiling	  of	  plasma	  samples	  as	  proposed	  
above.	  	  We	  have	  identified	  a	  set	  of	  proteins	  that	  are	  dysregulated	  in	  the	  ALS	  discordant	  twin	  sets,	  as	  well	  as	  in	  
the	  familial	  and	  sporadic	  patient	  cohorts.	  	  Unexpectedly,	  some	  of	  these	  dysregulated	  proteins	  are	  either	  
directly	  associated	  with	  metal	  homeostasis,	  or	  are	  dependent	  upon	  metals	  for	  their	  biological	  function.	  
Therefore,	  we	  are	  keen	  to	  undertake	  precise	  analytical	  measurements	  of	  selected	  proteins	  from	  the	  same	  
plasma	  samples,	  to	  validate	  our	  findings	  and	  to	  also	  provide	  further	  insight	  into	  the	  potential	  metal	  
dyshomeostasis	  present	  in	  the	  plasma	  samples	  from	  ALS	  patients.	  
	  
Hypothesis:	  	  That	  there	  is	  dysregulation	  in	  metal	  homeostasis	  detectable	  in	  the	  plasma	  of	  ALS	  patients	  (versus	  
healthy	  controls),	  present	  at	  the	  time	  of	  first	  collection	  and	  changing	  over	  the	  timecourse	  of	  the	  disease.	  
	  
Research	  plan:	  we	  have	  already	  received	  a	  500µl	  plasma	  sample	  from	  the	  MND	  biobank	  within	  three	  cohorts;	  
discordant	  twin	  sets	  (ALS	  twin	  set	  with	  samples	  across	  7	  collection	  timepoints),	  familial	  cohort	  (11	  families	  
with	  affected,	  carriers	  and	  non-­‐affected)	  and	  sporadic	  cohort	  (21	  ALS,	  5	  PLS,	  4	  flail-­‐limb	  patients	  with	  samples	  
from	  3	  collection	  timepoints).	  	  We	  have	  used	  about	  50µl	  for	  our	  proteomics	  screening,	  and	  propose	  to	  send	  
up	  to	  400µl	  from	  the	  remaining	  plasma	  samples	  to	  our	  collaborators	  at	  the	  University	  of	  Wollongong	  for	  
metal	  analysis	  (A/Prof	  Dossetto	  and	  his	  PhD	  student	  Gabriel	  Enge).	  	  The	  metals	  to	  be	  analysed	  include	  iron,	  
zinc,	  copper,	  magnesium,	  manganese	  and	  selenium.	  	  	  
	  
Expected	  outcomes:	  The	  results	  from	  this	  metal	  analysis	  will	  contribute	  to	  a	  planned	  publication	  arising	  from	  
the	  proteomic	  plasma	  biomarker	  study,	  and	  contribute	  towards	  a	  PhD	  thesis	  for	  Gabriel	  Enge,	  the	  PhD	  
student	  who	  will	  undertake	  the	  metallomics	  analysis	  at	  University	  of	  Wollongong.	  	  We	  are	  also	  planning	  to	  
submit	  an	  application	  based	  upon	  this	  work	  for	  a	  MNDRIA	  grant-­‐in-­‐aid	  in	  2017	  (for	  funding	  in	  2018).	  
	  
	  
4. Project	  keywords	  
Please	  provide	  up	  to	  four	  (4)	  keywords	  to	  describe	  your	  project	  (e.g.	  biomarker,	  SOD1,	  exome)	  
	  
biomarker	   proteomics	   metallomics	   	  
	  
C.	  Sample	  Request	  
	  
5. Criteria	  for	  case	  sample	  selection	  
	  
Clinical	  Diagnosis	  (ALS,	  PLS	  
etc.)	  
	  
Familial	  or	  Sporadic	   	  
Gender	   	  
Age	  (give	  range	  or	  >	  or	  <)	   	  
Age	  of	  onset	  	  (give	  range	  or	  >	  
or	  <)	  
	  
Other	   	  
	  
6. Criteria	  for	  control	  sample	  selection	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Gender	   	  
Age	   	  
Other	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7. Typical	  Samples	  Available	  
	  
Sample	  Type	   Aliquots	  	   Max	  no.	  Aliquots	  per	  
Collection	  
Storage	  
DNA	   Variable	   1	  x	  stock,	  1	  x	  dilution	   -­‐30°C	  
RNA*	   Variable	   1	  x	  stock	   -­‐80°C	  
Plasma	   750μl	   10	   -­‐80°C	  
Serum	   500μl	   6	   -­‐80°C	  
Urine	   900μl	   5	   -­‐80°C	  
Hair	   Strands	   Variable	   Room	  Temp.	  
*Quality	  Score	  can	  be	  provided	  –	  discuss	  with	  Biobank	  staff	  
	  
8. Sample	  type	  and	  total	  number	  requested	  
	  
Sample	  Type	   Amount	  (e.g.	  ng)	   #	  Cases	   #	  Controls	  
DNA	   	   	   	  
RNA	   	   	   	  
Plasma	   	   	   	  
Serum	   	   	   	  
Urine	   	   	   	  
Hair	   	   	   	  
	  
9. Clinical	  Data	  Information	  Requested	  for	  each	  sample	  
Clinical	  &	  Demographics	  
	  
Patient	  Detail	   Require?	   Clinical	  Detail	   Require?	   Clinical	  Detail	   Require?	  
UID	   	  	   Date	  Of	  Onset	   	  	   Date	  of	  NIV	   	  	  
MQID	   	  	   Date	  Of	  
Diagnosis	  
	  	   Date	  of	  PEG	   	  	  
DOB	   	  	   Patient	  Site	  
Onset	  
	  	   ALSFRSR	  ID	   	  	  
Age	   	  	   Bulbar	  LMN	   	  	   *ALS-­‐FRS-­‐Total	  
Score	  
	  	  
DOD	   	  	   Bulbar	  LMN	   	  	   *ALS-­‐FRS-­‐
Creation	  Date	  
	  	  
DOD	   	  	   Bulbar	  UMN	   	  	   *ALS-­‐FRS-­‐
Creation	  Date	  
	  	  
Gender	   	  	   Cervical	  LMN	   	  	   *ALS-­‐FRS-­‐
Created	  By	  
	  	  
Familial	  ID	   	  	   Cervical	  UMN	   	  	   *ALS-­‐FRS-­‐
Notes	  
	  	  
Collection	  Date	   	  	   Lumbar	  LMN	   	  	   *ALS-­‐FRS	  not	  available	  for	  all	  
patients	  Patient	  Type	   	  	   Lumbar	  UMN	   	  	  
Please	  discuss	  with	  biobank	  staff	  before	  completing	  this	  section	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10. Project	  Conditions	  
Project	  request	  application	  conditions	  are	  required	  to	  ensure	  efficient	  running	  of	  biobank	  projects	  
and	  to	  comply	  with	  conditions	  of	  the	  MQ	  HREC	  approval.	  These	  conditions	  include:	  
	  
Condition	   Project	  Complies	  (Yes	  or	  No)	  
I. A	  MQ	  MND	  group	  leader	  must	  be	  the	  
principle	  investigator	  on	  the	  project	  
request.	  
yes	  
II. A	  MQ	  MND	  group	  leader	  must	  be	  an	  
investigator	  on	  existing	  or	  future	  grant	  
applications	  relating	  to	  this	  project.	  
yes	  
III. A	  staff	  member	  of	  the	  MQ	  MND	  group	  
leader	  must	  be	  named	  as	  an	  additional	  
investigator	  and	  in	  section	  A	  of	  the	  form,	  
to	  liaise	  between	  biobank	  staff	  and	  the	  
external	  researcher.	  
yes	  
IV. A	  fee	  will	  be	  charged	  as	  per	  current	  fee	  
schedule	  available	  from	  biobank	  manager	  
n/a	  (already	  have	  samples)	  
	  
11. Acknowledgement	  
In	  any	  publication	  resulting	  from	  use	  of	  samples	  and/or	  data	  from	  the	  Macquarie	  
Neurodegenerative	  Disease	  Biobank,	  please	  acknowledge	  the	  biobank	  with	  the	  following	  statement:	  
‘Biospecimens	  and	  related	  clinical	  data	  used	  in	  this	  research	  were	  obtained	  from	  the	  Macquarie	  
University	  Neurodegenerative	  Disease	  Biobank,	  Macquarie	  University,	  New	  South	  Wales,	  Australia.	  
All	  publications	  resulting	  from	  samples	  and/or	  data	  should	  be	  reported	  to	  the	  Neurodegenerative	  
Disease	  Biobank.	  
	  
PI	  Signature:	   	   	   	   	   Date:	  	  24/7/17	  
	  
	  
BIOBANK	  EXECUTIVE	  COMMITTEE	  USE	  ONLY	  
Note:	  original	  project	  was	  approved	  by	  Sarah	  Furlong	  on	  18/04/2016	  
	  
Amendment	  Approved	  by:	  Sarah	  Furlong	  
	  




Contact	  Details	  	  
Sarah	  Furlong	  PhD	  
Neurodegenerative	  Disease	  Biobank	  Manager	  
Faculty	  of	  Medicine	  &	  Health	  Sciences	  	  |	  	  	  	  
F10A	  Building	  2	  Technology	  Place	  Macquarie	  University,	  	  
NSW	  2109,	  Australia	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Ceterum censeo Carthaginem esse delendam.
[Cato the Elder (234 – 149 BC)]
•
